Time,LLM Timestamp,Post,Image,Link,Prompt,Input,Model
2024-08-30 08:01:00,2024-08-31 03:41:27,"ü©∫ **Breaking News: Mirdametinib Receives Priority Review for NF1-PN Treatment!**  
The FDA has granted Priority Review Designation to SpringWorks Therapeutics for mirdametinib as a potential treatment for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) in both children and adults.  
This investigational MEK inhibitor aims to address a significant unmet need, as patients suffer from severe tumors linked to this rare genetic disorder. The PDUFA date is set for February 28, 2025. Key findings from the phase 2b ReNeu trial indicate promising response rates and pain improvement.  
üëâ For more insights and to discuss the implications for your practice, check out the full story here: [Contemporary Pediatrics](https://www.contemporarypediatrics.com/view/priority-review-given-to-mirdametinib-to-treat-nf1-pn-in-children-adults)  
What are your thoughts on this development? Share your experiences and insights in the comments below!  
#NF1 #Mirdametinib #FDAApproval #Pediatrics #ClinicalPractice #MedicalResearch",https://medsii.azureedge.net/images/638606016653650935-66d17aa86157181811bbc863.jpg,https://www.contemporarypediatrics.com/view/priority-review-given-to-mirdametinib-to-treat-nf1-pn-in-children-adults,"You are a content creator tasked with crafting highly informative social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Thumbnail image URL: https://medsii.azureedge.net/images/638606016653650935-66d17aa86157181811bbc863.jpg  
Title: Priority Review given to mirdametinib to treat NF1-PN in children, adults

URL Source: https://www.contemporarypediatrics.com/view/priority-review-given-to-mirdametinib-to-treat-nf1-pn-in-children-adults

Published Time: 2024-08-29T16:10:32.023Z

Markdown Content:
Priority Review given to mirdametinib to treat NF1-PN in children, adults
===============
     

![Image 1: HCP Live](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)

*   [![Image 3: Contagion Live](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contagionlive.com/)
*   [![Image 5: CGT Live](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.cgtlive.com/)
*   [![Image 7: Neurology Live](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.neurologylive.com/)
*   [![Image 9: HCP Live](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/)
*   [![Image 11: Oncology Live](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.onclive.com/)
*   [![Image 13: Contemporary Pediatrics](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/)
*   [![Image 15: Contemporary OBGYN](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporaryobgyn.net/)
*   [![Image 17: Urology Times](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.urologytimes.com/)

[![Image 19](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/)

News

[All News](https://www.contemporarypediatrics.com/news)[PNP Corner](https://www.contemporarypediatrics.com/pnp-corner)

[AAP News](https://www.contemporarypediatrics.com/guidelines)

Media

[Around the Practice](https://www.contemporarypediatrics.com/around-the-practice)[Cure Connections](https://www.contemporarypediatrics.com/cure-connections)[Expert Interviews](https://www.contemporarypediatrics.com/expert-interviews)[Insights](https://www.contemporarypediatrics.com/insights)[Medical World News](https://www.medicalworldnews.com/)[Peer Exchange](https://www.contemporarypediatrics.com/peer-exchange)[Peers & Perspectives](https://www.contemporarypediatrics.com/peers-perspectives)[Podcasts](https://www.contemporarypediatrics.com/podcasts)[Webinars](https://www.contemporarypediatrics.com/webinars)

[Puzzler](https://www.contemporarypediatrics.com/case-studies)

Publications

[Contemporary Pediatrics Journal](https://www.contemporarypediatrics.com/journals/contemporary-peds-journal)[Supplements And Featured Publications](https://www.contemporarypediatrics.com/journals/supplements-and-featured-publications)

[CME/CE](https://www.contemporarypediatrics.com/continuing-medical-education)

Resources

[Handouts](https://www.contemporarypediatrics.com/handouts)[Job Board](http://jobs.modernmedicine.com/index.php?action=advanced_search&page=search&keywords=&mult_industries%5B%5D=Pediatrician&country=&zip_radius=&zip=&position_type=&min_salary=&max_salary=&salary_type=)[Sponsored](https://www.contemporarypediatrics.com/sponsored-resources)

Conferences

[Conference Coverage](https://www.contemporarypediatrics.com/latest-conference)[Conference Listing](https://www.contemporarypediatrics.com/conference)

[Partnerships](https://www.contemporarypediatrics.com/sap-partner)[Subscribe](https://one.contemporarypediatrics.com/subscribe)

Editorial

[Editorial Advisory Board](https://cdn.sanity.io/files/0vv8moc6/contpeds/ab931cf10c52363496c4c585e22e53be4a9cc4b8.pdf)[Writer‚Äôs Guidelines](https://cdn.sanity.io/files/0vv8moc6/contpeds/97efe6dc3b417f423a2317175ebdf8c5903affa0.pdf)[Reference Guidelines](https://cdn.sanity.io/files/0vv8moc6/contpeds/db68cfb068c7591ffbadb95dfd5f1433153f7227.pdf)[Meet the Editors](https://www.contemporarypediatrics.com/meet-the-editors)

Choose Specialty

[Allergy, Immunology, and ENT](https://www.contemporarypediatrics.com/clinical/allergy-immunology-and-ent)[Allergy, Immunology, and ENT](https://www.contemporarypediatrics.com/clinical/allergy-immunology-and-ent)[Allergy, Immunology, and ENT](https://www.contemporarypediatrics.com/clinical/allergy-immunology-and-ent)

[Cardiology](https://www.contemporarypediatrics.com/clinical/cardiology)[Cardiology](https://www.contemporarypediatrics.com/clinical/cardiology)

[Dermatology](https://www.contemporarypediatrics.com/clinical/dermatology)[Dermatology](https://www.contemporarypediatrics.com/clinical/dermatology)[Dermatology](https://www.contemporarypediatrics.com/clinical/dermatology)

[Emergency Medicine](https://www.contemporarypediatrics.com/clinical/emergency-medicine)

[Endocrinology](https://www.contemporarypediatrics.com/clinical/endocrinology)[Endocrinology](https://www.contemporarypediatrics.com/clinical/endocrinology)

[Gastroenterology](https://www.contemporarypediatrics.com/clinical/gastroenterology)[Gastroenterology](https://www.contemporarypediatrics.com/clinical/gastroenterology)[Gastroenterology](https://www.contemporarypediatrics.com/clinical/gastroenterology)[Gastroenterology](https://www.contemporarypediatrics.com/clinical/gastroenterology)

[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)

[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)

[Neurology](https://www.contemporarypediatrics.com/clinical/neurology)[Neurology](https://www.contemporarypediatrics.com/clinical/neurology)[Neurology](https://www.contemporarypediatrics.com/clinical/neurology)[Neurology](https://www.contemporarypediatrics.com/clinical/neurology)

[OB/GYN](https://www.contemporarypediatrics.com/clinical/obstetrics-gynecology-womens-health)[OB/GYN](https://www.contemporarypediatrics.com/clinical/obstetrics-gynecology-womens-health)

[Pain](https://www.contemporarypediatrics.com/clinical/pain)

[Pharmacology](https://www.contemporarypediatrics.com/clinical/pharmacology)[Pharmacology](https://www.contemporarypediatrics.com/clinical/pharmacology)

[Practice Improvement](https://www.contemporarypediatrics.com/clinical/practice-improvement)[Practice Improvement](https://www.contemporarypediatrics.com/clinical/practice-improvement)

[Respiratory](https://www.contemporarypediatrics.com/clinical/respiratory)[Respiratory](https://www.contemporarypediatrics.com/clinical/respiratory)[Respiratory](https://www.contemporarypediatrics.com/clinical/respiratory)

[Rheumatology](https://www.contemporarypediatrics.com/clinical/rheumatoid-arthritis)

[![Image 21](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/)

[](https://www.contemporarypediatrics.com/search)

Choose Specialty

[Allergy, Immunology, and ENT](https://www.contemporarypediatrics.com/clinical/allergy-immunology-and-ent)[Allergy, Immunology, and ENT](https://www.contemporarypediatrics.com/clinical/allergy-immunology-and-ent)[Allergy, Immunology, and ENT](https://www.contemporarypediatrics.com/clinical/allergy-immunology-and-ent)

[Cardiology](https://www.contemporarypediatrics.com/clinical/cardiology)[Cardiology](https://www.contemporarypediatrics.com/clinical/cardiology)

[Dermatology](https://www.contemporarypediatrics.com/clinical/dermatology)[Dermatology](https://www.contemporarypediatrics.com/clinical/dermatology)[Dermatology](https://www.contemporarypediatrics.com/clinical/dermatology)

[Emergency Medicine](https://www.contemporarypediatrics.com/clinical/emergency-medicine)

[Endocrinology](https://www.contemporarypediatrics.com/clinical/endocrinology)[Endocrinology](https://www.contemporarypediatrics.com/clinical/endocrinology)

[Gastroenterology](https://www.contemporarypediatrics.com/clinical/gastroenterology)[Gastroenterology](https://www.contemporarypediatrics.com/clinical/gastroenterology)[Gastroenterology](https://www.contemporarypediatrics.com/clinical/gastroenterology)[Gastroenterology](https://www.contemporarypediatrics.com/clinical/gastroenterology)

[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)

[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)

[Neurology](https://www.contemporarypediatrics.com/clinical/neurology)[Neurology](https://www.contemporarypediatrics.com/clinical/neurology)[Neurology](https://www.contemporarypediatrics.com/clinical/neurology)[Neurology](https://www.contemporarypediatrics.com/clinical/neurology)

[OB/GYN](https://www.contemporarypediatrics.com/clinical/obstetrics-gynecology-womens-health)[OB/GYN](https://www.contemporarypediatrics.com/clinical/obstetrics-gynecology-womens-health)

[Pain](https://www.contemporarypediatrics.com/clinical/pain)

[Pharmacology](https://www.contemporarypediatrics.com/clinical/pharmacology)[Pharmacology](https://www.contemporarypediatrics.com/clinical/pharmacology)

[Practice Improvement](https://www.contemporarypediatrics.com/clinical/practice-improvement)[Practice Improvement](https://www.contemporarypediatrics.com/clinical/practice-improvement)

[Respiratory](https://www.contemporarypediatrics.com/clinical/respiratory)[Respiratory](https://www.contemporarypediatrics.com/clinical/respiratory)[Respiratory](https://www.contemporarypediatrics.com/clinical/respiratory)

[Rheumatology](https://www.contemporarypediatrics.com/clinical/rheumatoid-arthritis)

![Image 23](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)

*   *   News
        
    *   [AAP News](https://www.contemporarypediatrics.com/guidelines)
    *   Media
        
    *   [Puzzler](https://www.contemporarypediatrics.com/case-studies)
    *   Publications
        
    *   [CME/CE](https://www.contemporarypediatrics.com/continuing-medical-education)
    *   Resources
        
    *   Conferences
        
    *   [Partnerships](https://www.contemporarypediatrics.com/sap-partner)
    *   [Subscribe](https://one.contemporarypediatrics.com/subscribe)
    *   Editorial
        

[](https://www.facebook.com/ContemporaryPediatrics/)[](https://twitter.com/ContempPEDS)[](https://www.linkedin.com/company/contemporary-pediatrics/about/)[](https://www.instagram.com/contemporarypediatrics/)[](https://www.contemporarypediatrics.com/rss)

Advertisement

* * *

Priority Review given to mirdametinib to treat NF1-PN in children, adults
=========================================================================

August 29, 2024

By [Joshua Fitch, Senior Editor](https://www.contemporarypediatrics.com/authors/joshua-fitch)

_News_

_Article_

The investigational MEK inhibitor has been assigned a Prescription Drug User Fee Act (PDUFA) date of February 28, 2025.

![Image 25](blob:https://www.contemporarypediatrics.com/b10db234f9bc7e77fa00a0de26d65ff2)![Image 26: Priority Review given to mirdametinib to treat NF1-PN in children, adults | Image Credit: ¬© Araki Illustrations - ¬© Araki Illustrations - stock.adobe.com.](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)

Priority Review given to mirdametinib to treat NF1-PN in children, adults | Image Credit: ¬© Araki Illustrations - ¬© Araki Illustrations - stock.adobe.com.

![Image 28](https://cdn.sanity.io/images/0vv8moc6/contpeds/c95ae87950c4cb9432fb0ac0f5c782e6bde6edb3-4600x2944.jpg?fit=crop&auto=format)

The FDA has granted Priority Review Designation to SpringWorks Therapeutics and accepted its New Drug Application for mirdametinib to treat adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).

The investigational MEK inhibitor has been assigned a Prescription Drug User Fee Act (PDUFA) date of February 28, 2025. The rare genetic disorder arises from loss-of-function variants in the NF1 gene, which encodes for neurofibromin, a key suppressor of the MAPK pathway. There is an estimated global birth incidence of approximately 1 in 2,500 individuals, and approximately 100,000 patients living with NF1 in the United States.

""NF1 patients have approximately a 30-50% lifetime risk of developing plexiform neurofibromas, or PN, which are tumors that grow in an infiltrative pattern along the peripheral nerve sheath and that can cause severe disfigurement, pain and functional impairment; in rare cases, NF1-PN may be fatal,"" stated Spring Works.

Submission to the FDA included data from the phase 2b ReNeu trial (NCT03962543) evaluating mirdametinib in patients aged 2 years or older with NF1-associated PN causing significant morbidity. Results, presented in an oral presentation at the 2024 American Society of Clinical Oncology Annual Meeting, demonstrated that mirdametinib objective response rates, improvement in pain and health-related quality of life, along with a ""manageable safety profile across both the adult and pediatric cohorts,"" according to SpringWorks.

The trial enrolled 114 patients to receive mirdametinib at a dose of 2 mg / m2 twice daily without regard to food. It was administered orally in a 3-week on, 1-week off dosing schedule as either a capsule or dispersible tablet.

The primary endpoint was confirmed objective response rate assessed by proportion of patients with a 20% or greater reduction in target tumor volume on consecutive scans in a 24 cycle treatment phase, measured by MRI.

""People living with NF1-PN are in need of new advances and we look forward to working with the FDA and EMA during their review processes as we prepare to bring our second medicine to patients suffering from devastating diseases,"" said Saqib Islam, Chief Executive Officer of SpringWorks, in the press release.

‚ÄúPlexiform neurofibromas may sit next to or surround vital organs and can cause serious medical complications for patients. While progress has been made, there remains a pressing need for more treatment options, particularly for adults who currently have no approved therapy,‚Äù said Annette Bakker, PhD, CEO, Children‚Äôs Tumor Foundation (CTF); Board Chair of CTF Europe. ‚ÄúCTF is dedicated to deploying its time, talent and funding towards accelerating the development of new treatments. We are thrilled that patients in the United States and Europe could soon have a new therapy available to them.‚Äù

**Reference**:

FDA Grants Priority Review to SpringWorks Therapeutics‚Äô New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN. SpringWorks Therapeutics Inc. Press release. August 28, 2024. Accessed August 29, 2024.

Recent Videos

[![Image 29: Lynn Malec, MD](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/altuviiio-phase-3-data-on-bleed-protection-in-children-with-hemophilia-a)[![Image 31: DB-OTO improved hearing to normal in child with profound genetic deafness | Image Credit: ¬© Marija - ¬© Marija - stock.adobe.com.](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/db-oto-improved-hearing-to-normal-in-child-with-profound-genetic-deafness)[![Image 33: Juanita Mora, MD](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/what-the-fda-approval-of-benralizumab-means-for-children-with-severe-asthma)[![Image 35: Rupa Wong, MD | Image Credit: Rupa Wong, MD](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/will-fda-approved-phentolamine-ophthalmic-solution-0-75-eye-drops-impact-pediatric-care-)[![Image 37: Tina Tan, MD, FAAP, FIDSA, FPIDS, editor in chief, Contemporary Pediatrics, professor of pediatrics, Feinberg School of Medicine, Northwestern University, pediatric infectious diseases attending, Ann & Robert H. Lurie Children's Hospital of Chicago](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/what-pfizer-s-maternal-rsv-vaccine-means-for-infant-population)[![Image 39: John Bradley, MD](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/discussing-fda-approved-nirsevimab-alip-for-rsv-prevention)[![Image 41](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/how-linaclotide-can-change-the-functional-constipation-treatment-landscape)[![Image 43](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/how-fda-approved-b-vec-will-help-children-with-dystrophic-epidermolysis-bullosa)[![Image 45: FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and older | Image Credit: bankrx - Image Credit: bankrx - stock.adobe.com.](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/fda-approves-b-vec-to-treat-dystrophic-epidermolysis-bullosa-patients-6-months-and-older)[![Image 47: Pfizer's infant RSV vaccine receives FDA Advisory Committee's support | Image Credit: Dr_Microbe - Image Credit: Dr_Microbe](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/pfizer-s-infant-rsv-vaccine-receives-fda-advisory-committee-s-support)

Related Content

Advertisement

* * *

[![Image 49: Roflumilast cream 0.05% shows long-term efficacy in children with AD | Image Credit: ¬© lial88 - ¬© lial88 - stock.adobe.com.](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/roflumilast-cream-0-05-shows-long-term-efficacy-in-children-with-ad?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Roflumilast cream 0.05% shows long-term efficacy in children with AD](https://www.contemporarypediatrics.com/view/roflumilast-cream-0-05-shows-long-term-efficacy-in-children-with-ad?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Joshua Fitch, Senior Editor](https://www.contemporarypediatrics.com/authors/joshua-fitch)

[August 28th 2024 Article Efficacy of roflumilast cream 0.05% improved over time among children aged 2 to 5 years with mild to moderate atopic dermatitis.](https://www.contemporarypediatrics.com/view/roflumilast-cream-0-05-shows-long-term-efficacy-in-children-with-ad?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

* * *

[![Image 51: FDA accepts setmelanotide NDA for obesity in patients down to 2 years | Image Credit: ¬© Araki Illustrations - ¬© Araki Illustrations - stock.adobe.com.](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/fda-accepts-setmelanotide-nda-for-obesity-in-patients-down-to-2-years?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[FDA accepts setmelanotide NDA for obesity in patients down to 2 years](https://www.contemporarypediatrics.com/view/fda-accepts-setmelanotide-nda-for-obesity-in-patients-down-to-2-years?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Joshua Fitch, Senior Editor](https://www.contemporarypediatrics.com/authors/joshua-fitch)

[August 26th 2024 Article Following the FDA's acceptance of the NDA, a PDUFA date of December 26, 2024 has been set for setmelanotide in patients as young as 2 years of age.](https://www.contemporarypediatrics.com/view/fda-accepts-setmelanotide-nda-for-obesity-in-patients-down-to-2-years?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

* * *

[![Image 53: FDA approves, authorizes updated mRNA COVID-19 vaccines | Image Credit: ¬© Calin - ¬© Calin - stock.adobe.com.](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/fda-approves-authorizes-updated-mrna-covid-19-vaccines?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[FDA approves, authorizes updated mRNA COVID-19 vaccines](https://www.contemporarypediatrics.com/view/fda-approves-authorizes-updated-mrna-covid-19-vaccines?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Joshua Fitch, Senior Editor](https://www.contemporarypediatrics.com/authors/joshua-fitch)

[August 22nd 2024 Article The federal agency advised manufacturers in June that 2024-2025 COVID-19 vaccines should be monovalent JN.1, with the preferred lineage being the KP.2 strain.](https://www.contemporarypediatrics.com/view/fda-approves-authorizes-updated-mrna-covid-19-vaccines?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

* * *

[![Image 55: Nipocalimab promising for preventing fetal, newborn hemolytic disease | Image Credit: ¬© annaperevozkina - ¬© annaperevozkina - stock.adobe.com.](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/nipocalimab-promising-for-preventing-fetal-newborn-hemolytic-disease?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Nipocalimab promising for preventing fetal, newborn hemolytic disease](https://www.contemporarypediatrics.com/view/nipocalimab-promising-for-preventing-fetal-newborn-hemolytic-disease?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Morgan Petronelli, Managing Editor](https://www.contemporarypediatrics.com/authors/morgan-petronelli)

[August 21st 2024 Article The investigational drug demonstrated promise in mitigating hemolytic disease of the fetus and newborn by blocking harmful antibodies.](https://www.contemporarypediatrics.com/view/nipocalimab-promising-for-preventing-fetal-newborn-hemolytic-disease?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

* * *

[![Image 57: FDA approves NexoBrid for pediatric severe thermal burn patients | Image Credit: ¬© Calin - ¬© Calin - stock.adobe.com.](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/fda-approves-anacaulase-bcdb-pediatric-severe-thermal-burn-patients?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[FDA approves anacaulase-bcdb for pediatric severe thermal burn patients](https://www.contemporarypediatrics.com/view/fda-approves-anacaulase-bcdb-pediatric-severe-thermal-burn-patients?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Joshua Fitch, Senior Editor](https://www.contemporarypediatrics.com/authors/joshua-fitch)

[August 20th 2024 Article The FDA approved anacaulase-bcdb for pediatric use, allowing its application for eschar removal in deep thermal burns for ages newborn to 18 years.](https://www.contemporarypediatrics.com/view/fda-approves-anacaulase-bcdb-pediatric-severe-thermal-burn-patients?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

* * *

[![Image 59: FDA approves axatilimab-csfr to treat graft-versus-host disease | Image Credit: ¬© Calin - ¬© Calin - stock.adobe.com.](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/fda-approves-axatilimab-csfr-to-treat-graft-versus-host-disease?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[FDA approves axatilimab-csfr to treat graft-versus-host disease](https://www.contemporarypediatrics.com/view/fda-approves-axatilimab-csfr-to-treat-graft-versus-host-disease?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Joshua Fitch, Senior Editor](https://www.contemporarypediatrics.com/authors/joshua-fitch)

[August 14th 2024 Article The approval is indicated for adult and pediatric patients who weigh at least 88 lbs (40 kg).](https://www.contemporarypediatrics.com/view/fda-approves-axatilimab-csfr-to-treat-graft-versus-host-disease?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

Related Content

Advertisement

* * *

[![Image 61: Roflumilast cream 0.05% shows long-term efficacy in children with AD | Image Credit: ¬© lial88 - ¬© lial88 - stock.adobe.com.](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/roflumilast-cream-0-05-shows-long-term-efficacy-in-children-with-ad?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Roflumilast cream 0.05% shows long-term efficacy in children with AD](https://www.contemporarypediatrics.com/view/roflumilast-cream-0-05-shows-long-term-efficacy-in-children-with-ad?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Joshua Fitch, Senior Editor](https://www.contemporarypediatrics.com/authors/joshua-fitch)

[August 28th 2024 Article Efficacy of roflumilast cream 0.05% improved over time among children aged 2 to 5 years with mild to moderate atopic dermatitis.](https://www.contemporarypediatrics.com/view/roflumilast-cream-0-05-shows-long-term-efficacy-in-children-with-ad?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

* * *

[![Image 63: FDA accepts setmelanotide NDA for obesity in patients down to 2 years | Image Credit: ¬© Araki Illustrations - ¬© Araki Illustrations - stock.adobe.com.](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/fda-accepts-setmelanotide-nda-for-obesity-in-patients-down-to-2-years?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[FDA accepts setmelanotide NDA for obesity in patients down to 2 years](https://www.contemporarypediatrics.com/view/fda-accepts-setmelanotide-nda-for-obesity-in-patients-down-to-2-years?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Joshua Fitch, Senior Editor](https://www.contemporarypediatrics.com/authors/joshua-fitch)

[August 26th 2024 Article Following the FDA's acceptance of the NDA, a PDUFA date of December 26, 2024 has been set for setmelanotide in patients as young as 2 years of age.](https://www.contemporarypediatrics.com/view/fda-accepts-setmelanotide-nda-for-obesity-in-patients-down-to-2-years?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

* * *

[![Image 65: FDA approves, authorizes updated mRNA COVID-19 vaccines | Image Credit: ¬© Calin - ¬© Calin - stock.adobe.com.](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/fda-approves-authorizes-updated-mrna-covid-19-vaccines?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[FDA approves, authorizes updated mRNA COVID-19 vaccines](https://www.contemporarypediatrics.com/view/fda-approves-authorizes-updated-mrna-covid-19-vaccines?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Joshua Fitch, Senior Editor](https://www.contemporarypediatrics.com/authors/joshua-fitch)

[August 22nd 2024 Article The federal agency advised manufacturers in June that 2024-2025 COVID-19 vaccines should be monovalent JN.1, with the preferred lineage being the KP.2 strain.](https://www.contemporarypediatrics.com/view/fda-approves-authorizes-updated-mrna-covid-19-vaccines?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

* * *

[![Image 67: Nipocalimab promising for preventing fetal, newborn hemolytic disease | Image Credit: ¬© annaperevozkina - ¬© annaperevozkina - stock.adobe.com.](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/nipocalimab-promising-for-preventing-fetal-newborn-hemolytic-disease?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Nipocalimab promising for preventing fetal, newborn hemolytic disease](https://www.contemporarypediatrics.com/view/nipocalimab-promising-for-preventing-fetal-newborn-hemolytic-disease?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Morgan Petronelli, Managing Editor](https://www.contemporarypediatrics.com/authors/morgan-petronelli)

[August 21st 2024 Article The investigational drug demonstrated promise in mitigating hemolytic disease of the fetus and newborn by blocking harmful antibodies.](https://www.contemporarypediatrics.com/view/nipocalimab-promising-for-preventing-fetal-newborn-hemolytic-disease?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

* * *

[![Image 69: FDA approves NexoBrid for pediatric severe thermal burn patients | Image Credit: ¬© Calin - ¬© Calin - stock.adobe.com.](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/fda-approves-anacaulase-bcdb-pediatric-severe-thermal-burn-patients?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[FDA approves anacaulase-bcdb for pediatric severe thermal burn patients](https://www.contemporarypediatrics.com/view/fda-approves-anacaulase-bcdb-pediatric-severe-thermal-burn-patients?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Joshua Fitch, Senior Editor](https://www.contemporarypediatrics.com/authors/joshua-fitch)

[August 20th 2024 Article The FDA approved anacaulase-bcdb for pediatric use, allowing its application for eschar removal in deep thermal burns for ages newborn to 18 years.](https://www.contemporarypediatrics.com/view/fda-approves-anacaulase-bcdb-pediatric-severe-thermal-burn-patients?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

* * *

[![Image 71: FDA approves axatilimab-csfr to treat graft-versus-host disease | Image Credit: ¬© Calin - ¬© Calin - stock.adobe.com.](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/fda-approves-axatilimab-csfr-to-treat-graft-versus-host-disease?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[FDA approves axatilimab-csfr to treat graft-versus-host disease](https://www.contemporarypediatrics.com/view/fda-approves-axatilimab-csfr-to-treat-graft-versus-host-disease?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Joshua Fitch, Senior Editor](https://www.contemporarypediatrics.com/authors/joshua-fitch)

[August 14th 2024 Article The approval is indicated for adult and pediatric patients who weigh at least 88 lbs (40 kg).](https://www.contemporarypediatrics.com/view/fda-approves-axatilimab-csfr-to-treat-graft-versus-host-disease?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[About Us](https://www.contemporarypediatrics.com/editorial-info)

[Advertise](https://www.contemporarypediatrics.com/advertise)

[Contact Us](https://www.mjhlifesciences.com/contact)

[Job Board](http://jobs.modernmedicine.com/index.php)

[Terms and Conditions](https://www.contemporarypediatrics.com/terms)

[Privacy](https://www.contemporarypediatrics.com/privacy)

[Do Not Sell My Personal Information](https://www.mjhlifesciences.com/ccpa?domain=www.contemporarypediatrics.com)

Contact Info

2 Commerce Drive  
Cranbury, NJ 08512

[609-716-7777](tel:609-716-7777)

![Image 73](blob:https://www.contemporarypediatrics.com/0b56f675ecfd870f746e03cb2a00669b)![Image 74](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)

[](https://www.facebook.com/ContemporaryPediatrics/)[](https://twitter.com/ContempPEDS)[](https://www.linkedin.com/company/contemporary-pediatrics/about/)[](https://www.instagram.com/contemporarypediatrics/)[](https://www.contemporarypediatrics.com/rss)

¬© 2024 MJH Life Sciences  
  
All rights reserved.
",gpt-4o-mini
2024-08-30 07:52:00,2024-08-31 03:41:58,"### Revolutionizing Anticoagulant Treatment: New Insights on Apixaban Versus Warfarin!
A recent study has successfully emulated the pivotal ARISTOTLE trial using real-world data from the UK Clinical Practice Research Datalink. This research indicates that apixaban shows noninferiority to warfarin in preventing stroke, but does not demonstrate superiority. Notably, the influence of warfarin‚Äôs therapeutic range on patient outcomes sheds light on treatment optimization. 

The implications are significant: understanding that effective anticoagulation management requires careful monitoring of individual patient circumstances and characteristics, especially when considering switching from warfarin to apixaban. As clinicians, how do you assess the appropriate use of anticoagulants in your practice? Share your experiences in the comments below!

üëâ Explore the full study here: [Comparison of Oral Anticoagulants for Stroke Prevention](http://dx.doi.org/10.1371/journal.pmed.1004377)  
üì∏ ![Thumbnail](https://medsii.azureedge.net/images/638606011219456220-66d1779b4e2a8b3bb83558de.jpg)  
#AtrialFibrillation #StrokePrevention #Anticoagulants #PatientCare #MedicalResearch #Cardiology",https://medsii.azureedge.net/images/638606011219456220-66d1779b4e2a8b3bb83558de.jpg,http://dx.doi.org/10.1371/journal.pmed.1004377,"You are a content creator tasked with crafting highly informative social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Thumbnail image URL: https://medsii.azureedge.net/images/638606011219456220-66d1779b4e2a8b3bb83558de.jpg  
Title: Comparison of oral anticoagulants for stroke prevention in atrial fibrillation using the UK clinical practice research Datalink Aurum: A reference trial (ARISTOTLE) emulation study

URL Source: http://dx.doi.org/10.1371/journal.pmed.1004377

Markdown Content:
*   Loading metrics
    

Open Access

Peer-reviewed

Research Article

*   Usha Gungabissoon,
*   John Tazare,
*   Liam Smeeth,
*   Paris J. Baptiste,
*   Turki M. Bin Hammad,
*   Angel Y. S. Wong,
*   Ian J. Douglas,
*   Kevin Wing

Comparison of oral anticoagulants for stroke prevention in atrial fibrillation using the UK clinical practice research Datalink Aurum: A reference trial (ARISTOTLE) emulation study
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*   Emma Maud Powell,¬†
*   Usha Gungabissoon,¬†
*   John Tazare,¬†
*   Liam Smeeth,¬†
*   Paris J. Baptiste,¬†
*   Turki M. Bin Hammad,¬†
*   Angel Y. S. Wong,¬†
*   Ian J. Douglas,¬†
*   Kevin Wing

![Image 1: PLOS](https://journals.plos.org/resource/img/logo-plos.png)

x

*   Published: August 29, 2024
*   [https://doi.org/10.1371/journal.pmed.1004377](https://doi.org/10.1371/journal.pmed.1004377)

Figures
-------

Abstract
--------

### Background

Stroke prevention guidance for patients with atrial fibrillation (AF) uses evidence generated from randomised controlled trials (RCTs). However, applicability to patient groups excluded from trials remains unknown. Real-world patient data provide an opportunity to evaluate outcomes in a trial analogous population of direct oral anticoagulants (DOACs) users and in patients otherwise excluded from RCTs; however, there remains uncertainty on the validity of methods and suitability of the data.

Successful reference trial emulation can support the generation of evidence around treatment effects in groups excluded or underrepresented in trials.

We used linked United Kingdom primary care data to investigate whether we could emulate the pivotal ARISTOTLE trial (apixaban versus warfarin) and extend the analysis to investigate the impact of warfarin time in therapeutic range (TTR) on results.

### Methods and findings

Patients with AF in the UK Clinical Practice Research Datalink (CPRD Aurum) prescribed apixaban or warfarin from 1 January 2013 to 31 July 2019 were selected. ARISTOTLE eligibility criteria were applied to this population and matched to the RCT apixaban arm on baseline characteristics creating a trial-analogous apixaban cohort; this was propensity-score matched to warfarin users in the CPRD Aurum. ARISTOTLE outcomes were assessed using Cox proportional hazards regression stratified by prior warfarin exposure status during 2.5 years of patient follow-up and results benchmarked against the trial results before treatment effectiveness was further evaluated based on (warfarin) TTR.

The dataset comprised 8,734 apixaban users and propensity-score matched 8,734 warfarin users. Results \[hazard ratio (95% confidence interval)\] confirmed apixaban noninferiority for stroke or systemic embolism (SE) \[CPRD 0.98 (0.82,1.19) versus trial 0.79 (0.66,0.95)\] and death from any cause \[CPRD 1.03 (0.93,1.14) versus trial 0.89 (0.80,0.998)\] but did not indicate apixaban superiority. Absolute event rates for stroke/SE were similar for apixaban in CPRD Aurum and ARISTOTLE (1.27%/year), whereas a lower event rate was observed for warfarin (CPRD Aurum 1.29%/year, ARISTOTLE 1.60%/year).

Analysis by TTR suggested similar effectiveness of apixaban compared with poorly controlled warfarin (TTR < 0.75) for stroke/SE \[0.91 (0.73, 1.14)\], all-cause death \[0.94 (0.84, 1.06)\], and superiority for major bleeding \[0.74 (0.63, 0.86)\]. However, when compared with well-controlled warfarin (TTR ‚â• 0.75), apixaban was associated with an increased hazard for all-cause death \[1.20 (1.04, 1.37)\], and there was no significant benefit for major bleeding \[1.08 (0.90, 1.30)\]. The main limitation of the study‚Äôs methodology are the risk of residual confounding, channelling bias and attrition bias in the warfarin arm, and selection bias and misclassification in the analysis by TTR.

### Conclusions

Analysis of noninterventional data generated results demonstrating noninferiority of apixaban versus warfarin consistent with prespecified benchmarking criteria. Unlike in ARISTOTLE, superiority of apixaban versus warfarin was not seen, possible due to the lower proportion of Asian patients and higher proportion of patients with well-controlled warfarin compared to ARISTOTLE. This methodological template can be used to investigate treatment effects of oral anticoagulants in patient groups excluded from or underrepresented in trials and provides a framework that can be adapted to investigate treatment effects for other conditions.

Author summary
--------------

### Why was this study done?

*   Stroke prevention treatment guidelines for patients with atrial fibrillation (AF) are based on results from randomised controlled trials (RCTs); we do not know if these results are relevant to patients that would not have been eligible to be included in the RCTs.
*   This study used routinely collected health data from the United Kingdom to emulate an RCT that compared apixaban to warfarin, ARISTOTLE, and also looked at whether the benefit of apixaban compared with warfarin was impacted by the quality of warfarin therapy (measured by time in therapeutic range (TTR)).
*   Emulating an RCT for stroke prevention in patients with AF should help to understand how transferable RCT results are to ‚Äúreal-world‚Äù practices and whether this methodological approach can help to improve treatment options and outcomes for patient groups currently underrepresented in clinical trials.

### What did the researchers do and find?

*   The researchers looked at patients with AF in a UK primary care data prescribed apixaban or warfarin and applied a ‚Äúreference trial emulation‚Äù approach, in which the ARISTOTLE trial eligibility, selection, and analysis approaches were applied to UK primary care data and results benchmarked against those of ARISTOTLE.
*   Patients prescribed apixaban had similar rates of outcomes to those prescribed warfarin in our cohort, and our results were successfully benchmarked against ARISTOTLE. Unlike ARISTOTLE, we did not see superiority of apixaban versus warfarin \[hazard ratio (95% confidence interval)\] for time to stroke or systemic embolism: 0.98 (0.82,1.19) in our cohort versus 0.79 (0.66,0.95) in ARISTOTLE.
*   We also found the benefit of apixaban versus warfarin differed for some outcomes depending on the quality of warfarin therapy with apixaban (i) superior only to poorly controlled warfarin therapy for major bleeding \[TTR < 0.75: 0.74 (0.63, 0.86), TTR ‚â• 0.75: 1.08 (0.90, 1.30)\] (ii) associated with an increased risk of death compared only to well-controlled warfarin therapy \[TTR ‚â• 0.75: 1.20 (1.04, 1.37), TTR < 0.75: 0.94 (0.84, 1.06)\].

### What do these findings mean?

*   Our results support the NICE guidelines on selecting treatment for stroke prevention in patients with AF and also provide reassurance on continuing warfarin in patients with high TTR.
*   We can use UK primary health care data to emulate a reference trial of treatments for the prevention of stroke in AF.
*   We can use the data and methods to look at how well treatments work in patients that would not have been included in RCTs such as those with multimorbidity or patient groups underrepresented in RCTs such as ethnic minority groups and older patients.
*   Study limitations include the possibility of residual confounding, a risk patients doing well on warfarin were overrepresented in our cohort, a lower proportion of Asian participants in our cohort compared with ARISTOTLE, and the likelihood of residual selection bias/misclassification in the TTR analysis.

**Citation:** Powell EM, Gungabissoon U, Tazare J, Smeeth L, Baptiste PJ, Bin Hammad TM, et al. (2024) Comparison of oral anticoagulants for stroke prevention in atrial fibrillation using the UK clinical practice research Datalink Aurum: A reference trial (ARISTOTLE) emulation study. PLoS Med 21(8): e1004377. https://doi.org/10.1371/journal.pmed.1004377

**Received:** September 15, 2023; **Accepted:** June 12, 2024; **Published:** August 29, 2024

**Copyright:** ¬© 2024 Powell et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability:** Data are not publicly available but are available subject to protocol approval via CPRD‚Äôs Research Data Governance Process ([https://cprd.com/data-access](https://cprd.com/data-access)) for researchers who meet the criteria for access to confidential data. The data underlying the results presented in the study are available from CPRD ([https://www.cprd.com](https://www.cprd.com/)).

**Funding:** This work was supported by the Medical Research Council (grant number MR/N013638/1 to EMP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** EMP was funded by a Medical Research Council studentship for this work, and is an employee of and holds stock in Compass Pathways outside the submitted work. UG is an employee of and holds stock in GSK. JT reports no conflict of interest and is supported by an unrestricted grant from GSK. LS reports grants from Wellcome, MRC, NIHR, BHF, Diabetes UK, ESRC, EU and GSK, personal fees from GSK and AstraZeneca, and is a trustee of the British Heart Foundation, outside the submitted work. PJB is supported by Barts Charity (MGU0504) and was supported by a GSK studentship at the time of writing. TBH reports no conflict of interest. AW reports no conflict of interest and is supported by a fellowship from British Heart Foundation (FS/19/19/34175). IJD reports grants, and holds stocks in GSK, outside the submitted work. KW has nothing to disclose.

**Abbreviations:** AF, atrial fibrillation; CPRD, Clinical Practice Research Datalink; DOAC, direct oral anticoagulant; EHR, electronic health record; HES, Hospital Episodes Statistics; HR, hazard ratio; INR, international normalised ratio; IPTW, inverse probability treatment weighting; MI, myocardial infarction; NICE, National Institute for Health and Care Excellence; OAC, oral anticoagulant; ONS, Office of National Statistics; PS, propensity score; PSM, propensity score matching; RCT, randomised controlled trial; SE, systemic embolism; TIA, transient ischaemic attack; TTR, time in therapeutic range; VKA, vitamin K antagonist

Introduction
------------

Atrial fibrillation (AF) is a common type of cardiac arrhythmia with an estimated prevalence of 3.3% in UK adults aged ‚â•35 years \[[1](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref001)\]. AF is a risk factor for stroke; patients with AF have a 5-fold increased risk of stroke compared with people without AF \[[2](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref002)\], and around a quarter of all strokes are attributed to this arrhythmia \[[3](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref003)\]. In addition, increased levels of mortality, morbidity, and disability with longer hospital stays are observed in stroke patients with AF compared with stroke patients without AF \[[4](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref004),[5](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref005)\].

Pharmacological therapy recommended to reduce the risk of stroke in AF includes the use of oral anticoagulants (OACs). The introduction of direct oral anticoagulants (DOACs) for AF since 2012 in the United Kingdom provided a choice of treatment alongside the older OAC class of vitamin K antagonists (VKAs), such as warfarin, which has been available for over 60 years. The VKA OACs require regular monitoring of international normalised ratio (INR) to keep patients in the optimal therapeutic range (typically 2.0 to 3.0) in which risk of both ischemic and bleeding events are minimised \[[6](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref006)\]. A patient may require dose adjustments to stay within their INR target range. A key measure of quality of warfarin treatment is, therefore, the time in therapeutic range (TTR), which estimates the proportion of time a patient has spent with INR within optimal range. A TTR of 0.75 or greater is often considered as indicating optimal INR control and suggests a patient is spending a high proportion of their time in their INR target range.

ARISTOTLE was a pivotal randomised controlled trial (RCT) of the DOAC apixaban designed to demonstrate noninferiority compared with warfarin in the prevention of stroke or systemic embolism (SE) in patients with AF. The results demonstrated superiority of apixaban over warfarin for both prevention of stroke/SE and safety (major bleeding) \[[7](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref007)\]. Results in the European Union patient subset from the trial suggested the observed superiority of apixaban might be dependent on how well warfarin therapy was managed in the comparator group \[[8](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref008)\], an analysis that has not yet been performed outside of trial settings. In the National Institute for Health and Care Excellence (NICE) review of ARISTOTLE, several professional groups noted the TTR of warfarin users in ARISTOTLE may be lower than what is typical in UK clinical practice \[[9](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref009)\].

Treatment guidelines for DOACs are based on evidence from RCTs; however, it is unclear whether these results extend to patient groups typically excluded from trials such as those with increased bleeding risk or severe comorbidities. While there have been a number of previous studies of DOAC effectiveness using noninterventional data, there remains uncertainty on whether the data sources and methods used have fully accounted for the lack of treatment randomisation and issues such as selection bias and confounding. Comparing results from real-world studies with RCT results is challenging due to differences in patient populations, treatment adherence, and study design. However, reference trial emulation involves use of an existing named RCT to (1) inform observational study design and (2) benchmark results against, providing confidence in validity of the selected observational methods and data \[[10](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref010)‚Äì[13](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref013)\]. The noninterventional analysis methods can then be applied, under a set of assumptions, to reliably estimate effects in groups of patients with AF who would have been excluded from (or underrepresented in) the reference trial \[[14](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref014)\] such as patients aged >80 that were underrepresented in ARISTOTLE compared with patients with AF in UK clinical practice and patients with increased bleeding risk that were excluded by the trial eligibility criteria.

There is increasing interest in trial emulation using observation data and in the application of recent developments in pharmacoepidemiology methods involving the inclusion of prevalent users. This study used a framework that involved coarsened exact matching to select patients matching the trial population on aggregate, and sampling of prevalent users in a way that avoids selection bias and emulates the process of screening into an RCT, to construct a cohort of patients similar to the target trial population that included both new and prevalent users. This methodological approach could be adapted to a variety of treatments and different therapeutic areas.

This study sought to (1) create an ARISTOTLE-analogous cohort using routinely collected primary and secondary care data in the UK, (2) benchmark results obtained in the ARISTOTLE-analogous cohort with ARISTOTLE results, and (3) explore whether apixaban treatment-effects in clinical practice are influenced by how well warfarin therapy is controlled.

Materials and methods
---------------------

This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline ([S1 STROBE](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.s001) Checklist).

### Study design

A propensity score (PS) matched cohort study with emulation of a reference trial (ARISTOTLE).

### Setting/data sources

#### UK electronic healthcare records.

This study used noninterventional data from UK Clinical Practice Research Datalink (CPRD) Aurum, a database containing anonymised data from 738 primary care practices across England (approximately 13% of the population of England with 19 million patient records and 7 million active as of September 2018 \[[15](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref015)\]). CPRD Aurum contains information on clinical diagnoses, prescribing, referrals, tests, and demographic/lifestyle factors and is representative of the population of England in geographical spread, social deprivation, age, and sex \[[15](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref015)\]. This study also used 2 additional data sources linked to CPRD Aurum: Hospital Episodes Statistics (HES) data, which contain data on patients admitted to NHS hopsitals including diagnoses, admission, and discharge, and Office of National Statistics (ONS) mortality data.

#### The reference trial (ARISTOTLE).

ARISTOTLE was a randomised, double-blind trial completed in 2011, comparing apixaban with warfarin in the prevention of stroke and SE. The trial included 18,201 patients with AF and at least 1 additional risk factor for stroke. The trial was designed to test for noninferiority of apixaban compared with warfarin (noninferiorirty margin of 1.38 for the upper limit of the 95% CI of the hazard ratio (HR) for the primary outcome) and showed apixaban superiority for (1) the primary outcome of stroke or SE (HR 0.79; 95% CI 0.66, 0.95), (2) the safety endpoint of major bleeding (HR 0.69; 95% CI 0.60, 0.80), and (3) death from any cause (HR 0.89; 95% CI 0.80, 0.99). The ARISTOTLE findings led to the NICE guidelines on stroke prophylaxis in patients with AF recommending apixaban as a treatment.

ARISTOTLE eligibility criteria and summary baseline patient characteristics were used to select a cohort of patients from CPRD Aurum analogous to the ARISTOTLE participants.

The use of CPRD and ARISTOTLE are described in a previous publication \[[14](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref014)\], and the use of CPRD for this project was approved by the MHRA Independent Scientific Advisory Committee ([S1 ISAC](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.s002) Protocol). All data used in this study were anonymised.

### Patient selection

#### Step 1: Application of trial eligibility criteria to patients in CPRD.

We first selected HES-linked patients registered in CPRD Aurum between 1 January 2013 and 31 July 2019, who had at least 6 months between registration and the index date. ARISTOTLE recruited both new (warfarin-na√Øve) and prevalent (warfarin-experienced) users of warfarin with randomisation stratified on prior warfarin (or other VKA) exposure status (warfarin na√Øve or experienced). To be classified as warfarin-na√Øve patients were required to have no evidence of exposure to warfarin or other VKA in the 5 years prior to the index date. To enable selection of a similar cohort of patients in CPRD Aurum (including both new and prevalent users of warfarin), the following process was used in determining index date:

\- apixaban users

index date = first prescription of apixaban in the study period;

apixaban user classified as warfarin-na√Øve or warfarin-experienced at this date

\- warfarin users

for new users of warfarin: index date = first prescription of warfarin in the study period;

for prevalent users of warfarin: a pool of potential index dates was selected containing all prescription dates in the study period, with index date selected at the later treatment-history sampling stage (see step 3).

ARISTOTLE eligibility criteria (Table A2 in [S1 Appendix](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.s003)) \[[7](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref007)\] were applied giving a trial-eligible cohort for apixaban users, a trial-eligible cohort of new users of warfarin, and a pool of potential index dates (with all potential index dates kept in regardless of ARISTOTLE eligibility at this stage) for warfarin continuers (prevalent warfarin users).

#### Step 2: Selection of apixaban trial-analogous patients in CPRD.

We selected a subset of the CPRD Aurum trial-eligible apixaban patients that better matched the ARISTOTLE apixaban participants based on aggregate summaries for the following key ARISTOTLE baseline characteristics:

*   Age
*   Sex
*   Congestive heart failure or left ventricular systolic dysfunction
*   Hypertension requiring treatment
*   Diabetes mellitus
*   Prior stroke/transient ischaemic attack (TIA)/SE
*   Level of renal impairment
*   Prior VKA/warfarin exposure

To characterise the baseline patient characteristics of ARISTOTLE, we used the key publication of the trial results \[[7](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref007)\], discussion of trial results by regulatory bodies \[[8](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref008),[9](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref009),[16](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref016)\], and publications on the trial presenting cross-tabulations on key characteristics \[[17](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref017),[18](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref018)\].

An ARISTOTLE-analogous cohort of CPRD Aurum apixaban patients was then selected using a modified form of coarsened exact matching \[[19](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref019)\] (see [S1 Appendix](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.s003) for details).

#### Step 3: Matching of apixaban trial-analogous patients to warfarin trial-eligible patients in CPRD.

To emulate ARISTOTLE, which stratified randomisation on prior VKA exposure status, patients in the CPRD cohort were matched separately within the VKA-na√Øve and VKA-experienced strata. A 3-step procedure, based on methods proposed by Suissa and colleagues \[[20](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref020)\] and Webster-Clark and colleagues \[[21](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref021)\], was used to select and match patients in the VKA-experienced strata while avoiding selection bias; this procedure is summarised in [Fig 1](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed-1004377-g001) and described in [S1 Appendix](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.s003).

[![Image 2: thumbnail](https://journals.plos.org/plosmedicine/article/figure/image?size=inline&id=10.1371/journal.pmed.1004377.g001)](https://journals.plos.org/plosmedicine/article/figure/image?size=medium&id=10.1371/journal.pmed.1004377.g001 ""Click for larger image"")

Fig 1. Matching of apixaban trial-analogous patients to warfarin trial-eligible patients \*This method has been found in a simulation study \[[21](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref021)\] to give unbiased results.

CPRD, Clinical Practice Research Datalink; RCT, randomised controlled trial; VKA, vitamin K antagonist.

[https://doi.org/10.1371/journal.pmed.1004377.g001](https://doi.org/10.1371/journal.pmed.1004377.g001)

The trial-analogous CPRD Aurum apixaban patients were matched to warfarin CPRD Aurum patients using greedy nearest-neighbour matching on the logit of the PS; a caliper of 0.2 times the standard deviation of the logit of the PS was used for matching as recommended by Austin \[[22](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref022)\].

The covariates included in the PS models are detailed in [Table 1](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed-1004377-t001).

The model resulting in the most balanced cohort was chosen with balance assessed by looking at standardised differences across all variables after matching using a target threshold of 0.05 for the maximum difference allowed for any individual variable. Balance of covariates considered to be most important in predicting outcome were prioritised, namely, age, sex, and stroke risk factors.

### Exposures and outcomes

#### Exposures.

Exposure to apixaban (5 mg/2.5 mg) or warfarin was determined using CPRD prescribing records with no restrictions on the dose prescribed.

#### Outcomes.

The primary effectiveness outcome was the composite of stroke (ischemic or haemorrhagic) or SE; individual components of this outcome (stroke, ischemic or uncertain type of stroke, haemorrhagic stroke, SE) and death from any cause were the key secondary effectiveness outcomes. Secondary effectiveness outcomes included myocardial infarction (MI), pulmonary embolism or deep vein thrombosis, and composite endpoints of effectiveness outcomes. The primary safety outcome was major bleeding (including by location‚Äîintracranial, gastrointestinal, or other location such as urinary or gynaecological). All outcomes involved hospitalisation or death and were ascertained using HES and ONS data. The ICD-10 codes used in ascertaining stroke occurrence have been recommended as having high positive predictive value \[[23](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref023)\].

### Statistical analysis

#### Methods of analysis.

A prospective protocol was published prior to the analysis detailing the planned analyses (\[[14](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref014)\]; also in [S1 Appendix](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.s003)).

Changes from the planned protocol are described in [Table 2](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed-1004377-t002).

All time-to-event endpoints were analysed using a Cox proportional hazards model, stratified by prior VKA status (experienced, na√Øve). The effectiveness outcomes were analysed using the intention-to-treat principle, and major bleeding was analysed using an on-treatment censoring scheme. Patients were censored at 2.5 years after index date reflecting typical maximum duration of follow-up in ARISTOTLE. Cluster-robust standard errors were used with pair membership as the clustering variable \[[24](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref024),[25](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref025)\]. The proportional hazards assumption was assessed by looking at the log-log of the Kaplan‚ÄìMeier survival curves and inspection of scaled Schoenfeld residuals plotted against time. Analyses were performed using SAS version 9.4 and R version 4.2.1.

#### Supplementary analyses.

A protocol planned analysis in the subset of patients deemed adherent (with adherence measured by TTR in the warfarin users and by proportion of days covered by prescriptions in the apixaban users) was planned to assess the impact of adherence on outcomes. The planned analysis was not possible due to the apixaban prescription data not providing a useful measure of adherence. An analysis by INR TTR was performed instead to assess the impact of warfarin control on results with all outcomes analysed by TTR (TTR < 0.75 and TTR ‚â• 0.75). Individual predicted TTR based on baseline variables was used for patients missing TTR. In order to perform the TTR analysis while maintaining balance in the baseline covariates, inverse probability treatment weighting (IPTW) was used to rebalance the baseline characteristics, applying stabilised weights to the ARISTOTLE-analogous apixaban users. A similar approach to the main analysis was used with PS models constructed separately for the new users and warfarin-experienced users.

An additional post hoc analysis was performed looking at the proportion of apixaban patients prescribed reduced-dose apixaban along with a comparison of the patients meeting the criteria for dose-reduction against the dose actually prescribed. In this analysis, apixaban dose in the ARISTOTLE-analogous CPRD cohort was assessed and compared against the ARISTOTLE protocol-specified criteria and NICE criteria for reduced apixaban dose. ARISTOTLE specified that participants meeting any 2 of the following criteria assessed at the time of randomisation should have their apixaban dose reduced to 2.5 mg BID: age ‚â•80 years, body weight ‚â§60 kg, or serum creatinine ‚â•1.5 mg/dL. These criteria are equivalent to the NICE guidelines for dose reduction with NICE having an additional criteria indicating reduced dose in those with creatinine clearance 15 to 29 mL/minute.

In addition, to assess the impact of the quality of dose-adjustment in the CPRD cohort on the observed effectiveness of apixaban relative to warfarin, a supplementary post hoc analysis was performed looking at the results in the subset of apixaban patients prescribed the correct dose compared with IPTW rebalanced warfarin comparators.

#### Sensitivity analyses.

Primary and secondary effectiveness outcomes were also analysed using the on-treatment censoring scheme to investigate whether treatment discontinuation compromises confidence in the effectiveness analyses.

Treatment persistence was defined by looking at longitudinal prescription data for OACs; OAC treatment windows were derived in which gaps > = 6 months between prescription dates were considered as distinct treatment windows. The end of each OAC treatment window was derived as the date of the last prescription of index OAC + the number of days supply given in the last prescription + a grace period of 30 days. In cases of overlapping OAC treatment windows, the date of the first prescription of the subsequent OAC treatment window was used to define the end of the prior OAC window. A prescription for a different OAC from the index OAC treatment was considered as a treatment switch. An ending of index OAC treatment with no subsequent prescription for any other OAC recorded was considered as treatment stop. Gaps of > = 6 months with no subsequent OAC prescriptions recorded were categorised as having stopped OAC treatment.

The set of patients who switched or discontinued treatment during follow-up were examined to ascertain whether selection bias due to attrition may have affected the on-treatment analyses (Table A9 in [S1 Appendix](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.s003)).

Apixaban was first launched for AF in the UK in January 2013, with relatively few patients receiving a prescription in the first year it was available; we therefore performed a sensitivity analysis with the start of study period shifted forwards a year to investigate the impact of inclusion of early adopters who may differ from later adopters of a new drug.

#### Confounding and bias.

In the study period, apixaban was a newly available treatment leading to the possibility of channelling bias \[[26](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref026)\]. By applying trial eligibility criteria to both treatment cohorts and matching using baseline covariates, we aimed to minimise channelling bias. To handle confounding, treatment arms were matched using propensity score matching (PSM) \[[27](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref027)\].

#### Benchmarking results against ARISTOTLE.

The study hypothesis was that results in the CPRD ARISTOTLE-analogous cohort would be comparable to the ARISTOTLE results, as defined by the prespecified benchmarking criteria. A slightly weaker benefit of apixaban versus warfarin was expected based on the weaker benefit seen in the EU subgroup of ARISTOTLE, and an expectation that the quality of warfarin control in UK patients may be higher than that observed in ARISTOTLE.

The benchmarking criteria for considering the results in the trial-analogous CPRD cohort to be comparable with ARISTOTLE were prespecified and published previously \[[14](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref014)\]:

*   The effect size must be clinically comparable with the ARISTOTLE findings; the HR for time to stroke/SE with the HR must be between 0.69 and 0.99. This range is not symmetrical around the ARISTOTLE estimate of 0.79 as it is anticipated the treatment effect in routine clinical care may be weaker than that seen in the optimised setting of a clinical trial.
*   The upper limit of the 95% CI for the HR for time to stroke/SE must be less than 1.38 (noninferiority margin used in ARISTOTLE, updated since protocol‚Äîsee [Table 2](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed-1004377-t002)).

The benchmarking step applied only to the primary effectiveness outcome in the trial-analogous CPRD cohort; results in other groups such as patients underrepresented or excluded from the trial would not necessarily be expected to remain consistent to the RCT results, given the relative risks may differ in these groups. Comparability of other outcomes was to be assessed descriptively with no formal criteria or hypothesis testing used.

### Missing data

Patients with missing systolic blood pressure (0.1%), body mass index (3.3%), smoking status (0.1%), or socioeconomic status (0.1%) were excluded from the trial-eligible cohort as the proportion of patients with these missing was low. Patients with missing renal function (1.3%), ethnicity (0.4%), or alcohol use (5.6%) were kept in the cohort through a missing indicator approach; this approach is valid under the assumption that these variables act as confounders and influence clinician prescribing decisions only when observed \[[28](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref028)\]. A total of 1,176 (13.3%) warfarin users in the CPRD cohort did not have INR measurements in the data during their treatment period with predicted TTR used for these patients in the analysis by TTR (see [S1 Appendix](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.s003) for details).

### Ethics

Scientific approval was provided by the London School of Hygiene and Tropical Medicine research ethics committee (ref 17682) and the independent scientific advisory committee of the Medicines and Healthcare Products Regulatory Agency (protocol no. 19\_066R). CPRD data are already approved via a national research ethics committee for purely noninterventional research of this type. CPRD data are analysed anonmymously; therefore, individual patient consent is not sought by contributing medical practices when data are shared with CPRD; however, patients are able to opt out of their patient information being shared for research.

Results
-------

### Participants

Between 1 January 2013 and 31 July 2019, there were 86,888 people with AF prescribed apixaban and 159,632 prescribed warfarin in HES-linked CPRD Aurum practices ([Fig 2](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed-1004377-g002)). Application of minimum registration period and ARISTOTLE inclusion criteria reduced this to 67,539 apixaban and 139,527 warfarin patients. After applying ARISTOTLE exclusion criteria, there were 41,487 apixaban and 101,159 warfarin patients.

[![Image 3: thumbnail](https://journals.plos.org/plosmedicine/article/figure/image?size=inline&id=10.1371/journal.pmed.1004377.g002)](https://journals.plos.org/plosmedicine/article/figure/image?size=medium&id=10.1371/journal.pmed.1004377.g002 ""Click for larger image"")

Fig 2. Selection of ARISTOTLE-analogous CPRD Aurum Cohort.

Flow of number of individuals included in the analysis. AF, atrial fibrillation; ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; BP, blood pressure; CPRD, Clinical Practice Research Datalink; HES, Hospital Episodes Statistics; Rx, Prescription; SES, socioeconomic status; ULN, upper limit of normal; VKA, vitamin K antagonist. aSevere comorbid condition with life expectancy <1 year or reasons making participation impractical; bALT or AST > 2X ULN or Total Bilirubin ‚â• 1.5X ULN; cPregnant or breastfeeding within 3 years prior. See Table A1 in [S1 Appendix](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.s003) for detailed list of inclusion and exclusion criteria. Note: For prevalent warfarin users, trial eligibility only revealed at point of random selection into the cohort for prevalent users. Numbers in figure show maximum theoretical number of warfarin users available should they be selected only at a time they were eligible for the trial.

[https://doi.org/10.1371/journal.pmed.1004377.g002](https://doi.org/10.1371/journal.pmed.1004377.g002)

Selecting apixaban patients to match ARISTOTLE on key baseline characteristics yielded 9,120 apixaban patients (3,912 new users and 5,208 prevalent users) available for PSM to 101,159 warfarin patients. For 274 apixaban patients, no match could be found giving a PS matched cohort of 8,846 apixaban and 8,846 warfarin patients.

### Application of ARISTOTLE inclusion/exclusion criteria and matching to ARISTOTLE

Applying the ARISTOTLE inclusion/exclusion criteria and matching to ARISTOTLE baseline patient characteristics resulted in a cohort similar to the ARISTOTLE apixaban participants ([Table 3](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed-1004377-t003)); for example, median age was 78 and mean CHADS2 score 2.4 in CPRD Aurum before applying trial criteria and matching, whereas the median age of 71 and mean CHADS2 score 2.1 after these steps matched the ARISTOTLE apixaban participants. The ARISTOTLE-analogous apixaban arm matched the trial arm on prior VKA exposure, age, sex, stroke risk factors and CHADS2 score, and proportion of patients with moderate or severe renal impairment.

[![Image 4: thumbnail](https://journals.plos.org/plosmedicine/article/figure/image?size=inline&id=10.1371/journal.pmed.1004377.t003)](https://journals.plos.org/plosmedicine/article/figure/image?size=medium&id=10.1371/journal.pmed.1004377.t003 ""Click for larger image"")

Table 3. Baseline characteristics of patients with AF prescribed apixaban and warfarin in CPRD Aurum compared with ARISTOTLE participants: (i) before and (ii) after applying ARISTOTLE inclusion and exclusion criteria and (iii) after matching to the trial participants.

[https://doi.org/10.1371/journal.pmed.1004377.t003](https://doi.org/10.1371/journal.pmed.1004377.t003)

Differences remained on baseline characteristics it was not feasible to match on, namely, ethnicity (95.2% white, 2.4% Asian in CPRD Aurum apixaban versus 82.6% white, 14.4% Asian in ARISTOTLE) and concomitant medications (amiodarone 3.8%, aspirin 5.8%, digoxin 13.9% in CPRD Aurum apixaban users versus amiodarone 11.1%, aspirin 31.3%, digoxin 32.0% in ARISTOTLE apixaban arm). See [S1 Appendix](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.s003) for details on matching feasibility.

### Propensity score matching of CPRD Aurum trial-analogous apixaban users to CPRD Aurum warfarin users

#### Results of propensity score matching.

Before PSM, differences between treatment groups were evident for most baseline variables including age (median age 71 in apixaban versus 78 in warfarin), sex (apixaban 35.6% female versus warfarin 43.6%), and stroke risk factors (see [Table 3](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed-1004377-t003)). After PSM, all baseline characteristics were well balanced (maximum standardised difference .031). From 9,120 apixaban users, only 274 (3.0%) were dropped due to unsuccessful matching.

### Main results

The HR for stroke/SE in the PS matched groups was 0.98 (95% CI 0.82,1.19) ([Fig 3](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed-1004377-g003) and Table A3 in [S1 Appendix](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.s003)). This association was consistent with the noninferiority margin (upper limit of the 95% CI less than 1.38) \[[7](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref007)\] but did not show superiority as predicted by ARISTOTLE \[HR 0.79 (95% CI 0.66,0.95)\] ([Fig 3](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed-1004377-g003) and Table A2 in [S1 Appendix](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.s003)). The outcome of all-cause mortality also showed noninferiority \[Aurum 1.03 (0.93,1.14) versus trial 0.89 (0.80,0.998)\] but did not indicate apixaban superiority. Absolute event rates for the primary outcome and components were close to the trial for apixaban‚Äîfor example \[comparing Aurum versus trial\], stroke/SE event rate of 1.27%/year versus 1.27%, whereas the warfarin group had a lower event rate compared with ARISTOTLE (stroke/SE event rate of 1.29%/year versus 1.60% and hemorrhagic stroke 0.33%/year versus 0.47%/year) ([Fig 3](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed-1004377-g003)). Mean duration of follow-up in the cohort was 1.8 years in the apixaban arm and 2.2 years in the warfarin arm.

[![Image 5: thumbnail](https://journals.plos.org/plosmedicine/article/figure/image?size=inline&id=10.1371/journal.pmed.1004377.g003)](https://journals.plos.org/plosmedicine/article/figure/image?size=medium&id=10.1371/journal.pmed.1004377.g003 ""Click for larger image"")

Fig 3. Forest plot showing HRs (dots) and 95% CIs (lines) for apixaban vs.

**warfarin.** Absolute event rates (%/year) and HR (95% CIs) are presented for key effectiveness outcomes in (i) ARISTOTLE, (ii) CPRD Aurum trial-matched cohort, (iii) CPRD Aurum trial-matched with TTR < 0.75, and (iv) CPRD Aurum trial-matched with TTR ‚â• 0.75. Dashed line shows noninferiority margin 1.38 for the upper bound of the 95% CI of the HR used in ARISTOTLE for the primary outcome of stroke or SE. For the analysis by TTR, IPTW was applied to the apixaban users targeting the treatment effect in the warfarin users with TTR < 0.75 and TTR ‚â• 0.75. CI, confidence interval; CPRD, Clinical Practice Research Datalink; HR, hazard ratio; IPTW, inverse probability treatment weighting; SE, systemic embolism; TTR, time in therapeutic range.

[https://doi.org/10.1371/journal.pmed.1004377.g003](https://doi.org/10.1371/journal.pmed.1004377.g003)

### Analysis of impact of warfarin time in therapeutic range (TTR)

TTR was higher in the CPRD cohort than in ARISTOTLE (mean 0.73 versus 0.62, median 0.76 versus 0.66).

Analysis by TTR suggested noninferiority of apixaban versus warfarin in those with TTR < 0.75 \[stroke/SE 0.91 (0.73,1.14), all-cause death 0.94 (0.84, 1.06)\] ([Fig 3](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed-1004377-g003)). Apixaban was associated with similar hazards for stroke by category of TTR and increased hazards of death compared to warfarin in those with well-controlled warfarin treatment (TTR ‚â• 0.75) \[stroke/SE 1.05 (0.82, 1.34), all-cause death 1.20 (1.04, 1.37)\] ([Fig 3](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed-1004377-g003)).

### Analysis of apixaban dose-adjustment

The proportion of patients meeting the criteria for reduced dose apixaban ([Table 4](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed-1004377-t004)) was similar between the CPRD ARISTOTLE-analogous apixaban, warfarin, and RCT apixaban groups (4.9%, 4.9%, and 4.7%, respectively). When including the additional NICE criteria of creatinine clearance, 5.1% of apixaban users in the ARISTOTLE-analogous cohort had an indication for reduced-dose apixaban, yet a larger proportion (14.3%) were prescribed reduced dose apixaban implying some patients in CPRD Aurum may have been prescribed the wrong dose and/or information on criteria for dose reduction may have been missing from CPRD Aurum.

A futher analysis of the quality of dose-adjustment in patients in CPRD Aurum ([Table 5](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed-1004377-t005)) indicated 10.5% of patients may have been prescribed an incorrect dose of apixaban at the index prescription based on the data contained in their electronic health records (EHRs). The majority of incorrect dose relating to patients being prescribed reduced-dose apixaban despite not meeting the criteria for dose reduction. A large proportion of patients prescribed an incorrect dose had only 1 dose adjustment criteria (59.6% of those with incorrect dose), suggesting some prescribers may have thought a dose reduction was warranted when only 1 criteria was present. Other possible reasons for the incorrect dose-adjustment observed here may be data on the criteria missing from the EHR (i.e., incorrect ascertainment) or consideration of other medical history that made a prescriber adjust the dose.

To assess the impact of the quality of dose-adjustment in the CPRD cohort on the effectiveness of apixaban, a supplementary post hoc analysis was performed looking at the results in the subset of apixaban patients prescribed the correct dose (_N_ = 7,921) compared with IPTW rebalanced warfarin comparators. The results in this subset were consistent with the primary results showing apixaban to be noninferior to warfarin (stroke/SE 0.96 \[0.78,1.17\], death 0.97 \[0.87,1.09\]) with the results moving slightly closer to those observed in ARISTOTLE.

### Safety results

The analysis for safety outcomes is presented in [Fig 4](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed-1004377-g004) and Table A5 in [S1 Appendix](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.s003); patients on apixaban had a lower risk of major bleeding compared with those on warfarin, HR (95% CI) 0.88 (0.77,1.00), consistent with ARISTOTLE. Analysis by TTR suggested superiority of apixaban for major bleeding in those with TTR <0.75 \[0.74 (0.63, 0.86)\], whereas apixaban users had a similar risk of major bleeding compared with those with optimal warfarin control (TTR ‚â• 0.75) \[1.08 (0.90,1.30)\].

[![Image 6: thumbnail](https://journals.plos.org/plosmedicine/article/figure/image?size=inline&id=10.1371/journal.pmed.1004377.g004)](https://journals.plos.org/plosmedicine/article/figure/image?size=medium&id=10.1371/journal.pmed.1004377.g004 ""Click for larger image"")

Fig 4. Forest plot showing HRs (dots) and 95% CIs (lines) for apixaban vs.

**warfarin.** Absolute event rates (%/year) and HR (95% CIs) are presented for key safety outcomes in (i) ARISTOTLE, (ii) CPRD Aurum trial-matched cohort, (iii) CPRD Aurum trial-matched with TTR < 0.75, and (iv) CPRD Aurum trial-matched with TTR ‚â• 0.75. For the analysis by TTR, IPTW was applied to the apixaban users targeting the treatment effect in the warfarin users with TTR <0.75 and TTR ‚â•0.75. CI, confidence interval; CPRD, Clinical Practice Research Datalink; HR, hazard ratio; IPTW, inverse probability treatment weighting; TTR, time in therapeutic range.

[https://doi.org/10.1371/journal.pmed.1004377.g004](https://doi.org/10.1371/journal.pmed.1004377.g004)

### Sensitivity analyses

Table A7 in [S1 Appendix](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.s003) shows the proportion of patients switching treatment. A higher proportion of patients on warfarin switched to an alternative OAC during follow-up compared with those on apixaban (16.3% versus 6.1%).

Comparing patients who switched treatment during follow-up with those that continued on index treatment (Table A8 in [S1 Appendix](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.s003)) suggests possible selection bias due to attrition in on-treatment analyses with median TTR markedly lower in warfarin users who switched treatments compared with persistent warfarin users (median TTR 0.64 versus 0.78). On-treatment analyses would likely be biased against apixaban since patients doing badly on warfarin (i.e., with low TTR) who would be more likely to experience events in the warfarin arm would be censored at treatment switch.

On-treatment analyses censoring around treatment switch or discontinuation are presented for the effectiveness analyses in the appendix (Table A6 in [S1 Appendix](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.s003)); the results show evidence of the expected attrition bias against apixaban when compared with the ITT results in [Fig 2](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed-1004377-g002), for example, HR for stroke/SE is 1.04 (0.86, 1.25) in the on-treatment compared with 0.98 (95% CI 0.82, 1.19) in the ITT analysis.

Repeating the analysis with start of study period shifted forwards a year to investigate the impact of inclusion of early adopters yielded similar results to the primary analysis (Table A9 in [S1 Appendix](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.s003)).

Prior INR control was not included in the PS models for the VKA-experienced due to a high rate of missing prior INR data (missing for 34% in the apixaban arm). A post hoc sensitivity analysis including a prior INR control variable in the PSM gave results consistent with the primary results \[stroke/SE HR 95% CI 1.02 (0.86,1.21)\]. Details of this post hoc analysis are in [S1 Appendix](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.s003).

Discussion
----------

In our emulation of ARISTOTLE using UK routinely collected healthcare data, we found results that met our predefined criteria for comparability with the trial. We saw noninferiority of apixaban versus warfarin for prevention of stroke or SE, all-cause mortality, and major bleeding but did not see superiority of apixaban versus warfarin for these outcomes as was seen in ARISTOTLE. We found higher TTR in the patients using warfarin in our cohort compared with the warfarin arm of ARISTOTLE (median 0.76 versus 0.66). While our analysis by TTR showed noninferiority of apixaban versus warfarin for our stroke or SE outcome, we observed an increased risk of death on apixaban compared with patients well-controlled on warfarin (TTR ‚â• 0.75) but not when compared with those on poorly controlled warfarin (TTR < 0.75). For major bleeding, while apixaban was superior when compared to those on poorly controlled warfarin, there was no difference when compared to those on well-controlled warfarin. We saw evidence suggesting suboptimal dosing of apixaban in our cohort with approximately 10% of patients in the apixaban arm prescribed the reduced dose without meeting the criteria for the reduced dose.

We found the differences in the overall treatment-effect estimates between our cohort and ARISTOTLE may be explained by the lower proportion of Asian patients in our cohort, differences in INR control in the warfarin arm of our cohort compared with ARISTOTLE, and the higher proportion of patients prescribed a reduced dose of apixaban in our cohort compared with ARISTOTLE.

Our findings are consistent with a UK study of ischemic stroke, which compared DOACs with warfarin \[[29](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref029)\]. A Danish study found similar results to ours for stroke/SE \[[30](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref030)\], although they found apixaban users had a lower risk of death; a study of US claims data \[[31](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref031)\] also found apixaban was associated with a lower risk of death. A systematic review and meta-analysis of 16 studies \[[32](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref032)\] found pooled results for stroke and intracranial haemorrhage that were consistent with ours. One study (in US claims data) also aimed to replicate ARISTOTLE \[[33](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref033),[34](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref034)\] and, in contrast to our study, found superiority for apixaban for stroke/SE, which may be linked to population differences such as lower TTR in US patients on warfarin \[[35](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref035)\] and differences in ethnicity. None of these studies matched to the ARISTOTLE trial participants, included prevalent users, or looked at how warfarin control impacted results. Further details on these studies including design and key results are summarised in Table A10 in [S1 Appendix](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.s003).

A key strength of our study was the use of a framework that sampled prevalent users (the continuing users of warfarin in this study) in a way that avoided selection bias facilitating the construction of a cohort of patients similar to the target trial population, which included both new users of apixaban and warfarin (VKA-na√Øve) and patients with prior VKA exposure (VKA-experienced) that were randomised to stay on warfarin or switch to apixaban. The use of PSM, stratified by treatment history, enabled us to select a matched cohort well balanced on important covariates. The successful emulation of ARISTOTLE by our study shows that valid treatment effects can be obtained for important outcomes with OACs using noninterventional methods with routinely collected clinical data. Having validated this framework, in future studies, we can look at the effectiveness of OACs in AF patient groups not included or underrepresented in the RCT, such as elderly patients and those at increased bleeding risk. We also recommend future analyses with an extended follow-up period compared with this study to compare the long-term outcomes seen in the noninterventional cohort with projected long-term outcomes from the RCT.

An additional strength of our study was the ability to explore the quality of warfarin treatment in our cohort and the impact of INR control on the treatment effect estimates. Our finding that the benefits of apixaban versus warfarin for some outcomes depended on the quality of INR control in the warfarin arm answers questions raised in the NICE premeeting briefing, which looked at apixaban in the NVAF population and noted the TTR seen in ARISTOTLE ‚Äúmay be lower than what is typical in UK clinical practice‚Äù and ‚Äúapixaban compared with well-controlled warfarin (TTR 75% or more) may not be superior in the long term‚Äù \[[8](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref008)\]. ARISTOTLE presented outcomes by centre (for example, hospital) TTR quartile and did not show a signal of treatment efficacy differing by centre TTR quartile. We were able to use IPTW to estimate the treatment effect in the different warfarin TTR groups and used predicted TTR for warfarin users missing TTR to attempt to limite the risk of selection bias.

While our study aimed to emulate ARISTOTLE using suitable methods, there were several limitations. Some of the criteria assessed for ARISTOTLE eligibility may not be well recorded in CPRD leading to a risk of misclassification. Furthermore, misclassification of ARISTOTLE eligibility criteria and baseline covariates could be differential by treatment in the VKA-experienced patients if criteria such as renal function are more likely to be checked before changing treatment. However, the most important risk factors for the primary outcome of stroke (the components of CHA2DS2\-VASc stroke risk score) are mostly well recorded in CPRD Aurum and HES.

Our cohort did not attempt to match the trial on the use of concomitant medications in order for our cohort to reflect typical UK prescribing. In ARISTOTLE, 31% of participants were using aspirin and 11% using amiodarone at baseline, whereas in our cohort, only 6% were recorded as using aspirin and 4% amiodarone. Amiodarone potentiates the effects of warfarin, and concomitant use of amiodarone with DOACs is associated with increased risk of major bleeding \[[36](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref036)\], while concomitant use of aspirin increases the risk of bleeding for both warfarin \[[37](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref037)\] and DOACs \[[38](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref038)\]. The difference in concomitant medication usage between our cohort and the trial population may explain some of the observed differences in treatment effects.

A key limitation of our study was the inability to match ARISOTLE on ethnicity, meaning the CPRD Aurum cohort included a low number of patients from Asian and Hispanic groups when compared with the RCT (14.5% of participants in ARISTOTLE were Asian compared to 2.4% in our ARISTOTLE-analogous CPRD cohort). There are known racial differences in the treatment effects of OACs with Asian patients experiencing a higher risk of haemorrhagic stroke and intracranial haemorrhage compared with white patients; in ARISTOTLE, Asian participants experienced double the risk of stroke or SE when on warfarin therapy when compared with white participants \[[39](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref039)\]. The reasons for the increased risk of bleeding associated with warfarin therapy in Asian patients is hypothesised to be associated with differences in drug metabolism and prevelance of cerebral microbleeds \[[40](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref040)\]. The difference in proportion of Asian patients between our cohort and ARISTOTLE is therefore likely to explain some of the differences in treatment effects seen and limits the generalisability of our study, with the results of our study of most relevanance to white patients. This limitation on ethnicity arose from the data source used and time period studied (patients with AF in CPRD Aurum 2013‚Äì2019), which had a low proportion of Asian patients, likely due to AF being associated with older age combined with a lower prevalence of AF in Asian patients compared with white patients \[[41](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref041)\]. While CPRD Aurum is largely representative of the UK population in relation to ethnicity \[[42](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref042)\], diversity is still limited for older individuals. Despite this, CPRD Aurum has shown to be a useful resource for investigating treatment effects in different ethnic groups for indications such as hypertension, which is more prevalent and occurs at a younger age in ethnic minority groups, with similar trial replication methods used to compare antihypertensive treatment effects in underrepresented ethnic groups \[[13](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref013)\].

The approach our study used for handling missing data on baseline covariates relied on assumptions on the relationship between missingness, treatment, and outcomes, which may not be valid; however, the low proportion of missing data means that this is unlikely to have impacted the results. In the coarsened exact matching step, the choice of variables will have an impact on the resulting cohort selected, meaning a different combination of variables could lead to different results. There is a risk that residual confounding may be present despite the use of PSM. The use of PSM also has the potential to introduce bias by dropping patients from the cohort \[[19](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref019)\]; however, PSM is well suited to the process of trial emulation including prevalent users, and a low number of apixaban users were dropped due to unsuccessful matching. The inclusion of prevalent users of warfarin in the cohort risks the introduction of selection bias \[[20](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref020),[21](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref021)\]; this was avoided by use of a method shown to produce unbiased estimates in a simulation study \[[21](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref021)\]. We found consistent results between our new and prevalent user strata across multiple outcomes providing reassurance the method used was likely to have successfully avoided selection bias.

Apixaban along with other DOACs were rapidly adopted as preferred first-line OAC in AF during the study period; it was therefore not possible to match on calendar date leading to a difference in follow-up time between the treatment arms in our cohort. A higher proportion of warfarin users switched to alternative OAC during follow-up compared with those prescribed apixaban (16% versus 6%). The impact of this differential switching during follow-up was addressed in the sensitivity analyses. The availability of new alternative treatments during the study period also means there is a risk of channelling bias in that over time the patients still on warfarin are more likely to be those doing well on warfarin. INR control prior to the index date was not included in the PS for the prevalent users due to a high rate of missing data; however, other variables associated with poor INR control were included in the models, and an exploratory post hoc analysis including a variable for poor INR control gave results consistent with the primary results.

Adherence to treatment was difficult to assess in our study due to automatic repeat prescriptions; treatment persistence was more useful in providing a measure of pattern of medicine use over time. In the analysis by TTR, the adherence of patients using apixaban was not accounted for; however, a previous UK study showed apixaban had higher adherence than VKAs \[[43](http://dx.doi.org/10.1371/journal.pmed.1004377#pmed.1004377.ref043)\], meaning we would expect to see better effectiveness outcomes in apixaban. Futhermore, the use of IPTW in the analysis by TTR means predictors of poor adherence are likely to have been balanced between treatments. The analysis of TTR is limited by this being a post-baseline measure available for only 1 treatment arm leading to a risk of selection bias in this analysis‚Äîpatients with TTR available in the study may be more healthy than those without this measure given that patients have to survive and not be hospitalised to have INR measurements available in CPRD Aurum. The limitation of use of a post-baseline measurement available for 1 treatment arm was also evident in the RCTs of DOACs versus warfarin and is mitigated in our study through the use of IPTW and predicted TTR for patients that were missing TTR (using a model to predict TTR that used INR measurements restricted to the first year of follow-up). Given the risk of selection bias in the analysis by TTR and risk of misclassification of TTR for those missing TTR, these results should be considered exploratory and interpreted with caution. Sensitivity analyses in our cohort using an on-treatment censoring scheme showed evidence of attrition bias. The regular measurement of INR and availability of alternative anticoagulants makes warfarin therapy particularly prone to attrition bias since a patient may be more likely to switch to a DOAC if their INR is frequently out of the optimal range or if they have not been adhering to scheduled INR testing.

To conclude, we found that applying a reference trial emulation approach allowed us to emulate a landmark randomised trial of apixaban versus warfarin using UK noninterventional data, with results meeting prespecified benchmarking criteria based on the reference trial results. This trial emulation method provides valid treatment effect estimates for apixaban compared to warfarin and can be used to determine risks and benefits of AF medications in people treated in routine clinical care. This study demonstrates a successful real-world application of novel methods that have been proposed for the inclusion of prevalent users in observational studies, with the application of an adaptation to mimic the screening process making the method suitable for emulation of RCTs that include prevalent users. These methods could be adapted for emulation of RCTs in other therapeutic areas and for looking at patient groups underrepresented or excluded from RCTs.

The weaker overall treatment benefit observed in our cohort appears to be due to a higher proportion of patients with well-controlled warfarin in the UK clinical context, compared with the trial. Our exploratory analysis by TTR showed similar results for stroke and a greater benefit for apixaban for major bleeding compared with TTR <0.75; conversely, a slightly higher risk of death was observed on apixaban compared with well-controlled warfarin.

Disclaimer
----------

The views expressed in this paper are those of the author and not do not necessarily reflect those of the SFDA or its stakeholders. Guaranteeing the accuracy and the validity of the data is a sole responsibility of the research team.

Supporting information
----------------------

### [S1 Appendix.](https://journals.plos.org/plosmedicine/article/file?type=supplementary&id=10.1371/journal.pmed.1004377.s003) Containing supporting information.

Table A1. ARISTOTLE inclusion and exclusion criteria applied to CPRD Aurum. Table A2. Efficacy outcomes results from ARISTOTLE. Table A3. Effectiveness outcomes results in the CPRD Aurum ARISTOTLE-analogous cohort. Table A4. Bleeding outcomes and net clinical outcomes results from ARISTOTLE RCT. Table A5. Bleeding outcomes and net clinical outcomes results in the CPRD Aurum ARISTOTLE-analogous cohort. Table A6. Effectiveness outcomes results in the CPRD Aurum ARISTOTLE-analogous cohort using the on-treatment censoring scheme. Table A7. Treatment status of apixaban and warfarin users in CPRD Aurum ARISTOTLE-analogous cohort during 2.5 years of follow-up. Table A8. Characteristics of apixaban and warfarin users in CPRD Aurum ARISTOTLE-analogous cohort by treatment persistence during 2.5 years of follow-up. Table A9. Effectiveness outcomes results in the CPRD Aurum ARISTOTLE-analogous cohort using later study start date (1 January 2014). Table A10. Summary of noninterventional studies comparing apixaban and warfarin in AF patients.

[https://doi.org/10.1371/journal.pmed.1004377.s003](https://doi.org/10.1371/journal.pmed.1004377.s003)

(DOCX)

References
----------

1.  1\. Adderley NJ, Ryan R, Nirantharakumar K, Marshall T. Prevalence and treatment of atrial fibrillation in UK general practice from 2000 to 2016. Heart. 2019;105(1):27‚Äì33. pmid:29991504
    *   [View Article](https://doi.org/10.1136/heartjnl-2018-312977 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/29991504 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Prevalence+and+treatment+of+atrial+fibrillation+in+UK+general+practice+from+2000+to+2016+Adderley+2019 ""Go to article in Google Scholar"")
2.  2\. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983‚Äì988. pmid:1866765
    *   [View Article](https://doi.org/10.1161/01.str.22.8.983 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/1866765 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Atrial+fibrillation+as+an+independent+risk+factor+for+stroke%3A+the+Framingham+Study+Wolf+1991 ""Go to article in Google Scholar"")
3.  3\. Friberg L, Rosenqvist M, Lindgren A, Ter√©nt A, Norrving B, Asplund K. High prevalence of atrial fibrillation among patients with ischemic stroke.Stroke. 2014;45(9):2599‚Äì2605. pmid:25034713
    *   [View Article](https://doi.org/10.1161/STROKEAHA.114.006070 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/25034713 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=High+prevalence+of+atrial+fibrillation+among+patients+with+ischemic+stroke+Friberg+2014 ""Go to article in Google Scholar"")
4.  4\. Ali AN, Abdelhafiz A. Clinical and Economic Implications of AF Related Stroke. J Atr Fibrillation. 2016;8(5):1279. pmid:27909470
    *   [View Article](https://doi.org/10.4022/jafib.1279 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/27909470 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Clinical+and+Economic+Implications+of+AF+Related+Stroke+Ali+2016 ""Go to article in Google Scholar"")
5.  5\. Andrew NE, Thrift AG, Cadilhac DA. The prevalence, impact and economic implications of atrial fibrillation in stroke: what progress has been made? Neuroepidemiology. 2013;40(4):227‚Äì39. pmid:23364221
    *   [View Article](https://doi.org/10.1159/000343667 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/23364221 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=The+prevalence%2C+impact+and+economic+implications+of+atrial+fibrillation+in+stroke%3A+what+progress+has+been+made%3F+Andrew+2013 ""Go to article in Google Scholar"")
6.  6\. Apostolakis S, Sullivan RM, Olshansky B, Lip GYH. 053 Factors affecting quality of warfarin anticoagulation in patients with atrial fibrillation: insights from affirm. Heart. 2012;98:A32.
    *   [View Article](https://doi.org/10.1136/heartjnl-2012-301877b.53 ""Go to article"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=053+Factors+affecting+quality+of+warfarin+anticoagulation+in+patients+with+atrial+fibrillation%3A+insights+from+affirm+Apostolakis+2012 ""Go to article in Google Scholar"")
7.  7\. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981‚Äì92. pmid:21870978
    *   [View Article](https://doi.org/10.1056/NEJMoa1107039 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/21870978 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Apixaban+versus+warfarin+in+patients+with+atrial+fibrillation+Granger+2011 ""Go to article in Google Scholar"")
8.  8\. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) Assessment report Eliquis apixaban. Procedure No.:EMEA/H/C/002148/X/04/G. EMA/641505/2012, 2012, page 35. Available from: [https://www.ema.europa.eu/en/documents/variation-report/eliquis-h-c-2148-x-0004-g-epar-assessment-report-extension\_en.pdf](https://www.ema.europa.eu/en/documents/variation-report/eliquis-h-c-2148-x-0004-g-epar-assessment-report-extension_en.pdf)
    
9.  9\. National Institute for Health and Clinical Excellence. Premeeting briefing. Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation. Issue date: November 2012. Available from: [https://www.nice.org.uk/guidance/ta275/documents/stroke-and-systemic-embolism-prevention-nonvalvular-atrial-fibrillation-apixaban-premeeting-briefing2](https://www.nice.org.uk/guidance/ta275/documents/stroke-and-systemic-embolism-prevention-nonvalvular-atrial-fibrillation-apixaban-premeeting-briefing2)
    
10.  10\. Franklin JM, Patorno E, Desai RJ, Glynn RJ, Martin D, Quinto K, et al. Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative. Circulation. 2021;143(10):1002‚Äì1013. Epub 2020 Dec 17. pmid:33327727
    *   [View Article](https://doi.org/10.1161/CIRCULATIONAHA.120.051718 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/33327727 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Emulating+Randomized+Clinical+Trials+With+Nonrandomized+Real-World+Evidence+Studies%3A+First+Results+From+the+RCT+DUPLICATE+Initiative+Franklin+2021 ""Go to article in Google Scholar"")
11.  11\. Wing K, Williamson E, Carpenter JR, Wise L, Schneeweiss S, Smeeth L, et al. Real world effects of COPD medications: a cohort study with validation against results from randomised controlled trials. Eur Respir J. 2021 Mar 25;57(3):2001586. pmid:33093119
    *   [View Article](https://doi.org/10.1183/13993003.01586-2020 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/33093119 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Real+world+effects+of+COPD+medications%3A+a+cohort+study+with+validation+against+results+from+randomised+controlled+trials+Wing+2021 ""Go to article in Google Scholar"")
12.  12\. Dahabreh IJ, Robins JM, Hern√°n MA. Benchmarking Observational Methods by Comparing Randomized Trials and Their Emulations. Epidemiology. 2020;31(5):614‚Äì619. pmid:32740470
    *   [View Article](https://doi.org/10.1097/EDE.0000000000001231 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/32740470 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Benchmarking+Observational+Methods+by+Comparing+Randomized+Trials+and+Their+Emulations+Dahabreh+2020 ""Go to article in Google Scholar"")
13.  13\. Baptiste PJ, Wong AYS, Schultze A, Clase CM, Leyrat C, Williamson E, et al. Comparative effectiveness of ARB and ACEi for cardiovascular outcomes and risk of angioedema among different ethnic groups in England: an analysis in the UK Clinical Practice Research Datalink with emulation of a reference trial (ONTARGET). medRxiv \[Preprint\]. 2024. [https://doi.org/10.1101/2024.01.17.24301397](https://doi.org/10.1101/2024.01.17.24301397)
    
14.  14\. Powell EM, Douglas IJ, Gungabissoon U, Smeeth L, Wing K. Real-world effects of medications for stroke prevention in atrial fibrillation: protocol for a UK population-based non-interventional cohort study with validation against randomized trial results. BMJ Open. 2021;11:e042947.
    *   [View Article](https://doi.org/10.1136/bmjopen-2020-04294 ""Go to article"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Real-world+effects+of+medications+for+stroke+prevention+in+atrial+fibrillation%3A+protocol+for+a+UK+population-based+non-interventional+cohort+study+with+validation+against+randomized+trial+results+Powell+2021 ""Go to article in Google Scholar"")
15.  15\. Wolf A, Dedman D, Campbell J, Booth H, Lunn D, Chapman J, et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. Int J Epidemiol. 2019;48(6):1740‚Äì1740g. pmid:30859197
    *   [View Article](https://doi.org/10.1093/ije/dyz034 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/30859197 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Data+resource+profile%3A+Clinical+Practice+Research+Datalink+%28CPRD%29+Aurum+Wolf+2019 ""Go to article in Google Scholar"")
16.  16\. Rose M, Beasley N. Center for Drug Evaluation and Research Application number: 202155Orig1s000 MEDICAL REVIEW(S). Available from: [https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2012/202155Orig1s000TOC.cfm](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000TOC.cfm)
    
17.  17\. Vinereanu D, Stevens SR, Alexander JH, Al-Khatib SM, Avezum A, Bahit MC, et al. Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. Eur Heart J. 2015;36(46):3268‚Äì3275. pmid:26371113
    *   [View Article](https://doi.org/10.1093/eurheartj/ehv447 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/26371113 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Clinical+outcomes+in+patients+with+atrial+fibrillation+according+to+sex+during+anticoagulation+with+apixaban+or+warfarin%3A+a+secondary+analysis+of+a+randomized+controlled+trial+Vinereanu+2015 ""Go to article in Google Scholar"")
18.  18\. Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014;35(28):1864‚Äì1872. pmid:24561548
    *   [View Article](https://doi.org/10.1093/eurheartj/ehu046 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/24561548 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Efficacy+and+safety+of+apixaban+compared+with+warfarin+according+to+age+for+stroke+prevention+in+atrial+fibrillation%3A+observations+from+the+ARISTOTLE+trial+Halvorsen+2014 ""Go to article in Google Scholar"")
19.  19\. Iacus SM, King G, Porro G. Causal Inference without Balance Checking: Coarsened Exact Matching Political Analysis. 2012;20(1):1‚Äì24.
    *   [View Article](https://doi.org/10.1093/pan/mpr013 ""Go to article"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Causal+Inference+without+Balance+Checking%3A+Coarsened+Exact+Matching+Political+Analysis+Iacus+2012 ""Go to article in Google Scholar"")
20.  20\. Suissa S, Moodie EE, Dell‚ÄôAniello S. Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores. Pharmacoepidemiol Drug Saf. 2017;26(4):459‚Äì468. pmid:27610604
    *   [View Article](https://doi.org/10.1002/pds.4107 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/27610604 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Prevalent+new-user+cohort+designs+for+comparative+drug+effect+studies+by+time-conditional+propensity+scores+Suissa+2017 ""Go to article in Google Scholar"")
21.  21\. Webster-Clark M, Mavros P, Garry EM, St√ºrmer T, Shmuel S, Young J, et al. Alternative analytic and matching approaches for the prevalent new-user design: A simulation study. Pharmacoepidemiol Drug Saf. 2022;31(7):796‚Äì803. pmid:35505471
    *   [View Article](https://doi.org/10.1002/pds.5446 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/35505471 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Alternative+analytic+and+matching+approaches+for+the+prevalent+new-user+design%3A+A+simulation+study+Webster-Clark+2022 ""Go to article in Google Scholar"")
22.  22\. Austin P.C. (2009), Some methods of propensity-score matching had superior performance to others: results of an empirical Investigation and Monte Carlo simulations. Biom J. 2009;51(1): 171‚Äì84. pmid:19197955
    *   [View Article](https://doi.org/10.1002/bimj.200810488 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/19197955 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Some+methods+of+propensity-score+matching+had+superior+performance+to+others%3A+results+of+an+empirical+Investigation+and+Monte+Carlo+simulations+Austin+2009 ""Go to article in Google Scholar"")
23.  23\. Woodfield R, Grant I, UK Biobank Stroke Outcomes Group, UK Biobank Follow-Up and Outcomes Working Group, Sudlow CL. Accuracy of Electronic Health Record Data for Identifying Stroke Cases in Large-Scale Epidemiological Studies: A Systematic Review from the UK Biobank Stroke Outcomes Group. PLoS ONE. 2015;10(10):e0140533. pmid:26496350
    *   [View Article](https://doi.org/10.1371/journal.pone.0140533 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/26496350 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Accuracy+of+Electronic+Health+Record+Data+for+Identifying+Stroke+Cases+in+Large-Scale+Epidemiological+Studies%3A+A+Systematic+Review+from+the+UK+Biobank+Stroke+Outcomes+Group+Woodfield+2015 ""Go to article in Google Scholar"")
24.  24\. Austin P.C, Small DS. The use of bootstrapping when using propensity-score matching without replacement: A simulation study. Stat Med. 2014;33(24):4306‚Äì4319. pmid:25087884
    *   [View Article](https://doi.org/10.1002/sim.6276 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/25087884 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=The+use+of+bootstrapping+when+using+propensity-score+matching+without+replacement%3A+A+simulation+study+Austin+2014 ""Go to article in Google Scholar"")
25.  25\. Abadie A., Spiess J. Robust Post-Matching Inference. J Am Stat Assoc, 2022;117(538)983‚Äì995.
    *   [View Article](https://doi.org/10.1080/01621459.2020.1840383 ""Go to article"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Robust+Post-Matching+Inference+Abadie+2022 ""Go to article in Google Scholar"")
26.  26\. Lobo FS, Wagner S, Gross CR, Schommer JC. Addressing the issue of channeling bias in observational studies with propensity scores analysis. Res SocialAdm Pharm. 2006;2(1):143‚Äì151. pmid:17138506
    *   [View Article](https://doi.org/10.1016/j.sapharm.2005.12.001 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/17138506 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Addressing+the+issue+of+channeling+bias+in+observational+studies+with+propensity+scores+analysis+Lobo+2006 ""Go to article in Google Scholar"")
27.  27\. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41‚Äì55.
    *   [View Article](https://doi.org/10.1093/biomet/70.1.41 ""Go to article"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=The+central+role+of+the+propensity+score+in+observational+studies+for+causal+effects+Rosenbaum+1983 ""Go to article in Google Scholar"")
28.  28\. Blake HA, Leyrat C, Mansfield KE, Seaman S, Tomlinson LA, Carpenter J, et al. Propensity scores using missingness pattern information: a practical guide. Stat Med. 2020;39(11):1641‚Äì1657. pmid:32103533
    *   [View Article](https://doi.org/10.1002/sim.8503 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/32103533 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Propensity+scores+using+missingness+pattern+information%3A+a+practical+guide+Blake+2020 ""Go to article in Google Scholar"")
29.  29\. Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018;362:k2505 Erratum in: BMJ. 2018 Oct 18;363:k4413. pmid:29973392
    *   [View Article](https://doi.org/10.1136/bmj.k2505 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/29973392 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Risks+and+benefits+of+direct+oral+anticoagulants+versus+warfarin+in+a+real+world+setting%3A+cohort+study+in+primary+care+Vinogradova+2018 ""Go to article in Google Scholar"")
30.  30\. Larsen TB, Skj√∏th F, Nielsen PB, Kj√¶ldgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;16(353):i3189. pmid:27312796
    *   [View Article](https://doi.org/10.1136/bmj.i3189 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/27312796 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Comparative+effectiveness+and+safety+of+non-vitamin+K+antagonist+oral+anticoagulants+and+warfarin+in+patients+with+atrial+fibrillation%3A+propensity+weighted+nationwide+cohort+study+Larsen+2016 ""Go to article in Google Scholar"")
31.  31\. Li XS, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K, et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in ‚Äúreal-world‚Äù clinical practice. A propensity-matched analysis of 76,940 patients. Thromb Haemost. 2017;117(6):1072‚Äì1082. pmid:28300870
    *   [View Article](https://doi.org/10.1160/TH17-01-0068 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/28300870 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Effectiveness+and+safety+of+apixaban+versus+warfarin+in+non-valvular+atrial+fibrillation+patients+in+%E2%80%9Creal-world%E2%80%9D+clinical+practice.+A+propensity-matched+analysis+of+76%2C940+patients+Li+2017 ""Go to article in Google Scholar"")
32.  32\. Proietti M, Romanazzi I, Romiti GF, Farcomeni A, Lip GYH. Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis. Stroke. 2018;49(1):98‚Äì106. pmid:29167388
    *   [View Article](https://doi.org/10.1161/STROKEAHA.117.018395 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/29167388 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Real-World+Use+of+Apixaban+for+Stroke+Prevention+in+Atrial+Fibrillation%3A+A+Systematic+Review+and+Meta-Analysis+Proietti+2018 ""Go to article in Google Scholar"")
33.  33\. Franklin J, Brigham and Women‚Äôs Hospital. Replication of the ARISTOTLE Anticoagulant Trial in Healthcare Claims Data. Available from: [https://www.clinicaltrials.gov/ct2/show/NCT04593030](https://www.clinicaltrials.gov/ct2/show/NCT04593030)
    
34.  34\. Wang SV, Schneeweiss S, RCT-DUPLICATE initiative, Franklin JM, Desai RJ, Feldman W, et al. Emulation of Randomized Clinical Trials With Nonrandomized Databse Analyses: Results of 32 Clinical Trials. JAMA. 2023;329(16):1376‚Äì1385. pmid:37097356
    *   [View Article](https://doi.org/10.1001/jama.2023.4221 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/37097356 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Emulation+of+Randomized+Clinical+Trials+With+Nonrandomized+Databse+Analyses%3A+Results+of+32+Clinical+Trials+Wang+2023 ""Go to article in Google Scholar"")
35.  35\. Pokorney SD, Simon DN, Thomas L, Fonarow GC, Kowey PR, Chang P, et al. Patients‚Äô time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. Am Heart J. 2015;170(1):141‚Äì148.e1. pmid:26093875
    *   [View Article](https://doi.org/10.1016/j.ahj.2015.03.017 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/26093875 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Patients%E2%80%99+time+in+therapeutic+range+on+warfarin+among+US+patients+with+atrial+fibrillation%3A+Results+from+ORBIT-AF+registry+Pokorney+2015 ""Go to article in Google Scholar"")
36.  36\. Chang SH, Chou IJ, Yeh YH, Chiou MJ, Wen MS, Kuo CT, et al. Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation. JAMA. 2017;318(13):1250‚Äì1259. pmid:28973247
    *   [View Article](https://doi.org/10.1001/jama.2017.13883 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/28973247 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Association+Between+Use+of+Non-Vitamin+K+Oral+Anticoagulants+With+and+Without+Concurrent+Medications+and+Risk+of+Major+Bleeding+in+Nonvalvular+Atrial+Fibrillation+Chang+2017 ""Go to article in Google Scholar"")
37.  37\. Schaefer JK, Li Y, Gu X, Souphis NM, Haymart B, Kline-Rogers E, et al. Association of Adding Aspirin to Warfarin Therapy Without an Apparent Indication With Bleeding and Other Adverse Events. JAMA Intern Med. 2019;179(4):533‚Äì541. pmid:30830172
    *   [View Article](https://doi.org/10.1001/jamainternmed.2018.7816 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/30830172 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Association+of+Adding+Aspirin+to+Warfarin+Therapy+Without+an+Apparent+Indication+With+Bleeding+and+Other+Adverse+Events+Schaefer+2019 ""Go to article in Google Scholar"")
38.  38\. Almas T, Musheer A, Ejaz A, Shaikh FN, Paracha AA, Raza F, et al. Efficacy and safety of direct oral anticoagulants with and without Aspirin: A systematic review and Meta-analysis. Int J Cardiol Heart Vasc. 2022;40:101016. pmid:35355928
    *   [View Article](https://doi.org/10.1016/j.ijcha.2022.101016 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/35355928 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Efficacy+and+safety+of+direct+oral+anticoagulants+with+and+without+Aspirin%3A+A+systematic+review+and+Meta-analysis+Almas+2022 ""Go to article in Google Scholar"")
39.  39\. Sabir I, Khavandi K, Brownrigg J, Camm AJ. Oral anticoagulants for Asian patients with atrial fibrillation. Nat Rev Cardiol. 2014;11(5):290‚Äì303. pmid:24614113
    *   [View Article](https://doi.org/10.1038/nrcardio.2014.22 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/24614113 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Oral+anticoagulants+for+Asian+patients+with+atrial+fibrillation+Sabir+2014 ""Go to article in Google Scholar"")
40.  40\. Kim HK, Tantry US, Smith SC Jr, Jeong MH, Park S-J, Kim MH, et al. The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. Thromb Haemost. 2021;121(4):422‚Äì432. pmid:33171520
    *   [View Article](https://doi.org/10.1055/s-0040-1718729 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/33171520 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=The+East+Asian+Paradox%3A+An+Updated+Position+Statement+on+the+Challenges+to+the+Current+Antithrombotic+Strategy+in+Patients+with+Cardiovascular+Disease+Kim+2021 ""Go to article in Google Scholar"")
41.  41\. Gillott RG, Willan K, Kain K, Sivananthan UM, Tayebjee MH. South Asian ethnicity is associated with a lower prevalence of atrial fibrillation despite greater prevalence of established risk factors: a population-based study in Bradford Metropolitan District. Europace. 2017;19(3):356‚Äì363. pmid:26941337
    *   [View Article](https://doi.org/10.1093/europace/euw010 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/26941337 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=South+Asian+ethnicity+is+associated+with+a+lower+prevalence+of+atrial+fibrillation+despite+greater+prevalence+of+established+risk+factors%3A+a+population-based+study+in+Bradford+Metropolitan+District+Gillott+2017 ""Go to article in Google Scholar"")
42.  42\. Shiekh SI, Harley M, Ghosh RE, Ashworth M, Myles P, Booth HP, et al. Completeness, agreement, and representativeness of ethnicity recording in the United Kingdom‚Äôs Clinical Practice Research Datalink (CPRD) and linked Hospital Episode Statistics (HES). Popul Health Metr. 2023;21:3. pmid:36918866
    *   [View Article](https://doi.org/10.1186/s12963-023-00302-0 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/36918866 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Completeness%2C+agreement%2C+and+representativeness+of+ethnicity+recording+in+the+United+Kingdom%E2%80%99s+Clinical+Practice+Research+Datalink+%28CPRD%29+and+linked+Hospital+Episode+Statistics+%28HES%29+Shiekh+2023 ""Go to article in Google Scholar"")
43.  43\. Banerjee A, Benedetto V, Gichuru P, Burnell J, Antoniou S, Schilling RJ, et al. Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study. Heart. 2020;106(2):119‚Äì126. pmid:31601729
    *   [View Article](https://doi.org/10.1136/heartjnl-2019-315307 ""Go to article"")
    *   [PubMed/NCBI](http://www.ncbi.nlm.nih.gov/pubmed/31601729 ""Go to article in PubMed"")
    *   [Google Scholar](http://scholar.google.com/scholar?q=Adherence+and+persistence+to+direct+oral+anticoagulants+in+atrial+fibrillation%3A+a+population-based+study+Banerjee+2020 ""Go to article in Google Scholar"")
",gpt-4o-mini
2024-08-30 07:36:00,2024-08-31 03:42:05,"üö® **Breakthrough in Cardiac Surgery: Intravenous Amino Acids Reduce Acute Kidney Injury!** üö®  
A recent multinational, double-blind trial published in the *New England Journal of Medicine* has revealed that intravenous amino acids significantly lower the risk of acute kidney injury (AKI) in patients undergoing cardiac surgery with cardiopulmonary bypass. The study involved over 3,500 patients, showing a reduction in AKI occurrences from 31.7% in the placebo group to 26.9% in the amino acid group (P=0.002). This is a substantial finding for cardiac surgeons and anesthesiologists aiming to enhance patient outcomes in high-risk surgical environments.  
Dive deeper into the study for more insights on methodology and results! Read the full article [here](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769).  
üë©‚Äç‚öïÔ∏èüë®‚Äç‚öïÔ∏è **Have you used amino acids in your practice? Share your experience below!**  
#KidneyHealth #CardiacSurgery #AminoAcids #MedicalResearch #ACG #NEJM",https://medsii.azureedge.net/images/638606002082997176-66d17521ac48c5e342a26033.jpg,https://www.nejm.org/doi/full/10.1056/NEJMoa2403769,"You are a content creator tasked with crafting highly informative social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Thumbnail image URL: https://medsii.azureedge.net/images/638606002082997176-66d17521ac48c5e342a26033.jpg  
Title: A Randomized Trial of Intravenous Amino Acids for Kidney Protection

URL Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2403769

Markdown Content:
A Randomized Trial of Intravenous Amino Acids for Kidney Protection | New England Journal of Medicine
===============                 

[Skip to main content](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769#mainContent)

[![Image 1: The New England Journal of Medicine homepage](https://www.nejm.org/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg)](https://www.nejm.org/ ""The New England Journal of Medicine homepage"")

[![Image 2: Device Global Header](https://www.nejm.org/pb-assets/contextual_messaging/device-glbal-header-2x-1515103614157.png)](https://www.nejm.org/action/clickThrough?id=125703&url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2403769%26promo%3DONFQNRH5&loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2403769&pubId=41296434&placeholderId=101351&productId=1058)

[Subscribe or Renew](https://www.nejm.org/action/clickThrough?id=125703&url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26promo%3DONFQNRH5&loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2403769&pubId=41296434&placeholderId=101351&productId=1058)[](https://www.nejm.org/action/clickThrough?id=125703&url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2403769%26promo%3DONFQNRH5&loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2403769&pubId=41296434&placeholderId=101351&productId=1058)

[Advanced Search](https://www.nejm.org/search/advanced)SEARCH

[![Image 3: The New England Journal of Medicine homepage](https://www.nejm.org/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg)](https://www.nejm.org/ ""The New England Journal of Medicine homepage"")

*   [SPECIALTIES](https://www.nejm.org/medical-specialties)
    
    *   [Cardiology](https://www.nejm.org/browse/specialty/cardiology)
    *   [Clinical Medicine](https://www.nejm.org/browse/specialty/clinical-medicine)
    *   [Emergency Medicine](https://www.nejm.org/browse/specialty/emergency-medicine)
    *   [Endocrinology](https://www.nejm.org/browse/specialty/endocrinology)
    *   [Gastroenterology](https://www.nejm.org/browse/specialty/gastroenterology)
    *   [Hematology/Oncology](https://www.nejm.org/browse/specialty/hematology-oncology)
    *   [Infectious Disease](https://www.nejm.org/browse/specialty/infectious-disease)
    *   [Nephrology](https://www.nejm.org/browse/specialty/nephrology)
    *   [Neurology/Neurosurgery](https://www.nejm.org/browse/specialty/neurology-neurosurgery)
    *   [Obstetrics/Gynecology](https://www.nejm.org/browse/specialty/obstetrics-gynecology)
    *   [Pediatrics](https://www.nejm.org/browse/specialty/pediatrics)
    *   [Pulmonary/Critical Care](https://www.nejm.org/browse/specialty/pulmonary-critical-care)
    *   [View All Specialties](https://www.nejm.org/medical-specialties)
    
*   [TOPICS](https://www.nejm.org/topics)
    
    *   [AI in Medicine](https://www.nejm.org/ai-in-medicine)
    *   [Climate Crisis and Health](https://www.nejm.org/browse/specialty/climate-change)
    *   [Coronavirus](https://www.nejm.org/coronavirus)
    *   [Fundamentals of Health Law](https://www.nejm.org/fundamentals-of-health-law)
    *   [Fundamentals of Medical Ethics](https://www.nejm.org/fundamentals-of-medical-ethics)
    *   [Gray Matters](https://www.nejm.org/gray-matters)
    *   [Health Policy](https://www.nejm.org/browse/specialty/health-policy)
    *   [Medicine and Society](https://www.nejm.org/medicine-and-society)
    *   [Nutrition in Medicine](https://www.nejm.org/nutrition-in-medicine)
    *   [Race and Medicine](https://www.nejm.org/race-and-medicine)
    *   [Recognizing Historical Injustices and the Journal](https://www.nejm.org/recognizing-historical-injustices)
    *   [View All Topics](https://www.nejm.org/topics)
    
*   [MULTIMEDIA](https://www.nejm.org/multimedia)
    
    *   [Podcasts](https://www.nejm.org/rss-feed)
    *   [Double Takes](https://www.nejm.org/double-take)
    *   [Illustrated Glossary](https://illustrated-glossary.nejm.org/)
    *   [Image Challenge](https://www.nejm.org/image-challenge)
    *   [Images in Clinical Medicine](https://www.nejm.org/browse/nejm-media-type/images-in-clinical-medicine)
    *   [Interactive Medical Cases](https://www.nejm.org/browse/nejm-media-type/interactive-medical-case)
    *   [Plain Language/Research Summaries](https://www.nejm.org/plain-language-research-summaries)
    *   [Quick Takes](https://www.nejm.org/multimedia/quick-take-video)
    *   [Videos in Clinical Medicine](https://www.nejm.org/browse/nejm-media-type/videos-in-clinical-medicine)
    *   [View All Multimedia](https://www.nejm.org/multimedia)
    
*   [current issue](https://www.nejm.org/toc/nejm/current)
    
    *   [CURRENT ISSUE](https://www.nejm.org/toc/nejm/current)
    *   [BROWSE RECENTLY PUBLISHED](https://www.nejm.org/toc/nejm/recently-published)
    *   [BROWSE FULL ISSUE INDEX](https://www.nejm.org/loi/nejm)
    
*   [LEARNING/CME](https://www.nejm.org/learning)
    
    *   [Weekly CME](https://www.nejm.org/continuing-medical-education)
    *   [Obesity CME/CE](https://www.nejm.org/cme-ce/obesity)
    *   [VIEW ALL LEARNING/CME](https://www.nejm.org/learning)
    
*   [AUTHOR CENTER](https://www.nejm.org/author-center/home)
*   Publications
    
    *   [NEJM Catalyst](https://catalyst.nejm.org/)
    *   [NEJM Evidence](https://evidence.nejm.org/)
    *   [NEJM AI](https://ai.nejm.org/)
    *   [NEJM Journal Watch](https://www.jwatch.org/)
    

[Sign In](https://www.nejm.org/sign-in?uri=/doi/full/10.1056/NEJMoa2403769)|[Create Account](https://www.nejm.org/action/storeProxy?action=register&promo=ONFLNRC1)

[Subscribe](https://www.nejm.org/action/storeProxy?action=subscribe&promo=ONF4NRS1)

[![Image 4: Device Global Header](https://www.nejm.org/pb-assets/contextual_messaging/device-glbal-header-2x-1515103614157.png)](https://www.nejm.org/action/clickThrough?id=125703&url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2403769%26promo%3DONFQNRH5&loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2403769&pubId=41296434&placeholderId=101351&productId=1058)

[Subscribe or Renew](https://www.nejm.org/action/clickThrough?id=125703&url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26promo%3DONFQNRH5&loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2403769&pubId=41296434&placeholderId=101351&productId=1058)[](https://www.nejm.org/action/clickThrough?id=125703&url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2403769%26promo%3DONFQNRH5&loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2403769&pubId=41296434&placeholderId=101351&productId=1058)

**This content is available to subscribers.** [Subscribe now.](https://www.nejm.org/action/clickThrough?id=125857&url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2403769%26promo%3DONFLNRSE&loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2403769&pubId=41296434&placeholderId=101349&productId=1035) Already have an account? [Sign in.](https://www.nejm.org/action/clickThrough?id=125857&url=%2Fsign-in%3Furi%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2403769&loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2403769&pubId=41296434&placeholderId=101349&productId=1035)

Save

##### Create an E-mail Alert for This Article

[Original Article](https://www.nejm.org/browse/nejm-article-type/original-article)

Share on

*   
*   
*   
*   

A Randomized Trial of Intravenous Amino Acids for Kidney Protection
===================================================================

Authors: Giovanni Landoni, M.D., Fabrizio Monaco, M.D., Lian Kah Ti, M.B., B.S., M.Med., Martina Baiardo Redaelli, M.D., Nikola Bradic, M.D., Marco Comis, M.D., Yuki Kotani, M.D. [https://orcid.org/0000-0002-9532-2859](https://orcid.org/0000-0002-9532-2859), +41 , Claudio Brambillasca, M.D., Eugenio Garofalo, M.D., Anna Mara Scandroglio, M.D., Cristina Viscido, M.D., Gianluca Paternoster, M.D., Ph.D., Annalisa Franco, M.D., Sabrina Porta, M.D., Federica Ferrod, M.D., Maria Grazia Calabr√≤, M.D., Antonio Pisano, M.D., Igor Vendramin, M.D., Gaia Barucco, M.D., Francesco Federici, M.D., Luca Severi, M.D., Alessandro Belletti, M.D., Andrea Cortegiani, M.D., Andrea Bruni, M.D., Carola Galbiati, P.T., M.Sc., Angelo Covino, M.D., Ekaterina Baryshnikova, Ph.D., Giuseppe Giardina, R.N., M.Sc., Maria Venditto, M.D., Daniel Kroeller, M.D., Cristina Nakhnoukh, M.Sc., Lorenzo Mantovani, M.D., Simona Silvetti, M.D., Margherita Licheri, M.D., Fabio Guarracino, M.D., Rosetta Lobreglio, M.D., Ambra Licia Di Prima, M.D., Stefano Fresilli, M.D., Rosa Labanca, M.D., Marta Mucchetti, M.D., Rosalba Lembo, M.Sc., Rosario Losiggio, M.S., Tiziana Bove, M.D., Marco Ranucci, M.D., Evgeny Fominskiy, M.D., Federico Longhini, M.D., Alberto Zangrillo, M.D., and Rinaldo Bellomo, M.D., for the PROTECTION Study Group[\*](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769#fn1) \-41[Author Info & Affiliations](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769#tab-contributors)

Published June 12, 2024

N Engl J Med 2024;391:687\-698

DOI: 10.1056/NEJMoa2403769

[VOL. 391 NO. 8](https://www.nejm.org/toc/nejm/391/8)

[](https://www.nejm.org/servlet/linkout?type=rightslink&url=publisherName%3Dmassmed%26author%3DGiovanni%2BLandoni%252C%2BFabrizio%2BMonaco%252C%2BLian%2BKah%2BTi%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D391%26issueNum%3D8%26contentID%3D10.1056%252FNEJMoa2403769%26title%3DA%2BRandomized%2BTrial%2Bof%2BIntravenous%2BAmino%2BAcids%2Bfor%2BKidney%2BProtection%26publicationDate%3D08%252F22%252F2024 ""Permissions"")[](https://www.nejm.org/about/reprints ""Reprints"")[](https://www.nejm.org/author-center/letters-to-the-editor ""Submit a Letter"")

##### Permissions

For permission requests, please contact NEJM Reprints at [reprints@nejm.org](mailto:reprints@nejm.org)

[](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769#tab-citations ""View Citations"")

[](https://cme.nejm.org/weekly/10.1056/NEJMcme2403769 ""View CME"")

*   Contents
    
    *   [Abstract](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769#summary-abstract)
    *   [Notes](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769#backnotes)
    *   [Supplementary Material](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769#supplementary-materials)
    
*   *   [Information & Authors](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769#core-collateral-info)
    *   [Metrics & Citations](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769#core-collateral-metrics)
    *   [Get Access](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769#core-collateral-purchase-access)
    *   [References](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769#core-collateral-references)
    *   [Media](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769#core-collateral-media)
    *   [Tables](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769#core-collateral-tables)
    *   [Share](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769#core-collateral-share)
    

Abstract
--------

### Background

Acute kidney injury (AKI) is a serious and common complication of cardiac surgery, for which reduced kidney perfusion is a key contributing factor. Intravenous amino acids increase kidney perfusion and recruit renal functional reserve. However, the efficacy of amino acids in reducing the occurrence of AKI after cardiac surgery is uncertain.

### Methods

In a multinational, double-blind trial, we randomly assigned adult patients who were scheduled to undergo cardiac surgery with cardiopulmonary bypass to receive an intravenous infusion of either a balanced mixture of amino acids, at a dose of 2 g per kilogram of ideal body weight per day, or placebo (Ringer‚Äôs solution) for up to 3 days. The primary outcome was the occurrence of AKI, defined according to the Kidney Disease: Improving Global Outcomes creatinine criteria. Secondary outcomes included the severity of AKI, the use and duration of kidney-replacement therapy, and all-cause 30-day mortality.

![Image 5](https://www.nejm.org/cms/10.1056/NEJMoa2403769/asset/61261dcc-be4a-4e61-9129-f47ffcd2e9d1/assets/images/large/nejmoa2403769_f0.jpg)

Download a PDF of the [Plain Language Summary](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769#ap0).

### Results

We recruited 3511 patients at 22 centers in three countries and assigned 1759 patients to the amino acid group and 1752 to the placebo group. AKI occurred in 474 patients (26.9%) in the amino acid group and in 555 (31.7%) in the placebo group (relative risk, 0.85; 95% confidence interval \[CI\], 0.77 to 0.94; P=0.002). Stage 3 AKI occurred in 29 patients (1.6%) and 52 patients (3.0%), respectively (relative risk, 0.56; 95% CI, 0.35 to 0.87). Kidney-replacement therapy was used in 24 patients (1.4%) in the amino acid group and in 33 patients (1.9%) in the placebo group. There were no substantial differences between the two groups in other secondary outcomes or in adverse events.

### Conclusions

Among adult patients undergoing cardiac surgery, infusion of amino acids reduced the occurrence of AKI. (Funded by the Italian Ministry of Health; PROTECTION ClinicalTrials.gov number, [NCT03709264](http://clinicaltrials.gov/show/NCT03709264).)

[![Image 6](https://content.jwplatform.com/thumbs/5k196tyT-720.jpg)](https://www.nejm.org/do/10.1056/NEJMdo007583/full)

[Quick Take](https://www.nejm.org/browse/nejm-media-type/quick-take)

###### [Amino Acid Infusion and Kidney Protection](https://www.nejm.org/do/10.1056/NEJMdo007583/full)

2m 14s

Continue reading this article
-----------------------------

Select an option below:

### Create your account to get 2 free subscriber-only articles each month.

[Get Free Access Now](https://www.nejm.org/action/clickThrough?id=125840&url=%2Faction%2FstoreProxy%3Faction%3DregisterMeteredAccess%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2403769%26promo%3DONFGMM02&loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2403769&pubId=41296434&placeholderId=101345&productId=1035) [Subscribe For Full Access](https://www.nejm.org/action/clickThrough?id=125840&url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2403769%26promo%3DONFGRH78&loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2403769&pubId=41296434&placeholderId=101345&productId=1035)

### Already have an account?

[Sign In](https://www.nejm.org/action/clickThrough?id=125840&url=%2Fsign-in%3Furi%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2403769%26origReqDoi%3D10.1056%252FNEJMoa2403769&loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2403769&pubId=41296434&placeholderId=101345&productId=1035)

### Print subscriber?

[Activate your online access.](https://www.nejm.org/action/clickThrough?id=125840&url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2403769%26promo%3DONFGAMM1&loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2403769&pubId=41296434&placeholderId=101345&productId=1035)

Are you a member of an institution such as a university or hospital?  
[Learn more about Institutional Access](https://www.nejm.org/action/clickThrough?id=125840&url=%2Fabout-nejm%2Finstitutional-access&loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2403769&pubId=41296434&placeholderId=101345&productId=1035)

Notes
-----

This article was published on June 12, 2024, at NEJM.org.

A [data sharing statement](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769#ap4) provided by the authors is available with the full text of this article at NEJM.org.

Supported by a grant (RF-2016-02363260) from the Italian Ministry of Health.

[Disclosure forms](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769#ap3) provided by the authors are available with the full text of this article at NEJM.org.

We thank Sean Bagshaw, John Kellum, Ary Serpa Neto, and Paul Young for their thoughtful review of our manuscript before submission; and the physicians, nurses, and data managers of the trial sites. We express our heartfelt sorrow for the loss of our respected and valued colleague, Dr. Zdenko Povsic-Cevra, who was among the collaborators for this manuscript.

Supplementary Material
----------------------

Plain Language Summary (nejmoa2403769\_plain-language-summary.pdf)

*   Download
*   2.21 MB

Protocol (nejmoa2403769\_protocol.pdf)

*   Download
*   1.18 MB

Supplementary Appendix (nejmoa2403769\_appendix.pdf)

*   Download
*   2.09 MB

Disclosure Forms (nejmoa2403769\_disclosures.pdf)

*   [Download](https://www.nejm.org/doi/suppl/10.1056/NEJMoa2403769/suppl_file/nejmoa2403769_disclosures.pdf)
*   2.90 MB

Data Sharing Statement (nejmoa2403769\_data-sharing.pdf)

*   [Download](https://www.nejm.org/doi/suppl/10.1056/NEJMoa2403769/suppl_file/nejmoa2403769_data-sharing.pdf)
*   73.12 KB

Information & Authors
---------------------

### Information

#### Published In

New England Journal of Medicine

[Volume 391 ‚Ä¢ Number 8 ‚Ä¢ August 22, 2024](https://www.nejm.org/toc/nejm/391/8)

Pages: 687\-698

#### Copyright

Copyright ¬© 2024 Massachusetts Medical Society. All rights reserved.

#### Translation

Chinese Translation ‰∏≠ÊñáÁøªËØë

#### History

**Published online**: June 12, 2024

**Published in issue**: August 22, 2024

#### Topics

1.  [Acute Kidney Injury](https://www.nejm.org/browse/topic/acute-kidney-injury)

3.  [Cardiology General](https://www.nejm.org/browse/topic/cardiology-general)

5.  [Cardiovascular Surgery](https://www.nejm.org/browse/topic/cardiovascular-surgery)

7.  [Coronary Disease/Myocardial Infarction](https://www.nejm.org/browse/topic/coronary-disease-myocardial-infarction)

9.  [Critical Care](https://www.nejm.org/browse/topic/critical-care)

11.  [Hospital-Based Clinical Medicine](https://www.nejm.org/browse/topic/hospital-based-clinical-medicine)

13.  [Pulmonary/Critical Care General](https://www.nejm.org/browse/topic/pulmonary-critical-care-general)

### Authors

#### Authors

Giovanni Landoni, M.D., Fabrizio Monaco, M.D., Lian Kah Ti, M.B., B.S., M.Med., Martina Baiardo Redaelli, M.D., Nikola Bradic, M.D., Marco Comis, M.D., Yuki Kotani, M.D. [https://orcid.org/0000-0002-9532-2859](https://orcid.org/0000-0002-9532-2859), Claudio Brambillasca, M.D., Eugenio Garofalo, M.D., Anna Mara Scandroglio, M.D., Cristina Viscido, M.D., Gianluca Paternoster, M.D., Ph.D., Annalisa Franco, M.D., Sabrina Porta, M.D., Federica Ferrod, M.D., Maria Grazia Calabr√≤, M.D., Antonio Pisano, M.D., Igor Vendramin, M.D., Gaia Barucco, M.D., Francesco Federici, M.D., Luca Severi, M.D., Alessandro Belletti, M.D., Andrea Cortegiani, M.D., Andrea Bruni, M.D., Carola Galbiati, P.T., M.Sc., Angelo Covino, M.D., Ekaterina Baryshnikova, Ph.D., Giuseppe Giardina, R.N., M.Sc., Maria Venditto, M.D., Daniel Kroeller, M.D., Cristina Nakhnoukh, M.Sc., Lorenzo Mantovani, M.D., Simona Silvetti, M.D., Margherita Licheri, M.D., Fabio Guarracino, M.D., Rosetta Lobreglio, M.D., Ambra Licia Di Prima, M.D., Stefano Fresilli, M.D., Rosa Labanca, M.D., Marta Mucchetti, M.D., Rosalba Lembo, M.Sc., Rosario Losiggio, M.S., Tiziana Bove, M.D., Marco Ranucci, M.D., Evgeny Fominskiy, M.D., Federico Longhini, M.D., Alberto Zangrillo, M.D., and Rinaldo Bellomo, M.D., for the PROTECTION Study Group[\*](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769#fn1)

#### Affiliations

From the Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute (G.L., F.M., M.B.R., A.M.S., A.F., M.G.C., G.B., A. Belletti, C.G., G.G., C.N., M.L., A.L.D.P., S.F., R. Labanca, M.M., R. Lembo, R. Losiggio, E.F., A.Z.), Vita-Salute San Raffaele University (G.L., A.Z.), and Dipartimento di Chirurgia Cardiovascolare, Unit√† Operativa di Anestesia e Terapia Intensiva, IRCCS Centro Cadiologico Monzino (C.B.), Milan, S.C. Anestesia e Rianimazione Cardiovascolare, A.O. Ordine Mauriziano Umberto I di Torino, Turin (M.C., C.V., S.P., F. Ferrod), the Department of Medical and Surgical Sciences, University Hospital ‚ÄúR. Dulbecco,‚Äù Magna Graecia University, Catanzaro (E.G., A. Bruni, F.L.), Cardiovascular Anesthesia and ICU San Carlo Hospital, Potenza (G.P., A. Covino), Cardiac Anesthesia and ICU, AORN ‚ÄúDei Colli,‚Äù Monaldi Hospital, Naples (A.P., M.V.), the Department of Medicine, University of Udine (I.V., T.B.), the Division of Cardiac Surgery, Azienda Sanitaria Universitaria Friuli Centrale (I.V.), and the Department of Anesthesia and Intensive Care Medicine, ASUFC University-Hospital of Central Friuli (T.B.), Udine, UOC Anestesia e Rianimazione, Azienda Ospedaliero Universitaria Sant‚ÄôAndrea (F. Federici), and UO Complessa Anestesia e Rianimazione, Dipartimento Cardio-Toraco-Vascolare, Azienda Ospedaliera San Camillo Forlanini (L.S.), Rome, the Department of Precision Medicine in Medical, Surgical and Critical Care, University of Palermo, and the Department of Anesthesia Analgesia Intensive Care and Emergency, University Hospital Policlinico Paolo Giaccone, Palermo (A. Cortegiani), the Department of Cardiovascular Anesthesia and Intensive Care, IRCCS Policlinico San Donato, San Donato Milanese (E.B., M.R.), IRCCS Humanitas Research Hospital, Anestesia e Terapia Intensiva Cardiochirurgica, Rozzano (D.K.), the Department of Anesthesia and ICU Maria Cecilia Hospital GVM Care and Research, Cotignola (L.M.), the Department of Cardiac Anesthesia and Intensive Care, Ospedale Policlinico San Martino IRCCS‚ÄìIRCCS Cardiovascular Network, Genoa (S.S.), the Department of Cardiothoracic and Vascular Anaesthesia and Intensive Care, Azienda Ospedaliero Universitaria Pisana, Pisa (F.G.), and the Department of Anesthesia, Intensive Care and Emergency, ‚ÄòCitta della Salute e della Scienza‚Äô University Hospital, Turin (R. Lobreglio) ‚Äî all in Italy; the Department of Anaesthesia, National University Hospital, Singapore (L.K.T.); the Clinic of Anesthesiology, Resuscitation, and Intensive Medicine, University Hospital Dubrava, Zagreb, and University North, Department of Nursing, Varazdin ‚Äî both in Croatia (N.B.); the Department of Intensive Care Medicine, Kameda Medical Center, Kamogawa, Japan (Y.K.); and the Department of Critical Care, University of Melbourne, the Australian and New Zealand Intensive Care Research Centre, Monash University, and the Department of Intensive Care, Austin Hospital ‚Äî all in Melbourne, VIC, Australia (R.B.).

#### Notes

Dr. Landoni can be contacted at [landoni.giovanni@hsr.it](mailto:landoni.giovanni@hsr.it) or at the Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy.

\*

The members of the PROTECTION study group are listed in the [Supplementary Appendix](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769#ap2), available at NEJM.org.

Metrics & Citations
-------------------

### Metrics

#### Altmetrics

### Citations

#### Export citation

Select the format you want to export the citation of this publication.

  

Format\* 

 Direct Import

Export citation

#### Cited by

1.  *   Lizelle Bernhardt,
    *   Ashley Thomas,
    
    Highlighting the latest research: August 2024, British Journal of Cardiac Nursing, **19**, 8, (1-4), (2024).[https://doi.org/10.12968/bjca.2024.0050](https://doi.org/10.12968/bjca.2024.0050 ""Crossref"")
    
    [Crossref](https://doi.org/10.12968/bjca.2024.0050)
    
2.  *   Wilfred Druml,
    *   Thomas Staudinger,
    *   Michael Joannidis,
    
    The kidney: the critical organ system for guiding nutrition therapy in the ICU-patient?, Critical Care, **28**, 1, (2024).[https://doi.org/10.1186/s13054-024-05052-5](https://doi.org/10.1186/s13054-024-05052-5 ""Crossref"")
    
    [Crossref](https://doi.org/10.1186/s13054-024-05052-5)
    
3.  *   Marlies Ostermann,
    *   Andrew D. Shaw,
    
    Amino Acid Infusion to Protect Kidney Function after Cardiac Surgery, New England Journal of Medicine, **391**, 8, (759-760), (2024).[/doi/full/10.1056/NEJMe2408632](https://www.nejm.org/doi/full/10.1056/NEJMe2408632 ""Abstract"")
    
    [Abstract](https://www.nejm.org/doi/full/10.1056/NEJMe2408632)
    
4.  Nephroprotektion durch Aminos√§uren, DMW - Deutsche Medizinische Wochenschrift, **149**, 15, (862-862), (2024).[https://doi.org/10.1055/a-2228-0067](https://doi.org/10.1055/a-2228-0067 ""Crossref"")
    
    [Crossref](https://doi.org/10.1055/a-2228-0067)
    
5.  *   Alessandro Pruna,
    *   Rosario Losiggio,
    *   Giovanni Landoni,
    *   Yuki Kotani,
    *   Martina Baiardo Redaelli,
    *   Marta Veneziano,
    *   Todd C. Lee,
    *   Alberto Zangrillo,
    *   Mario F.L. Gaudino,
    *   Rinaldo Bellomo,
    
    Amino Acid Infusion for Perioperative Functional Renal Protection: A Meta-analysis, Journal of Cardiothoracic and Vascular Anesthesia, (2024).[https://doi.org/10.1053/j.jvca.2024.08.033](https://doi.org/10.1053/j.jvca.2024.08.033 ""Crossref"")
    
    [Crossref](https://doi.org/10.1053/j.jvca.2024.08.033)
    
6.  *   Daniel S. Cormican,
    *   David A. Broadbent,
    *   Meha Bhargava,
    
    Amino Acids for Renal Protection: Promising, but Cautiously So, Journal of Cardiothoracic and Vascular Anesthesia, (2024).[https://doi.org/10.1053/j.jvca.2024.08.026](https://doi.org/10.1053/j.jvca.2024.08.026 ""Crossref"")
    
    [Crossref](https://doi.org/10.1053/j.jvca.2024.08.026)
    
7.  *   Akinori Maeda,
    *   Anis Chaba,
    *   Ryota Inokuchi,
    *   Dinesh Pandey,
    *   Sofia Spano,
    *   Atthaphong Phongphithakchai,
    *   Yukiko Hikasa,
    *   Nuttapol Pattamin,
    *   Glenn Eastwood,
    *   Hossein Jahanabadi,
    *   Siven Seevanayagam,
    *   Andrew Motley,
    *   Rinaldo Bellomo,
    
    Carboxyhemoglobin as Potential Biomarker for Cardiac Surgery Associated Acute Kidney Injury, Journal of Cardiothoracic and Vascular Anesthesia, (2024).[https://doi.org/10.1053/j.jvca.2024.07.016](https://doi.org/10.1053/j.jvca.2024.07.016 ""Crossref"")
    
    [Crossref](https://doi.org/10.1053/j.jvca.2024.07.016)
    
8.  *   Martine G. E. Knol,
    *   Vera C. Wulfmeyer,
    *   Roman-Ulrich M√ºller,
    *   Markus M. Rinschen,
    
    Amino acid metabolism in kidney health and disease, Nature Reviews Nephrology, (2024).[https://doi.org/10.1038/s41581-024-00872-8](https://doi.org/10.1038/s41581-024-00872-8 ""Crossref"")
    
    [Crossref](https://doi.org/10.1038/s41581-024-00872-8)
    

Loading...

View Options
------------

### View options

#### PDF

[View PDF](https://www.nejm.org/doi/pdf/10.1056/NEJMoa2403769 ""View PDF"")

#### Full Text

[View Full Text](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769 ""View full text"")

Media
-----

### Figures

### Other

Tables
------

Share
-----

### Share

#### CONTENT LINK

Copy Link

Copied!

Copying failed.

#### Share

[Facebook](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769# ""Share on Facebook"")[X (formerly Twitter)](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769# ""Share on X (formerly Twitter)"")[Linkedin](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769# ""Share on Linkedin"")[email](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769# ""Share on email"")

 

Now Reading:

[Share](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769#)

*   [](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769# ""Share on Facebook"")
*   [](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769# ""Share on X (formerly Twitter)"")
*   [](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769# ""Share on Linkedin"")
*   [](https://www.nejm.org/doi/full/10.1056/NEJMoa2403769# ""Share on email"")

[###### PREVIOUS ARTICLE Preventing and Controlling Global Antimicrobial Resistance ‚Äî Implementing a Whole-System Approach Previous](https://www.nejm.org/doi/full/10.1056/NEJMp2401360)[###### NEXT ARTICLE Azithromycin to Reduce Mortality ‚Äî An Adaptive Cluster-Randomized Trial Next](https://www.nejm.org/doi/full/10.1056/NEJMoa2312093)

Create your account for 2 FREE subscriber-only articles each month. [Get Free Access Now.](https://www.nejm.org/action/clickThrough?id=125822&url=%2Faction%2FstoreProxy%3Faction%3DregisterMeteredAccess%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2403769%26promo%3DONFGMM01&loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2403769&pubId=41296434&placeholderId=101388&productId=1035)
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

#### ARTICLE CATEGORIES

*   [Research](https://www.nejm.org/browse/nejm-article-category/research)
*   [Reviews](https://www.nejm.org/browse/nejm-article-category/review)
*   [Clinical Cases](https://www.nejm.org/browse/nejm-article-category/clinical-cases)
*   [Perspective](https://www.nejm.org/browse/nejm-article-category/perspective)
*   [Commentary](https://www.nejm.org/browse/nejm-article-category/commentary)
*   [Other](https://www.nejm.org/browse/nejm-article-category/other)
*   [Browse all Articles](https://www.nejm.org/medical-article-index)
*   [Current Issue](https://www.nejm.org/toc/nejm/current)
*   [Issue Index](https://www.nejm.org/loi/nejm)

#### RESOURCES

*   [Authors & Reviewers](https://www.nejm.org/author-center/home)
*   [Submit a Manuscript](https://www.nejm.org/author-center/home)
*   [Subscribers](https://www.nejm.org/about-nejm/products-and-services)
*   [Institutional Administrators](https://tools.ovid.com/ovidtools/nejm.html)
*   [Media](https://www.nejm.org/media)
*   [Advertisers](https://www.nejm.org/about-nejm/how-to-advertise)
*   [Agents](https://www.nejm.org/information-for-subscription-agents)
*   [Permissions & Licensing](https://www.nejm.org/about-nejm/permissions)
*   [Reprints](https://www.nejm.org/about-nejm/reprints)
*   [NEJM CareerCenter](https://www.nejmcareercenter.org/)

#### ABOUT US

*   [About NEJM](https://www.nejm.org/about-nejm/about-nejm)
*   [NEJM Group](https://www.nejmgroup.org/)
*   [Products & Services](https://www.nejm.org/about-nejm/products-and-services)
*   [Editors & Publishers](https://www.nejm.org/about-nejm/editors-and-publishers)
*   [Advertising Policies](https://www.nejm.org/about-nejm/advertising-policies)
*   [Contact Us](https://www.nejm.org/contact-nejm)
*   [Accessibility](https://www.nejm.org/about-nejm/frequently-asked-questions?#Accessibility)
*   [FAQs](https://www.nejm.org/about-nejm/frequently-asked-questions)
*   [Help](https://www.nejm.org/about-nejm/help)
*   [Site Feedback](https://www.nejm.org/cdn-cgi/l/email-protection#e4978d9081828181808685878fa48a818e89ca8b9683)

#### SUBSCRIPTIONS

*   [Subscribe](https://www.nejm.org/action/storeProxy?action=subscribe&promo=ONF4NRS3)
*   [Renew](https://www.nejm.org/action/storeProxy?action=renew&product=nejm&promo=ONFLNRR3&prc=ONFARN52)
*   [Activate Subscription](https://www.nejm.org/action/storeProxy?action=activate&promo=ONFLNAA1)
*   [Create Account](https://www.nejm.org/action/storeProxy?action=register&promo=ONFLNRC4)
*   [Manage Account](https://myaccount.nejm.org/)
*   [Pay Bill](https://www.nejm.org/action/storeProxy?action=paybill&product=nejm&promo=BNFLPBA1)
*   [Institution Subscriptions](https://info.lww.com/Request-NEJM-for-your-institution.html)
*   [Special Content](https://myaccount.nejm.org/special-content)

#### STAY CONNECTED

*   [Email Alerts](https://myaccount.nejm.org/emails?section=NEJM)
*   [Create Account](https://www.nejm.org/action/storeProxy?action=register&promo=ONFLNRC3)
*   [Apps](https://www.nejm.org/about-nejm/products-and-services)
*   [NEJM CareerCenter](https://www.nejmcareercenter.org/)
*   [Podcasts](https://www.nejm.org/rss-feed/)
*   [RSS Feed](https://www.nejm.org/rss-feed/)
*   [Remote Access](https://www.nejm.org/about-nejm/institutional-access)

#### FOLLOW US

*   [Facebook](https://www.facebook.com/TheNewEnglandJournalofMedicine)
*   [X (formerly Twitter)](https://twitter.com/nejm)
*   [Instagram](https://www.instagram.com/nejm/)
*   [Youtube](https://www.youtube.com/user/NEJMvideo)
*   [LinkedIn](https://www.linkedin.com/company/nejm-group)

#### JOURNALS

*   [The New England Journal of Medicine](https://www.nejm.org/)
*   [NEJM Catalyst Innovations in Care Delivery](https://catalyst.nejm.org/)
*   [NEJM Evidence](https://evidence.nejm.org/)
*   [NEJM AI](https://ai.nejm.org/)

Copyright ¬© 2024 [Massachusetts Medical Society](https://www.massmed.org/). All rights reserved. Electronic ISSN 1533-4406. Print ISSN 0028-4793.

The content of this site is intended for health care professionals.

*   [Copyright](https://www.nejmgroup.org/legal/copyright-information.htm)
*   [Terms](https://www.nejmgroup.org/legal/terms-of-use.htm)
*   [Privacy Policy](https://www.nejmgroup.org/legal/privacy-policy.htm)

[![Image 7: NEJM Group logo](https://www.nejm.org/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg)](https://www.nejmgroup.org/ ""NEJM Group"")

Back to top
",gpt-4o-mini
2024-08-29 08:38:00,2024-08-31 03:42:34,"**Breakthrough in Antibiotic Design: Velcro-like Mechanism of Plectasin**  
Doctor, have you heard of the latest research revealing the plectasin antibiotic's binding mechanism? This innovative antibiotic, which attaches to the lipid II in bacterial membranes, could inspire new drugs against resistant infections.  
Recent findings from Utrecht University research team highlight how plectasin forms dense structures, enhancing its effectiveness against gram-positive bacteria and providing insights into antibiotic design that focuses on both target binding and supramolecular formation. As we face rising antibiotic resistance, exploring the potential of plectasin could be crucial.  
üîó Dive into the findings and share your thoughts: [Read more here](https://www.drugdiscoverynews.com/velcro-like-antibiotic-may-inform-new-antibiotic-design-16028)  
üí¨ What‚Äôs your take on this new approach in antibiotic development? Let‚Äôs discuss!  
#Antibiotics #Plectasin #MedicalResearch #InfectiousDiseases #DrugDevelopment",https://medsii.azureedge.net/images/638605175224954478-66d0324a6157181811bbc82f.jpg,https://www.drugdiscoverynews.com/velcro-like-antibiotic-may-inform-new-antibiotic-design-16028,"You are a content creator tasked with crafting highly informative social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Thumbnail image URL: https://medsii.azureedge.net/images/638605175224954478-66d0324a6157181811bbc82f.jpg  
Title: Velcro-like antibiotic may inform new antibiotic design

URL Source: https://www.drugdiscoverynews.com/velcro-like-antibiotic-may-inform-new-antibiotic-design-16028

Markdown Content:
![Image 1: A group of four scientists, two men and two women, wearing white lab coats stand on a wooden platform in a laboratory setting.](https://cdn.drugdiscoverynews.com/assets/articleNo/16028/aImg/41782/low-res-utrecht-university-s.jpg)

**Top Image:**

Markus Weingarth‚Äôs research team studies antibiotics that target lipids only found in bacterial membranes. From left to right: Maik Derks, Eefjan Breukink, Shehrazade Miranda Jekhmane, and Markus Weingarth.

credit: Utrecht University

Register for free to listen to this article

[Markus Weingarth](https://www.weingarth-group.net/), a biochemist at Utrecht University, considers lipid II, a building block of bacteria cell walls, one of the most promising antibiotic targets. Human cells don‚Äôt produce it ‚Äî so targeting it avoids toxicity ‚Äî and bacteria struggle to develop resistance against it.

His research group recently published a [study](https://www.nature.com/articles/s41564-024-01696-9) in _Nature Microbiology_, in which they reported that the antibiotic plectasin binds lipid II by forming dense structures on bacterial membranes (1). The findings improve researchers‚Äô understanding of how lipid II binding disrupts the cell walls of bacteria, which can help them develop better antibiotics.

![Image 2: 3D rendering of plectasin binding lipid II on the bacterial cell surface to disrupt cell wall formation.](https://cdn.drugdiscoverynews.com/assets/articleNo/16028/iImg/41784/low-res-plectasin-gloria-fuentes-l.jpg)

Like Velcro, the antibiotic plectasin binds its target on the bacterial cell surface.

credit: Gloria Fuentes

Novozyme‚Äôs scientists first [described](https://www.science.org/doi/10.1126/science.1185723?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed) plectasin‚Äôs mechanism of action in 2010 (2). However, in their experiments, they used artificial membranes called micelles and showed that each plectasin molecule paired with one lipid II molecule. However, micelles do not accurately mimic the membrane environment. ‚ÄúWe took a gamble, believing that what happened in micelles was not the real deal, and this turned out to be the case,‚Äù said Weingarth. In biological membranes, the team found that plectasin formed massive supramolecular structures upon lipid II binding. ‚ÄúWe saw that the supramolecular mechanism was not the exception, but rather the rule among the lipid II binders.‚Äù

**How is plectasin‚Äôs mechanism of action different from that of other antibiotics?**
------------------------------------------------------------------------------------

Conventional antimicrobial peptides selectively bind bacteria based on electrostatics, as bacterial membranes are negatively charged while human cell membranes are positively charged. This electrostatic interaction is fairly unspecific. However, plectasin targets lipid II specifically based on both structure and charge, making it a highly selective target binder. This specificity marks its first major difference. Most drugs follow a conventional ""one drug, one target"" mechanism, where the drug and the target interact directly. In contrast, plectasin and other lipid II binders form massive supramolecular structures upon target binding. This formation is not just a feature but a critical aspect of the mechanism. Without these superstructures, there would be no stable target binding. These two prominent features of plectasin ‚Äî highly specific interaction with the target and supramolecular recognition ‚Äî distinguish it from conventional antimicrobial peptides.

The other thing that stands out about plectasin‚Äôs mechanism is that it is calcium modulated, which was an unexpected discovery. In hindsight, it seems obvious given the presence of a large ionic pocket that naturally binds calcium. However, this aspect had not been mentioned in any previous publications on plectasin.

**What makes lipid II a good antibiotic target?**
-------------------------------------------------

Lipid II has fatty acid tails and a pyrophosphate head group, which bacteria cannot alter. There are no known cases of bacteria replacing the pyrophosphate group for peptidoglycan synthesis, making it an absolute bottleneck for their cell wall biosynthesis. However, bacteria might be able to develop indirect resistance mechanisms, such as making the target inaccessible. They could make the peptidoglycan layer so dense that the drug never reaches the target. This is energy-intensive and unstable. Additionally, bacteria cannot make more lipid II once it‚Äôs captured, so targeting lipid II at these immutable sites makes it difficult for bacteria to develop stable resistance mechanisms.

> We saw that the supramolecular mechanism was not the exception, but rather the rule among the lipid II binders.¬†  
> ‚Äì Markus Weingarth, Utrecht University

**How effective is plectasin as an antibiotic?**
------------------------------------------------

Plectasin is not effective against gram-negative bacteria because it cannot overcome their outer membrane. However, plectasin is highly efficient against gram-positive bacteria and maintains this effectiveness in animal models of infection. Despite its potential as a relevant therapeutic, I am pessimistic about its future because the clinical development of plectasin was discontinued, and the work was never published. However, plectasin ticks many important boxes: It is stable in serum, non-cytotoxic, and highly efficient against a broad range of superbugs, including in animal models of infection, making it a compelling clinical candidate.

Although plectasin‚Äôs future as a therapeutic is uncertain, the study‚Äôs findings have significant implications for the design of lipid II-binding antibiotics. It‚Äôs crucial to optimize both the part of the drug that binds the target and the part responsible for oligomerization. This aspect has been ignored so far, as the focus has traditionally been on target binding alone. However, target binding and oligomerization are strongly interdependent. Only when both are optimized can ideal target binding occur.

_This interview has been condensed and edited for clarity._

### References

1.  Jekhmane, S. _et al._ [Host defence peptide plectasin targets bacterial cell wall precursor lipid II by a calcium-sensitive supramolecular mechanism](https://www.nature.com/articles/s41564-024-01696-9). _Nat Microbiol_¬† **9,** 1778‚Äì1791 (2024).
2.  Schneider, T. _et al._ [Plectasin, a Fungal Defensin, Targets the Bacterial Cell Wall Precursor Lipid II](https://www.science.org/doi/10.1126/science.1185723?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed). _Science_¬† **328,** 1168‚Äì1172 (2010).
",gpt-4o-mini
2024-08-15 00:00:00,2024-08-31 03:49:39,"üöÄ **Revolutionizing Surgery with AI!**  
Berlin-based Caresyntax has successfully raised a whopping **$180 million** in a Series C extension to develop its AI-driven data platform for surgery! üè•‚ú®  
This innovative technology aims to transform operating room efficiency by leveraging AI algorithms to monitor vital signs and work alongside existing surgical tools. By collecting over **1,000 data points** per surgical case, Caresyntax is on a mission to help surgeons enhance patient outcomes and reduce hospital costs associated with operations, which currently account for **30%** of healthcare expenditure.  
With applications already in **3,000 operating rooms** globally, this funding will accelerate customer adoption in the U.S. and EMEA regions as well as support new AI developments.  
üëâ What challenges do you see in integrating AI in surgery within your practice? Share your thoughts below!  
#SurgicalInnovation #HealthcareTechnology #AIMed #PatientCare #Caresyntax #Surgery",,https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/,"You are a content creator tasked with crafting highly informative social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Title: AI surgery tech startup raises $180m from investors including BlackRock | Sifted

URL Source: https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/

Markdown Content:
Berlin-based Caresyntax, which is building an AI-driven data platform for surgery, has raised a $180m Series C extension.

The round is made up of $80m in equity and $100m in debt ‚Äî and is tied to specific milestones. The fresh funding tops up the startup‚Äôs [$130m Series C,](https://sifted.eu/articles/caresyntax-raises-100m) raised across two rounds in 2021, and takes its total equity funding to $220m.

It‚Äôs the latest in a string of big money raises for European startups developing tech for hospital operating theatres as healthcare systems across the globe scramble to increase efficiency amid staff shortages and the rising costs of treating ageing populations.

Caresyntax will use the funds to scale customer adoption in the US and EMEA region, develop AI applications and finance M&A opportunities.

### **AI for hospitals**

Caresyntax says it wants to build the ‚ÄúAndroid‚Äù platform for surgery. Its tech uses AI algorithms to make sense of data collected before, during and after an operation to help surgeons improve patient outcomes, spot risks during procedures and reduce hospitals‚Äô surgery costs by improving efficiency and reducing readmissions.

The company‚Äôs platform can pick up on warning signs like drops in heart rate that surgeons might not be aware of during a procedure, for example. It can also streamline operative workflows, inform post-treatment care pathways post-operation and collect 1,000 data points per surgical case.

While some surgical robotics solutions in the market only work with certain products, Caresyntax‚Äôs platform can plug into any operating room technology to pull together data, according to a company spokesperson.

‚ÄúEffectively using AI in the operating room requires input from a wide variety of data sources, but today this data exists in silos where it is difficult for clinicians to access and operationalise,‚Äù they add.

If it does what it sets out to do, it‚Äôs a big opportunity.

Costs associated with operations account for [30%](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586534/#:~:text=Older%20estimates%20suggest%20that%20inpatient,healthcare%20costs%20%5B2%203%5D.) of healthcare expenditure, a huge sum given that Europe spends [11%](https://www.medtecheurope.org/datahub/expenditure/#:~:text=In%20Europe%2C%20an%20average%20of,less%20than%201%25%20of%20GDP.) of GDP on health.

Founded in 2013 in Germany ‚Äî Caresyntax also expanded to San Francisco in 2019 ‚Äî its data platform is currently used in 3k operating rooms globally, in more than 3m surgeries annually, according to the company. 40% of the company‚Äôs revenue comes from the Americas and 60% from the EMEA region.

### **The rise of smart surgery**

The round comes on the back of a strong 18 months for startups developing tech for the operating theatre.

Since the start of 2023, three of the four biggest medtech raises have all gone to startups building robots to help surgeons. The UK‚Äôs CMR Surgical picked up [¬£165m](https://sifted.eu/articles/cmr-surgical-raise-2023) in September last year, Switzerland‚Äôs DistalMotion $150m in April 2023 and Italy‚Äôs Medical Microinstruments $110m in February this year.

Investors in Caresyntax‚Äôs round include Symbiotic Capital, MTIP AG, BIONIQ Capital, PFM Health Sciences, Pictet Alternative Advisors, surgical.ai, BlackRock Innovation Capital, Aescuvest, Optum Ventures, Cure Capital, Relyens Group, Vesalius Biocapital, Lauxera Capital, Plug & Play Growth Fund and ProAssurance Corp.
",gpt-4o-mini
2024-07-30 00:00:00,2024-08-31 03:57:06,"ü©∫ **A Milestone in Femtech: Europe Welcomes Its First Unicorn**  
Flo Health, a leading UK femtech company, has secured over **$200 million** in equity investment from General Atlantic, becoming Europe's first femtech unicorn! üöÄ This groundbreaking Series C funding marks a pivotal moment not just for Flo but for the entire femtech landscape, which has been historically underfunded compared to its counterparts in wider healthtech.

With a focus on expanding into areas such as perimenopause and menopause, Flo aims to enhance its platform through AI-driven personalized health insights. The company reported significant growth in revenue from **$35 million in 2022 to $112 million in 2023**, solidifying its leadership in women‚Äôs health solutions.

üìä As we witness this exciting development, how do you see the evolution of femtech impacting patient care and outcomes in your practice? Share your thoughts below!  

#Femtech #HealthTech #Innovation #WomensHealth #FloHealth #InvestmentNews  

![Flo Health Unicorn](https://sifted.eu/wp-content/uploads/2023/04/flo-health.jpg)",,https://sifted.eu/articles/flo-health-unicorn-raise-news/,"You are a content creator tasked with crafting highly informative social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Title: Europe gets its first femtech unicorn after record $200m investment from General Atlantic | Sifted

URL Source: https://sifted.eu/articles/flo-health-unicorn-raise-news/

Markdown Content:
UK femtech Flo Health is set to raise more than $200m in equity from US growth investor General Atlantic ‚Äî¬†a backer of companies like Uber and Airbnb.

The period-tracking app‚Äôs Series C is the joint-biggest ever raise for a femtech ‚Äî along with US fertility startup Prelude Fertility ‚Äî according to data platform Dealroom. It also gives Europe its first femtech unicorn and takes Flo‚Äôs total funding to more than $290m.

All the funds have been committed and a stock purchase agreement has been signed, cofounder and CEO Dmitry Gurski tells Sifted. The funding round is expected to close in coming weeks, subject to regulatory approvals.

Flo will use the funds to expand into new user segments like perimenopause and menopause and invest in R&D for AI-driven personalised insights tools.

### **Europe‚Äôs first femtech unicorn**

While in the US just a few femtechs have hit unicorn status ‚Äî including fertility clinics Maven and Kindbody ‚Äî in Europe the sector‚Äôs unicorn stable has been bare until now. Previously, the largest raise by a femtech startup was [Elvie‚Äôs](https://sifted.eu/articles/elvie-uk-healthtech-raise) ¬£70m Series C, picked up across two rounds in 2021.

Flo isn‚Äôt disclosing what its exact valuation will be when the funds hit its account, but Gurski tells Sifted the company hit a pre-money valuation of $1bn. ""Reaching unicorn status is a significant milestone for Flo and the entire femtech industry,"" he says.

It comes after a challenging time in the market across the last couple years, says Gurski. ‚ÄúBut despite everything, Flo has shown steady, significant growth, after more than eight years of continuous expansion.‚Äù

Flo‚Äôs revenue in 2023 was $112m ‚Äî up from $35m in 2022, according to the company‚Äôs latest annual accounts. Losses over the same period fell from $35m to $25m. The company has just under 500 employees globally, Gurski tells Sifted.

It plans to deploy some of the fresh capital to increase R&D headcount with ‚Äúinvestments in top-tier talent across \[our\] global offices in Europe and North America,‚Äù Gurski says.

On longer-term plans, he tells Sifted that, ‚Äúwhile we're not announcing specific IPO plans at this time, this funding broadens our range of future paths and gives us the flexibility to choose the best path forward for Flo's continued success and impact in the women's health space.‚Äù Gurski adds: ‚ÄúOur immediate focus remains on executing our growth strategy and further solidifying our position as a leader in femtech.‚Äù

### **The most downloaded women‚Äôs health app**

Flo was founded in 2015 ‚Äî a year before the term ‚Äúfemtech‚Äù was first coined by Ida Tin, founder of soon-to-be rival period tracking app Clue. It‚Äôs since grown into the most-downloaded women‚Äôs health app on both Google Play and AppStore, according to market insights platform Sensor Tower.

Flo‚Äôs platform allows users to track their period cycle and monitor symptoms, as well as providing them with tailored health insights and educational content.

The startup says it has 70m monthly active users and close to 5m paid subscribers as of June 2024. About 50% of those are based in the US, with the remaining half split evenly between the UK and EU.

### **Historically underfunded**

Femtech has long been considered an underfunded sector. In 2023 European startups raised just $191m, a fraction of the $9.7bn shelled out on the wider healthtech sector. On top of that funding in the wider digital health sector ‚Äî which encompasses the vast majority of femtechs ‚Äî has been [hit hard](https://sifted.eu/articles/digital-health-startups-are-running-out-of-cash) by the downturn.

But despite that, Flo isn‚Äôt the only femtech that‚Äôs raised a sizeable sum in 2024. In May, Swedish digital birth control startup Natural Cycles picked up $55m, one of the largest European digital health rounds of the year.

Others haven‚Äôt been so fortunate. At the start of 2023, Clue announced it was [making layoffs](https://sifted.eu/articles/brainly-clue-aiven-tech-layoffs-arent-over-in-2023) and audio erotica site Emjoy shuttered earlier this year.
",gpt-4o-mini
2024-08-30 02:59:00,2024-08-31 04:04:09,"üîç **Understanding Anogenital Warts: Key Insights for Primary Care!**  
Anogenital warts, primarily caused by low-risk HPV types 6 and 11, are a prevalent sexually transmitted infection, especially among 20-24-year-olds. With new guidance from the British Association for Sexual Health and HIV (BASHH) released in August 2024, it's crucial for primary care practitioners to stay updated on diagnosis and management.

‚ú® **Top Six Key Learning Points:**  
1Ô∏è‚É£ **Clinical Diagnosis is Essential:** Visual inspection and a comprehensive sexual history are critical.  
2Ô∏è‚É£ **Empower Patient Choices:** Options range from self-administered treatments like Imiquimod to clinician-administered options such as cryotherapy.  
3Ô∏è‚É£ **Follow-up is Crucial:** Encourage patients to return if symptoms persist, and discuss smoking cessation to reduce recurrence rates.  
4Ô∏è‚É£ **Pathway to Referrals:** Know when to refer for specialist evaluation, especially if atypical features are present.  
5Ô∏è‚É£ **Psychosexual Support Matters:** Address mental health impacts as patients often deal with anxiety related to their diagnosis.  
6Ô∏è‚É£ **Promote HPV Vaccination:** The HPV vaccine significantly reduces the incidence of anogenital warts.
  
These updates not only enhance patient care but also normalize discussions around sexual health in primary practice. How do you approach management of anogenital warts in your practice? Share your strategies below!  

#AnogenitalWarts #STI #PrimaryCare #BASHH #HPV #SexualHealth #MentalHealth #PatientCare",,http://medscape.co.uk/viewarticle/key-learning-points-bashh-anogenital-warts-2024a1000esn,"You are a content creator tasked with crafting highly informative social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Thumbnail image URL: nan  
Title: Key Learning Points: BASHH Anogenital Warts

URL Source: http://medscape.co.uk/viewarticle/key-learning-points-bashh-anogenital-warts-2024a1000esn

Published Time: 2024-08-30T02:59:00-04:00

Markdown Content:
Key Learning Points: BASHH Anogenital Warts
===============
                                     

This site is intended for UK healthcare professionals

[![Image 1: Medscape UK Univadis Logo](http://img.wbmdstatic.com/medscapeuk_static_vue/medscape-uk-page-article/client/img/medscape-uk-logo.4a9c814f.svg)](http://medscape.co.uk/)

*   Recent Searches [Clear](http://medscape.co.uk/viewarticle/key-learning-points-bashh-anogenital-warts-2024a1000esn#)

Log In Register

[![Image 2: Medscape UK Univadis Logo](http://img.wbmdstatic.com/medscapeuk_static_vue/medscape-uk-page-article/client/img/medscape-uk-logo.4a9c814f.svg)](http://medscape.co.uk/)

*   Recent Searches [Clear](http://medscape.co.uk/viewarticle/key-learning-points-bashh-anogenital-warts-2024a1000esn#)

Log In Register

*   Recent Searches [Clear](http://medscape.co.uk/viewarticle/key-learning-points-bashh-anogenital-warts-2024a1000esn#)

*   Menu
*   News
    
*   Guidelines
    
*   Drugs
    
*   Quizzes
    
*   Search

![Image 3](blob:http://medscape.co.uk/97197544e7d3f69d0df5d7bac7685319)

![Image 4](http://img.wbmdstatic.com/medscapeuk_static_vue/medscape-uk-page-article/client/img/medscape-uk-logo.4a9c814f.svg)![Image 5](blob:http://medscape.co.uk/9ef8406a8b57feca58cd71da69ad13a9)![Image 6](http://img.wbmdstatic.com/medscapeuk_static_vue/medscape-uk-page-article/client/img/ginp-logo.2f11b0b5.svg)

Welcome to the new home of Guidelines in Practice

Browse our expert articles to support best practice for UK healthcare professionals.

Got it

For Primary Care | Key learning points

Key Learning Points: BASHH Anogenital Warts
===========================================

Dr Amy Cleese | [Disclosures](http://medscape.co.uk/viewarticle/key-learning-points-bashh-anogenital-warts-2024a1000esn#) | 30 August 2024

### Disclosures

[](http://medscape.co.uk/viewarticle/key-learning-points-bashh-anogenital-warts-2024a1000esn#)

Author(s)

![Image 7: Dr Amy Cleese](https://img.medscapestatic.com/vim/live/professional_assets/medscape/person/CLEESE%20Amy.jpg)

**Dr Amy Cleese**

GP Registrar, Tower Hamlets Vocational Training Scheme

[](http://medscape.co.uk/viewarticle/key-learning-points-bashh-anogenital-warts-2024a1000esn#)

**Dr Amy Cleese Reviews the Diagnosis and Management of Anogenital Warts in General Practice, Offering Six Key Learning Points From Updated Guidance**

Continue Reading Below

| Read This Article to Learn More About: |
| --- |
| 
*   the role of primary care in diagnosing and treating anogenital warts
*   when to refer suspected anogenital warts to sexual health services
*   other ways in which primary care practitioners can support patients with anogenital warts.

A list of key points can be found at the end of the article.[Reflect on your learning and download our Reflection Record](https://www.medscape.co.uk/viewarticle/reflection-record-2022a10023ox).

 |

Anogenital warts are benign, proliferative growths that can appear anywhere in the genital region.1 In almost all cases, anogenital warts are spread via sexual transmission;1 very rarely, transmission can occur through hand2 or perinatal3 contact. It is important to note that transmission can occur when no warts are visible, and that the time interval between infection and presentation can be highly variable‚Äîan average of 3 months for women and 11 months for men.4 There are more than 100 genotypes of human papillomavirus (HPV), but over 90% of cases of anogenital warts are caused by ‚Äòlow-risk‚Äô HPV (genotypes 6 and 11).4,5

Anogenital warts are a common sexually transmitted infection (STI), with an estimated lifetime risk of 10% for sexually active people.6 They are most common in 20‚Äì24-year-olds, but can occur at any age.7 The yearly occurrence of new cases is usually around 50,000 in the UK,1 although cases have dropped to around 27,000 per year since 2020.8 Patients who present with anogenital warts are also at risk of other STIs ; these may be asymptomatic, and could be tested for and treated at the time of presentation.7

Advertisement

Primary care plays an essential role in providing sexual health screening and treatment. Proactive clinicians can reduce barriers to sexual health, normalise STI screening, provide education on safe sex, and open discussions around psychosexual wellbeing.9

The British Association for Sexual Health and HIV (BASHH) published an update to its national guideline for the management of anogenital warts in adults in 2024.1 Although it is primarily aimed at level-3 sexual health clinics, it contains some important updates for primary care.1 This article offers six key learning points from this guideline for primary care practitioners to consider when seeing a patient with suspected anogenital warts.

Continue Reading Below

Continue Reading Below

1\. Examine Suspected Anogenital Warts Carefully, Considering Common Differential Diagnoses¬†
--------------------------------------------------------------------------------------------

If anogenital warts are suspected, a brief sexual history should be taken, including consideration of any new sexual partners, number of sexual partners in the last year, and barrier contraception use.1,10

Anogenital warts can generally be diagnosed clinically, via visual inspection under direct illumination.1,4 There will usually be multiple lesions less than 10 mm in size, although these can coalesce to form larger lesions.11 The lesions are often soft and flesh-coloured, but can sometimes be hyperpigmented or keratinised.1,4,6 They are predominantly asymptomatic, but occasionally pain or itching can occur.1,7

For women, a speculum examination is only indicated if warts are present at the vaginal introitus or if there are internal vaginal symptoms such as irritation, bleeding, or discharge.1 For all patients, proctoscopic examination should be performed if there are warts at the anal margin or anal symptoms.1 Patients should be seen in a sexual health centre if this examination cannot be done in primary care.

Differential diagnoses should also be considered when inspecting suspected anogenital warts.1 Key differential diagnoses of anogenital warts are listed in Box 1.1,6,11

| Box 1: Key Differential Diagnoses of Anogenital Warts1,6,11 |
| --- |
| 
*   Pearly penile papules
*   Sebaceous glands of the vulva or foreskin
*   Fordyce spots
*   Epidermoid cysts
*   Skin tags
*   Granuloma annulare
*   Lichen planus
*   Seborrhoeic keratoses
*   Molluscum contagiosum
*   Condylomata lata (lesions found in secondary syphilis)
*   Intraepithelial neoplasia
*   Malignancy
*   Fibroma.¬†

 |

2\. Manage Anogenital Warts Based on Number of Lesions, Patient Preference, and Recurrence¬†
-------------------------------------------------------------------------------------------

Not all cases of anogenital warts will require treatment.6,11 This is especially true of smaller, asymptomatic warts, as spontaneous clearance occurs in around 30% of patients within the first 4 months.7¬†Nevertheless, a variety of treatment options exist, some of which are self-administered and others administered by clinicians.1,4,11 The current evidence on the treatment of anogenital warts is not strong enough for guidance to explicitly recommend one treatment over others; rather, when choosing a treatment option, clinicians should consider patient preference, number of lesions, and response to prior treatments.1,4 See Box 2 for a list of recommended treatment options.1,4,6,11,12

| Box 2: Treatment Options for Anogenital Warts1,4,6,11,12 |
| --- |
| **Self-administered Treatments Available in Primary Care**
*   Imiquimod 5% cream
    *   patients should be advised that this treatment can weaken condoms
*   Podophyllotoxin 0.15% cream or 0.5% solution
    *   the solution is more effective but harder to apply, so should be given to those with easy-to-reach warts
    *   note: podophyllotoxin is not currently licensed for use on perianal lesions, or for a duration of >4 weeks; however, evidence from RCTs\[A\] has demonstrated its safety in these situations
*   Sinecatechins (_Camellia sinensis_ extract)
    *   mild inflammatory reactions may occur at the site of application.

**Clinician-administered Treatments**

*   Trichloroacetic acid 80‚Äì90%¬†
*   Cryotherapy¬†
*   Laser therapy (with local anaesthetic)¬†
*   Electrosurgery (with local anaesthetic)
*   Surgical excision (with local anaesthetic).

**Alternative Treatments**\[B\]

*   5-fluorouracil 5% cream
*   Potassium hydroxide 5% solution¬†
*   Nitrizinc complex
*   Photodynamic therapy.¬†

\[A\] The BASHH guideline cites the following RCTs as evidence of podophyllotoxin's safety in this scenario:

*   Gilson R, Nugent D, Bennett K et al. Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT. _Health Technol Assess_ 2020; **24** (47): 1‚Äì86.
*   Hellberg D, Svarrer T, Nilsson S et al. Self-treatment of female external genital warts with 0.5% podophyllotoxin cream (Condyline) vs weekly applications of 20% podophyllin solution. _Int J STD AIDS_ 1995; **6** (4): 257‚Äì261.
*   Tyring S, Edwards L, Cherry L et al. Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts. _Arch Dermatol_ 1998; **134** (1): 33‚Äì38.

\[B\] As per the 2024 BASHH guideline, these treatments are not licensed for anogenital warts, but have been shown to be effective and could be used in cases where other treatments have failed.RCT=randomised controlled trial; BASHH=British Association for Sexual Health and HIV

 |

### Local Treatment Pathways¬†

Choice of treatment will also depend on the skillset present in primary care and local pathways.11 For example, if the correct training and equipment are available for cryotherapy, this treatment can be performed in primary care. To this end, BASHH recommends setting up local treatment pathways in conjunction with nearby level-3 sexual health services, and has provided an example treatment algorithm for these pathways (see Figure 1).1

### Figure 1: Suggested Treatment Algorithm for External Genital Warts Only in Individuals Who Are Not Currently Pregnant or Breastfeeding 1¬†

![Image 8: BASHH anogenital warts figure 1](https://img.medscapestatic.com/vim/live/professional_assets/medscape/articles/Anogenital%20warts%20figure%201%20high%20res.jpg)

Nugent D, Apoola A, Coleman H et al, _Int J STD AIDS_ (**35** \[7\])  
pp. 498‚Äì509, copyright ¬© 2024 by The Authors.  
Reprinted by Permission of SAGE Publications

### Patient Education¬†

Patients should be informed that the aim of treatment is to reduce the visibility of warts and return to having normal anogenital skin.1 Clinicians should emphasise that treatment does not affect transmission to sexual partners and that sexual transmission to a partner can still happen when there are no visible lesions, and healthcare practitioners must also counsel patients on condom use.1 BASHH recommends signposting patients to its patient information leaflet on anogenital warts [here](https://www.bashh.org/resources/52/genital_warts).1

### Follow-Up Review¬†

It is also important that patients are empowered to return to the GP if symptoms do not improve. BASHH recommends that an alternative treatment should be started if anogenital warts reduce by less than 50% after 8 weeks of imiquimod or sinecatechins, or 4 weeks of podophyllotoxin.1

#### _Smoking Cessation Advice_

Advertisement

The follow-up review is an opportune time to discuss smoking cessation. Smoking is correlated with higher incidence and recurrence of anogenital warts, so BASHH explicitly recommends providing smoking cessation advice to patients with the condition.1,13

3\. Refer Patients for Further Investigations or Specialist Management as Appropriate¬†
--------------------------------------------------------------------------------------

Patients with atypical features on examination should be considered for biopsy, as these findings may indicate malignant or premalignant lesions.1,11 Some examples of signs and symptoms that would prompt this referral include bleeding, ulceration, and physician concerns regarding malignancy.1

The Royal College of General Practitioners‚Äô guidance on STIs in primary care recommends that, when there is diagnostic uncertainty, patients should be referred to specialist care.11 Other reasons for referral to a level-3 sexual health service include the following:1,11

*   the patient is pregnant or breastfeeding
*   the patient is a child
*   the patient is immunocompromised
*   there is internal involvement (vaginal, anal, urethral)
*   there is bleeding, ulceration, or another clinical concern
*   the patient has recurrent anogenital warts.

Although contact tracing is not required for anogenital warts,1,4 sexual health services are best set up for contact tracing, so it may be appropriate to refer to one of these services if the patient has a concurrent STI and there are concerns of nondisclosure to sexual partners.14 It is essential that pregnant patients, children, and those who are immunocompromised are referred to sexual health, as these are high-risk groups.1,11¬†

### Pregnancy and Breastfeeding¬†

Anogenital warts can increase in number and size during pregnancy.1,4 Many cases will self-resolve in the puerperium, so sexual health teams may advise pregnant patients to delay consideration of treatment until after delivery.1

None of the self-administered topical treatments are currently approved in pregnancy, and none of the self-administered treatments are licensed for patients who are breastfeeding.1,3 Therefore, these patients should be referred to sexual health services for treatment with cryotherapy, laser therapy, electrosurgery, surgical excision, or trichloroacetic acid.1 Patients should discuss the implications for delivery with their sexual health and obstetric teams.1

### Children¬†

If children present with anogenital warts, the possibility of sexual abuse will need to be considered.15 If there are any concerns regarding possible sexual abuse, wider input should be sought from safeguarding teams or paediatrics.15

### Immunocompromise¬†

Immunocompromised patients are at higher risk for extensive wart formation and malignancy, so should be referred to specialist services.1,16 However, as evidence is lacking, treatment recommendations for these patients are the same as for the general population.1

4\. Prioritise Patients With Recurrent Anogenital Warts for Ablative Treatments¬†
--------------------------------------------------------------------------------

Studies have demonstrated highly variable recurrence rates for anogenital warts.1,4,7 Nevertheless, patients should be counselled that they are at higher risk of recurrence if they:1,4,7

*   have lesions at more than one anatomical site
*   are immunocompromised
*   are a smoker.

BASHH recommends prioritising those who experience recurrent or recalcitrant anogenital warts for surgical and laser treatments.1 When aiming to prevent recurrence, specific recommendation is given to laser treatment followed by 4‚Äì8 weeks of imiquimod.1¬†

5\. Understand the Psychosexual and Mental Health Impacts of Anogenital Warts¬†
------------------------------------------------------------------------------

Patients with anogenital warts have higher rates of anxiety, depression, and psychosexual dysfunction than the general population.1,17‚Äì19 This may be due to associated pain, discomfort, feelings of shame or guilt, negative views of their self-image, or fears around transmission. A diagnosis of anogenital warts may also contribute to sexual dysfunction, such as vaginismus, dyspareunia, erectile dysfunction, or an orgasmic disorder.18

Therefore, a sexual function history should be taken at diagnosis and, if the patient has symptoms, they should be offered support and reassured that sexual dysfunction is common among people of all genders, ages, sexualities, and cultural backgrounds.1,11 The mental health of patients with recurrent anogenital warts should also be reviewed,1,11 as there can be significant impairment of their psychosocial wellbeing.19 In the author's opinion, the broad skillset of primary care doctors places them in an effective position for exploring the psychosocial implications of an anogenital warts diagnosis and managing any related or coexisting mental health issues.

6\. Offer the HPV Vaccine to Eligible Patients, and Explain That Different Forms of HPV Have Different Levels of Risk¬†
----------------------------------------------------------------------------------------------------------------------

The HPV vaccination programme began in 2008, and has been associated with a significant decline in the prevalence of anogenital warts:1,20,21 in the 2010‚Äì2019 period, prevalence dropped by 35%.1 Indeed, there is clear evidence that the HPV vaccine is highly effective at preventing anogenital warts when given prior to a first sexual encounter.20,21 Primary care professionals therefore play an important role in promoting public health and improving the prevention of anogenital warts by encouraging the uptake of the HPV vaccine to those who are eligible.

However, there is no evidence that the HPV vaccine has an impact on recurrent anogenital warts, and it is not recommended as a treatment for the condition.1,22 It should be clarified to patients that there are different forms of the virus, and that anogenital warts are associated with low-risk HPV genotypes, whereas cancer is associated with different high-risk HPV genotypes.1 Eligible patients should be counselled both to receive HPV vaccination and to continue attending their cervical screening at the recommended intervals, irrespective of whether they have been previously diagnosed with anogenital warts.1,11

Summary¬†
--------

Anogenital warts are a common, benign STI associated with low-risk HPV infection that can largely be diagnosed clinically. Although many cases resolve without treatment, there is a wide range of management options (including self- and clinician-administered treatments). It is important that primary care practitioners are familiar with these options, and are also aware of when they need to refer to sexual health services. Other important considerations in primary care include normalising sexual health screening, promoting public health measures, and discussing the psychosexual implications, as appropriate.

| Key Points |
| --- |
| 
*   Many cases of anogenital warts do not need treating and will self-resolve
*   Patients should be aware that the aim of treatment is to remove the visible lesions, but that sexual transmission to a partner can still happen when there are no visible lesions
*   Speculum or proctoscopic examination should be performed if there is suspicion of internal anogenital warts
*   Clinicians should always give advice to patients with anogenital warts on condom use and smoking cessation, and screen for other STIs¬†
*   Referral to a sexual health service should be offered if diagnosis is uncertain, if the patient is immunocompromised, pregnant, breastfeeding, or a child, or if they have internal involvement, recurrence of anogenital warts, or another feature of significant clinical concern
*   No treatment option is recommend over others, but podophyllotoxin and imiquimod are two self-administered treatment options
*   Podophyllotoxin 0.5% solution can be more effective than the 0.15% cream if used on easy-to-reach areas¬†
*   Patients should be empowered to swap to an alternative treatment if there is limited response
*   Patients with difficult-to-treat or recurrent anogenital warts should be prioritised for laser treatment and/or surgical removal¬†
*   Contact tracing is not required for anogenital warts¬†
*   Eligible patients should be encouraged to get the HPV vaccine, as it is shown to be highly effective at preventing anogenital warts and cancer
*   Patients with a cervix should continue to attend cervical screening at the standard intervals
*   Primary care practitioners should discuss psychosexual wellbeing with patients, and refer to specialist services if required.

STI=sexually transmitted infection; BASHH=British Association for Sexual Health and HIV; HPV=human papillomavirus |

<table data-height-full=""97:942"" style=""width: 100%;""><tbody><tr><td>Note: The terms ‚Äòman‚Äô/‚Äòmen‚Äô and ‚Äòwoman‚Äô/‚Äòwomen‚Äô have been used throughout this article to refer to people of male and female sex, respectively. However, in certain circumstances, a patient‚Äôs gender may not match their biological sex. Sensitivity should be used in such circumstances, including using the patient‚Äôs preferred pronouns.&nbsp;</td></tr></tbody></table>

<table data-height-full=""163:942"" style=""width: 100%;""><tbody><tr><td>Note: At the time of publication (September 2024), some of the treatments discussed in this article did not have UK marketing authorisation for the indications discussed. Prescribers should refer to the individual summaries of product characteristics for further information and recommendations regarding the use of pharmacological therapies. For off-licence use of medicines, the prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council‚Äôs <a class=""cms-external-link"" href=""https://www.gmc-uk.org/ethical-guidance/ethical-guidance-for-doctors/good-practice-in-prescribing-and-managing-medicines-and-devices"" target=""_blank""><em>Good practice in prescribing and managing medicines and devices</em></a> for further information.&nbsp;</td></tr></tbody></table>

| **Implementation Actions for ICSs** |
| --- |
| **written by Dr David Jenner, GP, Cullompton, Devon**
The following implementation actions are designed to support ICSs with the challenges involved in implementing new guidance at a system level. Our aim is to help you to consider how to deliver improvements to healthcare within the available resources.

*   **Ensure** rapid patient access to sexual health clinics following both self-presentation and referral by primary care practitioners
*   **Publish** guidelines on the management of anogenital warts on local health websites to support primary care staff
*   **Include** treatments for anogenital warts in local formularies, with guidance on their indications
*   **Encourage**¬†uptake of the HPV vaccine, in partnership with local Public Health colleagues.

ICS=integrated care system; HPV=human papillomavirus

 |

Continue reading with a FREE Medscape UK account

Access the latest UK medical news, UK-specific clinical guideline summaries,  
UK vaccination schedule and more for free.

Register Today

Already a member? Log in

* * *

#### 

References

1.  Nugent D, Apoola A, Coleman H et al. British Association for Sexual Health and HIV national guideline for the management of anogenital warts in adults (2024). _Int J STD AIDS_¬†2024; **35** (7): 498‚Äì509.
2.  Fairley C, Gay N, Forbes A et al. Hand-‚Äìgenital transmission of genital warts? An analysis of prevalence data. _Epidemiol Infect_ 1995; **115** (1): 169‚Äì176.
3.  Lee S, Park J, Norwitz E et al. Risk of vertical transmission of human papillomavirus throughout pregnancy: a prospective study. _PLoS One_ 2013; **8** (6): e66368.
4.  Gilson R, Nugent D, Werner R et al. 2019 IUSTI‚ÄìEurope guideline for the management of anogenital warts. _J Eur Acad Dermatol Venereol_¬†2020; **34** (8), 1644‚Äì1653.
5.  Centers for Disease Control and Prevention. _Sexually transmitted infections treatment guidelines, 2021_. Atlanta: CDC, 2021. Available at: [www.cdc.gov/std/treatment-guidelines/STI-Guidelines-2021.pdf](http://www.cdc.gov/std/treatment-guidelines/STI-Guidelines-2021.pdf)
6.  Karnes J, Usatine R. Management of external genital warts. _Am Fam Physician_¬†2014; **90** (5): 312‚Äì318.
7.  Leslie S, Sajjad H, Kumar S. Genital warts. In: _StatPearls \[internet\]._ Treasure Island: StatPearls Publishing, 2024. Available at: [www.ncbi.nlm.nih.gov/books/NBK441884](https://www.ncbi.nlm.nih.gov/books/NBK441884)
8.  UK Health Security Agency website. _Sexually transmitted infections (STIs): annual data tables._¬† [www.gov.uk/government/statistics/sexually-transmitted-infections-stis-annual-data-tables](https://www.gov.uk/government/statistics/sexually-transmitted-infections-stis-annual-data-tables) (accessed 13 August 2024).
9.  Ramlachan P, Naidoo K. Enhancing sexual health in primary care: guidance for practitioners. _S Afr Fam Pract_ 2024; **66** (1): e1‚Äìe5.
10.  Brook G, Church H, Evans C et al. 2019 UK national guideline for consultations requiring sexual history taking: Clinical Effectiveness Group British Association for Sexual Health and HIV. _Int J STD AIDS_¬†2020; **31** (10): 920‚Äì938.¬†
11.  Royal College of General Practitioners, British Association for Sexual Health and HIV. _Sexually transmitted infections in primary care_. London: RCGP, 2013. Available at: [www.bashh.org/\_userfiles/pages/files/sexuallytransmittedinfectionsinprimarycare2013.pdf](http://www.bashh.org/_userfiles/pages/files/sexuallytransmittedinfectionsinprimarycare2013.pdf)
12.  NICE. _Imiquimod_. British National Formulary. [bnf.nice.org.uk/drugs/imiquimod](https://bnf.nice.org.uk/drugs/imiquimod) (accessed 13 August 2024).
13.  Kaderli R, Schnuriger B, Brugger L. The impact of smoking on HPV infection and the development of anogenital warts. _Int J Colorectal Dis_ 2014; **29** (8): 899‚Äì908.
14.  McClean H, Radcliffe K, Sullivan A, Ahmed-Jushuf I. 2012 BASHH statement on partner notification for sexually transmissible infections. _Int J STD AIDS_¬†2013; **24** (1): 253‚Äì261.
15.  NICE. _Child maltreatment: when to suspect maltreatment in under 18s._ NICE Clinical Guideline 89. NICE, 2009 (updated October 2017). Available at: [www.nice.org.uk/cg89](http://www.nice.org.uk/cg89)
16.  Werner R, Westfechtel L, Dressler C et al. Anogenital warts and other HPV-associated anogenital lesions in the HIV-positive patient: a systematic review and meta- analysis of the efficacy and safety of interventions assessed in controlled clinical trials. _Sex Transm Infect_ 2017; **93** (8): 543‚Äì550.
17.  Kucukunal A, Altunay I, Mercan S. Sexual dysfunction in men suffering from genital warts. _J Sex Med_¬†2013;**10** (6): 1585‚Äì1591.
18.  Adeli M, Moghaddam-Banaem L, Shahali S. Sexual dysfunction in women with genital warts: a systematic review. _BMC Women‚Äôs Health_ 2022; **22** (1): 516.¬†
19.  Dominiak-Felden G, Cohet C, Atrux-Tallau S et al. Impact of human papillomavirus-related genital diseases on quality of life and psychosocial wellbeing: results of an observational, health-related quality of life study in the UK. _BMC Publ Health_ 2013; **13**: 1065.
20.  Checchi M, Mesher D, Mohammed H, et al. Declines in anogenital warts diagnoses since the change in 2012 to use the quadrivalent HPV vaccine in England: data to end 2017. _Sex Transm Infect_ 2019; **95** (5): 368‚Äì373.
21.  UK Health Security Agency website_. Sexually transmitted infections and screening for chlamydia in England: 2023 report_. [www.gov.uk/government/statistics/sexually-transmitted-infections-stis-annual-data-tables/sexually-transmitted-infections-and-screening-for-chlamydia-in-england-2023-report](https://www.gov.uk/government/statistics/sexually-transmitted-infections-stis-annual-data-tables/sexually-transmitted-infections-and-screening-for-chlamydia-in-england-2023-report) (accessed 13 August 2024).
22.  Coskuner E, Ozkan T, Karakose A et al. Impact of the quadrivalent HPV vaccine on disease recurrence in men exposed to HPV Infection: a randomized study. _J Sex Med_ 2014; **11** (11): 2785‚Äì2791.

* * *

EDITOR'S RECOMMENDATIONS
------------------------

*   [Sexually Transmitted Infections: Treatment](https://www.medscape.co.uk/viewarticle/treatment-trichomonas-vaginalis-mycoplasma-genitalium-2024a1000dqr)
    
    Clinical features, diagnosis, and treatment of infections caused by Trichomonas vaginalis and Mycoplasma genitalium, and treatment for vulvovaginal candidiasis, bacterial vaginosis, and anogenital warts resulting from HPV infection
    
    World Health Organization | New 26 July 2024
    
*   [Sexual and Reproductive Health, Men](https://www.medscape.co.uk/viewarticle/eau-guidelines-sexual-and-reproductive-health-men-2023a1000o09)
    
    Summary covering EAU recommendations on the medical aspects of sexual health in adult men
    
    European Association of Urology | Updated 20 May 2024
    
*   [Sexually Transmitted Infections, Symptomatic: Diagnosis and Assessment](https://www.medscape.co.uk/viewarticle/diagnosis-and-assessment-symptomatic-sexually-transmitted-2023a10006io)
    
    An evidence-based summary of WHO‚Äôs symptomatic STIs guideline, covering diagnosis and assessment including examination findings
    
    World Health Organization | 11 May 2023
    

YOU MAY ALSO LIKE
-----------------

[![Image 9: Could a Vape Flavour Ban Drive Users Back to Smoking?](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240830_disposable_flavored_vape_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/could-vape-flavour-ban-drive-users-back-smoking-2024a1000fug ""Could a Vape Flavour Ban Drive Users Back to Smoking?"")

[Could a Vape Flavour Ban Drive Users Back to Smoking?](https://www.medscape.co.uk/viewarticle/could-vape-flavour-ban-drive-users-back-smoking-2024a1000fug ""Could a Vape Flavour Ban Drive Users Back to Smoking?"")

The BMA has called for a ban on all flavoured vape liquids except tobacco in a move that users say, if enacted, would drive them back to smoking.

*   Medscape News UK
*   11 hours ago

[Pancreatic Cancer: NICE Quality Standard](https://www.medscape.co.uk/viewarticle/pancreatic-cancer-quality-standard-2024a1000fqo ""Pancreatic Cancer: NICE Quality Standard"")

A summary of the NICE quality standard for the diagnosis of pancreatic cancer and management of pancreatic ductal adenocarcinoma in adults

*   Guidelines Summary: Secondary Care
*   12 hours ago

[![Image 10: Mother's Vascular Skin Lesions Increase Risk for Offspring](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_230712_capillary_malformation_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/mothers-vascular-skin-lesions-increase-risk-offspring-2024a1000fq5 ""Mother's Vascular Skin Lesions Increase Risk for Offspring"")

[Mother's Vascular Skin Lesions Increase Risk for Offspring](https://www.medscape.co.uk/viewarticle/mothers-vascular-skin-lesions-increase-risk-offspring-2024a1000fq5 ""Mother's Vascular Skin Lesions Increase Risk for Offspring"")

Findings of a large population-based study supported a possible heritable component for angioma and especially for port-wine stain.

*   Medscape News UK
*   13 hours ago

[![Image 11: GPs Encouraged to Test, Treat Latent TB in Immigrants](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_230601_immigrants_refugees_walking_sunset_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/gps-encouraged-test-treat-latent-tb-immigrants-2024a1000fpa ""GPs Encouraged to Test, Treat Latent TB in Immigrants"")

[GPs Encouraged to Test, Treat Latent TB in Immigrants](https://www.medscape.co.uk/viewarticle/gps-encouraged-test-treat-latent-tb-immigrants-2024a1000fpa ""GPs Encouraged to Test, Treat Latent TB in Immigrants"")

Primary care in the United Kingdom is poised to take over TB management.

*   Medscape News UK
*   14 hours ago

[![Image 12: Back to School Measles Surge Feared](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_211102_child_vaccination_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/back-school-measles-surge-feared-2024a1000ftp ""Back to School Measles Surge Feared"")

[Back to School Measles Surge Feared](https://www.medscape.co.uk/viewarticle/back-school-measles-surge-feared-2024a1000ftp ""Back to School Measles Surge Feared"")

Experts warn of a potential surge in measles cases when children return to school next week and have urged parents to ensure children are up to date with vaccinations.

*   Medscape News UK
*   15 hours ago

[![Image 13: A Tale of Rheumatologist Volunteers Overseas and in the US](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/ht_240823_james_gore_and_patient_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/tale-rheumatologist-volunteers-overseas-and-united-states-2024a1000ftq ""A Tale of Rheumatologist Volunteers Overseas and in the US"")

[A Tale of Rheumatologist Volunteers Overseas and in the US](https://www.medscape.co.uk/s/viewarticle/tale-rheumatologist-volunteers-overseas-and-united-states-2024a1000ftq ""A Tale of Rheumatologist Volunteers Overseas and in the US"")

Two rheumatologists give insights about the great rewards of rheumatology volunteer work while also providing insights on its challenges across different settings.

*   Medscape Medical News
*   15 hours ago

[![Image 14: Seated Doctors Satisfy Patients](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240318_doctor_female_senior_patient_talking_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/seated-doctors-satisfy-patients-2024a1000ftl ""Seated Doctors Satisfy Patients"")

[Seated Doctors Satisfy Patients](https://www.medscape.co.uk/s/viewarticle/seated-doctors-satisfy-patients-2024a1000ftl ""Seated Doctors Satisfy Patients"")

A doctor's decision to sit at the bedside is associated with increased patient satisfaction, data suggested.

*   Medscape Medical News
*   16 hours ago

[![Image 15: Beyond the Paycheck: Top Non-Salary Perks for Doctors](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240829_happy_excited_doctor_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/beyond-paycheck-top-non-salary-perks-doctors-2024a1000fto ""Beyond the Paycheck: Top Non-Salary Perks for Doctors"")

[Beyond the Paycheck: Top Non-Salary Perks for Doctors](https://www.medscape.co.uk/s/viewarticle/beyond-paycheck-top-non-salary-perks-doctors-2024a1000fto ""Beyond the Paycheck: Top Non-Salary Perks for Doctors"")

When it comes to compensation, a doctor's paycheck is just the beginning. Discover the top non-salary perks that make the job even more rewarding.

*   Medscape Medical News
*   16 hours ago

[![Image 16: NHS Doctors Face Bullying and Reprisal for Speaking Out](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_220902_stressed_doctor_covering_face_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/nhs-doctors-face-bullying-and-reprisal-speaking-out-2024a1000ftj ""NHS Doctors Face Bullying and Reprisal for Speaking Out"")

[NHS Doctors Face Bullying and Reprisal for Speaking Out](https://www.medscape.co.uk/s/viewarticle/nhs-doctors-face-bullying-and-reprisal-speaking-out-2024a1000ftj ""NHS Doctors Face Bullying and Reprisal for Speaking Out"")

Less than 20% of doctors in Scotland are satisfied with their organisation's response to whistleblowing, a new BMA survey has revealed.

*   Press Association
*   16 hours ago

[![Image 17: Intermittent Fasting Aids Patients With Prediabetes or T2D](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/dt_240813_intermittent_fasting_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/intermittent-fasting-aids-patients-prediabetes-or-t2d-2024a1000ftc ""Intermittent Fasting Aids Patients With Prediabetes or T2D"")

[Intermittent Fasting Aids Patients With Prediabetes or T2D](https://www.medscape.co.uk/s/viewarticle/intermittent-fasting-aids-patients-prediabetes-or-t2d-2024a1000ftc ""Intermittent Fasting Aids Patients With Prediabetes or T2D"")

The approach is associated with reductions in body weight, BMI, and A1c levels.

*   Medscape Medical News
*   17 hours ago

[Cervical Screening Guidance for Nurses](https://www.medscape.co.uk/viewarticle/human-papillomavirus-cervical-screening-and-cervical-cancer-2024a1000dpy ""Cervical Screening Guidance for Nurses"")

Covers cervical cancer and screening recommendations for nursing undertaking consultations and examinations

*   Guidelines Summary: Primary Care
*   18 hours ago

[![Image 18: The '10 Commandments' of Endocarditis Management](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240614_afib_heart_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/10-commandments-endocarditis-management-2024a1000ft3 ""The '10 Commandments' of Endocarditis Management"")

[The '10 Commandments' of Endocarditis Management](https://www.medscape.co.uk/viewarticle/10-commandments-endocarditis-management-2024a1000ft3 ""The '10 Commandments' of Endocarditis Management"")

Significant updates in the 2023 European Society of Cardiology endocarditis guidelines include revised antibiotic prophylaxis and surgical indications.

*   Medscape News UK
*   18 hours ago

[![Image 19: Balloon Catheters for Blood Loss in Placenta Accreta Cases](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_231121_ultrasound_pregnant_obgyn_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/balloon-catheters-blood-loss-placenta-accreta-cases-2024a1000ft1 ""Balloon Catheters for Blood Loss in Placenta Accreta Cases"")

[Balloon Catheters for Blood Loss in Placenta Accreta Cases](https://www.medscape.co.uk/s/viewarticle/balloon-catheters-blood-loss-placenta-accreta-cases-2024a1000ft1 ""Balloon Catheters for Blood Loss in Placenta Accreta Cases"")

Prophylactic placement of balloon catheters or sheaths prior to planned cesarean delivery may reduce blood loss in women with placenta accreta spectrum disorder.

*   MDedge News
*   19 hours ago

[![Image 20: Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/pa_240829_chris_jones_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/breast-cancer-drug-may-slow-aggressive-brain-tumour-kids-2024a1000fra ""Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids"")

[Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids](https://www.medscape.co.uk/s/viewarticle/breast-cancer-drug-may-slow-aggressive-brain-tumour-kids-2024a1000fra ""Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids"")

Ribociclib, commonly used for breast cancer, has been found to stabilise a subtype of diffuse hemispheric glioma for about 17 months before regrowth begins.

*   Press Association
*   29 Aug 2024

[![Image 21: Alternate Insomnia Therapy Has Good Showing](https://img.medscapestatic.com/vim/live/professional_assets/dt_240313_insomnia_800x450px.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu ""Alternate Insomnia Therapy Has Good Showing"")

[Alternate Insomnia Therapy Has Good Showing](https://www.medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu ""Alternate Insomnia Therapy Has Good Showing"")

The brief nurse-delivered therapy aimed at restricting and standardising time in bed could make treatment more accessible to primary care patients.

*   Medscape News UK
*   29 Aug 2024

[![Image 22: Listeriosis During Pregnancy Can Be Fatal for the Fetus](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/dt_240828_listeria_bacteria_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/listeriosis-during-pregnancy-can-be-fatal-fetus-2024a1000frm ""Listeriosis During Pregnancy Can Be Fatal for the Fetus"")

[Listeriosis During Pregnancy Can Be Fatal for the Fetus](https://www.medscape.co.uk/s/viewarticle/listeriosis-during-pregnancy-can-be-fatal-fetus-2024a1000frm ""Listeriosis During Pregnancy Can Be Fatal for the Fetus"")

The rate of fetal loss or neonatal death from invasive listeriosis is 29%.

*   Medscape Medical News
*   29 Aug 2024

[![Image 23: Prisons Often Waste Ambulance Crew Time](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240829_prison_in_uk_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/prisons-often-waste-ambulance-crew-time-2024a1000fqp ""Prisons Often Waste Ambulance Crew Time"")

[Prisons Often Waste Ambulance Crew Time](https://www.medscape.co.uk/viewarticle/prisons-often-waste-ambulance-crew-time-2024a1000fqp ""Prisons Often Waste Ambulance Crew Time"")

Unnecessary 999 calls are being made by prison staff due to lack of experience and concerns over legal repercussions.

*   Medscape News UK
*   29 Aug 2024

[![Image 24: Recurrent UTI: Undercultured, Overtreated Despite Resistance](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_230216_urine_analysis_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/recurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni ""Recurrent UTI: Undercultured, Overtreated Despite Resistance"")

[Recurrent UTI: Undercultured, Overtreated Despite Resistance](https://www.medscape.co.uk/viewarticle/recurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni ""Recurrent UTI: Undercultured, Overtreated Despite Resistance"")

Roughly 40% of general practitioners do not culture recurrent UTIs and instead, just treat.

*   Medscape News UK
*   29 Aug 2024

[![Image 25: High-Dose Psilocybin Shows Promising Results for Depression](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_220215_psilocybin_mushrooms_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/high-dose-psilocybin-shows-promising-results-depression-2024a1000fqw ""High-Dose Psilocybin Shows Promising Results for Depression"")

[High-Dose Psilocybin Shows Promising Results for Depression](https://www.medscape.co.uk/s/viewarticle/high-dose-psilocybin-shows-promising-results-depression-2024a1000fqw ""High-Dose Psilocybin Shows Promising Results for Depression"")

A meta-analysis found that high-dose psilocybin for depressive symptoms showed better responses than placebo or escitalopram in antidepressant trials.

*   Medscape Medical News
*   29 Aug 2024

![Image 26](blob:http://medscape.co.uk/6742166de2ffdc98a2fc8b83a0aa235b)

[](https://www.medscape.co.uk/)

#### Find Us On

[](https://www.facebook.com/GuidelinesMedscape/)[](https://twitter.com/medscapeuk)[](http://www.linkedin.com/company/24356)[](https://www.youtube.com/user/medscape/)[](https://www.instagram.com/medscape/)

#### About

[About Medscape](https://www.medscape.com/public/about)[Privacy Policy](https://www.medscape.co.uk/public/privacy)[Editorial Policy](https://www.medscape.com/public/editorialpolicies)[Cookies](https://www.medscape.co.uk/public/cookies) [Manage Preferences](javascript:void\(0\);) [Terms of Use](https://www.medscape.com/public/termsofuse)[UK Modern Slavery Statement](https://www.medscape.co.uk/public/antislavery)[Advertising Policy](https://www.medscape.com/public/adpolicy)[Help Center](https://help.medscape.com/hc/en-us)

#### App

[Medscape](https://www.medscape.com/public/medscapeapp?pid=Medscape_footer&c=FooterIcon)

All material on this website is protected by copyright, Copyright ¬© 1994-2024 by WebMD LLC. This website also contains material copyrighted by 3rd parties.

           

![Image 27](https://t.co/i/adsct?bci=3&eci=2&event_id=0e0eb5cb-9132-4f5e-8783-3e9012821639&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=4995d7d5-8d05-4450-854b-f302eb14953a&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Fkey-learning-points-bashh-anogenital-warts-2024a1000esn&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=o5zto&type=javascript&version=2.3.30)![Image 28](https://analytics.twitter.com/i/adsct?bci=3&eci=2&event_id=0e0eb5cb-9132-4f5e-8783-3e9012821639&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=4995d7d5-8d05-4450-854b-f302eb14953a&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Fkey-learning-points-bashh-anogenital-warts-2024a1000esn&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=o5zto&type=javascript&version=2.3.30)![Image 29](https://t.co/i/adsct?bci=3&eci=2&event_id=c0207092-de57-40d3-8b63-1e9f9dd0947e&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=4995d7d5-8d05-4450-854b-f302eb14953a&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Fkey-learning-points-bashh-anogenital-warts-2024a1000esn&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=nvb1e&type=javascript&version=2.3.30)![Image 30](https://analytics.twitter.com/i/adsct?bci=3&eci=2&event_id=c0207092-de57-40d3-8b63-1e9f9dd0947e&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=4995d7d5-8d05-4450-854b-f302eb14953a&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Fkey-learning-points-bashh-anogenital-warts-2024a1000esn&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=nvb1e&type=javascript&version=2.3.30)![Image 31](https://t.co/i/adsct?bci=3&eci=2&event_id=0a81e410-e100-4920-9912-ae18d95b2d84&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=4995d7d5-8d05-4450-854b-f302eb14953a&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Fkey-learning-points-bashh-anogenital-warts-2024a1000esn&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=o5ztw&type=javascript&version=2.3.30)![Image 32](https://analytics.twitter.com/i/adsct?bci=3&eci=2&event_id=0a81e410-e100-4920-9912-ae18d95b2d84&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=4995d7d5-8d05-4450-854b-f302eb14953a&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Fkey-learning-points-bashh-anogenital-warts-2024a1000esn&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=o5ztw&type=javascript&version=2.3.30)

![Image 33](https://thrtle.com/insync?vxii_pid=10015&vxii_pdid=)

![Image 34](https://bh-eu.contextweb.com/bh/sr?action=add&token=Q4S7ZMWDWRFR&ch=1&url=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Fkey-learning-points-bashh-anogenital-warts-2024a1000esn&rr=&us_privacy=&param1=$$event$$&epid=&did=30644155357264568460625426357661507460&pf=0&usp=0&auth_channel=100&ev_id=0&topicid=$$topicid$$&conceptid=$$conceptid$$&ssp=34&gdpr_consent=&val=$$val$$&val=${val})![Image 35](https://bh.contextweb.com/bh/rtset?pid=562507&ev=0&us_privacy=)![Image 36](https://bh.contextweb.com/bh/rtset?pid=561967&ev=1&us_privacy=&gdpr=0&gdpr_consent=&rurl=https%3A%2F%2Fdsum.casalemedia.com%2Frum%3Fcm_dsp_id%3D189%26external_user_id%3D%25%25VGUID%25%25%26expiration%3D[EXPIRATION]%26us_privacy%3D%24%24us_privacy%24%24%26gdpr%3D%24%24gdpr%24%24%26gdpr_consent%3D%24%24gdpr_consent%24%24)![Image 37](https://bh.contextweb.com/bh/rtset?pid=561590&ev=1&us_privacy=&gdpr=0&gdpr_consent=&rurl=https%3A%2F%2Fpixel.rubiconproject.com%2Ftap.php%3Fv%3D390200%26nid%3D5120%26put%3D%25%25VGUID%25%25%26us_privacy%3D%24%24us_privacy%24%24%26gdpr%3D%24%24gdpr%24%24%26gdpr_consent%3D%24%24gdpr_consent%24%24)![Image 38](https://bh.contextweb.com/bh/rtset?pid=558356&ev=1&us_privacy=&gdpr=0&gdpr_consent=&rurl=https%3A%2F%2Feb2.3lift.com%2Fxuid%3Fmid%3D2636%26xuid%3D%25%25VGUID%25%25%26dongle%3D8bee%26us_privacy%3D%24%24us_privacy%24%24%26gdpr%3D%24%24gdpr%24%24%26gdpr_consent%3D%24%24gdpr_consent%24%24)
",gpt-4o-mini
2024-08-29 08:27:00,2024-08-31 05:12:39,"üîé **European Commission Authorizes Akantior for Acanthamoeba Keratitis Treatment** üöÄ

Exciting news for the ophthalmology community! The European Commission has granted marketing authorization for Akantior, the first medicinal treatment approved globally for Acanthamoeba keratitis. Highlights from the pivotal phase 3 trial show an impressive 84.8% curing rate and a 66.7% vision restoration rate without needing optical cornea transplants. üåçüí°

Akantior, marketed by Avanzanite Bioscience, marks a significant advancement in treating this rare condition, with exclusive rights secured across 26 European countries. üè•

Explore how this breakthrough could impact your practice and patient care. ü§ù

#AcanthamoebaKeratitis #Akantior #Ophthalmology #MedicalInnovation 

Share your thoughts or experiences with Acanthamoeba keratitis treatments below! üëáüîó [Read more](https://www.healio.com/news/ophthalmology/20240828/european-commission-grants-marketing-authorization-to-akantior-for-acanthamoeba-keratitis)",https://medsii.azureedge.net/images/638605168410416521-66d0300b6157181811bbc82c.jpg,https://www.healio.com/news/ophthalmology/20240828/european-commission-grants-marketing-authorization-to-akantior-for-acanthamoeba-keratitis,"You are a content creator tasked with crafting highly informative, easy to digest social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Thumbnail image URL: https://medsii.azureedge.net/images/638605168410416521-66d0300b6157181811bbc82c.jpg  
Title: European Commission grants marketing authorization to Akantior for<i> </i><i>A</i><i>canthamoeba</i> keratiti

URL Source: https://www.healio.com/news/ophthalmology/20240828/european-commission-grants-marketing-authorization-to-akantior-for-acanthamoeba-keratitis

Published Time: 2024-08-28

Markdown Content:
European Commission grants marketing authorization to Akantior for A canthamoeba keratitis
===============

[![Image 1: Healio](https://m1.healio.com/~/media/images/healio/healiologooptimized.svg)](https://www.healio.com/)

*   [News News](https://www.healio.com/news ""News"")
*   [CME CME](https://www.healio.com/cme ""CME"")
*   [Clinical Guidance Clinical Guidance](https://www.healio.com/clinical-guidance ""Clinical Guidance"")

*   [_Account_](https://www.healio.com/footer/account-information/my-account "" "")
*   [_Account Anonymous User_](javascript:void\($j.get\('/loginregistration/modals/loadloginmodal',function\(data\){$j\('body'\).append\(data\);}\)\) "" "")
*   [Log In Log In](javascript:void\($j.get\('/utilityapp/json/na/li/healiotwo/{ACC50322-FB7D-42FC-940E-84BDDAD3B84D}',function\(data\){$j\('body'\).append\(data\);}\)\) ""Log In"")
*   [Log Out Log Out](javascript:; ""Log Out"")

*   [News News](https://www.healio.com/news ""News"")
*   [CME CME](https://www.healio.com/cme ""CME"")
*   [Clinical Guidance Clinical Guidance](https://www.healio.com/clinical-guidance ""Clinical Guidance"")

*   [_Account_](https://www.healio.com/footer/account-information/my-account "" "")
*   [_Account Anonymous User_](javascript:void\($j.get\('/loginregistration/modals/loadloginmodal',function\(data\){$j\('body'\).append\(data\);}\)\) "" "")

*   [Specialties](https://www.healio.com/news/ophthalmology/20240828/european-commission-grants-marketing-authorization-to-akantior-for-acanthamoeba-keratitis#)
    
    Choose a specialty
    
    [All Specialties](https://www.healio.com/) [Allergy/Asthma](https://www.healio.com/allergy-asthma) [Hematology/Oncology](https://www.healio.com/hematology-oncology) [Infectious Disease](https://www.healio.com/infectious-disease) [Orthopedics](https://www.healio.com/orthopedics) [Rheumatology](https://www.healio.com/rheumatology)
    
*   [Home](https://www.healio.com/)
*   [Headline News](https://www.healio.com/news)
*   [Meeting News](https://www.healio.com/news/meeting-news)
*   [Podcasts](https://www.healio.com/news/podcasts)
*   [Blogs & Columns](https://www.healio.com/news/blogs-and-columns)
*   [Resources](https://www.healio.com/news/resources)

Menu Close

[Specialties](https://www.healio.com/news/ophthalmology/20240828/european-commission-grants-marketing-authorization-to-akantior-for-acanthamoeba-keratitis#collapseSpecialty)

*   [All Specialties](https://www.healio.com/news/?showall=1)
*   [Allergy/Asthma](https://www.healio.com/allergy-asthma)
*   [Hematology/Oncology](https://www.healio.com/hematology-oncology)
*   [Infectious Disease](https://www.healio.com/infectious-disease)
*   [Orthopedics](https://www.healio.com/orthopedics)
*   [Rheumatology](https://www.healio.com/rheumatology)

[Home](https://www.healio.com/)

[Headline News](https://www.healio.com/news/ophthalmology)

*   [Ophthalmology Subspecialties](https://www.healio.com/news/ophthalmology)
*   [Cataract Surgery](https://www.healio.com/news/ophthalmology/cataract-surgery)
*   [Contact Lenses](https://www.healio.com/news/ophthalmology/contact-lenses)
*   [Cornea/External Disease](https://www.healio.com/news/ophthalmology/cornea-external-disease)
*   [Glaucoma](https://www.healio.com/news/ophthalmology/glaucoma)
*   [Imaging/Diagnostics](https://www.healio.com/news/ophthalmology/imaging-diagnostics)
*   [Neurosciences](https://www.healio.com/news/ophthalmology/neurosciences)
*   [Ocular Oncology](https://www.healio.com/news/ophthalmology/ocular-oncology)
*   [Oculoplastics](https://www.healio.com/news/ophthalmology/oculoplastics)
*   [Ophthalmic Business](https://www.healio.com/news/ophthalmology/ophthalmic-business)
*   [Optics](https://www.healio.com/news/ophthalmology/optics)
*   [Pediatrics Strabismus](https://www.healio.com/news/ophthalmology/pediatrics-strabismus)
*   [Practice Management](https://www.healio.com/news/ophthalmology/practice-management)
*   [Presbyopia](https://www.healio.com/news/ophthalmology/presbyopia)
*   [Refractive Surgery](https://www.healio.com/news/ophthalmology/refractive-surgery)
*   [Regulatory/Legislative](https://www.healio.com/news/ophthalmology/regulatory-legislative)
*   [Retina/Vitreous](https://www.healio.com/news/ophthalmology/retina-vitreous)
*   [Technology](https://www.healio.com/news/ophthalmology/technology)
*   [Trauma](https://www.healio.com/news/ophthalmology/trauma)

[Meeting News](https://www.healio.com/news/meeting-news)

[Podcasts](https://www.healio.com/news/podcasts)

[Blogs & Columns](https://www.healio.com/news/blogs-and-columns)

[Resources](https://www.healio.com/news/resources)

[Account Account](https://www.healio.com/footer/account-information/my-account ""Account"")

[Log In Log In](javascript:void\($j.get\('/utilityapp/json/na/li/healiotwo/{ACC50322-FB7D-42FC-940E-84BDDAD3B84D}',function\(data\){$j\('body'\).append\(data\);}\)\) ""Log In"")

[Log Out Log Out](javascript:; ""Log Out"")

[![Image 2: Healio](https://m1.healio.com/~/media/images/healio/healiologooptimized.svg)](https://www.healio.com/)

Close Searchbar

1.  [Healio](https://www.healio.com/)
2.  [News](https://www.healio.com/news)
3.  [Ophthalmology](https://www.healio.com/news/ophthalmology)
4.  [Ophthalmic Business](https://www.healio.com/news/ophthalmology/ophthalmic-business)

![Image 3: occular surgery news logo](https://www.healio.com/~/media/h5/feature/news/publogos/osn.svg?la=en&h=32&w=145&hash=C099A5ADC410818ECDF2097A4CD3C51F)

Fact checked by[Gina Brockenbrough, MA](https://www.healio.com/authors/gbrockenbrough)

[](https://www.healio.com/news/ophthalmology/20240828/european-commission-grants-marketing-authorization-to-akantior-for-acanthamoeba-keratitis#)

#### Read more

#### [](https://www.healio.com/news/ophthalmology/20240828/european-commission-grants-marketing-authorization-to-akantior-for-acanthamoeba-keratitis#)

#### [](https://www.healio.com/news/ophthalmology/20240828/european-commission-grants-marketing-authorization-to-akantior-for-acanthamoeba-keratitis#)

#### [](https://www.healio.com/news/ophthalmology/20240828/european-commission-grants-marketing-authorization-to-akantior-for-acanthamoeba-keratitis#)

#### [](https://www.healio.com/news/ophthalmology/20240828/european-commission-grants-marketing-authorization-to-akantior-for-acanthamoeba-keratitis#)

August 28, 2024

1 min read

Save

European Commission grants marketing authorization to Akantior for _A__canthamoeba_ keratitis
=============================================================================================

![Image 4: occular surgery news logo](https://www.healio.com/~/media/h5/feature/news/publogos/osn.svg?la=en&h=32&w=145&hash=C099A5ADC410818ECDF2097A4CD3C51F)

Fact checked by[Gina Brockenbrough, MA](https://www.healio.com/authors/gbrockenbrough)

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

**You've successfully added to your alerts. You will receive an email when new content is published.**  
  
**[Click Here to Manage Email Alerts](javascript:void\(0\))**

**You've successfully added to your alerts. You will receive an email when new content is published.**  
  
**[Click Here to Manage Email Alerts](javascript:void\(0\))**  
  
Back to Healio

**We were unable to process your request. Please try again later. If you continue to have this issue please contact [customerservice@slackinc.com](mailto:customerservice@slackinc.com).**  
  
Back to Healio

Key takeaways:
--------------

*   The authorization is supported by positive data from a phase 3 pivotal trial.
*   Avanzanite Bioscience has exclusive rights to market Akantior in 26 countries in Europe.

The European Commission granted marketing authorization to Akantior for the treatment of _A__canthamoeba_ [keratitis](https://www.healio.com/news/ophthalmology/20240304/video-oxygen-does-not-play-a-role-in-crosslinking-for-infectious-keratitis), according to a press release from Avanzanite Bioscience.

The decision was backed by positive results from the phase 3 pivotal Orphan Drug for _Acanthamoeba_ Keratitis (ODAK) trial, which included 135 patients. Of these patients, 84.8% were cured of _A__canthamoeba_ keratitis (AK) after treatment with Akantior (polyhexanide, Avanzanite Bioscience). In addition, 66.7% of patients achieved full vision restoration without the need for optical [cornea transplants](https://www.healio.com/news/ophthalmology/20240718/blog-choose-the-transplantsaving-path).

     ![Image 5: Generic Breaking News infographic](https://www.healio.com/~/media/slack-news/generic-infographics/2023/generic-breaking-news.jpg?w=800)

The European Commission granted marketing authorization to Akantior for the treatment of _Acanthamoeba_ keratitis.  
  

According to the release, the drug is the first and only authorized medicinal treatment for AK globally. It previously received a positive opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use and a positive recommendation from the EMA Committee for Orphan Medicinal Products.

Akantior is the second rare disease medicine commercialized by Avanzanite, which has secured exclusive rights to commercialize the treatment in 26 countries in Europe.

‚ÄúThis marketing authorization is the beginning of a new chapter for the treatment of _A__canthamoeba_ keratitis and a monumental victory for AK patients in Europe,‚Äù **Adam Plich,** founder and CEO of Avanzanite Bioscience, said in the release. ‚ÄúAt Avanzanite, we are committed to supporting broad access to our innovative therapies and look forward to collaborating with local health authorities in 26 European countries to secure sustainable access agreements so we can save the eyes of as many eligible patients as possible.‚Äù

Published by: ![Image 6: occular surgery news logo](https://www.healio.com/~/media/h5/feature/news/publogos/osn.svg?la=en&h=32&w=145&hash=C099A5ADC410818ECDF2097A4CD3C51F)

Sources/DisclosuresCollapse

**Source:**[Press Release](https://www.businesswire.com/news/home/20240826744342/en/Avanzanite-Bioscience-Reports-European-Commissions-Authorisation-of-Orphan-Medicinal-Product-AKANTIOR%C2%AE)

Read more about

[acanthamoeba keratitis](https://www.healio.com/topics/acanthamoeba-keratitis)

[cornea transplants](https://www.healio.com/topics/cornea-transplants)

[marketing](https://www.healio.com/topics/marketing)

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

**You've successfully added to your alerts. You will receive an email when new content is published.**  
  
**[Click Here to Manage Email Alerts](javascript:void\(0\))**

**You've successfully added to your alerts. You will receive an email when new content is published.**  
  
**[Click Here to Manage Email Alerts](javascript:void\(0\))**  
  
Back to Healio

**We were unable to process your request. Please try again later. If you continue to have this issue please contact [customerservice@slackinc.com](mailto:customerservice@slackinc.com).**  
  
Back to Healio

*   [Facebook](javascript:void\(0\))
*   [Twitter](javascript:void\(0\))
*   [LinkedIn](javascript:void\(0\))
*   [Email](mailto:?subject=IsawthisarticleonHealio.comandthoughtyoumightbeinterestedinit&Body=https%3a%2f%2fwww.healio.com%2fnews%2fophthalmology%2f20240828%2feuropean-commission-grants-marketing-authorization-to-akantior-for-acanthamoeba-keratitis%3futm_source%3dselligent%26utm_medium%3demail%26utm_campaign%3dnews)
*   [Print](javascript:void\(0\))
*   [Comment](https://www.healio.com/footer/healio-dot-com/contact-the-news-desk)

[Continue Reading](javascript:void\(0\))

Related Content
---------------

[Play on Healio ![Image 7: Word Doc](https://m2.healio.com/~/media/images/footer/worddoc_desktop.svg)](https://www.healio.com/worddoc)

Follow Healio

*   [Twitter](https://twitter.com/GoHealio)
*   [Facebook](https://www.facebook.com/HealioNetwork)
*   [Instagram](https://www.instagram.com/gohealio)
*   [Threads](https://www.threads.net/gohealio)
*   [LinkedIn](http://www.linkedin.com/company/healio)

About

*   [About Healio About Healio](https://www.healio.com/about-healio ""About Healio"")
*   [About the Wyanoke Group About the Wyanoke Group](https://www.healio.com/about-the-wyanoke-group ""About the Wyanoke Group"")
*   [Editorial Policy and Philosophy Editorial Policy and Philosophy](https://www.healio.com/editorial-policy-and-philosophy ""Editorial Policy and Philosophy"")
*   [Sitemap Sitemap](https://www.healio.com/sitemap ""Sitemap"")

Account Information

*   [My Account Login](javascript:void\($j.get\('/utilityapp/json/na/li/healiotwo/{ACC50322-FB7D-42FC-940E-84BDDAD3B84D}?returnUrl=https://preview.healio.com/footer/account-information/my-account',function\(data\){$j\('body'\).append\(data\);}\)\) ""My Account"")
*   [My Account My Account](https://www.healio.com/my-account ""My Account"")
*   [Help Help](https://www.healio.com/help ""Help"")
*   [Email Subscriptions Email Subscriptions](https://www.healio.com/my-account/email-subscriptions-and-alerts ""Email Subscriptions"")
*   [Email Subscriptions Email Subscriptions Unknown](javascript:void\($j.get\('/utilityapp/json/na/li/healiotwo/{ACC50322-FB7D-42FC-940E-84BDDAD3B84D}?returnUrl=https://www.healio.com/my-account/email-subscriptions-and-alerts',function\(data\){$j\('body'\).append\(data\);}\)\) ""Email Subscriptions"")
*   [Newspaper and Journal Subscriptions Newspaper and Journal Subscriptions](https://www.healio.com/subscribe ""Newspaper and Journal Subscriptions"")

Contact Us

*   [Email Us Email Us](https://www.healio.com/help#request ""Email Us"")
*   [Contact Newsroom Contact Newsroom](https://www.healio.com/contact-newsroom ""Contact Newsroom"")
*   [Advertising Information Advertising Information](https://www.healio.com/advertising-information ""Advertising Information"")
*   [Permissions and Reprints Permissions and Reprints](https://www.healio.com/reprints-permissions ""Permissions and Reprints"")

Legal

*   [Do Not Sell My Personal Information Do Not Sell My Personal Information](https://www.healio.com/do-not-sell-my-personal-information ""Do Not Sell My Personal Information"")
*   [Terms and Conditions Terms and Conditions](https://www.healio.com/terms-and-conditions ""Terms and Conditions"")
*   [Medical Disclaimer Medical Disclaimer](https://www.healio.com/medical-disclaimer ""Medical Disclaimer"")
*   [Privacy Policy Privacy Policy](https://www.healio.com/privacy-policy ""Privacy Policy"")

Sign Up for Email

Get the latest news and education delivered to your inbox

Email address 

Enter your email

[Update email address](https://www.healio.com/footer/account-information/my-account/edit-profile)

Specialty

Choose your specialty\*

*   All Specialties
*   Allergy & Asthma
*   Cardiology
*   Dermatology
*   Endocrinology
*   Gastroenterology/Hepatology
*   Hematology Oncology
*   Infectious Disease
*   Nephrology
*   Neurology
*   Ophthalmology
*   Optometry
*   Orthopedics
*   Pediatrics
*   Primary Care
*   Psychiatry
*   Pulmonology
*   Rheumatology
*   Women‚Äôs Health & OB/GYN

Choose your specialty

Subscribe

Update email address
--------------------

The email address associated with your Healio account is:

If you would like to edit or change the email address that your subscriptions and alerts are sent to, use the ""Update email address"" link.

[Update email address](https://www.healio.com/footer/account-information/my-account/edit-profile)

¬© 2024 Healio All Rights Reserved.

We‚Äôre sorry, but an unexpected error has occurred.
--------------------------------------------------

**Please refresh your browser and try again. If this error persists, please contact [ITSupport@wyanokegroup.com](mailto:itsupport@wyanokegroup.com) for assistance.**

Close
",gpt-4o-2024-08-06
2024-08-27 00:00:00,2024-08-31 05:12:45,"‚ö° Top 11 MedTech Startups Revolutionizing Healthcare: VCs Share Their Picks! ‚ö°

As the medtech sector continues to innovate, key players are emerging with groundbreaking solutions. Discover standout startups like Medical Microinstruments' surgical robots and CorWave's heart failure therapy. These companies, spotlighted by VCs, are pioneering advancements in surgical aids, diagnostic tools, and more! 

Stay ahead of the curve by exploring these game-changers and share your insights on how they could transform patient care. 

#MedTech #Innovation #Healthcare #Robotics #Diagnostics

üëâ [Explore more](https://sifted.eu/articles/medtech-startup-vc-trends/)",https://images.sifted.eu/wp-content/uploads/2024/08/23145641/Linus-final-Kopie-scaled-e1724421412663.jpg?auto=format&fit=max&w=3840&q=75,https://sifted.eu/articles/medtech-startup-vc-trends/,"You are a content creator tasked with crafting highly informative, easy to digest social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Title: 11 medtech startups to watch, according to VCs | Sifted

URL Source: https://sifted.eu/articles/medtech-startup-vc-trends/

Markdown Content:
Medtech has had a mixed few years. In 2023, startups in the sector raised $2.2bn with 2024 looking similar ‚Äî roughly half of the $4bn picked up in 2021, according to [Sifted data.](https://sifted.eu/pro/briefings/medtech-2024)

But there have still been some sizable rounds in recent times. Since the start of 2023, surgical robotics startups have been the biggest winners. The UK‚Äôs CMR Surgical picked up [¬£165m](https://sifted.eu/articles/cmr-surgical-raise-2023) in September last year, Switzerland‚Äôs DistalMotion $150m in April 2023 and Italy‚Äôs Medical Microinstruments $110m in February this year.

There‚Äôs also been some buzz around next-gen diagnostic devices, as founders ‚Äî including [Spotify‚Äôs Daniel Ek](https://sifted.eu/articles/daniel-eks-body-scanning-neko-health-is-expanding-to-the-uk-news) with his body scanning startup Neko Health ‚Äî look to tap into the trend of more people using wellbeing and fitness devices like Apple Watches and Oura rings.

But which non-portfolio medtech startups are investors keeping a close eye on? To find out, Sifted spoke to VCs at 415 Capital, Sofinnova Partners, MIG Capital and SHS Capital.

### **Linus Rieder, principal at 415 Capital**

![Image 1](https://images.sifted.eu/wp-content/uploads/2024/08/23145641/Linus-final-Kopie-scaled-e1724421412663.jpg?auto=format&fit=max&w=3840&q=75)

#### **Medical Microinstruments (MMI) ‚Äì Italy**

MMI is building surgical robots to help with micro-surgery. Its robotics platform can be used in reconstructive surgery, plastic surgery and head-neck surgery. The startup is looking to solve key issues in microsurgery like the effects of surgeon tremor and reduces the need for microsurgery training.

#### **Gradient Denervation Technologies ‚Äî France**

Gradient Denervation Technologies is developing a device for treating heart failure patients with associated pulmonary hypertension. As many as [half of heart failure patients](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199161/) around the world have elevated pulmonary vascular resistance, which is shown to lead to an increased risk of mortality and hospitalisation. There are no approved drug or device therapies for this group of pulmonary hypertension patients. By using minimally invasive ultrasound to treat hyperactive nerves in the pulmonary arteries, however, the startup‚Äôs technology has the potential to treat and help tens of thousands of patients each year.

#### **CorWave ‚Äî France**

CorWave's left ventricular assist device (LVAD) mimics the natural heart's function to treat patients with advanced heart failure. This technology enables the device to replicate the heart pulses, reducing the mechanical damage to blood cells common with current LVADs.

### **Anne Osdoit, partner at Sofinnova Partners**

![Image 2](https://images.sifted.eu/wp-content/uploads/2024/08/23145729/%C2%A9Delporte-AnneOsdoit02-scaled-e1724421470674.jpg?auto=format&fit=max&w=3840&q=75)

#### **Ganymed Robotics ‚Äî France**¬†

Ganymed is working on a robotics platform to assist surgeons with implant placement during knee replacement surgery. The Paris-based company's approach uses computer vision and artificial intelligence to perceive, and extract knowledge from, the surgical environment in a non-invasive manner, removing imaging and registration steps that add time and complexity to knee surgery.

#### **Gleamer ‚Äî France**

Gleamer is developing AI tools to enhance image interpretation for radiologists. The startup‚Äôs main product helps clinicians identify bone trauma at the point of care. Gleamer has achieved multiple regulatory approvals and successfully commercially deployed in both the US and EU.

#### **Salvia BioElectronics ‚Äî The Netherlands**¬†

Salvia BioElectronics is developing drug-free neuromodulation therapies ‚Äî which refers to a group of medical procedures that look to change brain activity by stimulating nerves ‚Äî for migraines. Salvia's paper-thin implant is designed to be placed under the forehead to reduce the frequency and intensity of migraine attacks by delivering gentle electrical pulses to the nerves associated with the condition. The company is currently in the clinical stage, having received the Breakthrough Device Designation from the United States Food and Drug Administration (FDA), which facilitates expedited market access for devices that treat life-threatening or irreversibly debilitating conditions.

### **Fei Tian, principal at MIG Capital**

![Image 3](https://images.sifted.eu/wp-content/uploads/2024/08/23150100/image001-4-scaled-e1724421677917.jpg?auto=format&fit=max&w=3840&q=75)

#### **Artidis ‚Äî Switzerland**

Artidis is developing imaging tools for cancer diagnostics. It combines a nanotechnology device which analyses tissue with a digital data platform to measure the physical characteristics of both tumour cells and the tumour microenvironment. After determining if a tumour is benign or malignant, Artidis‚Äô technology identifies if it will spread to other sites and can help inform chemotherapy and immunotherapy permeability and treatment response.

#### **CoreMedic ‚Äî Switzerland**¬†

CoreMedic has developed an implant which treats the heart condition mitral valve regurgitation (MR). The CoreMedic implant can replace ruptured mitral ‚Äî a part of the heart ‚Äî in a minimally invasive procedure that is physiological and reproducible, promising long-term clinical benefits.

### **Cornelius Maas, partner at SHS Capital**

![Image 4](https://images.sifted.eu/wp-content/uploads/2023/06/27174537/Dr.-Cornelius-Maas_SHS_38_retouched-scaled-e1724421707488.jpg?auto=format&fit=max&w=3840&q=75)

#### **Vitestro ‚Äî The Netherlands**

Vitestro is developing an autonomous blood drawing device. This innovative device combines robotics and AI to perform blood drawing more efficiently and safely. Over the past year, Vitestro has made significant strides in clinical trials and secured an additional ‚Ç¨20m in funding in April. Vitestro‚Äôs tool could mean less burden for patients, less work for the medical staff and consequently reduce costs for the healthcare system.

#### **Saphenus ‚Äî Austria**

Saphenus is developing sensory feedback systems for prosthetics. Their key product, the Suralis system, provides users of lower-limb prosthetics with the sensation of foot contact, significantly improving balance and gait. Recently, Saphenus received FDA approval with their Suralis systema and received reimbursement status with key German medical insurers.

#### **Bluedrop Medical ‚Äî Ireland**

Bluedrop Medical is developing a medical device to monitor foot health and prevent diabetic foot ulcers. It looks like a weighing scale and aims to enable early detection of foot ulcers, which can lead to amputation. Bluedrop Medical is a good example of how remote monitoring can replace doctor visits while preventing serious disease progression, improving patient outcomes and reducing healthcare costs.
",gpt-4o-2024-08-06
2024-08-13 00:00:00,2024-08-31 05:12:52,"**GLP-1 Weight Loss Drugs: A Game-Changer in Obesity Treatment?** üöÄüíä

The emergence of GLP-1s, such as Ozempic and Wegovy, is creating ripples in the healthcare sector, presenting a potential $150 billion market by the early 2030s. These drugs, initially designed for diabetes, have been lauded for their impressive weight loss outcomes.

Startups like Oviva and Embla are riding this wave, incorporating GLP-1s into their treatment regimes and poised for significant growth. Yet, challenges remain with supply chain constraints and regulatory hurdles in Europe‚Äîparticularly around securing reimbursement through national healthcare systems.

How do you view the integration of GLP-1s in weight management? Share your insights on adapting healthcare delivery in response to these emerging trends! #HealthTech #GLP1Drugs #WeightLossInnovation

![Image](https://images.sifted.eu/wp-content/uploads/2023/09/07164512/Screenshot-2023-09-07-at-16.45.04.png?auto=format&fit=crop&crop=faces%2Cedges%2Centropy&ar=3%3A1&w=3840&q=75)",https://images.sifted.eu/wp-content/uploads/2023/09/07164512/Screenshot-2023-09-07-at-16.45.04.png?auto=format&fit=crop&crop=faces%2Cedges%2Centropy&ar=3%3A1&w=3840&q=75,https://sifted.eu/articles/startups-wegovy-ozempic-shift/,"You are a content creator tasked with crafting highly informative, easy to digest social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Open navigation menu

[](https://sifted.eu/)

*   News
*   Insights
*   Newsletters
*   Events
[Podcasts](https://sifted.eu/podcasts)

[](https://sifted.eu/search)

[SubscribeSubscribe](https://sifted.eu/subscribe)

[Log in](https://sifted.eu/members/login?redirectUrl=%2Farticles%2Fstartups-wegovy-ozempic-shift)

[](https://sifted.eu/)

**Startup Europe.** Grown up reporting.

[Subscribe](https://sifted.eu/subscribe)

[Log in](https://sifted.eu/members/login?redirectUrl=%2Farticles%2Fstartups-wegovy-ozempic-shift)

*   ### News
    
*   ### Insights
    
*   ### Newsletters
    
*   ### Events
    
*   [Podcasts](https://sifted.eu/podcasts)

*   [Search](https://sifted.eu/search)

Backed by

### Company

*   [About](https://sifted.eu/about)
*   [Careers](https://sifted.eu/careers)
*   [Advertising](https://sifted.eu/advertising)
*   [Controllership](https://sifted.eu/controllership/)
*   [Cookie Policy](https://sifted.eu/cookie-policy)
*   [Privacy policy](https://sifted.eu/privacy-policy)
*   [AI Code of Conduct](https://sifted.eu/ai-code-of-conduct)
*   [Terms of use](https://sifted.eu/terms-of-use)

### Sifted Pro

*   [Subscribe](https://sifted.eu/subscribe)
*   [~/Briefings](https://sifted.eu/pro/briefings/about)
*   [~/Pitches](https://sifted.eu/pro/roundtables)
*   [~/Scout](https://sifted.eu/scout)

### Products

*   [~/Newsletters](https://sifted.eu/newsletters)
*   [~/Rankings](https://sifted.eu/rankings)
*   [~/Reports](https://sifted.eu/intelligence/reports)

### Community

*   [~/Talks](https://sifted.eu/talks)
*   [~/Podcasts](https://sifted.eu/podcasts)
*   [~/Summit](https://summit.sifted.eu/)
*   [Jobs board](https://jobs.sifted.eu/?source=navbar&utm_source=navbar&utm_medium=partner_referral)

*   [![Image 51: X Logo](https://www.datocms-assets.com/60124/1697443751-x-logo.svg)](https://twitter.com/siftedeu)
*   [![Image 52: LinkedIn Logo](https://www.datocms-assets.com/60124/1689076682-linkedin.svg)](https://www.linkedin.com/company/siftedeu/)
*   [![Image 53: Facebook Logo](https://www.datocms-assets.com/60124/1689076874-facebook.svg)](https://www.facebook.com/siftedeu)
*   [![Image 54: RSS Feed Logo](https://www.datocms-assets.com/60124/1689076939-rss-feed.svg)](https://sifted.eu/feed/?post_type=article)

¬© 2024 Sifted EU Ltd. All Rights Reserved.

[Analysis](https://sifted.eu/categories/analysis/)August 13, 2024

Riding the Wegovy wave: The startups shifting focus to GLP-1s to tap the $150bn weight loss drug market
=======================================================================================================

Founders and investors see massive potential in the new drug class ‚Äî but funding is yet to flood startups in the sector
-----------------------------------------------------------------------------------------------------------------------

* * *

[Kai Nicol-Schwarz](https://sifted.eu/author/kai-nicol-schwarz/)

7 min read

![Image 55](https://images.sifted.eu/wp-content/uploads/2023/09/07164512/Screenshot-2023-09-07-at-16.45.04.png?auto=format&fit=crop&crop=faces%2Cedges%2Centropy&ar=3%3A1&w=3840&q=75)

The meteoric rise of a new class of weight loss drugs over the past two years, known as GLP-1s, has seen a new name take the title of Europe‚Äôs most valuable company, helped a country dodge a recession and hit grocery sales in the US.

The valuations of the companies that make this so-called ‚Äúmiracle‚Äù class of drugs ‚Äî which includes Danish pharma giant Novo Nordisk (maker of Ozempic and Wegovy) and US rival Eli Lilly (maker of Mounjaro and Zepbound) ‚Äî have [soared](https://www.economist.com/business/2024/03/04/the-battle-over-the-trillion-dollar-weight-loss-bonanza)¬†as investors bet big on a medication projected by some to hit [$150bn in sales](https://www.reuters.com/business/healthcare-pharmaceuticals/weight-loss-drug-forecasts-jump-150-billion-supply-grows-2024-05-28/) by the early 2030s.

The potential of the market has not been lost on founders.

It‚Äôs a ‚Äúhuge‚Äù opportunity, says Kai Eberhardt, the founder and CEO of Oviva, a Swiss weight loss management platform which operates in the UK, France and Germany, alongside its home market. It began offering GLP-1 drugs as part of its treatment options in the second quarter of this year.

Advertisement

‚ÄúFor us \[GLP-1 drugs\] are already a strong growth driver,‚Äù he says. ‚ÄúThe newer GLP-1 class of medications have created real excitement due to their impressive outcomes in weight loss, transforming the treatment options available for those living with obesity.‚Äù

While treatment involving GLP-1 drugs is currently a small part of Oviva‚Äôs overall business ‚Äî Eberhardt says it‚Äôs growing total patient and revenue numbers by ‚Äúdouble digit‚Äù percentage points year-on-year ‚Äî the meds could become the startup‚Äôs ‚Äúlargest‚Äù growth driver in the future, he tells Sifted.

### **Riding the wave**

Oviva‚Äôs not alone. There are a slew of startups in Europe looking to tap into the opportunity ‚Äî many of which have recently shifted operations to focus on selling GLP-1 drugs or provide treatment pathways around the medication, which was first designed to treat diabetes but was later found to be effective at suppressing appetite and helping people lose weight.

In the last two years GLP-1s have become a go-to weight loss solution popularised by a roster of celebrity users. According to Walmart‚Äôs CEO, [food sales have fallen](https://www.bloomberg.com/news/articles/2023-10-04/walmart-says-ozempic-weight-loss-drugs-causing-slight-pullback-by-shoppers?sref=MTy2GeXk) as the [one in eight adults](http://cnbc.com/2024/05/14/healthy-returns-1-in-8-adults-have-taken-glp-1s-like-ozempic-survey.html) in the US who have used the meds slim down their buying habits. The drug class has also seen Novo Nordisk overtake luxury fashion brand LVMH as Europe‚Äôs [most valuable company,](https://www.ft.com/content/19357584-62e0-452f-a06f-7cda1d8cd0e3) propping up [Denmark‚Äôs GDP](https://www.thetimes.com/business-money/economics/article/wegovy-proves-to-be-wonder-drug-for-danish-economy-rgd6lqjh5) in the process.

All of the attention has got VCs excited, and companies on both sides of the Atlantic have [convinced them to get out their chequebook](https://sifted.eu/articles/weight-loss-drug-mania-reaches-europe-denmarks-embla-raises-10m): Danish startup Embla, which prescribes GLP-1 meds alongside ongoing clinical care and lifestyle advice for patients looking to lose weight in its home market and the UK, picked up a [‚Ç¨10m Series A](https://sifted.eu/articles/weight-loss-drug-mania-reaches-europe-denmarks-embla-raises-10m) in August 2023 a year on from a ‚Ç¨3.5m seed round. Swedish startup Yazen, which says it too prescribes GLP-1 drugs in combination with clinical care, also raised ‚Ç¨3.1m last summer.

Many startups operating in the GLP-1 space didn‚Äôt start life offering them ‚Äî largely due to launching before the drugs were popularised for weight loss. Ozempic was approved for sale in the US in 2017 and Europe in 2018; Wegovy was approved in the US in 2021 and Europe in 2022.

UK-based Numan, a digital medication and supplements provider founded in 2016, started by selling sexual health treatments; it began prescribing weight loss drugs in 2022. For years the company marketed itself as a [‚Äúmen‚Äôs health‚Äù](https://sifted.eu/articles/numan-mens-health-stigma) brand, but has recently changed that. The company‚Äôs website uses images of men _and_ women on its landing page for weight-loss treatments.

![Image 56](https://images.sifted.eu/wp-content/uploads/2024/08/12165326/unnamed-24-e1723478018874.png?auto=format&fit=max&w=3840&q=75)

Screenshot from Numan's website

Yazen, which launched its weight loss service in 2022, initially set out to exclusively target obese men, but broadened its focus before launching to include obesity more generally, after seeing how effective GLP-1 drugs were, says CEO Fredrik Meurling.

Meurling tells Sifted it had hit ‚Ç¨14m annual recurring revenue and treated 15k patients by June this year. It‚Äôs now active in Sweden, Norway, The Netherlands and Spain, and has pilot projects in England and Germany.

Other startups like UK-based Manual, which like Numan started out offering men‚Äôs sexual health treatments, also started prescribing weight loss medications in 2022.

Advertisement

‚Äú\[GLP-1 meds\] are a game changer,‚Äù says Michael Treskow, partner at Eight Roads Ventures, adding it would be ‚Äústrange‚Äù if a startup working in the weight loss space wasn‚Äôt looking into how they could add the drugs into their offering.

While GLP-1 meds have been part of some treatment courses at Embla since it launched in 2021, the ‚Äúhype‚Äù surrounding the drug class has ‚Äúopened doors‚Äù for the startup, says co-CEO and cofounder Nicholas Syhler ‚Äî adding that the startup managed to raise its ‚Ç¨400k pre-seed round in 2021 just three weeks after incorporation. It‚Äôs now gearing up for a fundraise in 2025 and expanding to the US, where it‚Äôll look to target US employers ‚Äî who pay for the majority of healthcare in the country.

### **Kinks in the supply chain**

There are still big questions hanging over European startups in the sector ‚Äî not least around whether a European GLP-1 startup can raise the kinds of funds needed to hit real scale.

Some of the biggest rounds for startups vending GLP-1 drugs have been in the US, including Calibrate‚Äôs $100m in 2021 and Form Health‚Äôs $38m in June this year. In Europe, no company selling the drug or treatment pathways around it has raised more than ‚Ç¨10m in a single round.

Investors and founders tell Sifted supply chain issues are part of that problem. Manufacturers have struggled to keep up with demand for the drug, and last year, startups in the UK were told by the government to remove Ozempic from sale due to shortages of the drug for diabetics ‚Äî [Manual was still selling past the deadline.](https://sifted.eu/articles/healthtech-manual-selling-ozempic-beyond-uk-government-deadline)

If a startup's revenues are closely tied to the availability of those drugs, they could be at the mercy of manufacturing capability. But as pharma bolsters production capabilities those issues could diminish, says Christoph Ruedig, partner at Albion VC.

‚ÄúAs there are severe shortages of GLP-1 drugs in Europe (Eli Lilly and Novo Nordisk are prioritising the US as pricing is higher) the opportunity to date in Europe has been limited but growing.‚Äù

### **Who‚Äôll stump up the cash?**

There‚Äôs also a challenge finding the right people to pay, and in Europe, national healthcare providers need to open up to reimbursing startups providing weight loss care, investors say.

While Numan‚Äôs head of medical Luke Pratsides says that the ‚Äúsuccess of private sector companies offering GLP-1 \[drugs\] shows that the public are willing to pay to meet a significant need that is being underserved by the NHS‚Äù, many in the sector think that only serving consumers paying out of their own pocket won‚Äôt be enough to hit real scale.

‚ÄúUS investors have told us that they will only invest in companies that get on enterprise contracts \[selling to whole organisations like health insurers\],‚Äù says Syhler. ‚ÄúThis means proving that they can deliver high-quality and sustainable care ‚Äî where the economics and outcomes make sense long-term for both patients and payors.‚Äù

In Europe, where the majority of people have their healthcare paid for by the state, hitting scale will likely come down to whether or not companies can get their services reimbursed by national healthcare providers, say some investors.

In the UK Wegovy is approved for use to manage obesity in the NHS, but it is currently only available through specialist weight management clinics, limiting availability.

Oviva is one the few startups that has had its supply of GLP-1 drugs alongside its weight loss platform reimbursed by the NHS ‚Äî but it had a head start on others, being reimbursed by the organisation long before the rise of weight loss meds, in 2016. Embla co-CEO and cofounder Laust Axelsen tells Sifted that it‚Äôs in ‚Äúmature dialogues with several health systems‚Äù.

‚ÄúIt is still a struggle with reimbursement, in every country,‚Äù says Hekla Arnardottir, partner at Crowberry Capital, which has backed Embla, pointing to difficult regulation and healthcare systems that [don‚Äôt always want to work with startups.](https://sifted.eu/articles/ai-healthcare-nhs-startup) Without reimbursement in Europe, she adds, it will be hard for companies to reach the sort of revenue figures needed to raise growth capital and hit unicorn status.

Whether a European startup will be able to do that remains to be seen ‚Äî but what is clear is that the hype surrounding GLP-1 meds is unlikely to die down anytime soon. ‚ÄúI've never been an investor in a company that‚Äôs got so much attention ‚Äî in a space that‚Äôs got so much attention,‚Äù says Arnardottir.

Advertisement

Editor's picks

*   [News](https://sifted.eu/categories/news/)
    
    [Three cofounders leave French AI startup H just three months after raising $220m seed](https://sifted.eu/articles/three-cofounders-leave-h-news/)
    
    * * *
    
*   [Analysis](https://sifted.eu/categories/analysis/)
    
    [Lost millions, a luxury cottage under threat and Oussama Ammar‚Äôs new startup accelerator: What‚Äôs going on with the dispute at The Family?](https://sifted.eu/articles/the-family-oussama-ammar-startup-latest/)
    
    * * *
    
*   [News](https://sifted.eu/categories/news/)
    
    [Mike Lynch‚Äôs impact on UK tech](https://sifted.eu/articles/mike-lynch-tech-legacy/)
    
    * * *
    

Advertisement

[Kai Nicol-Schwarz](https://sifted.eu/author/kai-nicol-schwarz/)

Kai Nicol-Schwarz is a reporter at Sifted. He covers UK tech and healthtech, and can be found on [X](https://twitter.com/NicolSchwarzK) and [LinkedIn](https://www.linkedin.com/in/kains/)

[# Healthtech](https://sifted.eu/sector/healthtech/)

5x a week

~/¬†Sifted Daily
---------------

Stay one step ahead with news and experts analysis on what‚Äôs happening across startup Europe.

By Sifted journalists

Sign up

Recommended

*   [![Image 57](https://images.sifted.eu/wp-content/uploads/2024/08/23150208/%C2%A9Delporte-AnneOsdoit02-1-scaled-e1724421752987.jpg?auto=format&fit=max&w=3840&q=75)](https://sifted.eu/articles/medtech-startup-vc-trends/)
    
    [11 medtech startups to watch, according to VCs](https://sifted.eu/articles/medtech-startup-vc-trends/)[VCs at 415 Capital, Sofinnova Partners, MIG Capital and SHS Capital share their picks](https://sifted.eu/articles/medtech-startup-vc-trends/)[Kai Nicol-Schwarz](https://sifted.eu/author/kai-nicol-schwarz/)
    
*   [![Image 58](https://images.sifted.eu/wp-content/uploads/2024/08/14175205/Caresyntax4.jpg?auto=format&fit=max&w=3840&q=75)](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/)
    
    [AI surgery tech startup raises $180m from investors including BlackRock](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/)[More than a dozen investors were involved in the equity and debt round for Berlin-based Caresyntax](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/)[Kai Nicol-Schwarz](https://sifted.eu/author/kai-nicol-schwarz/)
    
*   [![Image 59](https://images.sifted.eu/wp-content/uploads/2024/07/30122008/Flo-For-Partners-_-Flow-e1722338418859.png?auto=format&fit=max&w=3840&q=75)](https://sifted.eu/articles/male-founded-startup-europes-first-femtech-unicorn/)
    
    [A male-founded startup became Europe‚Äôs first femtech unicorn. Does it matter?](https://sifted.eu/articles/male-founded-startup-europes-first-femtech-unicorn/)[Some founders and investors are frustrated that the first European femtech unicorn is run by men](https://sifted.eu/articles/male-founded-startup-europes-first-femtech-unicorn/)[Anne Sraders](https://sifted.eu/author/anne-sraders/)
    

Backed by

### Company

*   [About](https://sifted.eu/about)
*   [Careers](https://sifted.eu/careers)
*   [Advertising](https://sifted.eu/advertising)
*   [Controllership](https://sifted.eu/controllership/)
*   [Cookie Policy](https://sifted.eu/cookie-policy)
*   [Privacy policy](https://sifted.eu/privacy-policy)
*   [AI Code of Conduct](https://sifted.eu/ai-code-of-conduct)
*   [Terms of use](https://sifted.eu/terms-of-use)

### Sifted Pro

*   [Subscribe](https://sifted.eu/subscribe)
*   [~/Briefings](https://sifted.eu/pro/briefings/about)
*   [~/Pitches](https://sifted.eu/pro/roundtables)
*   [~/Scout](https://sifted.eu/scout)

### Products

*   [~/Newsletters](https://sifted.eu/newsletters)
*   [~/Rankings](https://sifted.eu/rankings)
*   [~/Reports](https://sifted.eu/intelligence/reports)

### Community

*   [~/Talks](https://sifted.eu/talks)
*   [~/Podcasts](https://sifted.eu/podcasts)
*   [~/Summit](https://summit.sifted.eu/)
*   [Jobs board](https://jobs.sifted.eu/?source=footer&utm_source=footer&utm_medium=partner_referral)

*   [![Image 60: X Logo](https://www.datocms-assets.com/60124/1697443751-x-logo.svg)](https://twitter.com/siftedeu)
*   [![Image 61: LinkedIn Logo](https://www.datocms-assets.com/60124/1689076682-linkedin.svg)](https://www.linkedin.com/company/siftedeu/)
*   [![Image 62: Facebook Logo](https://www.datocms-assets.com/60124/1689076874-facebook.svg)](https://www.facebook.com/siftedeu)
*   [![Image 63: RSS Feed Logo](https://www.datocms-assets.com/60124/1689076939-rss-feed.svg)](https://sifted.eu/feed/?post_type=article)

¬© 2024 Sifted EU Ltd. All Rights Reserved.

 ![Image 64: Cookiebot session tracker icon loaded](https://imgsct.cookiebot.com/1.gif?dgi=33e59a16-c6e6-406b-8161-7e6b9693bc2e)
",gpt-4o-2024-08-06
2024-08-01 00:00:00,2024-08-31 05:13:00,"**Breaking Barriers or Setting Up Blocks? Europe's First Femtech Unicorn**

Flo Health has recently hit a $1bn valuation, making it Europe's first femtech unicorn. However, the fact that it was founded by an all-male team has sparked extensive debate in the tech and medical communities. Critics argue it highlights systemic gender biases in funding, while others say it proves the money-making potential in women's health, thus possibly opening doors for more investments in the sector.

Flo themselves note over half their employees are women, hinting at a more balanced leadership pipeline.

How do you see this impact the future of women's health innovation? ü©∫üí° #Femtech #Innovation

Join the conversation below üëá or read the full story [here](https://sifted.eu/articles/male-founded-startup-europes-first-femtech-unicorn/)",,https://sifted.eu/articles/male-founded-startup-europes-first-femtech-unicorn/,"You are a content creator tasked with crafting highly informative, easy to digest social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Title: A male-founded startup became Europe‚Äôs first femtech unicorn. Does it matter? | Sifted

URL Source: https://sifted.eu/articles/male-founded-startup-europes-first-femtech-unicorn/

Markdown Content:
**_A version of this article first appeared in Sifted‚Äôs Daily newsletter,_ _[sign up here](https://sifted.eu/newsletters?utm_medium=onsite&utm_source=article&utm_campaign=daily_big_story&utm_content=flagshipnl)._**

On Wednesday UK-based period tracking app Flo Health announced it had raised $200m ‚Äî pushing its valuation beyond $1bn and making it Europe‚Äôs first femtech unicorn.

It turned out to be a very [buzzy story](https://email.sifted.eu/e3t/Ctc/LZ+113/d2mfCN04/VWd7S56fts6_W5MRMLq4ZH5wFW6YVQGc5jbfNKN5j5FQx3qgyTW7lCdLW6lZ3nfW33mt2d9fhswPW6cbbn42Gk2LbW8scjQ_6cnrxDW1clnhC2ShJQHVccVZ53gzXq5W4wQdZG67pwTSW2-JWpF92k-_3W7wvb489fJTrcW8Yc8WL2J2BxbVsVjMQ2l0S96W8kJSgJ8PlPBnW3C2JWZ7p72hNW6XXzRB8xLSLCW1Qsggq5_4Rb1W2TDtZV1qFp0NW8cjBvC794-SqW6CX8JV3JLP8SW3PhCFV1MtGl5N2XnVkqP0RWYVJ5lGy5VWWL_W95gKqH7mC7fGN8ZGCJCNps2DW3hhNk75-4tsCW6zlG0Z5p-vJhf88-NBl04): as people were quick to point out online, Flo also became Europe‚Äôs first women‚Äôs health unicorn _with an all-male founding team_ ‚Äî a detail which sparked a backlash online.

‚ÄúA company founded by men, led by men and funded by men became the first WOMEN'S health app to achieve unicorn status. If this doesn't show you everything that's wrong with the ecosystem, I don't know what will,‚Äù Anna-Sophie Hartvigsen, cofounder of investment learning app and community for women Female Invest, wrote [in a viral LinkedIn post](https://email.sifted.eu/e3t/Ctc/LZ+113/d2mfCN04/VWd7S56fts6_W5MRMLq4ZH5wFW6YVQGc5jbfNKN5j5FPl5bRGYW50kH_H6lZ3l8W4LGN588Q_4ZsW8wQ5KR6wTrX5W7yCq0w85CZG9W3vhYPj1slFYHN7B_Ncv_0lQFW5X-v0Q51XxGqW6MPX5p5pwYL9W1D4cXM5h1_MGW7W96ly7MtK-lW381wDG8L1J_PW2_GGrC99Nz87N7QYN_6c-6xhVbl3C8715Xk_MpwjzGcNvlcW3dD_dz5jH-v9W49__9X8Dl27zN6pG5cpR5Y8-W1P9wsl5X0QKfW7pKmFX4zN8c0Vvdxk071SZSSW3r-vWY72Kwv1W4rpnn35WQhWCW6mSf3c1Z9ZHfVtbKWF8SQ18NW74YWXR83cqHnW4jGq_N5RH-nDW2tGsJ33h0LCbW4zWMDM5z_R9CW2_sJfz188vZJW4qtZ453fg7NWW5LGdY_77tcmZW3F37Zc24XYyMf7-GWgH04), citing stats on the [lack of funding for female founders](https://email.sifted.eu/e3t/Ctc/LZ+113/d2mfCN04/VWd7S56fts6_W5MRMLq4ZH5wFW6YVQGc5jbfNKN5j5FQx3qgyTW7lCdLW6lZ3npVZ6rdY6xdTkKW5dqdCC3CpbHkW6hmw1f8YJJx8W2h-hSY5hYtf0W3HtTS183-N4gN7hMSn23njKxW18dFQG93dPz7N7_1xPQZKQbwW3tfkLc5rhD5vW3kmy8562PSf5VVJMdj80mh0VW2xYdCC11lSqMW4Bjfsz1z2prLW17bbCc8ffd1CW548x4q6l5pqWN1H52hZxSG9WW2_7TbZ8zJD61W1spH161xBM0CW3YV1dC5_NGBBW3_BcXt8sdfLPW8vx_yh1pZ3FtW2rLJgd7p8_CsW7d4VW93Y2nkzW5PBwYY4SptZgf3zzZbM04). ‚ÄúI‚Äôm not saying it‚Äôs bad that a femtech company is doing well,‚Äù she later added in the comments. ‚ÄúI‚Äôm saying it‚Äôs bad that only men are able to succeed in this space.‚Äù

Some founders in the comments underneath Hartvigsen's post said that they‚Äôve struggled with fundraising as a woman; there was also a debate in a private WhatsApp group seen by Sifted about whether female founders should add a token male founder to their team in an effort to increase their chances of getting cheques. Someone in that group added that we won‚Äôt fix the trend of men funding men until there are more female investors.

But others didn‚Äôt see it that way.

‚ÄúThis achievement should actually be celebrated. As a women's health investor that has invested in 7+ women's health companies, we are yet to see any of them scale,‚Äù Deepali Nangia, a partner at Speedinvest, wrote in response to Hartvigsen‚Äôs LinkedIn post. ‚ÄúFlo's achievement is a very strong signal to the market that \[direct to consumer\] women's health is monetizable in Europe and that there is money to be made here; this is what investors need to see so more money flows into women's health companies. Not to say that the challenges faced by women in pitching are any less, but we must celebrate all wins that lead to more capital deployed into this sector,‚Äù she argued.

Nangia added that she wasn‚Äôt doubting there‚Äôs a problem, ‚Äúbut every win should not be turned around to a problem‚Ä¶ Many people have been working on solving for this problem, which includes many women of course but also men.‚Äù

Another commenter added: ‚ÄúIf anything, let this be a door for more investors to look closely at the female health industry and invest their money there? Could this be an example of men allies? If it had to be a company founded and led by men, well thank you very much for opening the door, now let the rest go through.‚Äù

Priya Oberoi, partner at women‚Äôs health-focused VC Goddess Gaia Ventures, added: ‚ÄúFlo reaching series C \[unicorn\] status with 60 mln active users is a win for #womenshealth - helping to close that 131 year gender health gap and getting products and services out there to improve the lives of women.‚Äù

""We firmly believe that women's health has been critically overlooked, undervalued and underfunded for far too long,"" Flo said in a statement to Sifted. ""Our sincere hope is that Flo‚Äôs funding will inspire more investors to recognise the immense potential in this space."" The company added: ""We're proud to say that more than half (56%) of Flo's employees are women, including our leadership team.""

It‚Äôs an important debate, and, readers, I‚Äôm curious to hear your thoughts: why aren‚Äôt there more female-founded femtech unicorns? Is it a problem that the first European femtech unicorn is founded by men, if the product helps women? Does it open doors for female founders in the space, or actually keep them shut? [Get in touch with me](mailto:anne@sifted.eu) or [Kai](mailto:kai@sifted.eu).
",gpt-4o-2024-08-06
2024-08-30 10:00:00,2024-08-31 05:13:07,"**Groundbreaking Study: Maternal Angioma History Elevates Risk of Vascular Abnormalities in Offspring**

A recent cohort study from the UK delves into the link between maternal angiomas and increased rates of infantile hemangioma (IH) and port-wine stains (PWS) in children. The research analyzed over 639,000 mother-child pairs, revealing that children of mothers with angiomas were 60% more likely to develop IH, while those of mothers with PWS were nearly 20 times more likely to have PWS themselves. However, cross-association (IH with maternal PWS and PWS with maternal angioma) was not observed, indicating specific hereditary pathways. 

This data underscores the importance of genetic counseling for expecting mothers with angioma or PWS histories. 

üîó Discuss your thoughts on the genetic implications of this study or read more here: https://link.springer.com/article/10.1007/s00403-024-03247-y

#PediatricHealth #MaternalHealth #Genetics #VascularAbnormalities",https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_230712_capillary_malformation_800x450.jpg,https://link.springer.com/article/10.1007/s00403-024-03247-y,"You are a content creator tasked with crafting highly informative, easy to digest social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Thumbnail image URL: https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_230712_capillary_malformation_800x450.jpg  
Title: Maternal history of angioma is associated with infantile hemangioma and port-wine stain in children: a population-based, cohort study of mother-child pairs from the United Kingdom

URL Source: https://link.springer.com/article/10.1007/s00403-024-03247-y

Markdown Content:
Abstract
--------

The two most prevalent childhood vascular abnormalities are infantile hemangioma (IH) and port-wine stain (PWS). They become apparent shortly after birth but have distinct pathophysiology and clinical manifestations. The goal of this study was to determine if mother‚Äôs history of angioma or PWS is associated with these vascular abnormalities. We evaluated an UK anonymized electronic medical records database with medical records that were linked between children and their mothers. Cox proportional hazards models were used to evaluate the association between maternal factors and the time of onset of either IH or PWS in children. Between 2004 and 2021, 639,085 children were linked to their mom‚Äôs medical data with a total of 4,270,773 person-years of follow up. Children born to mothers with an angioma as compared to a mother without an angioma were more than 60% more likely to have an IH (HR: 1.64 \[1.07, 2.52\]). Children born to mothers with a PWS as compared to children born to mothers without a PWS were nearly 20 times more likely to have a PWS (18.95 \[4.71,76.26\]). Mothers with angiomas were not more likely to have children with PWS and mothers with PWS were not more likely to have children with IH. The effect estimates were minimally changed after adjustment. We demonstrated that children born to mothers with angiomas or PWS were at increased risk of IH or PWS, respectively.

Access this article
-------------------

[Log in via an institution](https://wayf.springernature.com/?redirect_uri=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00403-024-03247-y)

Subscribe and save
------------------

*   Get 10 units per month
*   Download Article/Chapter or eBook
*   1 Unit = 1 Article or 1 Chapter
*   Cancel anytime

[Subscribe now](https://link.springer.com/product/springer-plus)

Buy Now
-------

Price excludes VAT (USA)  
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Data availability
-----------------

No datasets were generated or analysed during the current study.

References
----------

1.  Hinen HB, Trenor CC 3 (2020) Wine Lee L. Childhood Vascular Tumors. Front Pediatr 8:573023
    
    [Article](https://doi.org/10.3389%2Ffped.2020.573023)¬† [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33194900)¬† [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642460)¬† [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Wine%20Lee%20L.%20Childhood%20Vascular%20Tumors&journal=Front%20Pediatr&doi=10.3389%2Ffped.2020.573023&volume=8&publication_year=2020&author=Hinen%2CHB&author=Trenor%2CCC)
    
2.  Colletti G, Negrello S, Rozell-Shannon L, Levitin GM, Colletti L, Chiarini L et al (2023) Surgery for Port-Wine stains: a systematic review. J Pers Med. ;13(7)
    
3.  Sun Y, Zhao J, Meng Y, Luo X, Jiang C, Deng G et al (2024) The prevalence, complications, and risk factors for infantile hemangioma: a systematic review and meta-analysis. Int J Dermatol 63(6):737‚Äì746
    
    [Article](https://doi.org/10.1111%2Fijd.17062)¬† [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38329175)¬† [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20prevalence%2C%20complications%2C%20and%20risk%20factors%20for%20infantile%20hemangioma%3A%20a%20systematic%20review%20and%20meta-analysis&journal=Int%20J%20Dermatol&doi=10.1111%2Fijd.17062&volume=63&issue=6&pages=737-746&publication_year=2024&author=Sun%2CY&author=Zhao%2CJ&author=Meng%2CY&author=Luo%2CX&author=Jiang%2CC&author=Deng%2CG)
    
4.  Poliner A, Fernandez Faith E, Blieden L, Kelly KM, Metry D (2022) Port-wine birthmarks: update on diagnosis, Risk Assessment for Sturge-Weber Syndrome, and management. Pediatr Rev 43(9):507‚Äì516
    
    [Article](https://doi.org/10.1542%2Fpir.2021-005437)¬† [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36045161)¬† [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Port-wine%20birthmarks%3A%20update%20on%20diagnosis%2C%20Risk%20Assessment%20for%20Sturge-Weber%20Syndrome%2C%20and%20management&journal=Pediatr%20Rev&doi=10.1542%2Fpir.2021-005437&volume=43&issue=9&pages=507-516&publication_year=2022&author=Poliner%2CA&author=Fernandez%20Faith%2CE&author=Blieden%2CL&author=Kelly%2CKM&author=Metry%2CD)
    
5.  Van Trigt WK, Kelly KM, Hughes CCW (2022) GNAQ mutations drive port wine birthmark-associated Sturge-Weber syndrome: a review of pathobiology, therapies, and current models. Front Hum Neurosci 16:1006027
    
    [Article](https://doi.org/10.3389%2Ffnhum.2022.1006027)¬† [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36405075)¬† [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670321)¬† [Google Scholar](http://scholar.google.com/scholar_lookup?&title=GNAQ%20mutations%20drive%20port%20wine%20birthmark-associated%20Sturge-Weber%20syndrome%3A%20a%20review%20of%20pathobiology%2C%20therapies%2C%20and%20current%20models&journal=Front%20Hum%20Neurosci&doi=10.3389%2Ffnhum.2022.1006027&volume=16&publication_year=2022&author=Trigt%2CWK&author=Kelly%2CKM&author=Hughes%2CCCW)
    
6.  Shirley MD, Tang H, Gallione CJ, Baugher JD, Frelin LP, Cohen B et al (2013) Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med 368(21):1971‚Äì1979
    
    [Article](https://doi.org/10.1056%2FNEJMoa1213507)¬† [CAS](https://link.springer.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXhtVOgsL7O)¬† [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23656586)¬† [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749068)¬† [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Sturge-Weber%20syndrome%20and%20port-wine%20stains%20caused%20by%20somatic%20mutation%20in%20GNAQ&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1213507&volume=368&issue=21&pages=1971-1979&publication_year=2013&author=Shirley%2CMD&author=Tang%2CH&author=Gallione%2CCJ&author=Baugher%2CJD&author=Frelin%2CLP&author=Cohen%2CB)
    
7.  Auger N, Fraser WD, Arbour L, Healy-Profit√≥s J, Drolet BA (2017) Pre-eclampsia and risk of infantile haemangioma. Br J Dermatol 176(2):371‚Äì377
    
    [Article](https://doi.org/10.1111%2Fbjd.14958)¬† [CAS](https://link.springer.com/articles/cas-redirect/1:STN:280:DC%2BC2szgtF2ntQ%3D%3D)¬† [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27514292)¬† [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Pre-eclampsia%20and%20risk%20of%20infantile%20haemangioma&journal=Br%20J%20Dermatol&doi=10.1111%2Fbjd.14958&volume=176&issue=2&pages=371-377&publication_year=2017&author=Auger%2CN&author=Fraser%2CWD&author=Arbour%2CL&author=Healy-Profit%C3%B3s%2CJ&author=Drolet%2CBA)
    
8.  Greco MF, Frieden IJ, Drolet BA, Garzon MC, Mancini AJ, Chamlin SL et al (2016) Infantile hemangiomas in twins: a prospective cohort study. Pediatr Dermatol 33(2):178‚Äì183
    
    [Article](https://doi.org/10.1111%2Fpde.12781)¬† [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26863906)¬† [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Infantile%20hemangiomas%20in%20twins%3A%20a%20prospective%20cohort%20study&journal=Pediatr%20Dermatol&doi=10.1111%2Fpde.12781&volume=33&issue=2&pages=178-183&publication_year=2016&author=Greco%2CMF&author=Frieden%2CIJ&author=Drolet%2CBA&author=Garzon%2CMC&author=Mancini%2CAJ&author=Chamlin%2CSL)
    
9.  Munden A, Butschek R, Tom WL, Marshall JS, Poeltler DM, Krohne SE et al (2014) Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies. Br J Dermatol 170(4):907‚Äì913
    
    [Article](https://doi.org/10.1111%2Fbjd.12804)¬† [CAS](https://link.springer.com/articles/cas-redirect/1:STN:280:DC%2BC2crkslGlug%3D%3D)¬† [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24641194)¬† [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410180)¬† [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Prospective%20study%20of%20infantile%20haemangiomas%3A%20incidence%2C%20clinical%20characteristics%20and%20association%20with%20placental%20anomalies&journal=Br%20J%20Dermatol&doi=10.1111%2Fbjd.12804&volume=170&issue=4&pages=907-913&publication_year=2014&author=Munden%2CA&author=Butschek%2CR&author=Tom%2CWL&author=Marshall%2CJS&author=Poeltler%2CDM&author=Krohne%2CSE)
    
10.  Schoch JJ, Hunjan MK, Anderson KR, Lohse CM, Hand JL, Davis DMR et al (2018) Temporal trends in prenatal risk factors for the development of infantile hemangiomas. Pediatr Dermatol 35(6):787‚Äì791
    
    [Article](https://doi.org/10.1111%2Fpde.13659)¬† [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30187967)¬† [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219915)¬† [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Temporal%20trends%20in%20prenatal%20risk%20factors%20for%20the%20development%20of%20infantile%20hemangiomas&journal=Pediatr%20Dermatol&doi=10.1111%2Fpde.13659&volume=35&issue=6&pages=787-791&publication_year=2018&author=Schoch%2CJJ&author=Hunjan%2CMK&author=Anderson%2CKR&author=Lohse%2CCM&author=Hand%2CJL&author=Davis%2CDMR)
    
11.  Denburg MR, Haynes K, Shults J, Lewis JD, Leonard MB (2011) Validation of the Health Improvement Network (THIN) database for epidemiologic studies of chronic kidney disease. Pharmacoepidemiol Drug Saf 20(11):1138‚Äì1149
    
    [Article](https://doi.org/10.1002%2Fpds.2203)¬† [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22020900)¬† [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3245984)¬† [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Validation%20of%20the%20Health%20Improvement%20Network%20%28THIN%29%20database%20for%20epidemiologic%20studies%20of%20chronic%20kidney%20disease&journal=Pharmacoepidemiol%20Drug%20Saf&doi=10.1002%2Fpds.2203&volume=20&issue=11&pages=1138-1149&publication_year=2011&author=Denburg%2CMR&author=Haynes%2CK&author=Shults%2CJ&author=Lewis%2CJD&author=Leonard%2CMB)
    
12.  Lo Re V 3rd, Haynes K, Forde KA, Localio AR, Schinnar R, Lewis JD (2009) Validity of the Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. Pharmacoepidemiol Drug Saf 18(9):807‚Äì814
    
    [Article](https://doi.org/10.1002%2Fpds.1784)¬† [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19551699)¬† [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Validity%20of%20the%20Health%20Improvement%20Network%20%28THIN%29%20for%20epidemiologic%20studies%20of%20hepatitis%20C%20virus%20infection&journal=Pharmacoepidemiol%20Drug%20Saf&doi=10.1002%2Fpds.1784&volume=18&issue=9&pages=807-814&publication_year=2009&author=Lo%20Re%2CV&author=Haynes%2CK&author=Forde%2CKA&author=Localio%2CAR&author=Schinnar%2CR&author=Lewis%2CJD)
    
13.  Minassian C, Williams R, Meeraus WH, Smeeth L, Campbell OMR, Thomas SL (2019) Methods to generate and validate a pregnancy Register in the UK Clinical Practice Research Datalink primary care database. Pharmacoepidemiol Drug Saf 28(7):923‚Äì933
    
    [Article](https://doi.org/10.1002%2Fpds.4811)¬† [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31197928)¬† [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618019)¬† [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Methods%20to%20generate%20and%20validate%20a%20pregnancy%20Register%20in%20the%20UK%20Clinical%20Practice%20Research%20Datalink%20primary%20care%20database&journal=Pharmacoepidemiol%20Drug%20Saf&doi=10.1002%2Fpds.4811&volume=28&issue=7&pages=923-933&publication_year=2019&author=Minassian%2CC&author=Williams%2CR&author=Meeraus%2CWH&author=Smeeth%2CL&author=Campbell%2COMR&author=Thomas%2CSL)
    
14.  Chiesa Fuxench ZC, Mitra N, Del Pozo D, Hoffstad O, Shin DB, Margolis DJ (2024) Risk of atopic dermatitis and the atopic march paradigm in children of mothers with atopic illnesses: a birth cohort study from the United Kingdom. J Am Acad Dermatol 90(3):561‚Äì568
    
    [Article](https://doi.org/10.1016%2Fj.jaad.2023.11.013)¬† [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37984723)¬† [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Risk%20of%20atopic%20dermatitis%20and%20the%20atopic%20march%20paradigm%20in%20children%20of%20mothers%20with%20atopic%20illnesses%3A%20a%20birth%20cohort%20study%20from%20the%20United%20Kingdom&journal=J%20Am%20Acad%20Dermatol&doi=10.1016%2Fj.jaad.2023.11.013&volume=90&issue=3&pages=561-568&publication_year=2024&author=Chiesa%20Fuxench%2CZC&author=Mitra%2CN&author=Pozo%2CD&author=Hoffstad%2CO&author=Shin%2CDB&author=Margolis%2CDJ)
    
15.  Chiesa Fuxench Z, Mitra N, Del Pozo D, Hoffstad O, Shin DB, Langan SM et al (2023) In utero or early in life exposure to antibiotics and the risk of childhood atopic dermatitis, a population-based cohort study. Br J Dermatol
    

[Download references](https://citation-needed.springer.com/v2/references/10.1007/s00403-024-03247-y?format=refman&flavour=references)

Funding
-------

Support for this work was provided by the Penn Skin Biology and Diseases Resource-based Center, funded by NIH/NIAMS grant P30-AR069589 (Core C: DJM) and the University of Pennsylvania Perelman School of Medicine.

Author information
------------------

### Authors and Affiliations

1.  Department of Dermatology, University of Pennsylvania Perelman School of Medicine, 3400 Civic Center Blvd PCAM South Tower, 7th Floor , Philadelphia, PA 19104, USA
    
    Zelma C. Chiesa Fuxench,¬†Ole Hoffstad,¬†Stefanie Hinkle¬†&¬†David J. Margolis
    
2.  Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
    
    Nandita Mitra,¬†Jessica Wong¬†&¬†David J. Margolis
    
3.  Department of Obstetrics and Gynecology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
    
    Stefanie Hinkle
    

Authors

1.  Zelma C. Chiesa Fuxench
    
    You can also search for this author in [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Zelma%20C.%20Chiesa%20Fuxench)¬†[Google Scholar](http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Zelma%20C.%20Chiesa%20Fuxench%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
2.  Nandita Mitra
    
    You can also search for this author in [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Nandita%20Mitra)¬†[Google Scholar](http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Nandita%20Mitra%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
3.  Jessica Wong
    
    You can also search for this author in [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jessica%20Wong)¬†[Google Scholar](http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jessica%20Wong%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
4.  Ole Hoffstad
    
    You can also search for this author in [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ole%20Hoffstad)¬†[Google Scholar](http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ole%20Hoffstad%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
5.  Stefanie Hinkle
    
    You can also search for this author in [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Stefanie%20Hinkle)¬†[Google Scholar](http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Stefanie%20Hinkle%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
6.  David J. Margolis
    
    You can also search for this author in [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=David%20J.%20Margolis)¬†[Google Scholar](http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22David%20J.%20Margolis%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    

### Contributions

DJM, ZCF, NM, OH designed the study. DJM, NM and OH conducted or directed all analyses. ZCF, NM, DJM and JW wrote the initial manuscript. ZCF, NM, DJM, OH, SH, and JW reviewed, edited and approved the manuscript.

### Corresponding author

Correspondence to [David J. Margolis](mailto:margo@pennmedicine.upenn.edu).

Ethics declarations
-------------------

### Competing interests

The authors declare no competing interests.

Additional information
----------------------

### Publisher‚Äôs Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material
---------------------------------

Rights and permissions
----------------------

About this article
------------------

[![Image 1: Check for updates. Verify currency and authenticity via CrossMark](blob:https://link.springer.com/df43c82f6cb6dcd2a87db38f317bf9f2)](https://crossmark.crossref.org/dialog/?doi=10.1007/s00403-024-03247-y)

### Cite this article

Fuxench, Z.C.C., Mitra, N., Wong, J. _et al._ Maternal history of angioma is associated with infantile hemangioma and port-wine stain in children: a population-based, cohort study of mother-child pairs from the United Kingdom. _Arch Dermatol Res_ **316**, 506 (2024). https://doi.org/10.1007/s00403-024-03247-y

[Download citation](https://citation-needed.springer.com/v2/references/10.1007/s00403-024-03247-y?format=refman&flavour=citation)

*   Received: 27 June 2024
    
*   Revised: 27 June 2024
    
*   Accepted: 24 July 2024
    
*   Published: 07 August 2024
    
*   DOI: https://doi.org/10.1007/s00403-024-03247-y
    

### Keywords
",gpt-4o-2024-08-06
2024-08-30 09:00:00,2024-08-31 05:13:18,"**Breaking New Ground in TB Care for Migrants: Primary vs Secondary Settings**

Recent research published in the European Respiratory Journal explores the management of latent tuberculosis infections (LTBI) in migrants, emphasizing primary care's cost-effectiveness without compromising safety. The study compared treatment in primary versus secondary care settings, finding similar completion rates but at a lower cost in primary care. However, acceptance was lower in primary care (65.2% vs 94.2%).

Is your practice considering adopting cost-effective approaches for managing LTBI? Share your thoughts and experiences in the comments below!

Read the study ‚û°Ô∏è [European Respiratory Society](https://erj.ersjournals.com/content/early/2024/08/08/13993003.01733-2023.long)  

#Tuberculosis #PrimaryCare #MigrantHealth #MedicalResearch #HealthEconomics",https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_230601_immigrants_refugees_walking_sunset_800x450.jpg,https://erj.ersjournals.com/content/early/2024/08/08/13993003.01733-2023.long,"You are a content creator tasked with crafting highly informative, easy to digest social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Thumbnail image URL: https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_230601_immigrants_refugees_walking_sunset_800x450.jpg  
Title: The treatment of latent tuberculosis infection in migrants in primary care versus secondary care

URL Source: https://erj.ersjournals.com/content/early/2024/08/08/13993003.01733-2023.long

Markdown Content:
The treatment of latent tuberculosis infection in migrants in primary care versus secondary care | European Respiratory Society
===============

[Skip to main content](https://erj.ersjournals.com/content/early/2024/08/08/13993003.01733-2023.long#main-content)

Main menu
---------

*   [Home](https://erj.ersjournals.com/)
*   [Current issue](https://erj.ersjournals.com/content/current)
*   [ERJ Early View](https://erj.ersjournals.com/content/early/recent)
*   [Past issues](https://erj.ersjournals.com/content/by/year)
*   [ERS Guidelines](https://erj.ersjournals.com/cc/ers-official-documents-and-guidelines)
*   [Authors/reviewers](https://erj.ersjournals.com/authors)
    
    *   [Instructions for authors](https://erj.ersjournals.com/authors/instructions)
    *   [Submit a manuscript](http://mc.manuscriptcentral.com/erj)
    *   [Open access](https://erj.ersjournals.com/authors/instructions#OPEN_ACCESS)
    *   [Peer reviewer login](https://mc.manuscriptcentral.com/erj)
    *   [WoS Reviewer Recognition Service](https://www.ersjournals.com/reviewers/reviewer-recognition-service)
    
*   [Alerts](https://erj.ersjournals.com/alerts)
*   [Subscriptions](http://www.ersjournals.com/subscriptions)

*   [ERS Publications](http://www.ersjournals.com/)
    
    *   [European Respiratory Journal](http://erj.ersjournals.com/)
    *   [ERJ Open Research](http://openres.ersjournals.com/)
    *   [European Respiratory Review](http://err.ersjournals.com/)
    *   [Breathe](http://breathe.ersjournals.com/)
    *   [ERS Books](http://books.ersjournals.com/)
    *   [ERS publications home](http://www.ersjournals.com/ ""ERS publications home"")
    

User menu
---------

*   [Log in](https://erj.ersjournals.com/user/login?destination=/content/early/2024/08/08/13993003.01733-2023%3Fvariant%3Dlong)
*   [Subscribe](https://erj.ersjournals.com/)
*   [Contact Us](https://erj.ersjournals.com/)
*   [My Cart](https://erj.ersjournals.com/cart)

Search
------

Search for this keyword 

 

*   [Advanced search](https://erj.ersjournals.com/search ""Advanced search"")

*   [ERS Publications](http://www.ersjournals.com/)
    *   [European Respiratory Journal](http://erj.ersjournals.com/)
    *   [ERJ Open Research](http://openres.ersjournals.com/)
    *   [European Respiratory Review](http://err.ersjournals.com/)
    *   [Breathe](http://breathe.ersjournals.com/)
    *   [ERS Books](http://books.ersjournals.com/)
    *   [ERS publications home](http://www.ersjournals.com/ ""ERS publications home"")

[Login](https://erj.ersjournals.com/user/login?destination=front)

[![Image 1](https://erj.ersjournals.com/sites/default/files/additional-assets/social_facebook_blue.png)](https://www.facebook.com/EuropeanRespiratorySociety ""Facebook"") [![Image 2](https://erj.ersjournals.com/sites/default/files/additional-assets/social_twitter_blue.png)](https://twitter.com/erspublications ""Twitter"") [![Image 3](https://erj.ersjournals.com/sites/default/files/additional-assets/social_linkedin_blue.png)](https://www.linkedin.com/grp/home?gid=4348517 ""Linked In"")

[![Image 4: European Respiratory Society ](https://erj.ersjournals.com/sites/default/files/ERJ-Masthead_1.png)](https://erj.ersjournals.com/)

Search for this keyword 

 

[Advanced Search](https://erj.ersjournals.com/search)

*   [Home](https://erj.ersjournals.com/)
*   [Current issue](https://erj.ersjournals.com/content/current)
*   [ERJ Early View](https://erj.ersjournals.com/content/early/recent)
*   [Past issues](https://erj.ersjournals.com/content/by/year)
*   [ERS Guidelines](https://erj.ersjournals.com/cc/ers-official-documents-and-guidelines)
*   [Authors/reviewers](https://erj.ersjournals.com/authors)
    *   [Instructions for authors](https://erj.ersjournals.com/authors/instructions)
    *   [Submit a manuscript](http://mc.manuscriptcentral.com/erj)
    *   [Open access](https://erj.ersjournals.com/authors/instructions#OPEN_ACCESS)
    *   [Peer reviewer login](https://mc.manuscriptcentral.com/erj)
    *   [WoS Reviewer Recognition Service](https://www.ersjournals.com/reviewers/reviewer-recognition-service)
*   [Alerts](https://erj.ersjournals.com/alerts)
*   [Subscriptions](http://www.ersjournals.com/subscriptions)

![Image 5](https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_square.svg)

The treatment of latent tuberculosis infection in migrants in primary care _versus_ secondary care
==================================================================================================

Matthew Burman, Dominik Zenner, Andrew J Copas, Lara Gosc√©, Hassan Haghparast-Bidgoli, Peter J White, Vicky Hickson, Opal Greyson, Duncan Trathen, Richard Ashcroft, Adrian R Martineau, Ibrahim Abubakar, Christopher J Griffiths, Heinke Kunst

European Respiratory Journal 2024; DOI: 10.1183/13993003.01733-2023

Matthew Burman

1Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

*   [Find this author on Google Scholar](https://erj.ersjournals.com/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Matthew%2BBurman%2B)
*   [Find this author on PubMed](https://erj.ersjournals.com/lookup/external-ref?access_num=Burman%20M&link_type=AUTHORSEARCH)
*   [Search for this author on this site](https://erj.ersjournals.com/search/author1%3AMatthew%2BBurman%2B)

Dominik Zenner

1Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

*   [Find this author on Google Scholar](https://erj.ersjournals.com/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Dominik%2BZenner%2B)
*   [Find this author on PubMed](https://erj.ersjournals.com/lookup/external-ref?access_num=Zenner%20D&link_type=AUTHORSEARCH)
*   [Search for this author on this site](https://erj.ersjournals.com/search/author1%3ADominik%2BZenner%2B)

Andrew J Copas

3Institute for Global Health, University College London, London, UK

*   [Find this author on Google Scholar](https://erj.ersjournals.com/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Andrew%2BJ%2BCopas%2B)
*   [Find this author on PubMed](https://erj.ersjournals.com/lookup/external-ref?access_num=Copas%20AJ&link_type=AUTHORSEARCH)
*   [Search for this author on this site](https://erj.ersjournals.com/search/author1%3AAndrew%2BJ%2BCopas%2B)

Lara Gosc√©

3Institute for Global Health, University College London, London, UK

*   [Find this author on Google Scholar](https://erj.ersjournals.com/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Lara%2BGosc%C3%A9%2B)
*   [Find this author on PubMed](https://erj.ersjournals.com/lookup/external-ref?access_num=Gosc%C3%A9%20L&link_type=AUTHORSEARCH)
*   [Search for this author on this site](https://erj.ersjournals.com/search/author1%3ALara%2BGosc%25C3%25A9%2B)
*   [ORCID record for Lara Gosc√©](https://orcid.org/0000-0003-2392-6271)

Hassan Haghparast-Bidgoli

3Institute for Global Health, University College London, London, UK

*   [Find this author on Google Scholar](https://erj.ersjournals.com/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Hassan%2BHaghparast-Bidgoli%2B)
*   [Find this author on PubMed](https://erj.ersjournals.com/lookup/external-ref?access_num=Haghparast-Bidgoli%20H&link_type=AUTHORSEARCH)
*   [Search for this author on this site](https://erj.ersjournals.com/search/author1%3AHassan%2BHaghparast-Bidgoli%2B)

Peter J White

4MRC Centre for Global Infectious Disease Analysis, and NIHR Health Protection Research Unit in Modelling and Health Economics, Department of Infectious Disease Epidemiology, Imperial College London, London, UK

5Modelling & Economics Unit, UK Health Security Agency, London, UK

*   [Find this author on Google Scholar](https://erj.ersjournals.com/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Peter%2BJ%2BWhite%2B)
*   [Find this author on PubMed](https://erj.ersjournals.com/lookup/external-ref?access_num=White%20PJ&link_type=AUTHORSEARCH)
*   [Search for this author on this site](https://erj.ersjournals.com/search/author1%3APeter%2BJ%2BWhite%2B)
*   [ORCID record for Peter J White](https://orcid.org/0000-0002-6644-3512)

Vicky Hickson

1Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

*   [Find this author on Google Scholar](https://erj.ersjournals.com/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Vicky%2BHickson%2B)
*   [Find this author on PubMed](https://erj.ersjournals.com/lookup/external-ref?access_num=Hickson%20V&link_type=AUTHORSEARCH)
*   [Search for this author on this site](https://erj.ersjournals.com/search/author1%3AVicky%2BHickson%2B)

Opal Greyson

1Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

*   [Find this author on Google Scholar](https://erj.ersjournals.com/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Opal%2BGreyson%2B)
*   [Find this author on PubMed](https://erj.ersjournals.com/lookup/external-ref?access_num=Greyson%20O&link_type=AUTHORSEARCH)
*   [Search for this author on this site](https://erj.ersjournals.com/search/author1%3AOpal%2BGreyson%2B)

Duncan Trathen

6Newham Clinical Commissioning Group, London, UK

*   [Find this author on Google Scholar](https://erj.ersjournals.com/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Duncan%2BTrathen%2B)
*   [Find this author on PubMed](https://erj.ersjournals.com/lookup/external-ref?access_num=Trathen%20D&link_type=AUTHORSEARCH)
*   [Search for this author on this site](https://erj.ersjournals.com/search/author1%3ADuncan%2BTrathen%2B)

Richard Ashcroft

7City Law School, City, University of London, London, UK

*   [Find this author on Google Scholar](https://erj.ersjournals.com/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Richard%2BAshcroft%2B)
*   [Find this author on PubMed](https://erj.ersjournals.com/lookup/external-ref?access_num=Ashcroft%20R&link_type=AUTHORSEARCH)
*   [Search for this author on this site](https://erj.ersjournals.com/search/author1%3ARichard%2BAshcroft%2B)

Adrian R Martineau

1Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

*   [Find this author on Google Scholar](https://erj.ersjournals.com/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Adrian%2BR%2BMartineau%2B)
*   [Find this author on PubMed](https://erj.ersjournals.com/lookup/external-ref?access_num=Martineau%20AR&link_type=AUTHORSEARCH)
*   [Search for this author on this site](https://erj.ersjournals.com/search/author1%3AAdrian%2BR%2BMartineau%2B)

Ibrahim Abubakar

3Institute for Global Health, University College London, London, UK

*   [Find this author on Google Scholar](https://erj.ersjournals.com/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ibrahim%2BAbubakar%2B)
*   [Find this author on PubMed](https://erj.ersjournals.com/lookup/external-ref?access_num=Abubakar%20I&link_type=AUTHORSEARCH)
*   [Search for this author on this site](https://erj.ersjournals.com/search/author1%3AIbrahim%2BAbubakar%2B)
*   [ORCID record for Ibrahim Abubakar](https://orcid.org/0000-0002-0370-1430)

Christopher J Griffiths

1Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

*   [Find this author on Google Scholar](https://erj.ersjournals.com/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Christopher%2BJ%2BGriffiths%2B)
*   [Find this author on PubMed](https://erj.ersjournals.com/lookup/external-ref?access_num=Griffiths%20CJ&link_type=AUTHORSEARCH)
*   [Search for this author on this site](https://erj.ersjournals.com/search/author1%3AChristopher%2BJ%2BGriffiths%2B)

Heinke Kunst

8Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

9Barts Health NHS Trust, London, UK

*   [Find this author on Google Scholar](https://erj.ersjournals.com/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Heinke%2BKunst%2B)
*   [Find this author on PubMed](https://erj.ersjournals.com/lookup/external-ref?access_num=Kunst%20H&link_type=AUTHORSEARCH)
*   [Search for this author on this site](https://erj.ersjournals.com/search/author1%3AHeinke%2BKunst%2B)

*   [Article](https://erj.ersjournals.com/content/early/2024/08/08/13993003.01733-2023)[](https://erj.ersjournals.com/panels_ajax_tab/jnl_ers_tab_art/node:196925/1)
*   [Info & Metrics](https://erj.ersjournals.com/content/early/2024/08/08/13993003.01733-2023.article-info)[](https://erj.ersjournals.com/panels_ajax_tab/jnl_ers_tab_info/node:196925/1)
*   [PDF](https://erj.ersjournals.com/content/erj/early/2024/08/08/13993003.01733-2023.full.pdf)[](https://erj.ersjournals.com/panels_ajax_tab/jnl_ers_tab_pdf/node:196925/1)

![Image 6: Loading](https://erj.ersjournals.com/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)

Abstract
--------

**Background** Control of latent tuberculosis infection (LTBI) is a priority in the World Health Organization strategy to eliminate tuberculosis (TB). Many high-income low TB incidence countries have prioritised LTBI screening and treatment in recent migrants. We tested whether a novel model of care, based entirely within primary care, was effective and safe as compared to secondary care.

**Methods** This was a pragmatic cluster-randomised, parallel group, superiority trial conducted in 34 general practices in London, UK, comparing LTBI treatment in recent migrants in primary care to secondary care. The primary outcome was treatment completion, defined as taking at least 90% of antibiotic doses. Secondary outcomes included treatment acceptance, adherence, adverse effects, patient satisfaction, TB-incidence and a cost-effectiveness analysis. The trial is registered at ClinicalTrials.gov ([NCT03069807](https://erj.ersjournals.com/lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT03069807&atom=%2Ferj%2Fearly%2F2024%2F08%2F08%2F13993003.01733-2023.atom)). Analyses were performed on an intention-to-treat basis.

**Results** Between September 2016 and May 2019, 362 recent migrants with LTBI were offered treatment and 276 accepted. Treatment completion was similar in primary and secondary care (82¬∑6% _versus_ 86¬∑0%, aOR:0¬∑64, 95%CI:0¬∑31‚Äì1¬∑29). There was no difference in drug induced liver injury (DILI) between primary and secondary care (0¬∑7% _versus_ 2¬∑3%, aOR:0¬∑29, 95%CI:0¬∑03‚Äì2¬∑84). Treatment acceptance was lower in primary care (65¬∑2% (146/224) _versus_ 94.2% (130/138), aOR:0¬∑10, 95%CI:0¬∑03‚Äì0¬∑31). The estimated cost per patient completing treatment was lower in primary care, with an incremental saving of ¬£315. 27(¬£313.47-¬£317.07).

**Conclusions** The treatment of LTBI in recent migrants within primary care does not result in higher rates of treatment completion but is safe and costs less when compared to secondary care.

**Footnotes**

This manuscript has recently been accepted for publication in the _European Respiratory Journal_. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the _ERJ_ online. Please open or download the PDF to view this article.

Conflict of Interest: A. Versi has nothing to disclose.

Conflict of interest: Peter J White reports grants from UK Health Security Agency (formerly Public Health England), Medical Research Council, National Institute for Health Research; consulting fees from Pfizer; outside the submitted work.

Conflict of interest: All other authors have nothing to disclose.

This is a PDF-only article. Please click on the PDF link above to read it.

*   Received October 9, 2023.
*   Accepted July 31, 2024.

*   Copyright ¬©The authors 2024.

[http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)This version is distributed under the terms of the Creative Commons Attribution Licence 4.0.

[Previous](https://erj.ersjournals.com/content/early/2024/08/01/13993003.01368-2024 ""Rituximab and mycophenolate mofetil in interstitial lung disease (EVER-ILD): one-year follow up results of a randomized controlled trial"")[Next](https://erj.ersjournals.com/content/early/2024/08/08/13993003.00347-2024 ""Association of airway inflammation and smoking status with IL-33 level in sputum of patients with asthma or COPD"")

[Back to top](https://erj.ersjournals.com/content/early/2024/08/08/13993003.01733-2023.long#page)

[View this article with _**LENS**_](https://erj.ersjournals.com/lens/erj/early/2024/08/08/13993003.01733-2023)

**Vol 64 Issue 2** [Table of Contents](https://erj.ersjournals.com/content/64/2)

[![Image 7: European Respiratory Journal: 64 (2)](https://erj.ersjournals.com/sites/default/files/styles/medium/public/highwire/erj/64/2.cover-source.jpg?itok=8IB8h8R7)](https://erj.ersjournals.com/content/64/2)

*   [Table of Contents](https://erj.ersjournals.com/content/64/2.toc ""Table of Contents"")
*   [Index by author](https://erj.ersjournals.com/content/64/2.index-by-author ""Index by author"")

[Email](https://erj.ersjournals.com/)

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email \* 

Your Name \* 

Send To \*

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following [The treatment of latent tuberculosis infection in migrants in primary care versus secondary care](https://erj.ersjournals.com/content/early/2024/08/08/13993003.01733-2023)

Message Subject (Your Name) has sent you a message from European Respiratory Society

Message Body (Your Name) thought you would like to see the European Respiratory Society web site.

Your Personal Message

    

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

  

[Print](https://erj.ersjournals.com/content/erj/early/2024/08/08/13993003.01733-2023.full-text.print)

[Citation Tools](https://erj.ersjournals.com/highwire/citation/196925/download)

The treatment of latent tuberculosis infection in migrants in primary care _versus_ secondary care

Matthew Burman, Dominik Zenner, Andrew J Copas, Lara Gosc√©, Hassan Haghparast-Bidgoli, Peter J White, Vicky Hickson, Opal Greyson, Duncan Trathen, Richard Ashcroft, Adrian R Martineau, Ibrahim Abubakar, Christopher J Griffiths, Heinke Kunst

European Respiratory Journal Jan 2024, 2301733; DOI: 10.1183/13993003.01733-2023

Citation Manager Formats
------------------------

*   [BibTeX](https://erj.ersjournals.com/highwire/citation/196925/bibtext)
*   [Bookends](https://erj.ersjournals.com/highwire/citation/196925/bookends)
*   [EasyBib](https://erj.ersjournals.com/highwire/citation/196925/easybib)
*   [EndNote (tagged)](https://erj.ersjournals.com/highwire/citation/196925/endnote-tagged)
*   [EndNote 8 (xml)](https://erj.ersjournals.com/highwire/citation/196925/endnote-8-xml)
*   [Medlars](https://erj.ersjournals.com/highwire/citation/196925/medlars)
*   [Mendeley](https://erj.ersjournals.com/highwire/citation/196925/mendeley)
*   [Papers](https://erj.ersjournals.com/highwire/citation/196925/papers)
*   [RefWorks Tagged](https://erj.ersjournals.com/highwire/citation/196925/refworks-tagged)
*   [Ref Manager](https://erj.ersjournals.com/highwire/citation/196925/reference-manager)
*   [RIS](https://erj.ersjournals.com/highwire/citation/196925/ris)
*   [Zotero](https://erj.ersjournals.com/highwire/citation/196925/zotero)

[Share](https://erj.ersjournals.com/)

The treatment of latent tuberculosis infection in migrants in primary care _versus_ secondary care

Matthew Burman, Dominik Zenner, Andrew J Copas, Lara Gosc√©, Hassan Haghparast-Bidgoli, Peter J White, Vicky Hickson, Opal Greyson, Duncan Trathen, Richard Ashcroft, Adrian R Martineau, Ibrahim Abubakar, Christopher J Griffiths, Heinke Kunst

European Respiratory Journal Jan 2024, 2301733; DOI: 10.1183/13993003.01733-2023

Share This Article:  Copy

[![Image 8: del.icio.us logo](https://erj.ersjournals.com/sites/all/modules/highwire/highwire/images/delicious-32.png)](http://del.icio.us/post?url=https%3A//erj.ersjournals.com/content/early/2024/08/08/13993003.01733-2023&title=The%20treatment%20of%20latent%20tuberculosis%20infection%20in%20migrants%20in%20primary%20care%20versus%20secondary%20care ""Bookmark this post on del.icio.us"") [![Image 9: Technorati logo](https://erj.ersjournals.com/sites/all/modules/highwire/highwire/images/technorati.png)](http://technorati.com/search/https://erj.ersjournals.com/content/early/2024/08/08/13993003.01733-2023 ""Search Technorati for links to this post"") [![Image 10: Twitter logo](https://erj.ersjournals.com/sites/all/modules/highwire/highwire/images/twitter.png)](http://twitter.com/share?url=https%3A//erj.ersjournals.com/content/early/2024/08/08/13993003.01733-2023&text=The%20treatment%20of%20latent%20tuberculosis%20infection%20in%20migrants%20in%20primary%20care%20versus%20secondary%20care ""Share this on Twitter"") [![Image 11: Connotea logo](https://erj.ersjournals.com/sites/all/modules/highwire/highwire/images/connotea.png)](http://www.connotea.org/add?uri=https%3A//erj.ersjournals.com/content/early/2024/08/08/13993003.01733-2023&title=The%20treatment%20of%20latent%20tuberculosis%20infection%20in%20migrants%20in%20primary%20care%20versus%20secondary%20care ""Share on connotea"") [![Image 12: Facebook logo](https://erj.ersjournals.com/sites/all/modules/highwire/highwire/images/fb-blue.png)](http://www.facebook.com/sharer.php?u=https%3A//erj.ersjournals.com/content/early/2024/08/08/13993003.01733-2023&t=The%20treatment%20of%20latent%20tuberculosis%20infection%20in%20migrants%20in%20primary%20care%20versus%20secondary%20care ""Share on Facebook"") [![Image 13: Mendeley logo](https://erj.ersjournals.com/sites/all/modules/highwire/highwire/images/mendeley.png)](http://www.mendeley.com/import/?url=https%3A//erj.ersjournals.com/content/early/2024/08/08/13993003.01733-2023&title=The%20treatment%20of%20latent%20tuberculosis%20infection%20in%20migrants%20in%20primary%20care%20versus%20secondary%20care ""Share on Mendeley"")

[Full Text (PDF)](https://erj.ersjournals.com/content/erj/early/2024/08/08/13993003.01733-2023.full-text.pdf)

Jump To
-------

*   [Article](https://erj.ersjournals.com/content/early/2024/08/08/13993003.01733-2023)
    
    *   [Abstract](https://erj.ersjournals.com/content/early/2024/08/08/13993003.01733-2023.long#abstract-1)
    
*   [Info & Metrics](https://erj.ersjournals.com/content/early/2024/08/08/13993003.01733-2023.article-info)
*   [PDF](https://erj.ersjournals.com/content/early/2024/08/08/13993003.01733-2023.full.pdf)

*   [Tweet Widget](http://twitter.com/share?url=https%3A//erj.ersjournals.com/content/early/2024/08/08/13993003.01733-2023&count=horizontal&via=&text=The%20treatment%20of%20latent%20tuberculosis%20infection%20in%20migrants%20in%20primary%20care%20versus%20secondary%20care&counturl=https%3A//erj.ersjournals.com/content/early/2024/08/08/13993003.01733-2023 ""Tweet This"")
*   [Facebook Like](http://www.facebook.com/plugins/like.php?href=https%3A//erj.ersjournals.com/content/early/2024/08/08/13993003.01733-2023&layout=button_count&show_faces=false&action=like&colorscheme=light&width=100&height=21&font=&locale= ""I Like it"")
*   [Google Plus One](https://erj.ersjournals.com/content/early/2024/08/08/13993003.01733-2023 ""Plus it"")

### More in this TOC Section

*   [Pharmacological and pre-clinical safety profile of rSIV.F/HN, a hybrid lentiviral vector for cystic fibrosis gene therapy](https://erj.ersjournals.com/content/early/2024/08/08/13993003.01683-2023)
    
*   [Reassessing Halm's clinical stability criteria in community-acquired pneumonia management](https://erj.ersjournals.com/content/early/2024/08/08/13993003.00054-2024)
    

[Show more Original Research Article](https://erj.ersjournals.com/content/by/section/Original%20Research%20Article)

### Related Articles

Navigate
--------

*   [Home](https://erj.ersjournals.com/)
*   [Current issue](https://erj.ersjournals.com/content/current)
*   [Archive](https://erj.ersjournals.com/content/by/year)

About the ERJ
-------------

*   [Journal information](https://erj.ersjournals.com/journal/about)
*   [Editorial board](https://erj.ersjournals.com/journal/editorial-board)
*   [Press](http://www.ersjournals.com/press)
*   [Permissions and reprints](http://www.ersjournals.com/reuse)
*   [Advertising](http://www.ersjournals.com/advertising)

The European Respiratory Society
--------------------------------

*   [Society home](http://www.ersnet.org/)
*   [myERS](https://my.ersnet.org/Login.html)
*   [Privacy policy](http://www.ersjournals.com/site/privacy)
*   [Accessibility](http://www.ersjournals.com/site/accessibility)

ERS publications
----------------

*   [European Respiratory Journal](http://erj.ersjournals.com/)
*   [ERJ Open Research](http://openres.ersjournals.com/)
*   [European Respiratory Review](http://err.ersjournals.com/)
*   [Breathe](http://breathe.ersjournals.com/)
*   [ERS books online](http://www.erspublications.com/)
*   [ERS Bookshop](http://www.ersbookshop.com/)

Help
----

*   [Feedback](https://erj.ersjournals.com/feedback)

For authors
-----------

*   [Instructions for authors](https://erj.ersjournals.com/authors/instructions)
*   [Publication ethics and malpractice](https://www.ersjournals.com/about-us/publication-ethics-and-malpractice-statement)
*   [Submit a manuscript](http://mc.manuscriptcentral.com/erj)

For readers
-----------

*   [Alerts](https://erj.ersjournals.com/alerts)
*   [Subjects](https://erj.ersjournals.com/collection)
*   [Podcasts](https://erj.ersjournals.com/journal/podcast)
*   [RSS](https://erj.ersjournals.com/rss)

Subscriptions
-------------

*   [Accessing the ERS publications](https://www.ersjournals.com/subscriptions)

![Image 14](https://erj.ersjournals.com/sites/default/files/additional-assets/ers-footer-logo.png)

Contact us
----------

European Respiratory Society  
442 Glossop Road  
Sheffield S10 2PX  
United Kingdom  
Tel: +44 114 2672860  
Email: journals@ersnet.org

ISSN
----

Print ISSN: ¬†0903-1936  
Online ISSN: 1399-3003

Copyright ¬© 2024 by the European Respiratory Society
",gpt-4o-2024-08-06
2024-08-29 10:00:00,2024-08-31 05:13:26,"**New Insomnia Therapy Beats the Odds in Primary Care** üåôüë©‚Äç‚öïÔ∏è
Recent findings from the HABIT trial indicate that nurse-delivered sleep restriction therapy shows significant promise for insomnia treatment. With better efficacy and safety profiles than traditional methods, this approach could revolutionize how primary care manages insomnia, offering improved outcomes and cost-effectiveness. Delve deeper into this study and consider sharing how this could impact your practice. [Explore the full article](http://medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu) to see how nurse-led sleep strategies could be the future of insomnia care. üè•üí§

#InsomniaTreatment #PrimaryCare #NurseLedTherapy #SleepMedicine #HealthcareRevolution #MedscapeResearch",https://img.medscapestatic.com/vim/live/professional_assets/dt_240313_insomnia_800x450px.jpg,http://medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu,"You are a content creator tasked with crafting highly informative, easy to digest social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Thumbnail image URL: https://img.medscapestatic.com/vim/live/professional_assets/dt_240313_insomnia_800x450px.jpg  
Title: Alternate Insomnia Therapy Has Good Showing

URL Source: http://medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu

Published Time: 2024-08-29T10:00:00-04:00

Markdown Content:
Alternate Insomnia Therapy Has Good Showing
===============
                                      

This site is intended for UK healthcare professionals

[![Image 1: Medscape UK Univadis Logo](http://img.wbmdstatic.com/medscapeuk_static_vue/medscape-uk-page-article/client/img/medscape-uk-logo.4a9c814f.svg)](http://medscape.co.uk/)

*   Recent Searches [Clear](http://medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu#)

[![Image 2: Medscape UK Univadis Logo](http://img.wbmdstatic.com/medscapeuk_static_vue/medscape-uk-page-article/client/img/medscape-uk-logo.4a9c814f.svg)](http://medscape.co.uk/)

*   Recent Searches [Clear](http://medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu#)

*   Recent Searches [Clear](http://medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu#)

*   Menu
*   News
    
*   Guidelines
    
*   Drugs
    
*   Quizzes
    
*   Search

Clinical Summary

Alternate Insomnia Therapy Has Good Showing
===========================================

Susan London

[](http://medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu#)

**TOPLINE:**¬†
-------------

Brief nurse-delivered sleep restriction therapy is efficacious, safe, and likely cost-effective for treating insomnia disorder in primary care.

**METHODOLOGY:**¬†
-----------------

*   Investigators conducted an open-label, randomised controlled trial among adult patients with insomnia disorder from NHS general practices in England (the [HABIT trial](https://www.isrctn.com/ISRCTN42499563)).
*   A total of 642 patients were randomised to two groups:
    *   Nurse-delivered behavioural therapy intervention: Two in-person and two telephone sessions, plus support to follow a prescribed sleep schedule aimed at restricting and standardising time in bed, plus a sleep hygiene leaflet.
    *   Control: Sleep hygiene leaflet only.
*   The main outcome was the self-reported insomnia severity on the Insomnia Severity Index (range, 0-28) at 6 months.

**TAKEAWAY:**¬†
--------------

*   At 6 months, the mean Insomnia Severity Index score was 10.9 in the sleep restriction therapy group vs 13.9 in the control group (estimated adjusted mean difference, ‚Äì3.05; _P_ < .001).
*   Scores were also lower with the intervention at 3 months (10.9 vs 14.8; _P_ < .001) and at 12 months (10.4 vs 13.5; _P_ < .001).
*   Sleep restriction therapy was superior to control with respect to secondary outcomes too: self-reported sleep, mental health‚Äìrelated quality of life, depressive symptoms, work productivity impairment, and sleep-related quality of life.
*   Sixteen patients, evenly split between groups, experienced serious adverse events; none were deemed related to trial interventions.
*   Sleep restriction therapy had an incremental cost per quality-adjusted life-year gained of ¬£2075.71.

**IN PRACTICE:**
----------------

""The vast majority of people with insomnia in the \[United Kingdom\] cannot access the first-line treatment (cognitive behavioural therapy),"" the authors wrote. ""Our trial shows that nurses can be trained to deliver a focused and manualised behavioural insomnia treatment, leading to patient benefit, and without safety concerns. Moreover, the intervention is very likely to be cost-effective. Nurse-delivered \[sleep restriction therapy\] could therefore become part of primary care management of insomnia,"" they concluded.

**SOURCE:**
-----------

The study was led by Simon D. Kyle, PhD, MA, University of Oxford, Oxford, UK, and was [published online](https://www.journalslibrary.nihr.ac.uk/hta/RJYT4275#/abstract) in _Health Technology Assessment_.

**LIMITATIONS:**
----------------

Limitations included a predominantly White and better-educated trial population, discontinuations due to the perceived challenging nature of the intervention, and the possibility that some participants had other, undiagnosed sleep disorders.

**DISCLOSURES:**
----------------

The study was funded by the National Institute of Health and Care Research. Two authors disclosed affiliations with Big Health Ltd, which manufactures a digital sleep improvement programme.

Register Today

Already a member? Log in

EDITOR'S RECOMMENDATIONS
------------------------

*   ![Image 3: related](https://img.medscapestatic.com/pi/global/1x1.png)
    
    [Restless Nights? Here's How to Help Your Patients](https://www.medscape.co.uk/viewarticle/restless-nights-heres-how-help-your-patients-2024a1000fm8)
    
    Despite being the gold standard, cognitive behavioural therapy for insomnia is underutilised.
    
*   ![Image 4: related](https://img.medscapestatic.com/pi/global/1x1.png)
    
    [Sleep Patterns Predict Response to Fibromyalgia Treatment](https://www.medscape.co.uk/s/viewarticle/sleep-patterns-predict-response-fibromyalgia-treatment-2024a1000eqb)
    
    Patients with minimal pain relief from a serotonin and norepinephrine reuptake inhibitor had more sleep problems and tougher mornings than those who responded better to the medication.
    
*   ![Image 5: related](https://img.medscapestatic.com/pi/global/1x1.png)
    
    [Hyperarousal Is a Treatable Reason Behind Poor Sleep in Endometriosis](https://www.medscape.co.uk/viewarticle/hyperarousal-treatable-reason-behind-poor-sleep-2024a1000eao)
    
    A case-control study with 847 participants is the first to identify the importance of hyperarousal.
    

YOU MAY ALSO LIKE
-----------------

[](https://www.medscape.co.uk/viewarticle/could-vape-flavour-ban-drive-users-back-smoking-2024a1000fug ""Could a Vape Flavour Ban Drive Users Back to Smoking?"")

[Could a Vape Flavour Ban Drive Users Back to Smoking?](https://www.medscape.co.uk/viewarticle/could-vape-flavour-ban-drive-users-back-smoking-2024a1000fug ""Could a Vape Flavour Ban Drive Users Back to Smoking?"")

The BMA has called for a ban on all flavoured vape liquids except tobacco in a move that users say, if enacted, would drive them back to smoking.

*   Medscape News UK
*   13 hours ago

[Pancreatic Cancer: NICE Quality Standard](https://www.medscape.co.uk/viewarticle/pancreatic-cancer-quality-standard-2024a1000fqo ""Pancreatic Cancer: NICE Quality Standard"")

A summary of the NICE quality standard for the diagnosis of pancreatic cancer and management of pancreatic ductal adenocarcinoma in adults

*   Guidelines Summary: Secondary Care
*   14 hours ago

[](https://www.medscape.co.uk/viewarticle/mothers-vascular-skin-lesions-increase-risk-offspring-2024a1000fq5 ""Mother's Vascular Skin Lesions Increase Risk for Offspring"")

[Mother's Vascular Skin Lesions Increase Risk for Offspring](https://www.medscape.co.uk/viewarticle/mothers-vascular-skin-lesions-increase-risk-offspring-2024a1000fq5 ""Mother's Vascular Skin Lesions Increase Risk for Offspring"")

Findings of a large population-based study supported a possible heritable component for angioma and especially for port-wine stain.

*   Medscape News UK
*   15 hours ago

[](https://www.medscape.co.uk/viewarticle/gps-encouraged-test-treat-latent-tb-immigrants-2024a1000fpa ""GPs Encouraged to Test, Treat Latent TB in Immigrants"")

[GPs Encouraged to Test, Treat Latent TB in Immigrants](https://www.medscape.co.uk/viewarticle/gps-encouraged-test-treat-latent-tb-immigrants-2024a1000fpa ""GPs Encouraged to Test, Treat Latent TB in Immigrants"")

Primary care in the United Kingdom is poised to take over TB management.

*   Medscape News UK
*   16 hours ago

[](https://www.medscape.co.uk/viewarticle/back-school-measles-surge-feared-2024a1000ftp ""Back to School Measles Surge Feared"")

[Back to School Measles Surge Feared](https://www.medscape.co.uk/viewarticle/back-school-measles-surge-feared-2024a1000ftp ""Back to School Measles Surge Feared"")

Experts warn of a potential surge in measles cases when children return to school next week and have urged parents to ensure children are up to date with vaccinations.

*   Medscape News UK
*   17 hours ago

[](https://www.medscape.co.uk/s/viewarticle/tale-rheumatologist-volunteers-overseas-and-united-states-2024a1000ftq ""A Tale of Rheumatologist Volunteers Overseas and in the US"")

[A Tale of Rheumatologist Volunteers Overseas and in the US](https://www.medscape.co.uk/s/viewarticle/tale-rheumatologist-volunteers-overseas-and-united-states-2024a1000ftq ""A Tale of Rheumatologist Volunteers Overseas and in the US"")

Two rheumatologists give insights about the great rewards of rheumatology volunteer work while also providing insights on its challenges across different settings.

*   Medscape Medical News
*   17 hours ago

[](https://www.medscape.co.uk/s/viewarticle/seated-doctors-satisfy-patients-2024a1000ftl ""Seated Doctors Satisfy Patients"")

[Seated Doctors Satisfy Patients](https://www.medscape.co.uk/s/viewarticle/seated-doctors-satisfy-patients-2024a1000ftl ""Seated Doctors Satisfy Patients"")

A doctor's decision to sit at the bedside is associated with increased patient satisfaction, data suggested.

*   Medscape Medical News
*   18 hours ago

[](https://www.medscape.co.uk/s/viewarticle/beyond-paycheck-top-non-salary-perks-doctors-2024a1000fto ""Beyond the Paycheck: Top Non-Salary Perks for Doctors"")

[Beyond the Paycheck: Top Non-Salary Perks for Doctors](https://www.medscape.co.uk/s/viewarticle/beyond-paycheck-top-non-salary-perks-doctors-2024a1000fto ""Beyond the Paycheck: Top Non-Salary Perks for Doctors"")

When it comes to compensation, a doctor's paycheck is just the beginning. Discover the top non-salary perks that make the job even more rewarding.

*   Medscape Medical News
*   18 hours ago

[](https://www.medscape.co.uk/s/viewarticle/nhs-doctors-face-bullying-and-reprisal-speaking-out-2024a1000ftj ""NHS Doctors Face Bullying and Reprisal for Speaking Out"")

[NHS Doctors Face Bullying and Reprisal for Speaking Out](https://www.medscape.co.uk/s/viewarticle/nhs-doctors-face-bullying-and-reprisal-speaking-out-2024a1000ftj ""NHS Doctors Face Bullying and Reprisal for Speaking Out"")

Less than 20% of doctors in Scotland are satisfied with their organisation's response to whistleblowing, a new BMA survey has revealed.

*   Press Association
*   18 hours ago

[](https://www.medscape.co.uk/s/viewarticle/intermittent-fasting-aids-patients-prediabetes-or-t2d-2024a1000ftc ""Intermittent Fasting Aids Patients With Prediabetes or T2D"")

[Intermittent Fasting Aids Patients With Prediabetes or T2D](https://www.medscape.co.uk/s/viewarticle/intermittent-fasting-aids-patients-prediabetes-or-t2d-2024a1000ftc ""Intermittent Fasting Aids Patients With Prediabetes or T2D"")

The approach is associated with reductions in body weight, BMI, and A1c levels.

*   Medscape Medical News
*   19 hours ago

[Cervical Screening Guidance for Nurses](https://www.medscape.co.uk/viewarticle/human-papillomavirus-cervical-screening-and-cervical-cancer-2024a1000dpy ""Cervical Screening Guidance for Nurses"")

Covers cervical cancer and screening recommendations for nursing undertaking consultations and examinations

*   Guidelines Summary: Primary Care
*   20 hours ago

[](https://www.medscape.co.uk/viewarticle/10-commandments-endocarditis-management-2024a1000ft3 ""The '10 Commandments' of Endocarditis Management"")

[The '10 Commandments' of Endocarditis Management](https://www.medscape.co.uk/viewarticle/10-commandments-endocarditis-management-2024a1000ft3 ""The '10 Commandments' of Endocarditis Management"")

Significant updates in the 2023 European Society of Cardiology endocarditis guidelines include revised antibiotic prophylaxis and surgical indications.

*   Medscape News UK
*   20 hours ago

[](https://www.medscape.co.uk/s/viewarticle/balloon-catheters-blood-loss-placenta-accreta-cases-2024a1000ft1 ""Balloon Catheters for Blood Loss in Placenta Accreta Cases"")

[Balloon Catheters for Blood Loss in Placenta Accreta Cases](https://www.medscape.co.uk/s/viewarticle/balloon-catheters-blood-loss-placenta-accreta-cases-2024a1000ft1 ""Balloon Catheters for Blood Loss in Placenta Accreta Cases"")

Prophylactic placement of balloon catheters or sheaths prior to planned cesarean delivery may reduce blood loss in women with placenta accreta spectrum disorder.

*   MDedge News
*   21 hours ago

[Key Learning Points: BASHH Anogenital Warts](https://www.medscape.co.uk/viewarticle/key-learning-points-bashh-anogenital-warts-2024a1000esn ""Key Learning Points: BASHH Anogenital Warts"")

Dr Amy Cleese reviews the diagnosis and management of anogenital warts in general practice, offering six key learning points from updated guidance

*   Guidelines in Practice: Primary Care
*   22 hours ago

[](https://www.medscape.co.uk/s/viewarticle/breast-cancer-drug-may-slow-aggressive-brain-tumour-kids-2024a1000fra ""Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids"")

[Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids](https://www.medscape.co.uk/s/viewarticle/breast-cancer-drug-may-slow-aggressive-brain-tumour-kids-2024a1000fra ""Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids"")

Ribociclib, commonly used for breast cancer, has been found to stabilise a subtype of diffuse hemispheric glioma for about 17 months before regrowth begins.

*   Press Association
*   29 Aug 2024

[](https://www.medscape.co.uk/s/viewarticle/listeriosis-during-pregnancy-can-be-fatal-fetus-2024a1000frm ""Listeriosis During Pregnancy Can Be Fatal for the Fetus"")

[Listeriosis During Pregnancy Can Be Fatal for the Fetus](https://www.medscape.co.uk/s/viewarticle/listeriosis-during-pregnancy-can-be-fatal-fetus-2024a1000frm ""Listeriosis During Pregnancy Can Be Fatal for the Fetus"")

The rate of fetal loss or neonatal death from invasive listeriosis is 29%.

*   Medscape Medical News
*   29 Aug 2024

[](https://www.medscape.co.uk/viewarticle/prisons-often-waste-ambulance-crew-time-2024a1000fqp ""Prisons Often Waste Ambulance Crew Time"")

[Prisons Often Waste Ambulance Crew Time](https://www.medscape.co.uk/viewarticle/prisons-often-waste-ambulance-crew-time-2024a1000fqp ""Prisons Often Waste Ambulance Crew Time"")

Unnecessary 999 calls are being made by prison staff due to lack of experience and concerns over legal repercussions.

*   Medscape News UK
*   29 Aug 2024

[](https://www.medscape.co.uk/viewarticle/recurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni ""Recurrent UTI: Undercultured, Overtreated Despite Resistance"")

[Recurrent UTI: Undercultured, Overtreated Despite Resistance](https://www.medscape.co.uk/viewarticle/recurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni ""Recurrent UTI: Undercultured, Overtreated Despite Resistance"")

Roughly 40% of general practitioners do not culture recurrent UTIs and instead, just treat.

*   Medscape News UK
*   29 Aug 2024

[](https://www.medscape.co.uk/s/viewarticle/high-dose-psilocybin-shows-promising-results-depression-2024a1000fqw ""High-Dose Psilocybin Shows Promising Results for Depression"")

[High-Dose Psilocybin Shows Promising Results for Depression](https://www.medscape.co.uk/s/viewarticle/high-dose-psilocybin-shows-promising-results-depression-2024a1000fqw ""High-Dose Psilocybin Shows Promising Results for Depression"")

A meta-analysis found that high-dose psilocybin for depressive symptoms showed better responses than placebo or escitalopram in antidepressant trials.

*   Medscape Medical News
*   29 Aug 2024

![Image 6](blob:http://medscape.co.uk/6742166de2ffdc98a2fc8b83a0aa235b)
",gpt-4o-2024-08-06
2024-08-29 09:00:00,2024-08-31 05:13:37,"### Recurrent Urinary Tract Infections: Antibiotic Use and Resistance Challenges in Women

A recent study published in the _British Journal of General Practice_ highlights the prevalence and resistance patterns in women suffering from recurrent urinary tract infections (rUTIs) in Wales. The cross-sectional study reveals that 6% of women suffer from rUTIs and roughly 1.7% are prescribed prophylactic antibiotics. However, a significant portion of these women exhibit bacterial resistance, especially to commonly used antibiotics like trimethoprim and amoxicillin. The increased resistance underscores the need for frequent urine cultures to better inform antibiotic prescriptions and help combat antimicrobial resistance (AMR).

For doctors, this study reinforces the importance of aligning real-world practices with guidelines by encouraging urine cultures before initiating prophylactic antibiotics. Let's explore practical strategies and discuss how these insights could optimize patient care in your practice.

Read the full study here: [British Journal of General Practice 2024](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long)

üîó #UrinaryTractInfections #AntibioticResistance #PrimaryCare #AMR #PatientCare",https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_230216_urine_analysis_800x450.jpg,https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long,"You are a content creator tasked with crafting highly informative, easy to digest social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Thumbnail image URL: https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_230216_urine_analysis_800x450.jpg  
Title: Recurrent urinary tract infections and prophylactic antibiotic use in women: a cross-sectional study in primary care

URL Source: https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long

Markdown Content:
Research

, Victoria Best, Rebecca Cannings-John, Fiona Wood, Adrian Edwards, Ashley Akbari, Gail Hayward and Haroon Ahmed

British Journal of General Practice 2024; 74 (746): e619-e627. DOI: https://doi.org/10.3399/BJGP.2024.0015

Abstract
--------

**Background** Despite the considerable morbidity caused by recurrent urinary tract infections (rUTIs), and the wider personal and public health implications from frequent antibiotic use, few studies adequately describe the prevalence and characteristics of women with rUTIs or those who use prophylactic antibiotics.

**Aim** To describe the prevalence, characteristics, and urine profiles of women with rUTIs with and without prophylactic antibiotic use in Welsh primary care.

**Design and setting** This was a retrospective cross-sectional study in Welsh general practice using the Secure Anonymised Information Linkage (SAIL) Databank.

**Method** The characteristics of women aged ‚â•18 years with rUTIs or using prophylactic antibiotics from 2010 to 2020, and associated urine culture results from 2015 to 2020, are described.

**Results** In total, 6.0% (_n_ = 92 213/_N_ = 1 547 919) had rUTIs, and 1.7% (_n_ = 26 862/_N_ = 1 547 919) were prescribed prophylactic antibiotics with the rates increasing after 57 years of age. Only 49.0% (_n_ =13 149/_N_ = 26 862) of users of prophylactic antibiotics met the definition of rUTIs before initiation. The study found that 80.8% (_n_ = 44 947/_N_ = 55 652) of women with rUTIs had a urine culture result in the preceding 12 months with high rates of resistance to trimethoprim and amoxicillin. Of women taking prophylactic antibiotics, 64.2% (_n_ = 9926/_N_ = 15 455) had a urine culture result before initiation and 18.5% (_n_ = 320/_N_ = 1730) of women prescribed trimethoprim had resistance to it on the antecedent sample.

**Conclusion** A substantial proportion of women had rUTIs or incident prophylactic antibiotic use. However, 64.2% (_n_ = 9926/_N_ = 15 455) of women had urine cultured before starting prophylaxis. There was a high proportion of cultured bacteria resistant to two antibiotics used for rUTI prevention and evidence of resistance to the prescribed antibiotic. More frequent urine cultures for rUTI diagnosis and before prophylactic antibiotic initiation could better inform antibiotic choices.

*   [anti-infective agents](https://bjgp.org/keyword/anti-infective-agents)
*   [bacterial](https://bjgp.org/keyword/bacterial)
*   [drug resistance](https://bjgp.org/keyword/drug-resistance)
*   [electronic health records](https://bjgp.org/keyword/electronic-health-records)
*   [primary health care](https://bjgp.org/keyword/primary-health-care)
*   [urinary](https://bjgp.org/keyword/urinary)
*   [urinary tract infections](https://bjgp.org/keyword/urinary-tract-infections)

Introduction
------------

Urinary tract infections (UTIs) in women are common, and a proportion experience recurrent UTIs (rUTIs), defined as ‚â•2 UTIs in 6 months, or ‚â•3 in 12 months.1‚Äì3 rUTIs are a significant cause of morbidity and health service use.1,4,5 Estimates of the prevalence of rUTIs range from 3% to 44% of women, depending on the definition used and age or nationality studied.6‚Äì8 Women with rUTIs have frequent antibiotic exposure because of treatment for acute UTIs and potential long-term prophylaxis. Antibiotic exposure is a major driver of antimicrobial resistance (AMR), and antibiotic exposure for UTIs increases resistance within 2 months and persists for 12 months.[9](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-9),[10](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-10) Resistant UTIs have a greater impact on patients and are more costly to treat than susceptible infections.[11](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-11),[12](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-12)

Despite the considerable morbidity caused by rUTIs, and the wider personal and public health implications from frequent antibiotic use, few studies adequately describe the prevalence and characteristics of women with rUTIs. Furthermore, it is unclear how well clinical practice aligns with current guidelines recommending urine culture for rUTI diagnosis.[1](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-1) Understanding real-world practice related to diagnosing and treating rUTIs, a common condition seen and managed in primary care, is an important step towards improving patient care.

This study aimed to comprehensively describe the prevalence, characteristics, urine testing, and susceptibility profiles of women with rUTIs in Wales to understand current clinical practice and alignment with guidelines.

Method
------

### Design

This was a cross-sectional study using anonymised individual-level, population-scale linked electronic health record data sources within the Secure Anonymised Information Linkage (SAIL) Databank, the ISO 27001-certified national trusted research environment (TRE) for Wales.[13](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-13) All data sources within the SAIL Databank TRE are linkable following approvals using an anonymised linking field.[13](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-13) The data sources used include:

*   Welsh Longitudinal General Practice (WLGP) ‚Äî primary care general practice data using Read codes, covering 86.1% of the Welsh population registered with 82.4% of Welsh general practices;[14](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-14),[15](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-15)
    
*   Patient Episode Database for Wales (PEDW) ‚Äî secondary care hospital admission data using the International Classification of Disease version 10 (ICD-10);[16](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-16)
    
*   Welsh Results Reporting Service (WRRS) ‚Äî all-Wales urine specimen data from primary and secondary care; and[17](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-17)
    
*   Welsh Demographic Service Dataset (WDSD) and Annual District Death Extract (ADDE) ‚Äî demographic and death data.[18](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-18),[19](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-19)
    

Little is known about the prevalence, characteristics, urine testing, or the use of prophylactic antibiotics among women with recurrent urinary tract infections (rUTIs). This study found that 6.0% (_n_ = 92 213/_N_ = 1 547 919) of women had evidence of rUTIs in Wales from 2010 to 2020, and, from 2015‚Äì2020, 80.8% (_n_ = 44 947/_N_ = 55 652) had a urine culture result in the preceding 12 months. In total, 1.7% (_n_ = 26 862/_N_ = 1 547 919) of women used prophylactic antibiotics during the study period and, between 2015‚Äì2020, 64.2% (_n_ = 9926/_N_ = 15 455) had a urine culture result before starting prophylaxis, and of these 8.3% (_n_ = 410/_N_ = 4920) were resistant to the prescribed antibiotic. More frequent urine cultures in the workup of rUTI diagnosis and prophylactic antibiotic initiation could better inform antibiotic choice.

The Improving Prophylactic Antibiotic use for Recurrent urinary Tract infection (IMPART) patient and public team were involved in the design of this study.

### Population

Two cohorts were created. Cohort 1 included women who met the clinical definition of rUTIs (clinical cohort). Cohort 2 included women prescribed prophylactic antibiotics consistent with rUTI prevention (prophylaxis cohort; for definitions, see below). Eligibility criteria for the two cohorts are described in [Box 1](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#T2).

<table id=""table-2""><tbody id=""tbody-2""><tr id=""tr-2""><td rowspan=""1"" colspan=""1"" id=""td-2""><strong>Inclusion criteria</strong></td><td rowspan=""1"" colspan=""1"" id=""td-3""><ul id=""list-2""><li id=""list-item-5""><p id=""p-20"">Sufficient data linkage quality (Supplementary Box S1)</p></li><li id=""list-item-6""><p id=""p-21"">Sex recorded as female using the WDSD<sup><a id=""xref-ref-19-2"" href=""#ref-19"">19</a></sup></p></li><li id=""list-item-7""><p id=""p-22"">Aged ‚â•18 years and alive during the study period (1 January 2010 to 31 December 2020)</p></li><li id=""list-item-8""><p id=""p-23"">Registered with a SAIL-providing general practice during the study period</p></li><li id=""list-item-9""><p id=""p-24"">Registered for ‚â•12 months before cohort entry for women with rUTIs or registered for ‚â•18 months before cohort entry for women taking prophylactic antibiotics (to capture comorbidity and urine microbiology data)</p></li><li id=""list-item-10""><p id=""p-25"">Met the definition of an rUTI or prophylactic antibiotic use</p></li></ul></td></tr><tr id=""tr-3""><td rowspan=""1"" colspan=""1"" id=""td-4""><strong>Exclusion criteria</strong></td><td rowspan=""1"" colspan=""1"" id=""td-5""><ul id=""list-3""><li id=""list-item-11""><p id=""p-26"">Catheter use was recorded at any point before cohort entry</p></li><li id=""list-item-12""><p id=""p-27"">Pregnancy was recorded in the 40 weeks before the cohort entry date to ensure women were not pregnant at cohort entry. Patients were eligible subsequently, provided they met the inclusion criteria and if pregnancy was not recorded within 40 weeks before the cohort entry date</p></li></ul></td></tr></tbody></table>

Box 1.

Inclusion and exclusion criteria for study entry

### Case ascertainment

#### Definition of recurrent UTIs

In the current study, rUTIs were defined as ‚â•2 acute UTIs within 6 months, or ‚â•3 within 12 months.1 How acute UTIs were defined is shown in [Box 2](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#T3). Consultations and hospital admissions for acute UTIs were identified using Read and ICD-10 code lists (Supplementary Boxes S2‚ÄìS4). More than one acute UTI within a 28-day period was considered a repeat consultation for the same episode. The date of the first consultation was recorded as the acute UTI date (Supplementary Figure S1). For hospital-diagnosed UTIs, the start date of the UTI was the first date of an episode containing a UTI ICD-10 code and the end date was its final date. The first time a woman met the definition of rUTI was used as the date of rUTI diagnosis.

| **Clinical scenario** | **UTI-related Read code (WLGP data)** | **Antibiotic prescription[b](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#fn-3) (WLGP data)** | **UTI-related ICD-10 code (PEDW data)** | **Urine culture result (WRRS data)** | **Time period between codes** |
| --- | --- | --- | --- | --- | --- |
| 1\. General practice clinically diagnosed and treated UTI | ‚Ä¢ Yes | ‚Ä¢ Yes | ‚Ä¢ No | ‚Ä¢ No | ‚Ä¢ Same date |
| 2\. Hospital-diagnosed and treated UTI | ‚Ä¢ No | ‚Ä¢ No | ‚Ä¢ Yes | ‚Ä¢ No | ‚Ä¢ Not applicable |
| 3\. General practice clinically diagnosed, microbiologically confirmed, and treated UTI | ‚Ä¢ Yes | ‚Ä¢ Yes | ‚Ä¢ No | ‚Ä¢ Confirmed UTI | ‚Ä¢ Urine culture result within 7 days of general practice clinically diagnosed and treated UTI. Earliest code = date of UTI |
| 4\. Hospital-diagnosed, microbiologically confirmed, and treated UTI | ‚Ä¢ No | ‚Ä¢ No | ‚Ä¢ Yes | ‚Ä¢ ConfirmedUTI | ‚Ä¢ Within 7 days. Earliest code = date of UTI |

Box 2.

Definitions of acute UTIsa

#### Definition of prophylactic antibiotics

Prophylactic antibiotic use was defined as ‚â•3 consecutive prescriptions for the same UTI-specific antibiotic (trimethoprim, nitrofurantoin, or cefalexin) with 21‚Äì56 days between prescriptions (Supplementary Box S5 and Supplementary Figure S2). This approach was required as WLGP data include prescribing data only (not dispensing) without data on the quantity of tablets prescribed. Women who used prophylactic antibiotics in the preceding 12 months were excluded to identify new users and ascertain urine culture results before initiation.

#### Comorbidity identification

Relevant comorbidities that either increase the risk of UTIs or potentially influence antibiotic prescribing were identified using Read codes and/or ICD-10 codes in the WLGP and PEDW data sources, respectively. To define these, the authors looked back from the date of cohort entry. The length of lookback was specific to the condition and further details are included in Supplementary Box S6.

#### Urine microbiology

Reported urine culture results were identified using code lists for urine tests in the WRRS (Supplementary Box S7). Analyses of urine specimens were restricted to 2015‚Äì2020 as there was a marked increase in NHS Wales laboratories submitting urine data from 2015.[23](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-23) Urine culture results reported on the same day with the same result were regarded as duplicates. Urine microbiology results were categorised using a methodology based on the Public Health Wales Microbiology Division‚Äôs standard operating procedure using organism(s) cultured and white blood cell count (Supplementary Box S8).[24](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-24) Antibiotic susceptibility was categorised using the European Committee on Antimicrobial Susceptibility Testing guidelines 2019, where intermediate is described as susceptible at increased exposure.[25](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-25)

In the study, all reported urine culture results in the 12 months before diagnosis (clinical cohort) and 18 months before prophylactic antibiotic initiation (prophylactic cohort) and all urine culture results within 7 days of an acute UTI were analysed to define the number of women with microbiologically confirmed rUTIs. The rationale for using 18 months before study entry for the prophylactic cohort was to account for potential delays between rUTI diagnosis and investigation or referral before initiating antibiotics.

### Statistical analysis

Sociodemographic and clinical characteristics were summarised using counts and percentages for categorical variables and means (with standard deviation) or medians (with interquartile range \[IQR\]) for continuous variables. Rates were calculated according to 10-year age bands using all women in SAIL aged ‚â•18 years and their person-time over the study period (2010‚Äì2020) as the denominator.

For women in both cohorts, the number of urine cultures before cohort entry, organisms cultured, and antibiotic susceptibility with subgroup analyses for _Escherichia coli_ and coliforms are reported. The study also explored whether the proportions of urine cultures tested for susceptibility and the proportion that were resistant changed over the study period in view of changing incident prophylactic antibiotic use in the prophylaxis cohort.

For women in the prophylaxis cohort, antibiotic type and dose are also reported and how many met the definition of rUTIs was calculated. For those who did, time between meeting the rUTI definition and starting prophylactic antibiotics was calculated. Sensitivity analyses were conducted first restricting prophylactic antibiotic use to women on a consistent dose of antibiotics over consecutive prescriptions and secondly the definition used in this study for acute UTIs was adjusted to describe the proportion of women with rUTIs before starting prophylaxis to assess their impact on the estimates. Finally, how many women had a urine culture reported before initiating prophylactic antibiotics was estimated and the most recent result before initiation was used to ascertain their prophylactic antibiotic susceptibility.

Analyses were conducted in R version 4.1.3.26 The SAIL Databank Information Governance Review Panel approved the study. For analyses where counts are small, counts are rounded to the nearest 10 for the purposes of disclosure control and privacy protection. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist to guide reporting was used.[27](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-27)

Results
-------

In total, 92 213 women (6.0% of women aged ‚â•18 years between 2010 and 2020) who met the clinical definition of rUTIs were identified and were entered into the clinical cohort ([Figure 1](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#F1)), _N_ = 1 547 919. Median age was 60.0 years (IQR 38.0‚Äì76.0).

[![Image 1: Figure 1.](https://bjgp.org/content/bjgp/74/746/e619/F1.medium.gif)](https://bjgp.org/content/bjgp/74/746/e619/F1.large.jpg?width=800&height=600&carousel=1 ""Flow charts for final study cohorts. aPregnancy Read codes recorded against individuals aged ‚â•55 years at time of pregnancy event are assumed to be a coding error and are therefore retained within the project cohort. SAIL = Secure Anonymised Information Linkage. UTI = urinary tract infection. WDSD = Welsh Demographic Service Dataset."")

*   [Download figure](https://bjgp.org/content/bjgp/74/746/e619/F1.large.jpg?download=true ""Download Figure 1."")
*   [Open in new tab](https://bjgp.org/content/bjgp/74/746/e619/F1.large.jpg)
*   [Download powerpoint](https://bjgp.org/highwire/powerpoint/49362)

Figure 1.

Flow charts for final study cohorts. aPregnancy Read codes recorded against individuals aged ‚â•55 years at time of pregnancy event are assumed to be a coding error and are therefore retained within the project cohort. SAIL = Secure Anonymised Information Linkage. UTI = urinary tract infection. WDSD = Welsh Demographic Service Dataset.

The rate of women with rUTIs followed a ‚ÄòJ‚Äô shaped pattern rising with increasing age ([Figure 2](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#F2)).

The study identified 26 862 women (1.7%) with prescriptions for prophylactic antibiotics who formed the prophylaxis cohort ([Figure 1](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#F1)), _N_ = 1 547 919. Median age was 70.6 years (IQR 55.1‚Äì81.6). In all, 17 803 were included in both cohorts.

Prophylactic antibiotic initiation increased initially until 2012 before declining from 2013 (Supplementary Figure S3). Trimethoprim and cefalexin use declined with time, and nitrofurantoin use increased. The most used prophylactic antibiotic was trimethoprim (Supplementary Figure S4). A small proportion (<1.0%) of women appeared to be using multiple antibiotics concurrently. Most women were taking a consistent dose of the prophylactic antibiotic across the consecutive prescriptions (77.8%, _n_ = 20 892/_N_ = 26 862). The most prescribed dosages for trimethoprim were 100 mg and 200 mg, for nitrofurantoin were 50 mg or 100 mg, and for cefalexin were 250 mg and 500 mg.

The two cohorts were similar in terms of ethnic group and deprivation ([Table 1](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#T4)). Most women with rUTIs were fit or had mild frailty according to the electronic frailty index, whereas for prophylactic antibiotic users all levels of frailty were higher ([Table 1](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#T4)).[28](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-28),[29](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-29)

View this table:

*   [View inline](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long##)

Table 1.

Sociodemographic and clinical characteristics of women with recurrent UTIs and prophylactic antibiotic users

### Clinical cohort

When the clinical cohort was restricted to those with rUTIs between 2015 and 2020, the cohort reduced to 55 652 women and 125 971 urine culture results. Of these 55 652, 44 947 (80.8%) women had a urine culture reported in the preceding 12 months, and, of these, 41.1% (_n_ = 18 475/_N_ = 44 947) had ‚â•3 samples reported. Of all urine cultures reported, 28.1% (_N_ = 125 971) showed microbiological evidence of a UTI (Supplementary Figure S5) with _E. coli_ the most cultured uropathogen (76.8% _n_ = 41 987/_N_ = 54 667) (Supplementary Figure S6). Based on urine culture results within 7 days of an acute UTI, 5.1% (_n_ = 2866) had microbiologically confirmed rUTIs (that is, all UTIs contributing to the rUTI diagnosis were microbiologically confirmed).

Antibiotic susceptibility testing was low (under 40%) for most antibiotics except trimethoprim, nitrofurantoin, and amoxicillin. Trimethoprim and amoxicillin had high rates of resistance ([Table 2](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#T5)).

View this table:

*   [View inline](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long##)

Table 2.

Antibiotic susceptibility for all urine culture results that cultured any organism, _Escherichia coli_, and coliforms

### Prophylaxis cohort

In the prophylaxis cohort, 49.0% (_n_ = 13 149/_N_ = 26 862) of women met the definition of rUTIs in the preceding 18 months. Of these, 39.1% (_n_ = 5139/_N_ = 13 149) started prophylactic antibiotics within 3 months of meeting the rUTI definition (Supplementary Figure S7).

When restricted to incident prophylactic antibiotic users between 2015 and 2020, the cohort reduced to 15 455 women and 53 988 urine culture results. Of these, 64.2% (_n_ = 9926/_N_ = 15 455) had ‚â•1 urine culture reported in the preceding 18 months and, of these, 77.0% (_n_ = 7641/_N_ = 9926) had ‚â•3 samples reported. Of reported urine cultures, 32.2% (_n_ = 17 367/_N_ = 53 988) were microbiologically confirmed UTIs, _E.coli_ was the predominant organism (75.7%, _n_ = 19 669/_N_ = 25 984) cultured and 42.8% (_n_ = 6611/_N_ = 15 455) had at least one microbiologically confirmed UTI before starting prophylactic antibiotics (Supplementary Figures S8 and S9). Of women taking prophylactic antibiotics between 2015 and 2020, 49.8% (_n_ = 7695/_N_ = 15 455) had clinical rUTIs before initiation and, of these, 6.1% (_n_ = 472/_N_ = 7695) had microbiologically confirmed rUTIs. Like the clinical cohort, antibiotic susceptibility for trimethoprim and amoxicillin showed high rates of resistance ([Table 2](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#T5)). However, the proportions of urine cultures growing any organism with evidence of resistance to trimethoprim or amoxicillin decreased over the study period (Supplementary Figure S10).

Based on the most recent urine culture that cultured an organism before initiating antibiotic prophylaxis, there were 4983 culture results. In women taking either trimethoprim, nitrofurantoin, or cefalexin (_n_ = 4920), 8.3% (_n_ = 410/_N_ = 4920) had evidence of resistance to that antibiotic (Supplementary Table S1). This was highest in those taking trimethoprim (18.5%, _n_ = 320/_N_ = 1730), with a downward trend over the study period (Supplementary Figure S11). Resistance was lower for those taking nitrofurantoin (which was consistent over the study period) and cefalexin (trend not shown because of small numbers) (Supplementary Figure S11 and Supplementary Table S1). Resistance to these three prophylactic antibiotics, irrespective of which antibiotic was prescribed (including those taking multiple antibiotics), was 41.5% (_n_ = 2070/_N_ = 4983) for trimethoprim, 6.4% (_n_ = 320/_N_ = 4983) for nitrofurantoin, and 3.0% (_n_ = 150/_N_ = 4983) for cefalexin.

Sensitivity analyses only defining prophylactic antibiotic use if the dose prescribed was consistent across consecutive prescriptions did not meaningfully affect the estimates (Supplementary Table S2). Changing the minimum time between acute UTIs and changing the definition of an acute UTI to include Read codes only did not meaningfully have an impact on the estimate of women with rUTIs before starting prophylaxis (Supplementary Table S3). Changing the acute UTI definition used to include only UTI-related antibiotics did increase the proportion of women with rUTIs before starting prophylaxis to 74.3% (_n_ = 19 970/_N_ = 26 862).

Discussion
----------

### Summary

This is the first population-based study, to the authors‚Äô knowledge, to describe the prevalence of rUTIs, prophylactic antibiotic use, and associated microbiology in women in the UK. The current study found that, of women registered with a SAIL data-providing general practice in Wales between 2010 and 2020, 6.0% had rUTIs, and 1.7% were prescribed prophylactic antibiotics with the proportions rising sharply around 58‚Äì67 years of age. Nearly half of users of prophylactic antibiotics met the rUTI definition in the 18 months before initiation, and initiation of prophylactic antibiotics decreased over the study period.

In total 80.8% of women with rUTIs had a urine culture reported in the 12 months before the diagnosis with high levels of resistance to trimethoprim and amoxicillin. Microbiological evidence of a UTI was present in 28.1% (_n_ = 35 404/_N_ = 125 971) of all reported urine cultures. Urine culture before initiating prophylactic antibiotics was reported in 64.2%. Of women prescribed trimethoprim, 18.5% had evidence of resistance to it before initiation. As part of rUTI diagnosis and before initiating prophylactic antibiotics, more frequent urine cultures could better inform antibiotic choice for prophylaxis and treatment.

### Strengths and limitations

This study used a large population-based sample to identify women with rUTIs and prescribed prophylactic antibiotics with linked urine microbiology including all urine culture within NHS Wales. The authors comprehensively reported urine microbiology results and resistance patterns. This study population was representative of women in the wider Welsh population and women with and without adequate lookback data had similar characteristics[14](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-14) (Supplementary Figures S12‚ÄìS17). A conservative estimate of rUTI prevalence is likely both from using a 28-day window to avoid capturing UTI-relapse and not having data from out-of-hours general practice or hospital attendances not requiring admission. UTI-related codes were used to identify acute UTIs but if clinicians had used non-specific codes these UTIs would not be captured, again underestimating rUTI prevalence.

As a result of these potential limitations, when describing the proportion of women with rUTIs before prophylactic antibiotic initiation, the authors adjusted both the minimum time between UTIs and the definition of an acute UTI to include only UTI-specific Read codes (and potentially capture UTIs diagnosed in out-of-hours general practice or hospital attendances) or to include only antibiotics in sensitivity analyses. Changing the time between UTIs and defining an acute UTI based on UTI-specific Read codes had a minimal impact (Supplementary Table S3). Changing the definition of an acute UTI to include only antibiotics, increased the proportion with rUTIs but likely overestimated the true value (Supplementary Table S3).

The data used in the current study are primarily used for clinical practice, not research, with risks of coding errors, missing data, and misclassification. Misclassification of prophylactic antibiotics is possible where the women the authors defined as users of prophylactic antibiotics could have had three acute antibiotic courses. A variety of methods were used to reduce this risk, such as using a fixed timeframe between prescriptions and conducting a sensitivity analysis to assess the robustness of the estimates. Finally, the diagnosis of UTIs is especially challenging in older, frailer women where symptoms can be less specific, and they may have asymptomatic bacteriuria and thus be misdiagnosed as having a UTI. This could potentially falsely elevate the prevalence of rUTIs; however, the authors used UTI-specific Read codes in addition to antibiotic prescriptions to try to mitigate for this.

### Comparison with existing literature

To the authors‚Äô knowledge there is only one other study using population-based data describing women with rUTIs.[30](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-30) This US-based study identified women with incident rUTIs and found 60.9% of women had at least one urine culture over 12 months before diagnosis, lower than the proportion found in the current study. The current study cohort likely includes both incident and prevalent rUTIs as the authors did not stipulate a UTI-free period before rUTI cohort entry. Therefore urine culture, as per guidelines, might be more likely to occur in the current cohort in those with prevalent rUTIs. The US-based study also found a ‚ÄòJ‚Äô shaped curve for the incidence rate of rUTIs according to age. This likely relates to UTI risk factors such as sexual intercourse in early adulthood[5](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-5),[31](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-31) and hormonal changes of the menopause accounting for the increased rate at about 55 years of age (the typical age of menopause is between 45 and 55 years).[31](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-31)‚Äì[35](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-35) In terms of rUTI prevalence, the current results suggest the prevalence is higher than that of a survey conducted in 2015 that found a prevalence of 3%.[8](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-8) This is not surprising as certain populations such as frail women or those with cognitive impairment may not complete a survey, whereas they are more likely included in the current study‚Äôs cohort.

Prophylactic antibiotic use in the current study declined from 2013 to 2020. Overall antibiotic prescribing followed a similar pattern in both Wales and England, aligning with the UK Government‚Äôs strategy to reduce antibiotic use and combat increasing AMR.[36](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-36)‚Äì[38](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-38) Resistance in UTIs is an increasing problem and evidence of UTI resistance patterns in women with rUTIs is limited. The current study shows that trimethoprim and nitrofurantoin resistance in women with rUTIs are comparable with those reported in a 2018 and 2023 Public Health Wales report.[39](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-39),[40](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-40) This suggests resistance in women with rUTIs is not significantly higher than resistance patterns overall.

### Implications for practice

It could be clinically beneficial to encourage microbiological confirmation of rUTIs in primary care and before prophylactic antibiotic initiation in line with clinical guidelines.[5](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-5),[31](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-31) Women with rUTIs in the current study had high levels of resistance to trimethoprim and amoxicillin, which are two of the four prophylactic antibiotics recommended in the UK.[31](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-31) A low proportion of urine cultures reported susceptibility to cefalexin, and although resistance levels were relatively low they should be interpreted with caution because of likely selective testing. Despite low resistance levels, nitrofurantoin has limitations in chronic kidney disease and can result in lung and liver fibrosis with the risk increasing with age and duration of use.[41](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-41)‚Äì[43](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#ref-43) The current study has also shown that 18.5% of women prescribed trimethoprim had evidence of resistance before initiation. These findings emphasise urine culture‚Äôs potential importance in informing prophylactic antibiotic choice. However, increasing urine culture has limitations owing to negative culture results, culturing a mixed growth of organisms, or the initiator, in primary or secondary care, not having access to all recent urine microbiology results.

In conclusion, this is the first population-based study on rUTIs and prophylactic antibiotic use in women including urine microbiology. The prevalence of rUTIs in women and the incident use of prophylactic antibiotics in Wales, although declining with time, was substantial especially in older women. Women with rUTIs had high levels of resistance to two of the four recommended prophylactic antibiotics, 64.2% had urine culture before starting prophylactic antibiotics, and a significant proportion had evidence of resistance to that antibiotic.

Acknowledgments
---------------

This study makes use of anonymised data held in the SAIL Databank. The authors would like to acknowledge all the data providers who make anonymised data available for research.

Notes
-----

### Funding

This work was supported by the Welsh Government through Health and Care Research Wales (NIHR-FS-2021-LS to Leigh Sanyaolu).

### Ethical approval

All proposals to use SAIL data are subject to review by an independent Information Governance Review Panel (IGRP). Before any data can be accessed, approval must be given by the IGRP. The IGRP carefully considers each project to ensure the proper and appropriate use of SAIL data. When access has been granted, it is gained through a privacy-protecting trusted research environment and remote access system referred to as the SAIL Gateway. SAIL has established an application process to be followed by anyone who would like to access data via SAIL at [https://www.saildatabank.com/application-process](https://www.saildatabank.com/application-process). The SAIL Databank IGRP approved the study, project approval number 1169.

### Data

The data used in this study are available in the SAIL Databank at Swansea University, Swansea, UK, but, as restrictions apply, they are not publicly available. The code for preparing the data in SAIL and the analytical R code are available on reasonable request to the lead author.

### Provenance

Freely submitted; externally peer reviewed.

### Competing interests

The authors have declared no competing interests.

*   Received January 9, 2024.
*   Revision requested February 29, 2024.
*   Accepted May 13, 2024.

*   ¬© The Authors

References
----------

1.  1.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-1-1 ""View reference 1. in text"")
2.  2.
3.  3.
4.  4.
5.  5.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-5-1 ""View reference 5. in text"")
6.  6.
7.  7.
8.  8.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-8-3 ""View reference 8. in text"")
9.  9.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-9-1 ""View reference 9. in text"")
10.  10.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-10-1 ""View reference 10. in text"")
11.  11.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-11-1 ""View reference 11. in text"")
12.  12.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-12-1 ""View reference 12. in text"")
13.  13.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-13-1 ""View reference 13. in text"")
14.  14.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-14-1 ""View reference 14. in text"")
15.  15.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-15-1 ""View reference 15. in text"")
16.  16.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-16-1 ""View reference 16. in text"")
17.  17.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-17-1 ""View reference 17. in text"")
18.  18.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-18-1 ""View reference 18. in text"")
19.  19.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-19-1 ""View reference 19. in text"")
20.  20.
21.  21.
    
    (2018) National Institute for Health and Care Excellence. Urinary tract infection (lower): antimicrobial prescribing NG109 (NICE, London)
    
22.  22.
    
    (2018) National Institute for Health and Care Excellence. Pyelonephritis (acute): antimicrobial prescribing NG111 (NICE, London)
    
23.  23.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-23-1 ""View reference 23. in text"")
24.  24.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-24-1 ""View reference 24. in text"")
    
    (2021) Public Health Wales Microbiology Division. CDBBA 041 Bench aid: investigation of urine.
    
25.  25.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-25-1 ""View reference 25. in text"")
26.  26.
27.  27.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-27-1 ""View reference 27. in text"")
28.  28.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-28-1 ""View reference 28. in text"")
29.  29.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-29-1 ""View reference 29. in text"")
30.  30.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-30-1 ""View reference 30. in text"")
31.  31.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-31-1 ""View reference 31. in text"")
32.  32.
33.  33.
34.  34.
35.  35.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-35-1 ""View reference 35. in text"")
36.  36.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-36-1 ""View reference 36. in text"")
37.  37.
38.  38.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-38-1 ""View reference 38. in text"")
39.  39.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-39-1 ""View reference 39. in text"")
40.  40.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-40-1 ""View reference 40. in text"")
41.  41.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-41-1 ""View reference 41. in text"")
42.  42.
43.  43.[‚Üµ](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long#xref-ref-43-1 ""View reference 43. in text"")
",gpt-4o-2024-08-06
2024-08-29 08:52:56,2024-08-31 05:13:48,"**Unveiling Psilocybin: More Effective than Traditional Antidepressants for Depressive Symptoms?** üåøüíä

A new systematic review and Bayesian network meta-analysis released by BMJ dives deep into the comparative effectiveness of psychedelics and traditional antidepressants, such as escitalopram, for treating depressive symptoms. High-dose psilocybin stands out, showing a more significant impact than escitalopram 10 mg and 20 mg, suggesting potential for psychedelic treatment.üôå

However, it's important to note that the effectiveness of psilocybin, when blinding issues are addressed, is comparable to current antidepressants, with a standardised mean difference reported at a small effect size (0.31). These findings urge the medical community to approach psychedelic treatments with improved blinding methods for accurate efficacy evaluation.

üìÑ Dive deeper into the study to explore the nuanced potentials of psychedelic therapy for depression: [Link to Full Study](https://www.bmj.com/content/386/bmj-2023-078607)

üîÑ How do you view the role of psychedelics in modern medicine? Join the conversation with your insights or experiences in the comments below! 

#Psilocybin #Antidepressants #DepressionTreatment #BMJResearch",https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_220215_psilocybin_mushrooms_800x450.jpg,https://www.bmj.com/content/386/bmj-2023-078607,"You are a content creator tasked with crafting highly informative, easy to digest social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Thumbnail image URL: https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_220215_psilocybin_mushrooms_800x450.jpg  
Title: Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis

URL Source: https://www.bmj.com/content/386/bmj-2023-078607

Markdown Content:
1.  [Research](https://www.bmj.com/us/research)
2.  Comparative oral...
3.  Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis

Research BMJ 2024; 386 doi: [https://doi.org/10.1136/bmj-2023-078607](https://doi.org/10.1136/bmj-2023-078607) (Published 21 August 2024) Cite this as: BMJ 2024;386:e078607

1.  Tien-Wei Hsu, doctoral researcher[1](https://www.bmj.com/content/386/bmj-2023-078607#aff-1) [2](https://www.bmj.com/content/386/bmj-2023-078607#aff-2) [3](https://www.bmj.com/content/386/bmj-2023-078607#aff-3),
2.  Chia-Kuang Tsai, associate professor[4](https://www.bmj.com/content/386/bmj-2023-078607#aff-4),
3.  Yu-Chen Kao, associate professor[5](https://www.bmj.com/content/386/bmj-2023-078607#aff-5) [6](https://www.bmj.com/content/386/bmj-2023-078607#aff-6),
4.  Trevor Thompson, professor[7](https://www.bmj.com/content/386/bmj-2023-078607#aff-7),
5.  Andre F Carvalho, professor[8](https://www.bmj.com/content/386/bmj-2023-078607#aff-8),
6.  Fu-Chi Yang, professor[4](https://www.bmj.com/content/386/bmj-2023-078607#aff-4),
7.  Ping-Tao Tseng, assistant professor[9](https://www.bmj.com/content/386/bmj-2023-078607#aff-9) [10](https://www.bmj.com/content/386/bmj-2023-078607#aff-10) [11](https://www.bmj.com/content/386/bmj-2023-078607#aff-11) [12](https://www.bmj.com/content/386/bmj-2023-078607#aff-12),
8.  Chih-Wei Hsu, assistant professor[13](https://www.bmj.com/content/386/bmj-2023-078607#aff-13),
9.  Chia-Ling Yu, clinical pharmacist[14](https://www.bmj.com/content/386/bmj-2023-078607#aff-14),
10.  Yu-Kang Tu, professor[15](https://www.bmj.com/content/386/bmj-2023-078607#aff-15) [16](https://www.bmj.com/content/386/bmj-2023-078607#aff-16),
11.  Chih-Sung Liang[![Image 1](https://www.bmj.com/sites/default/themes/bmj/the_bmj/img/vector_iD_icon.svg)](https://orcid.org/0000-0003-1138-5586), assistant professor[5](https://www.bmj.com/content/386/bmj-2023-078607#aff-5) [6](https://www.bmj.com/content/386/bmj-2023-078607#aff-6)

1.  1Department of Psychiatry, E-DA Dachang Hospital, I-Shou University, Kaohsiung, Taiwan
    
2.  2Department of Psychiatry, E-DA Hospital, I-Shou University, Kaohsiung, Taiwan
    
3.  3Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
    
4.  4Department of Neurology, Tri-Service General Hospital, National Defense Medical Centre, Taipei, Taiwan
    
5.  5Department of Psychiatry, National Defense Medical Centre, Taipei, Taiwan
    
6.  6Department of Psychiatry, Beitou Branch, Tri-Service General Hospital, Taipei, Taiwan
    
7.  7Centre for Chronic Illness and Ageing, University of Greenwich, London, UK
    
8.  8IMPACT (Innovation in Mental and Physical Health and Clinical Treatment) Strategic Research Centre, School of Medicine, Barwon Health, Deakin University, Geelong, VIC, Australia
    
9.  9Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan
    
10.  10Department of Psychology, College of Medical and Health Science, Asia University, Taichung, Taiwan
    
11.  11Prospect Clinic for Otorhinolaryngology and Neurology, Kaohsiung, Taiwan
    
12.  12Institute of Precision Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan
    
13.  13Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
    
14.  14Department of Pharmacy, Chang Gung Memorial Hospital Linkou, Taoyuan, Taiwan
    
15.  15Institute of Health Data Analytics and Statistics, College of Public Health, National Taiwan University, Taipei, Taiwan
    
16.  16Department of Dentistry, National Taiwan University Hospital, Taipei, Taiwan
    

1.  Correspondence to: C-S Liang lcsyfw{at}gmail.com

*   Accepted 20 June 2024

Abstract
--------

**Objective** To evaluate the comparative effectiveness and acceptability of oral monotherapy using psychedelics and escitalopram in patients with depressive symptoms, considering the potential for overestimated effectiveness due to unsuccessful blinding.

**Design** Systematic review and Bayesian network meta-analysis.

**Data sources** Medline, Cochrane Central Register of Controlled Trials, Embase, PsycINFO, ClinicalTrial.gov, and World Health Organization‚Äôs International Clinical Trials Registry Platform from database inception to 12 October 2023.

**Eligibility criteria for selecting studies** Randomised controlled trials on psychedelics or escitalopram in adults with depressive symptoms. Eligible randomised controlled trials of psychedelics (3,4-methylenedioxymethamphetamine (known as MDMA), lysergic acid diethylamide (known as LSD), psilocybin, or ayahuasca) required oral monotherapy with no concomitant use of antidepressants.

**Data extraction and synthesis** The primary outcome was change in depression, measured by the 17-item Hamilton depression rating scale. The secondary outcomes were all cause discontinuation and severe adverse events. Severe adverse events were those resulting in any of a list of negative health outcomes including, death, admission to hospital, significant or persistent incapacity, congenital birth defect or abnormality, and suicide attempt. Data were pooled using a random effects model within a Bayesian framework. To avoid estimation bias, placebo responses were distinguished between psychedelic and antidepressant trials.

**Results** Placebo response in psychedelic trials was lower than that in antidepression trials of escitalopram (mean difference ‚àí3.90 (95% credible interval ‚àí7.10 to ‚àí0.96)). Although most psychedelics were better than placebo in psychedelic trials, only high dose psilocybin was better than placebo in antidepression trials of escitalopram (mean difference 6.45 (3.19 to 9.41)). However, the effect size (standardised mean difference) of high dose psilocybin decreased from large (0.88) to small (0.31) when the reference arm changed from placebo response in the psychedelic trials to antidepressant trials. The relative effect of high dose psilocybin was larger than escitalopram at 10 mg (4.66 (95% credible interval 1.36 to 7.74)) and 20 mg (4.69 (1.64 to 7.54)). None of the interventions was associated with higher all cause discontinuation or severe adverse events than the placebo.

**Conclusions** Of the available psychedelic treatments for depressive symptoms, patients treated with high dose psilocybin showed better responses than those treated with placebo in the antidepressant trials, but the effect size was small.

**Systematic review registration** PROSPERO, CRD42023469014.

Introduction
------------

Common psychedelics belong to two classes: classic psychedelics, such as psilocybin, lysergic acid diethylamide (known as LSD), and ayahuasca; and entactogens, such as 3,4-methylenedioxymethamphetamine (MDMA).[1](https://www.bmj.com/content/386/bmj-2023-078607#ref-1) Several randomised controlled trials have shown efficacy of psychedelics for people with clinical depression.[2](https://www.bmj.com/content/386/bmj-2023-078607#ref-2)[3](https://www.bmj.com/content/386/bmj-2023-078607#ref-3) The proposed mechanism of its fast and persistent antidepressant effects is to promote structural and functional neuroplasticity through the activation of intracellular 5-HT2A receptors in the cortical neurons.[4](https://www.bmj.com/content/386/bmj-2023-078607#ref-4) Additionally, the increased neuroplasticity was associated with psychedelic‚Äôs high affinity directly binding to brain derived neurotrophic factor receptor TrkB, indicating a dissociation between the hallucinogenic and plasticity promoting effects of psychedelics.[5](https://www.bmj.com/content/386/bmj-2023-078607#ref-5) A meta-analysis published in 2023 reported that the standardised mean difference of psychedelics for depression reduction ranged from 1.37 to 3.12,[2](https://www.bmj.com/content/386/bmj-2023-078607#ref-2) which are considered large effect sizes.[6](https://www.bmj.com/content/386/bmj-2023-078607#ref-6) Notably, the standardised mean difference of antidepressant trials is approximately 0.3 (a small effect size).[7](https://www.bmj.com/content/386/bmj-2023-078607#ref-7)[8](https://www.bmj.com/content/386/bmj-2023-078607#ref-8)

Although modern randomised controlled trials involving psychedelics usually use a double blinded design, the subjective effects of these substances can compromise blinding.[9](https://www.bmj.com/content/386/bmj-2023-078607#ref-9) Unsuccessful blinding may lead to differing placebo effects between the active and control groups, potentially introducing bias into the estimation of relative treatment effects.[10](https://www.bmj.com/content/386/bmj-2023-078607#ref-10) Concerns have arisen regarding the overestimated effect sizes of psychedelics due to the issues of blinding and response expectancy.[9](https://www.bmj.com/content/386/bmj-2023-078607#ref-9) Psychedelic treatment is usually administered with psychological support or psychotherapy, and thereby the isolated pharmacological effects of psychedelics remain to be determined.[2](https://www.bmj.com/content/386/bmj-2023-078607#ref-2) Surprisingly, on 1 July 2023, Australia approved psilocybin for the treatment of depression[11](https://www.bmj.com/content/386/bmj-2023-078607#ref-11); the first country to classify psychedelics as a medicine at a national level.

To date, only one double blind, head-to-head randomised controlled trial has directly compared a psychedelic drug (psilocybin) with an antidepressant drug (escitalopram) for patients with major depressive disorder.[12](https://www.bmj.com/content/386/bmj-2023-078607#ref-12) This randomised controlled trial reported that psilocybin showed a better efficacy than escitalopram on the 17 item Hamilton depression rating scale (HAMD-17).

We aimed to assess the comparative effectiveness and acceptability of oral monotherapy with psychedelics and escitalopram in patients experiencing depressive symptoms. Given that unsuccessful blinding can potentially lead to a reduced placebo response in psychedelic trials, we distinguished between the placebo responses in psychedelic and antidepressant trials. We also investigated the differences in patient responses between people who received extremely low dose psychedelics as a placebo and those who received a placebo in the form of a fake pill, such as niacin, in psilocybin trials.[13](https://www.bmj.com/content/386/bmj-2023-078607#ref-13)[14](https://www.bmj.com/content/386/bmj-2023-078607#ref-14) Our study allowed for a relative effect assessment of psychedelics compared with placebo responses observed in antidepressant trials.

Methods
-------

The study protocol was registered with PROSPERO (CRD42023469014). We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension statement for reporting systematic reviews incorporating network meta-analysis (NMA) (appendix 1).[15](https://www.bmj.com/content/386/bmj-2023-078607#ref-15)

### Data sources and searches

A comprehensive search of the Medline, Cochrane Central Register of Controlled Trials (CENTRAL), Embase, PsycINFO, ClinicalTrial.gov, and World Health Organization‚Äôs International Clinical Trials Registry Platform databases were performed without language restrictions from database inception to 12 October 2023. We also searched the grey literature and reviewed reference lists of the included studies and related systematic reviews.[2](https://www.bmj.com/content/386/bmj-2023-078607#ref-2)[3](https://www.bmj.com/content/386/bmj-2023-078607#ref-3)

### Study selection

Eligible studies were randomised controlled trials with parallel group or crossover designs. We included: (i) adults (‚â•18 years) with clinically diagnosed depression (eg, major depressive disorder, bipolar disorder, or other psychiatric disorders with comorbid clinical depression) or life threatening diagnoses and terminal illness with depressive symptoms; and (ii) adults with assessment of treatment response (preapplication/postapplication) using standard, validated, and internationally recognised instruments, such as HAMD-17. The outcome of interest was the change in depressive symptoms at the end of treatment compared with the controls, and we only extracted data from the first phase of crossover randomised controlled trials to avoid carry-over effects. Eligible psychedelic randomised controlled trials (including psilocybin, lysergic acid diethylamide, MDMA, and ayahuasca without dosage limit) required oral monotherapy without the concomitant use of antidepressants. For escitalopram, we included only fixed dose randomised controlled trials that compared at least two arms with different doses of oral form escitalopram (maximum dose of 20 mg/day) with placebo because psychedelic therapies usually use a fixed dose study design. We also included randomised controlled trials that evaluated psychedelic monotherapy compared with escitalopram monotherapy. We excluded follow-up studies and studies with healthy volunteers. We also excluded conference abstracts, editorials, reviews, meta-analyses, case reports, and case series, as well as publications reporting duplicate data. We did not consider ketamine because this drug is usually administered parenterally and is not a classic psychedelic.[16](https://www.bmj.com/content/386/bmj-2023-078607#ref-16) Screening and selection of the studies were performed independently by two authors. Discrepancies in study inclusion were resolved by deliberation among the reviewer pairs or with input from a third author. Appendix 2 shows the complete search strategies, and appendix 3 presents the reasons for exclusion.

### Definition of outcomes, data extraction, and risk of bias assessment

The primary outcome was change in depressive symptoms from baseline (continuous outcome), as measured by a validated rating scale, such as HAMD-17. When multiple measurement tools were used, they were selected in the following order: the HAMD-17, Montgomery-√Ösberg depression rating scale, and Beck depression inventory (second edition). To improve interpretability, all extracted depression scores were converted to corresponding HAMD-17 scores using a validated method.[17](https://www.bmj.com/content/386/bmj-2023-078607#ref-17) We used a conservative correlation coefficient of 0.5 or other statistics (eg, t statistics) to calculate the standard deviation of change from baseline when unreported.[18](https://www.bmj.com/content/386/bmj-2023-078607#ref-18) The secondary outcomes were all cause discontinuation and severe adverse events (categorical outcomes). Severe adverse events were classified as those resulting in any of a list of negative health outcomes including, death, admission to hospital, significant or persistent incapacity, congenital birth defect or abnormality, and suicide attempt. Outcome data were extracted from original intention-to-treat or last observation carrying forward analysis, as well as from estimates of mixed-effect models for repeated measures.

Two authors independently extracted and reviewed the data, each being reviewed by another author. WebPlot Digitizer ([https://automeris.io/WebPlotDigitizer/](https://automeris.io/WebPlotDigitizer/)) was used to extract numerical data from the figures. Two authors independently used the Cochrane randomised trial risk of bias tool (version 2.0) to assess the risk of bias in the included trials, and discrepancies were resolved by consensus.[19](https://www.bmj.com/content/386/bmj-2023-078607#ref-19)

### Data synthesis

To estimate the relative effect between two interventions, we computed mean difference on the basis of change values (with 95% credible interval) for continuous outcomes (change in depressive symptoms) and odds ratios for categorical outcomes (all cause discontinuation and severe adverse event). To assess the clinical significance of the relative effect, we evaluated whether the mean difference exceeded the minimal important difference, which is estimated to be 3 points for HAMD-17.[20](https://www.bmj.com/content/386/bmj-2023-078607#ref-20) We defined high, low, and extremely low doses of the included psychedelics as follows: (i) psilocybin: high dose (‚â•20 mg), extremely low dose (1-3 mg), low dose (other range); and (ii) MDMA: high dose (‚â•100 mg), extremely low dose (‚â§40 mg), low dose (other range). Escitalopram was divided into escitalopram 10 mg and escitalopram ‚â•20 mg. In previous clinical trials, a dose of 1 mg of psilocybin or a dose range of 1-3 mg/70 kg were used as an active control because these doses were believed not to produce significant psychedelic effects.[21](https://www.bmj.com/content/386/bmj-2023-078607#ref-21)[22](https://www.bmj.com/content/386/bmj-2023-078607#ref-22) A dose of 5 mg/70 kg can produce noticeable psychedelic effects.[22](https://www.bmj.com/content/386/bmj-2023-078607#ref-22) In many two arm psilocybin trials, the psilocybin dose in the active group typically falls within the range of 20-30 mg.[12](https://www.bmj.com/content/386/bmj-2023-078607#ref-12)[21](https://www.bmj.com/content/386/bmj-2023-078607#ref-21)[23](https://www.bmj.com/content/386/bmj-2023-078607#ref-23)[24](https://www.bmj.com/content/386/bmj-2023-078607#ref-24) In a three arm trial, 25 mg was defined as high dose, and 10 mg was considered a moderate dose.[21](https://www.bmj.com/content/386/bmj-2023-078607#ref-21) Another clinical trial also defined 0.215 mg/kg of psilocybin as a moderate dose for the active group.[25](https://www.bmj.com/content/386/bmj-2023-078607#ref-25) Therefore, we used 20 mg and 3 mg as the boundaries for grouping psilocybin doses; when the dosage was calculated per kilogram in the study, we converted it to per 70 kg. For MDMA, in two trials with three arms, 125 mg was defined as high dose, and 30-40 mg was defined as active control.[26](https://www.bmj.com/content/386/bmj-2023-078607#ref-26)[27](https://www.bmj.com/content/386/bmj-2023-078607#ref-27) Thus, we used 100 mg and 40 mg as the boundaries for grouping MDMA doses.

We conducted random effects network meta-analysis and meta-analysis within a Bayesian framework.[28](https://www.bmj.com/content/386/bmj-2023-078607#ref-28)[29](https://www.bmj.com/content/386/bmj-2023-078607#ref-29) Previous meta-analyses considered all control groups as a common comparator; however, concerns have been raised regarding the overestimated effect sizes of psychedelics because of unsuccessful blinding and poor placebo response.[9](https://www.bmj.com/content/386/bmj-2023-078607#ref-9) Therefore, we treated the three treatments as distinct interventions: the placebo response observed in psychedelic trials, the placebo response observed in antidepressant escitalopram trials, and extremely low dose psychedelics (ie, psilocybin and MDMA). We calculated the relative effects of all interventions compared with these three groups, indicating the following three conditions: (1) the treatment response of placebo response in the psychedelic trials is assumed to be lower than that of placebo response in antidepressant trials because of unsuccessful blinding.[9](https://www.bmj.com/content/386/bmj-2023-078607#ref-9) As such, the relative effects compared with placebo response in the psychedelic trials represented potential overestimated effect sizes. (2) the placebo response in antidepressant trials is assumed to be the placebo response in antidepressant trials with adequate blinding, therefore, the relative effects compared with placebo response in antidepressant trials represents effect sizes in trials with adequate blinding. (3) Psychedelic drugs are usually administered with psychotherapy[13](https://www.bmj.com/content/386/bmj-2023-078607#ref-13) or psychological support,[14](https://www.bmj.com/content/386/bmj-2023-078607#ref-14) the relative effects of psychedelics compared with extremely low dose psychedelics might eliminate the concomitant effects from psychotherapeutic support, approximating so-called pure pharmacological effects.

In network meta-analysis, the validity of indirect comparison relies on transitivity assumption.[30](https://www.bmj.com/content/386/bmj-2023-078607#ref-30) We assessed the transitivity assumption by comparing the distribution of potential effect modifies across treatment comparisons. In addition, we assessed whether the efficacy of escitalopram is similar in placebo controlled randomised controlled trials (escitalopram _v_ placebo response in antidepressant trials) and in the head-to-head randomised controlled trial (psilocybin _v_ escitalopram) using network meta-analysis.[12](https://www.bmj.com/content/386/bmj-2023-078607#ref-12) Furthermore, we assessed the efficacy of the different placebo responses (placebo response in the psychedelic trials _v_ placebo response in antidepressant trials) as additional proof of transitivity. If the placebo response in antidepressant trials was better than that in the psychedelic trials, the transitivity assumption did not hold when grouping placebo response in antidepressant trials and placebo response in the psychedelic trials together. Finally, for the primary outcome (change in depressive symptoms), network meta-regression analyses were conducted to evaluate the impact of potential effect modifiers, including proportion of men and women in the study, mean age, baseline depression severity, disorder type, and follow-up assessment period. We assumed a common effect on all treatment comparisons for each of the effect modifiers. In other words, all interactions between the treatment comparisons and the effect modifier were constrained to be identical.

We also conducted the following sensitivity analyses: analysing studies of patients with major depressive disorder; excluding studies with a high risk of bias; adjusting for baseline depression severity; and using correlation coefficient of zero (most conservative) to calculate the standard deviation of change from baseline when unreported.

Publication bias was assessed by visual inspection of a comparison adjusted funnel plots. The first funnel plot used placebo response in the psychedelic trials as the comparator. The second funnel plot used placebo response in antidepressant trials as the comparator. The third funnel plot used both placebo response in the psychedelic trials and placebo response in antidepressant trials as comparators simultaneously. Additionally, we conducted the Egger test, Begg test, and Thompson test to examine the asymmetry of the third funnel plot. A previous meta-analysis reported that the standardised mean difference of psychedelics for depression reduction ranged from 1.37 to 3.12.[2](https://www.bmj.com/content/386/bmj-2023-078607#ref-2) Therefore, we also transformed the effect size of mean difference to standardised mean difference (Hedges‚Äô g) for the primary outcome. The global inconsistency of the network meta-analysis was examined by fitting an unrelated main effects model. Local inconsistency of the network meta-analysis was examined using node splitting methods.[31](https://www.bmj.com/content/386/bmj-2023-078607#ref-31) Four Markov chains were implemented. 50‚Äâ000 iterations occurred per chain and the first 20‚Äâ000 iterations for each chain were discarded as a warm-up. Convergence was assessed by visual inspection of the trace plots of the key parameters for each analysis. The prior settings and convergence results are shown in appendix 4. All statistical analyses were done using R version 4.3.1. The network meta-analysis and pairwise meta-analysis within a Bayesian framework were fitted using the Bayesian statistical software called Stan within the R packages multinma[28](https://www.bmj.com/content/386/bmj-2023-078607#ref-28) and brms,[29](https://www.bmj.com/content/386/bmj-2023-078607#ref-29) respectively. The frequentist random effects network meta-analysis, funnel plots, and tests for funnel plot asymmetry were conducted using the R package netmeta. Reasons for protocol changes are in appendix 5.

### Assessment certainty of evidence for the primary outcome

The certainty of evidence produced by the network meta-analysis was evaluated using GRADE (Grading of recommendations, assessment, development and evaluation).[32](https://www.bmj.com/content/386/bmj-2023-078607#ref-32)[33](https://www.bmj.com/content/386/bmj-2023-078607#ref-33) We used a minimally contextualised framework with the value of 3 (minimal important difference) as our decision threshold. The certainty of evidence refers to our certainty that the intervention had, relative to minimal intervention, any clinically minimal important difference. The optimal information size was calculated using a validated method.[32](https://www.bmj.com/content/386/bmj-2023-078607#ref-32)[33](https://www.bmj.com/content/386/bmj-2023-078607#ref-33)[34](https://www.bmj.com/content/386/bmj-2023-078607#ref-34)

### Patient and public involvement

Both patients and the public are interested in research on novel depression treatments and their efficacy compared with existing antidepressants. However, due to a scarcity of available funding for recruitment and researcher training, patients and members of the public were not directly involved in the planning or writing of this manuscript. We did speak to patients about the study, and we asked a member of the public to read our manuscript after submission.

Results
-------

### Characteristics of included study

After searching the database and excluding duplicated records, we identified 3104 unique potential studies. We then screened the titles and abstracts of these studies for eligibility and excluded 3062 of them, in which 42 studies remained. Twenty six studies were excluded after an assessment of the full text for various reasons (appendix 3). We identified three additional studies through a manual search resulting in total 19 eligible studies (efigure 1). Details of the characteristics of the included studies are shown in etable 1. Protocols of psychological support or psychotherapy with psychedelic treatment are shown in etable 2. Overall, 811 people (mean age of 42.49 years, 54.2% (440/811) were women) were included in psychedelic trials (15 trials), and 1968 participants (mean age of 39.35 years, 62.5% (1230/1968) were women) were included in escitalopram trials (five trials).

### Risk of bias of the included studies

No psychedelic study (0/15) had a high overall risk of bias (efigure 2A and efigure 3A). The percentages of studies with high, some concerns, or low risk of bias in the 15 psychedelic trials were as follows: 0% (k=15), 33% (k=5), and 67% (k=10) for randomisation; 0% (k=0), 33% (k=5), and 67% (k=10) for deviations from intended interventions; 0% (k=0), 13% (k=2), and 87% (k=13) for missing outcome data; 0% (k=0), 33% (k=5), and 67% (k=10) for measurements of outcomes; 0% (k=0), 67% (k=1), and 93% (k=14) for selection of reported results. No non-psychedelic studies (0/5) were rated as high risk of bias (efigure 2B and efigure 3B). The percentages of studies with high, some concerns, and low risk of bias in the five non-psychedelic trials were as follows: 0% (k=0), 80% (k=4), and 20% (k=1) for randomisation; 0% (k=0), 100% (k=5), and 0% (k=0) for deviations from intended interventions; 0% (k=0), 80% (k=4), and 20% (k=1) for missing outcome data; 0% (k=0), 80% (k=4), and 20% (k=1) for measurements of outcomes; 0% (k=0), 20% (k=1), and 80% (k=4) for selection of reported results.

### Network meta-analysis

In the network structure, all interventions were connected, with two main structures ([fig 1](https://www.bmj.com/content/386/bmj-2023-078607#F1)). All psychedelics were compared with placebo response in the psychedelic trials, and escitalopram was compared with placebo response in antidepressant trials. A head-to-head comparison of high dose psilocybin and 20 mg escitalopram connected the two main structures.[12](https://www.bmj.com/content/386/bmj-2023-078607#ref-12)

In the main network meta-analysis, all interventions, except for extremely low dose and low dose MDMA, were associated with a larger mean difference exceeding the minimal important difference of 3 points on the HAMD-17 than with placebo response in the psychedelic trials ([fig 2](https://www.bmj.com/content/386/bmj-2023-078607#F2)). Notably, placebo response in antidepressant trials (3.79 (95% credibile interval 0.77 to 6.80)) and extremely low dose psilocybin (3.96 (0.61 to 7.17)) were better than placebo response in the psychedelic trials, with mean differences exceeding 3 and 95% credibile intervals that did not cross zero. Additionally, in comparison with placebo response in antidepressant trials ([fig 2](https://www.bmj.com/content/386/bmj-2023-078607#F2)), the relative effects of high dose psilocybin (6.52 (3.19 to 9.57)), escitalopram 10 mg (1.86 (0.21 to 3.50)), and escitalopram 20 mg (1.82 (0.16 to 3.43)) did not cross zero. Only high dose psilocybin resulted in a mean difference that was greater than 3. The standardised mean difference of high dose psilocybin decreased from large (0.88) to small (0.31) when the reference arm was changed from placebo response in the psychedelic trials to placebo response in antidepressant trials.

[![Image 2: Fig 2](https://www.bmj.com/content/bmj/386/bmj-2023-078607/F2.medium.jpg)](https://www.bmj.com/content/bmj/386/bmj-2023-078607/F2.large.jpg?width=800&height=600 ""Forest plots of network meta-analytical estimates v different reference arms by observed placebo response. The dotted line represents the minimal important difference of 3 whereas the red line indicates 0. LSD=lysergic acid diethylamide; MDMA=3,4-methylenedioxymethamphetamine"")

Fig 2

Forest plots of network meta-analytical estimates _v_ different reference arms by observed placebo response. The dotted line represents the minimal important difference of 3 whereas the red line indicates 0. LSD=lysergic acid diethylamide; MDMA=3,4-methylenedioxymethamphetamine

*   [Download figure](https://www.bmj.com/content/bmj/386/bmj-2023-078607/F2.large.jpg?download=true ""Download Fig 2"")
*   [Open in new tab](https://www.bmj.com/content/bmj/386/bmj-2023-078607/F2.large.jpg)
*   [Download powerpoint](https://www.bmj.com/highwire/powerpoint/1099995)

When compared with extremely low dose psilocybin ([fig 2](https://www.bmj.com/content/386/bmj-2023-078607#F2)), only the relative effects of high dose psilocybin (6.35 (95% credibile interval 3.41 to 9.21)) and placebo response in the psychedelic trials (‚àí3.96 (‚àí7.17 to ‚àí0.61)) showed a larger mean difference exceeding 3, without crossing zero. All relative effects between interventions are showed in efigure 4. Importantly, the mean differences of high dose psilocybin compared with escitalopram 10 mg (4.66 (1.36 to 7.74); standardised mean difference 0.22), escitalopram 20 mg (4.69 (1.64 to 7.54); 0.24), high dose MDMA (4.98 (1.23 to 8.67); 0.32), and low dose psilocybin (4.36 (1.20 to 7.51); 0.32) all exceeded 3 and did not cross zero (efigure 4).

### Transitivity assumption

The assessment of transitivity assumption is showed in efigure 5 and efigure 6. We compared the efficacy of escitalopram in the placebo controlled antidepressant trials[8](https://www.bmj.com/content/386/bmj-2023-078607#ref-8) with that in the head-to-head trial (psilocybin _v_ escitalopram)[12](https://www.bmj.com/content/386/bmj-2023-078607#ref-12) using network meta-analysis and pairwise meta-analysis. The results of the network meta-analysis showed that the relative effects between these two study designs (0.64 (95% credibile interval ‚àí4.41 to 5.40), efigure 6A; 1.94 (‚àí2.66 to 6.14), efigure 6B) included zero, and the mean differences did not exceed 3. Placebo response in antidepressant trials was better than placebo response in the psychedelic trials with a small effect size (3.79 (0.77 to 6.80), standardised mean difference 0.2), and the mean difference exceed 3 ([fig 2](https://www.bmj.com/content/386/bmj-2023-078607#F2)).

### Sensitivity analyses

When including only patients with major depressive disorder, the relative effects of escitalopram 20 mg, escitalopram 10 mg, ayahuasca, and high dose psilocybin were better than placebo response in antidepressant trials, while placebo response in the psychedelic trials was worse than placebo response in antidepressant trials ([fig 3](https://www.bmj.com/content/386/bmj-2023-078607#F3)). However, only the mean differences for high dose psilocybin (6.82 (95% credibile interval 3.84 to 9.67)), ayahuasca (5.38 (0.02 to 10.61)), and placebo response in the psychedelic trials (‚àí4.00 (‚àí6.87 to ‚àí1.13)) exceeded 3. When compared with extremely low dose psilocybin (excluding the effects from concomitant psychotherapeutic support), only the 95% credibile intervals of the relative effects of high dose psilocybin (4.36 (0.54 to 8.27); standardised mean difference 0.30) and placebo response in the psychedelic trials (‚àí6.46 (‚àí10.41 to ‚àí2.32), standardised mean difference ‚àí0.46) exceeded 3 and did not cross zero ([fig 3](https://www.bmj.com/content/386/bmj-2023-078607#F3)). All of the relative effects between interventions are showed in efigure 7. Notably, the relative effects of high dose psilocybin compared with escitalopram 10 mg (4.96 (1.97 to 7.82)), escitalopram 20 mg (4.97 (2.19 to 7.64)), and low dose psilocybin (3.82 (0.61 to 7.04)) all exceeded 3 and did not cross zero (efigure 7).

The other three sensitivity analyses showed similar findings with the main analyses: exclusion of studies with high risk of bias (efigure 8); adjustment of baseline depression severity (efigure 9); and use of most conservative correlation coefficient of zero (efigure 10).

### All cause discontinuation and severe adverse event

When referencing placebo in psychedelic trials, no interventions were associated with higher risks of all cause discontinuation rate nor severe adverse event rate (efigure 11).

### Network meta-regression and publication bias

In network meta-regression analyses, the 95% credibile intervals of the relative effects of the baseline depressive severity, mean age, and percentage of women, crossed zero (etable 3). The results of the statistical tests (Egger, Begg, and Thompson-Sharp tests) for funnel plot asymmetry and visual inspection of funnel plots did not show publication bias (efigure 12). The results of GRADE assessment are provided in the efigure 13. Most of the certainty of evidence for treatment comparisons was moderate or low.

### Consistency assumptions

The back calculation methods for all the models (appendix 6) did not show any inconsistencies. The node splitting methods also did not show any inconsistencies (appendix 7).

Discussion
----------

### Principal findings

This network meta-analysis investigated the comparative effectiveness between psychedelics and escitalopram for depressive symptoms. Firstly, we found that the placebo response observed in antidepressant trials was associated with greater effectiveness than that observed in psychedelic trials. Secondly, when compared with placebo responses in antidepressant trials, only escitalopram and high dose psilocybin were associated with greater effectiveness, and only high dose psilocybin exceeded minimal important difference of 3. Notably, the effect size of high dose psilocybin decreased from large to small. Thirdly, among the included psychedelics, only high dose psilocybin was more likely to be better than escitalopram 10 mg or 20 mg, exceeding the minimally important difference of 3. Fourthly, in patients with major depressive disorder, escitalopram, ayahuasca, and high dose psilocybin were associated with greater effectiveness than placebo responses in antidepressant trials; however, only high dose psilocybin was better than extremely low dose psilocybin, exceeding minimal important difference of 3. Taken together, our study findings suggest that among psychedelic treatments, high dose psilocybin is more likely to reach the minimal important difference for depressive symptoms in studies with adequate blinding design, while the effect size of psilocybin was similar to that of current antidepressant drugs, showing a mean standardised mean difference of 0.3.[7](https://www.bmj.com/content/386/bmj-2023-078607#ref-7)

### Comparison with other studies

In a randomised controlled trial, treatment response was defined as the response observed in the active arm; placebo response was defined as the response observed in the control (placebo) arm.[10](https://www.bmj.com/content/386/bmj-2023-078607#ref-10) Treatment response consists of non-specific effects, placebo effect, and true treatment effect; placebo response consisted of non-specific effects and placebo effect. Therefore, when the placebo effect is not the same for the active and control arms within an randomised controlled trial, the estimation of the true treatment effect is biased. For example, in a psychedelic trial, unsuccessful blinding may occur due to the profound subjective effects of psychedelics. This unblinding may lead to high placebo effect in the active arm and low placebo effect in the control arms, and the true treatment effect is overestimated.[10](https://www.bmj.com/content/386/bmj-2023-078607#ref-10) Without addressing unequal placebo effects within studies, the estimation of meta-analysis and network meta-analysis are biased.[10](https://www.bmj.com/content/386/bmj-2023-078607#ref-10) However, in most psychedelic trials, blinding was either reported as unsuccessful or not assessed at all. For example, two trials of lysergic acid diethylamide reported unsuccessful blinding,[35](https://www.bmj.com/content/386/bmj-2023-078607#ref-35)[36](https://www.bmj.com/content/386/bmj-2023-078607#ref-36) whereas the trial of ayahuasca only reported that five of 10 participants misclassified the placebo as ayahuasca.[37](https://www.bmj.com/content/386/bmj-2023-078607#ref-37) In trials of MDMA, participants' accuracy in guessing which treatment arm they were in ranged from approximately 60-90%.[26](https://www.bmj.com/content/386/bmj-2023-078607#ref-26)[27](https://www.bmj.com/content/386/bmj-2023-078607#ref-27)[38](https://www.bmj.com/content/386/bmj-2023-078607#ref-38)[39](https://www.bmj.com/content/386/bmj-2023-078607#ref-39)[40](https://www.bmj.com/content/386/bmj-2023-078607#ref-40) In the case of most psilocybin trials, blinding was not assessed, with the exception of the study by Ross and colleagues in 2016.[13](https://www.bmj.com/content/386/bmj-2023-078607#ref-13) In that study, participants were asked to guess whether the psilocybin or an active control was received, and the correct guessing rate was 97%. In our study, we established several network meta-analysis models addressing this issue, and we found that placebo response in the psychedelic trials was associated with less effectiveness than that in antidepressant trials. Therefore, the effect sizes of psychedelics compared with placebo response observed in psychedelic trials may be overestimated. All of the psychedelics‚Äô 95% credibile intervals of the relative effects crossed zero when compared with the placebo response in antidepressant trials, except for high dose psilocybin.

The comparisons between psychedelics and escitalopram showed that high dose psilocybin was more likely to be better than escitalopram. Psilocybin was usually administered with psychotherapy or psychological support.[13](https://www.bmj.com/content/386/bmj-2023-078607#ref-13)[14](https://www.bmj.com/content/386/bmj-2023-078607#ref-14) Therefore, the greater effectiveness of psilocybin may be from not only pharmacological effects but also psychotherapeutic support. However, we also found that high doses of psilocybin was associated greater effectiveness than extremely low doses of psilocybin. This effect also indicates that the effectiveness of psilocybin cannot be attributed only to concomitant psychotherapy or psychological support.

In patients with major depressive disorder, ayahuasca, low dose psilocybin, high dose psilocybin, escitalopram 10 mg, and escitalopram 20 mg were associated with greater effectiveness than the placebo response in antidepressant trials . However, when compared with extremely low dose psilocybin, only high dose psilocybin was associated with better effectiveness; the standardised mean difference decreased from 0.38 (compared with placebo response in antidepressant trials) to 0.30 (compared with extremely low dose psilocybin). As such, the effectiveness of psilocybin should be considered with concomitant psychotherapeutic support in people with major depressive disorder. The effect size of high dose psilocybin was similar with antidepressant trials of patients with major depressive disorder showing a mean standardised mean difference of 0.3.[7](https://www.bmj.com/content/386/bmj-2023-078607#ref-7)[8](https://www.bmj.com/content/386/bmj-2023-078607#ref-8)

### Strengths and limitations of this study

This study has several strengths. We conducted separate analyses for placebo response in antidepressant trials, placebo response in psychedelic trials, and an extremely low active dose of psychedelics, thereby mitigating the effect of placebo response variations across different studies. This approach allowed us to assess the efficacy of psychedelics more impartially and make relatively unbiased comparisons than if these groups were not separated. This study supported the transitivity assumption of the efficacy of escitalopram in placebo controlled antidepressant trials with that in psilocybin versus escitalopram head-to-head trial, thereby bridging the escitalopram trials and psychedelic trials. We also performed various sensitivity analyses to ensure the validation of our statistical results.

Nevertheless, our study has several limitations. Firstly, we extracted only the acute effects of the interventions. A comparison of the long term effects of psychedelics and escitalopram remains unclear. Secondly, participants in the randomised controlled trials on MDMA were predominantly diagnosed with post-traumatic stress disorder, whereas participants in the randomised controlled trials on escitalopram were patients with major depressive disorder. However, depressive symptoms in post-traumatic stress disorder could be relatively treatment resistant, requiring high doses of psychotropic drugs.[41](https://www.bmj.com/content/386/bmj-2023-078607#ref-41) Moreover, our study focused not only on major depressive disorder but also on the generalisability of psychedelic treatment for depressive symptoms. Thirdly, although all available studies were included, the sample size of the psychedelic randomised controlled trials was small (k=15). Fourthly, when using extremely low dose psychedelics as a reference group, the relative effect may also eliminate some pharmacological effects because our study found that extremely low dose psychedelics could not be considered a placebo. Fifthly, in network meta-analysis, direct evidence for one treatment comparison may serve as indirect evidence for other treatment comparisons,[42](https://www.bmj.com/content/386/bmj-2023-078607#ref-42) and biases in the direct evidence might affect estimates of other treatment comparisons. Because the absolute effect of escitalopram in the head-to-head trial (high dose psilocybin _v_ escitalopram 20 mg)[12](https://www.bmj.com/content/386/bmj-2023-078607#ref-12) was lower than those of placebo controlled trials, the relative effects of high dose psilocybin might be slightly overestimated when compared with other treatments in the current study. We addressed this issue by use of a Bayesian network meta-analysis, distinguishing between placebo response in psychedelic trials and placebo response in antidepressant trials. Specifically, we only considered that the 95% credibile interval of the relative effect between two comparisons did not cross zero. Indeed, the relative effect of escitalopram 20 mg between these two study designs included zero. Finally, our network meta-analysis may not have sufficient statistical power to detect potential publication bias due to the scarcity of trials and participants.

### Implications and conclusions

Serotonergic psychedelics, especially high dose psilocybin, appeared to have the potential to treat depressive symptoms. However, study designs may have overestimated the efficacy of psychedelics. Our analysis suggested that the standardised mean difference of high dose psilocybin was similar to that of current antidepressant drugs, showing a small effect size. Improved blinding methods and standardised psychotherapies can help researchers to better estimate the efficacy of psychedelics for depressive symptoms and other psychiatric conditions.

#### What is already known on this topic

*   Psychedelic treatment resulted in significant efficacy in treating depressive symptoms and alleviating distress related to life threatening diagnoses and terminal illness
    
*   Meta-analyses have reported standardised mean difference of psychedelics for depression reduction ranging from 1.37 to 3.12, while antidepressant trials were approximately 0.3
    
*   No network meta-analysis has examined comparative efficacy between psychedelics and antidepressants for depressive symptoms, and effect sizes of psychedelics might be overestimated because of unsuccessful blinding and response expectancies
    

#### What this study adds

*   To avoid estimation bias, placebo responses in psychedelic and antidepressant trials were separated; placebo response in psychedelic trials was lower than that in antidepressant trials
    
*   Among all psychedelics studied, only high dose psilocybin was associated with greater effectiveness than placebo response in antidepressant trials (standardised mean difference 0.31)
    
*   Among all psychedelics, only high dose psilocybin was associated with greater effectiveness than escitalopram
    

Ethics statements
-----------------

### Ethical approval

Not required because this study is an analysis of aggregated identified clinical trial data.

Data availability statement
---------------------------

The data that support the findings of this study are available from the corresponding author (C-SL) upon reasonable request.

Footnotes
---------

*   Contributors: T-WH and C-KT contributed equally to this work and are joint first authors. Y-KT and C-SL contributed equally to this work and are joint last/corresponding authors. C-SL, T-WH, and Y-KT conceived and designed the study. T-WH, C-KT, C-WH, and P-TT selected the articles, extracted the data, and assess the risk of bias. C-LY did the systemic search. T-WH and C-SL wrote the first draught of the manuscript. TT, AFC, Y-CK, F-CY, and Y-KT interpreted the data and contributed to the writing of the final version of the manuscript. C-KT and T-WH have accessed and verified the data. C-SL and Y-KT were responsible for the decision to submit the manuscript. All authors confirmed that they had full access to all the data in the study and accept responsibility to submit for publication. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.
    
*   Funding: The study was supported by grant from the National Science and Technology Council (NSTC 112-2314-B-016‚àí036-MY2 and NSTC 112-2314-B-002‚àí210-MY3). The funding source had no role in any process of our study.
    
*   Competing interests: All authors have completed the ICMJE uniform disclosure form at [www.icmje.org/disclosure-of-interest/](http://www.icmje.org/disclosure-of-interest/) and declare: support from National Science and Technology Council for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.
    
*   Transparency: The lead author (C-SL) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned
    
*   Dissemination to participants and related patient and public communities: Dissemination of the work to the public and clinical community through social media and lectures is planned.
    
*   Provenance and peer review: Not commissioned; externally peer reviewed.
    

References
----------

1.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-1-1 ""View reference 1 in text"")
2.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-2-1 ""View reference 2 in text"")
3.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-3-1 ""View reference 3 in text"")
4.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-4-1 ""View reference 4 in text"")
5.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-5-1 ""View reference 5 in text"")
6.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-6-1 ""View reference 6 in text"")
7.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-7-1 ""View reference 7 in text"")
8.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-8-1 ""View reference 8 in text"")
9.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-9-1 ""View reference 9 in text"")
10.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-10-1 ""View reference 10 in text"")
11.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-11-1 ""View reference 11 in text"")
12.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-12-1 ""View reference 12 in text"")
13.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-13-1 ""View reference 13 in text"")
14.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-14-1 ""View reference 14 in text"")
15.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-15-1 ""View reference 15 in text"")
16.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-16-1 ""View reference 16 in text"")
17.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-17-1 ""View reference 17 in text"")
18.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-18-1 ""View reference 18 in text"")
19.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-19-1 ""View reference 19 in text"")
20.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-20-1 ""View reference 20 in text"")
21.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-21-1 ""View reference 21 in text"")
22.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-22-1 ""View reference 22 in text"")
23.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-23-1 ""View reference 23 in text"")
24.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-24-1 ""View reference 24 in text"")
25.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-25-1 ""View reference 25 in text"")
26.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-26-1 ""View reference 26 in text"")
27.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-27-1 ""View reference 27 in text"")
28.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-28-1 ""View reference 28 in text"")
    
    Phillippo DM. multinma: Bayesian network meta-analysis of individual and aggregate data. 2020.
    
29.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-29-1 ""View reference 29 in text"")
30.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-30-1 ""View reference 30 in text"")
31.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-31-1 ""View reference 31 in text"")
32.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-32-1 ""View reference 32 in text"")
33.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-33-1 ""View reference 33 in text"")
34.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-34-1 ""View reference 34 in text"")
35.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-35-1 ""View reference 35 in text"")
36.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-36-1 ""View reference 36 in text"")
37.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-37-1 ""View reference 37 in text"")
38.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-38-1 ""View reference 38 in text"")
39.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-39-1 ""View reference 39 in text"")
40.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-40-1 ""View reference 40 in text"")
41.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-41-1 ""View reference 41 in text"")
42.  [‚Üµ](https://www.bmj.com/content/386/bmj-2023-078607#xref-ref-42-1 ""View reference 42 in text"")
",gpt-4o-2024-08-06
2024-09-02 08:01:00,2024-09-02 08:14:29,"üö® New Research Alert: A Study on Novel Therapy for Pediatric Brain Tumors! üö®  
Join us in exploring groundbreaking insights from the PNOC016 trial presented by Dr. Cassie Kline. This trial investigated a novel therapeutic approach using fimepinostat to enhance drug penetration in high-risk pediatric brain tumors, particularly focusing on diffuse intrinsic pontine gliomas, medulloblastoma, and other high-grade gliomas.  

Dr. Kline emphasizes the importance of evaluating not just survival but also how effectively therapies penetrate tumors and the pharmacodynamic markers that indicate response. This pivotal research could reshape the design of future clinical trials in pediatric oncology.  

Watch the full video for in-depth analysis and findings! üîç  
üîó [Watch the video here](https://www.healio.com/news/hematology-oncology/20240813/video-study-investigates-novel-therapy-for-penetration-of-pediatric-brain-tumors)  

üí¨ What are your thoughts on the potential implications of this study? Share your insights in the comments!  

üì∑ ![Pediatric Brain Tumor Research](https://medsii.azureedge.net/images/638608608986936625-66d56fee6157181811bbc99b.jpg)  

#PediatricOncology #NeuroOncology #BrainTumors #ClinicalTrials #MedicalResearch #InnovationInMedicine",https://medsii.azureedge.net/images/638608608986936625-66d56fee6157181811bbc99b.jpg,https://www.healio.com/news/hematology-oncology/20240813/video-study-investigates-novel-therapy-for-penetration-of-pediatric-brain-tumors,"You are a content creator tasked with crafting highly informative, easy to digest social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Thumbnail image URL: https://medsii.azureedge.net/images/638608608986936625-66d56fee6157181811bbc99b.jpg  
Title: VIDEO: Study investigates novel therapy for penetration of pediatric brain tumors

URL Source: https://www.healio.com/news/hematology-oncology/20240813/video-study-investigates-novel-therapy-for-penetration-of-pediatric-brain-tumors

Published Time: 2024-08-13

Markdown Content:
VIDEO: Study investigates novel therapy for penetration of pediatric brain tumors
===============

[![Image 1: Healio](https://m1.healio.com/~/media/images/healio/healiologooptimized.svg)](https://www.healio.com/)

*   [News News](https://www.healio.com/news ""News"")
*   [CME CME](https://www.healio.com/cme ""CME"")
*   [Clinical Guidance Clinical Guidance](https://www.healio.com/clinical-guidance ""Clinical Guidance"")

*   [_Account_](https://www.healio.com/footer/account-information/my-account "" "")
*   [_Account Anonymous User_](javascript:void\($j.get\('/loginregistration/modals/loadloginmodal',function\(data\){$j\('body'\).append\(data\);}\)\) "" "")
*   [Log In Log In](javascript:void\($j.get\('/utilityapp/json/na/li/healiotwo/{ACC50322-FB7D-42FC-940E-84BDDAD3B84D}',function\(data\){$j\('body'\).append\(data\);}\)\) ""Log In"")
*   [Log Out Log Out](javascript:; ""Log Out"")

*   [News News](https://www.healio.com/news ""News"")
*   [CME CME](https://www.healio.com/cme ""CME"")
*   [Clinical Guidance Clinical Guidance](https://www.healio.com/clinical-guidance ""Clinical Guidance"")

*   [_Account_](https://www.healio.com/footer/account-information/my-account "" "")
*   [_Account Anonymous User_](javascript:void\($j.get\('/loginregistration/modals/loadloginmodal',function\(data\){$j\('body'\).append\(data\);}\)\) "" "")

*   [Specialties](https://www.healio.com/news/hematology-oncology/20240813/video-study-investigates-novel-therapy-for-penetration-of-pediatric-brain-tumors#)
    
    Choose a specialty
    
    [All Specialties](https://www.healio.com/) [Allergy/Asthma](https://www.healio.com/allergy-asthma) [Hematology/Oncology](https://www.healio.com/hematology-oncology) [Infectious Disease](https://www.healio.com/infectious-disease) [Orthopedics](https://www.healio.com/orthopedics) [Rheumatology](https://www.healio.com/rheumatology)
    
*   [Home](https://www.healio.com/)
*   [Headline News](https://www.healio.com/news)
*   [Meeting News](https://www.healio.com/news/meeting-news)
*   [Podcasts](https://www.healio.com/news/podcasts)
*   [Blogs & Columns](https://www.healio.com/news/blogs-and-columns)
*   [Resources](https://www.healio.com/news/resources)

Menu Close

[Specialties](https://www.healio.com/news/hematology-oncology/20240813/video-study-investigates-novel-therapy-for-penetration-of-pediatric-brain-tumors#collapseSpecialty)

*   [All Specialties](https://www.healio.com/news/?showall=1)
*   [Allergy/Asthma](https://www.healio.com/allergy-asthma)
*   [Hematology/Oncology](https://www.healio.com/hematology-oncology)
*   [Infectious Disease](https://www.healio.com/infectious-disease)
*   [Orthopedics](https://www.healio.com/orthopedics)
*   [Rheumatology](https://www.healio.com/rheumatology)

[Home](https://www.healio.com/)

[Headline News](https://www.healio.com/news/hematology-oncology)

*   [Hematology/Oncology Subspecialties](https://www.healio.com/news/hematology-oncology)
*   [Bone Marrow Transplantation](https://www.healio.com/news/hematology-oncology/bone-marrow-transplantation)
*   [Breast Cancer](https://www.healio.com/news/hematology-oncology/breast-cancer)
*   [Cancer Prevention](https://www.healio.com/news/hematology-oncology/cancer-prevention)
*   [Cell Therapy](https://www.healio.com/news/hematology-oncology/cell-therapy)
*   [Gastrointestinal Cancer](https://www.healio.com/news/hematology-oncology/gastrointestinal-cancer)
*   [Genitourinary Cancer](https://www.healio.com/news/hematology-oncology/genitourinary-cancer)
*   [Geriatric Oncology](https://www.healio.com/news/hematology-oncology/geriatric-oncology)
*   [Gynecologic Cancer](https://www.healio.com/news/hematology-oncology/gynecologic-cancer)
*   [Head/Neck Cancer](https://www.healio.com/news/hematology-oncology/head-neck-cancer)
*   [Hematologic Malignancies](https://www.healio.com/news/)
*   [Hematology](https://www.healio.com/news/hematology-oncology/hematology)
*   [Leukemia](https://www.healio.com/news/hematology-oncology/leukemia)
*   [Lung Cancer](https://www.healio.com/news/hematology-oncology/lung-cancer)
*   [Lymphoma](https://www.healio.com/news/hematology-oncology/lymphoma)
*   [Melanoma/Skin Cancer](https://www.healio.com/news/hematology-oncology/melanoma-skin-cancer)
*   [Myeloma](https://www.healio.com/news/hematology-oncology/myeloma)
*   [Myeloproliferative Neoplasms](https://www.healio.com/news/hematology-oncology/myeloproliferative-neoplasms)
*   [Neuro-Oncology](https://www.healio.com/news/hematology-oncology/neuro-oncology)
*   [Palliative Care](https://www.healio.com/news/hematology-oncology/palliative-care)
*   [Pediatric Hematology](https://www.healio.com/news/)
*   [Pediatric Oncology](https://www.healio.com/news/hematology-oncology/pediatric-oncology)
*   [Practice Management](https://www.healio.com/news/hematology-oncology/practice-management)
*   [Prostate Cancer](https://www.healio.com/news/hematology-oncology/prostate-cancer)
*   [Sarcoma](https://www.healio.com/news/hematology-oncology/sarcoma)
*   [Survivorship](https://www.healio.com/news/hematology-oncology/survivorship)

[Meeting News](https://www.healio.com/news/meeting-news)

[Podcasts](https://www.healio.com/news/podcasts)

[Blogs & Columns](https://www.healio.com/news/blogs-and-columns)

[Resources](https://www.healio.com/news/resources)

[Account Account](https://www.healio.com/footer/account-information/my-account ""Account"")

[Log In Log In](javascript:void\($j.get\('/utilityapp/json/na/li/healiotwo/{ACC50322-FB7D-42FC-940E-84BDDAD3B84D}',function\(data\){$j\('body'\).append\(data\);}\)\) ""Log In"")

[Log Out Log Out](javascript:; ""Log Out"")

[![Image 2: Healio](https://m1.healio.com/~/media/images/healio/healiologooptimized.svg)](https://www.healio.com/)

Close Searchbar

1.  [Healio](https://www.healio.com/)
2.  [News](https://www.healio.com/news)
3.  [Hematology/Oncology](https://www.healio.com/news/hematology-oncology)
4.  [Pediatric Oncology](https://www.healio.com/news/hematology-oncology/pediatric-oncology)

    [![Image 3: Take Homes from ISPNO_banner](https://www.healio.com/~/media/d30a9065c4474709a36a7c27a8d4786c.png?w=960) Take Homes from ISPNO =====================](https://www.healio.com/news/hematology-oncology/resources/take-homes-from-ispno)

![Image 4: hemonc today logo](https://www.healio.com/~/media/h5/feature/news/publogos/hot.svg?la=en&h=24&w=141&hash=2F86D471C8514C0E334E329AA799E8B4)

By[Cassie Kline, MD, MAS](https://www.healio.com/authors/ckline)

By[Georgia I Salvaryn](https://www.healio.com/authors/gsalvaryn)

Fact checked by[Mindy Valcarcel, MS](https://www.healio.com/authors/mvalcarcel)

[](https://www.healio.com/news/hematology-oncology/20240813/video-study-investigates-novel-therapy-for-penetration-of-pediatric-brain-tumors#)

#### Read more

#### [](https://www.healio.com/news/hematology-oncology/20240813/video-study-investigates-novel-therapy-for-penetration-of-pediatric-brain-tumors#)

#### [](https://www.healio.com/news/hematology-oncology/20240813/video-study-investigates-novel-therapy-for-penetration-of-pediatric-brain-tumors#)

#### [](https://www.healio.com/news/hematology-oncology/20240813/video-study-investigates-novel-therapy-for-penetration-of-pediatric-brain-tumors#)

#### [](https://www.healio.com/news/hematology-oncology/20240813/video-study-investigates-novel-therapy-for-penetration-of-pediatric-brain-tumors#)

August 13, 2024

1 min watch

Save

VIDEO: Study investigates novel therapy for penetration of pediatric brain tumors
=================================================================================

![Image 5: hemonc today logo](https://www.healio.com/~/media/h5/feature/news/publogos/hot.svg?la=en&h=24&w=141&hash=2F86D471C8514C0E334E329AA799E8B4)

By[Cassie Kline, MD, MAS](https://www.healio.com/authors/ckline)

By[Georgia I Salvaryn](https://www.healio.com/authors/gsalvaryn)

Fact checked by[Mindy Valcarcel, MS](https://www.healio.com/authors/mvalcarcel)

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

**You've successfully added to your alerts. You will receive an email when new content is published.**  
  
**[Click Here to Manage Email Alerts](javascript:void\(0\))**

**You've successfully added to your alerts. You will receive an email when new content is published.**  
  
**[Click Here to Manage Email Alerts](javascript:void\(0\))**  
  
Back to Healio

**We were unable to process your request. Please try again later. If you continue to have this issue please contact [customerservice@slackinc.com](mailto:customerservice@slackinc.com).**  
  
Back to Healio

PHILADELPHIA ‚Äî In this video, **Cassie Kline, MD, MAS****,** discusses the results of the PNOC016 trial she presented at International Symposium on Pediatric Neuro-Oncology.

The study observed the intratumoral pharmacokinetics and pharmacodynamic results of fimepinostat (Curis) in treating high-risk brain tumors in children and young adults with newly diagnosed diffuse intrinsic pontine gliomas, recurrent medulloblastoma or recurrent high-grade gliomas.

‚Äú\[These\] novel clinical trials \[explore\] not just the impact of drug on survival but \[look\] at intratumoral drug penetration and pharmacodynamic markers of response and \[present\] on ways in which we should be thinking about trial design and how we are answering or addressing questions of ‚Äòhow‚Äô or ‚Äòwhy‚Äô a drug is working,‚Äù Kline, a pediatric neuro-oncology attending and director of neuro-oncology clinical research at Children‚Äôs Hospital of Philadelphia, said.

Reference:
----------

*   Kline C, et al. Abstract TRLS-07. Presented at: International Symposium on Pediatric Neuro-Oncology; June 28-July 2, 2024; Philadelphia.

Published by: ![Image 6: hemonc today logo](https://www.healio.com/~/media/h5/feature/news/publogos/hot.svg?la=en&h=24&w=141&hash=2F86D471C8514C0E334E329AA799E8B4)

Sources/DisclosuresCollapse

**Disclosures:** Kline reports grants from and/or clinical trial contracts with Bristol Myers Squibb, Cannonball Kids‚Äô cancer Foundation, Chimerix, Curis, Day One Biopharmaceuticals, Ipsen, Kazia Therapeutics, Kortney Rose Foundation, Midatech Pharma and Regeneron Pharmaceuticals.

Read more about

[recurrent medulloblastoma](https://www.healio.com/topics/recurrent-medulloblastoma)

[recurrent high-grade gliomas](https://www.healio.com/topics/recurrent-high-grade-gliomas)

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

**You've successfully added to your alerts. You will receive an email when new content is published.**  
  
**[Click Here to Manage Email Alerts](javascript:void\(0\))**

**You've successfully added to your alerts. You will receive an email when new content is published.**  
  
**[Click Here to Manage Email Alerts](javascript:void\(0\))**  
  
Back to Healio

**We were unable to process your request. Please try again later. If you continue to have this issue please contact [customerservice@slackinc.com](mailto:customerservice@slackinc.com).**  
  
Back to Healio

*   [Facebook](javascript:void\(0\))
*   [Twitter](javascript:void\(0\))
*   [LinkedIn](javascript:void\(0\))
*   [Email](mailto:?subject=IsawthisarticleonHealio.comandthoughtyoumightbeinterestedinit&Body=https%3a%2f%2fwww.healio.com%2fnews%2fhematology-oncology%2f20240813%2fvideo-study-investigates-novel-therapy-for-penetration-of-pediatric-brain-tumors)
*   [Print](javascript:void\(0\))
*   [Comment](https://www.healio.com/footer/healio-dot-com/contact-the-news-desk)

[Continue Reading](javascript:void\(0\))

Related Content
---------------

[Play on Healio ![Image 7: Word Doc](https://m2.healio.com/~/media/images/footer/worddoc_desktop.svg)](https://www.healio.com/worddoc)

Follow Healio

*   [Twitter](https://twitter.com/GoHealio)
*   [Facebook](https://www.facebook.com/HealioNetwork)
*   [Instagram](https://www.instagram.com/gohealio)
*   [Threads](https://www.threads.net/gohealio)
*   [LinkedIn](http://www.linkedin.com/company/healio)

About

*   [About Healio About Healio](https://www.healio.com/about-healio ""About Healio"")
*   [About the Wyanoke Group About the Wyanoke Group](https://www.healio.com/about-the-wyanoke-group ""About the Wyanoke Group"")
*   [Editorial Policy and Philosophy Editorial Policy and Philosophy](https://www.healio.com/editorial-policy-and-philosophy ""Editorial Policy and Philosophy"")
*   [Sitemap Sitemap](https://www.healio.com/sitemap ""Sitemap"")

Account Information

*   [My Account Login](javascript:void\($j.get\('/utilityapp/json/na/li/healiotwo/{ACC50322-FB7D-42FC-940E-84BDDAD3B84D}?returnUrl=https://preview.healio.com/footer/account-information/my-account',function\(data\){$j\('body'\).append\(data\);}\)\) ""My Account"")
*   [My Account My Account](https://www.healio.com/my-account ""My Account"")
*   [Help Help](https://www.healio.com/help ""Help"")
*   [Email Subscriptions Email Subscriptions](https://www.healio.com/my-account/email-subscriptions-and-alerts ""Email Subscriptions"")
*   [Email Subscriptions Email Subscriptions Unknown](javascript:void\($j.get\('/utilityapp/json/na/li/healiotwo/{ACC50322-FB7D-42FC-940E-84BDDAD3B84D}?returnUrl=https://www.healio.com/my-account/email-subscriptions-and-alerts',function\(data\){$j\('body'\).append\(data\);}\)\) ""Email Subscriptions"")
*   [Newspaper and Journal Subscriptions Newspaper and Journal Subscriptions](https://www.healio.com/subscribe ""Newspaper and Journal Subscriptions"")

Contact Us

*   [Email Us Email Us](https://www.healio.com/help#request ""Email Us"")
*   [Contact Newsroom Contact Newsroom](https://www.healio.com/contact-newsroom ""Contact Newsroom"")
*   [Advertising Information Advertising Information](https://www.healio.com/advertising-information ""Advertising Information"")
*   [Permissions and Reprints Permissions and Reprints](https://www.healio.com/reprints-permissions ""Permissions and Reprints"")

Legal

*   [Do Not Sell My Personal Information Do Not Sell My Personal Information](https://www.healio.com/do-not-sell-my-personal-information ""Do Not Sell My Personal Information"")
*   [Terms and Conditions Terms and Conditions](https://www.healio.com/terms-and-conditions ""Terms and Conditions"")
*   [Medical Disclaimer Medical Disclaimer](https://www.healio.com/medical-disclaimer ""Medical Disclaimer"")
*   [Privacy Policy Privacy Policy](https://www.healio.com/privacy-policy ""Privacy Policy"")

Sign Up for Email

Get the latest news and education delivered to your inbox

Email address 

Enter your email

[Update email address](https://www.healio.com/footer/account-information/my-account/edit-profile)

Specialty

Choose your specialty\*

*   All Specialties
*   Allergy & Asthma
*   Cardiology
*   Dermatology
*   Endocrinology
*   Gastroenterology/Hepatology
*   Hematology Oncology
*   Infectious Disease
*   Nephrology
*   Neurology
*   Ophthalmology
*   Optometry
*   Orthopedics
*   Pediatrics
*   Primary Care
*   Psychiatry
*   Pulmonology
*   Rheumatology
*   Women‚Äôs Health & OB/GYN

Choose your specialty

Subscribe

Update email address
--------------------

The email address associated with your Healio account is:

If you would like to edit or change the email address that your subscriptions and alerts are sent to, use the ""Update email address"" link.

[Update email address](https://www.healio.com/footer/account-information/my-account/edit-profile)

¬© 2024 Healio All Rights Reserved.

We‚Äôre sorry, but an unexpected error has occurred.
--------------------------------------------------

**Please refresh your browser and try again. If this error persists, please contact [ITSupport@wyanokegroup.com](mailto:itsupport@wyanokegroup.com) for assistance.**

Close

 

      

Would you like to receive email reminders to complete your saved activities from Healio CME?

 Yes

 No

Activity saved! You'll receive reminders to complete your saved activities from Healio CME.

Unsubscribe
",gpt-4o-mini
2024-09-02 07:42:00,2024-09-02 08:15:09,"**Finerenone: A Game-Changer for Heart Failure Management**  
New research presented at the European Society of Cardiology Congress indicates that finerenone significantly reduces the risk of cardiovascular death and worsening heart failure in patients with mildly reduced or preserved ejection fraction. In the FINEARTS-HF trial, finerenone showed a 16% reduction in these risks compared to placebo, marking an exciting advancement in treatment options following SGLT2 inhibitors.  

This study highlights the importance of integrating finerenone as a complementary therapy alongside existing treatments, such as SGLT2 inhibitors. With a robust efficacy profile and favorable safety outcomes, including manageable rates of hyperkalemia, finerenone could provide substantial benefits in this challenging patient population.  

‚ú® **Join the conversation:** What has been your experience with finerenone in patient care? Share your thoughts below!  

#Cardiology #HeartFailure #Finerenone #PatientCare #ResearchUpdate #MedicalCommunity  

![Finerenone improves outcomes in patients with mildly reduced, preserved ejection fraction](https://medsii.azureedge.net/images/638608597672059121-66d56b464e2a8b3bb8355998.jpg)",https://medsii.azureedge.net/images/638608597672059121-66d56b464e2a8b3bb8355998.jpg,https://www.healio.com/news/cardiology/20240901/finerenone-improves-outcomes-in-patients-with-mildly-reduced-preserved-ejection-fraction,"You are a content creator tasked with crafting highly informative, easy to digest social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Thumbnail image URL: https://medsii.azureedge.net/images/638608597672059121-66d56b464e2a8b3bb8355998.jpg  
Title: Finerenone improves outcomes in patients with mildly reduced, preserved ejection fraction

URL Source: https://www.healio.com/news/cardiology/20240901/finerenone-improves-outcomes-in-patients-with-mildly-reduced-preserved-ejection-fraction

Published Time: 2024-09-01

Markdown Content:
September 01, 2024

6 min read

![Image 1: cardiology today logo](https://www.healio.com/~/media/h5/feature/news/publogos/ct.svg?la=en&h=23&w=153&hash=A06CB53CC9857108FFDFA7B802CDF777)

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

**We were unable to process your request. Please try again later. If you continue to have this issue please contact [customerservice@slackinc.com](mailto:customerservice@slackinc.com).**

Key takeaways:
--------------

*   Finerenone reduced risk for CV death and worsening heart failure vs. placebo in this patient population.
*   Pooled analyses demonstrated the benefits of finerenone and other MRAs in high-risk patients.

In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone reduced risk for CV death and worsening HF by 16% compared with placebo, researchers reported at the European Society of Cardiology Congress.

The results of [the double-blind, randomized FINEARTS-HF trial](https://www.healio.com/news/cardiology/20240805/topline-results-finerenone-reduces-events-in-certain-patients-with-heart-failure), simultaneously published in _The New England Journal of Medicine_, mean that finerenone (Kerendia, Bayer), a nonsteroidal selective mineralocorticoid receptor antagonist, represents the second class of drugs to have a positive CV outcomes trial in patients with HFmrEF or HFpEF, following SGLT2 inhibitors, **Scott D. Solomon, MD,** the Edward D. Frohlich Distinguished Chair and professor of medicine at Harvard Medical School and senior physician and director of the Clinical Trials Outcomes Center at Brigham and Women‚Äôs Hospital, told Healio.

![Image 2](https://m3.healio.com/~/media/slack-news/cardiology/mugs/s/solomon_scott_david_2020_web.jpg)

****Scott D. Solomon**  
**

‚ÄúWe currently have one clear winner in [patients with heart failure and mildly reduced or preserved ejection fraction](https://www.healio.com/news/cardiology/20240828/glp1s-may-improve-outcomes-when-added-to-sglt2-therapy-for-hfpef-diabetes-and-obesity), which are SGLT2 inhibitors ... and in the U.S. we have the availability of sacubitril/valsartan (Entresto, Novartis), and the FDA has given it an expanded indication for mildly reduced or preserved ejection fraction, but they have qualified that by saying it is most effective in patients with ejection fraction below normal,‚Äù Solomon told Healio. ‚ÄúWith these data, we are now potentially able to add at least a second pillar ... to SGLT2 inhibitors in treating patients with heart failure with mildly reduced or preserved ejection fraction.‚Äù

In related Hot Line session presentations at the ESC Congress, a meta-analysis of trials of MRAs in patients with HF, simultaneously published in _The Lancet_, showed that the drug class lowers risk for CV death or HF hospitalization by 34% in patients with HF with reduced EF and by 13% in patients with HFmrEF or HFpEF. In addition, the FINE-HEART pooled analysis of the FINEARTS-HF, FIDELIO-DKD and FIGARO-DKD trials, simultaneously published in _Nature Medicine_, showed finerenone lowered risk for various heart- and kidney-related outcomes in patients with a variety of cardio-kidney-metabolic disorders including HF, diabetes and chronic kidney disease.

FINEARTS-HF
-----------

Solomon and colleagues randomly assigned 6,001 patients with symptomatic HF and EF of 40% or more (mean age, 72 years; 45% women; mean EF, 53%) to receive once-daily finerenone (maximum dose, 20 mg for patients with estimated glomerular filtration rate < 60 mL/min/1.73 m2 and 40 mg for patients with eGFR 60 mL/min/1.73 m2) or placebo on top of usual therapy. Median follow-up was 32 months.

‚ÄúWe knew that finerenone was beneficial in patients with chronic kidney disease and diabetes, because there had been two large outcome trials, FIDELIO-DKD and FIGARO-DKD, in that population,‚Äù Solomon told Healio. ‚ÄúThe efficacy of MRAs at all in patients with mildly reduced or preserved ejection fraction has not been established. The TOPCAT trial tested the steroidal MRA spironolactone in patients with HFpEF. TOPCAT did not meet its primary endpoint, but post hoc analyses suggested there were patients enrolled in that trial, primarily in Russia and the Republic of Georgia, who didn‚Äôt actually have heart failure and probably were not taking \[the study\] medication. A lot of people have said that had we done that trial in the right patients, then there may have been a benefit \[for MRAs in HFpEF\]. But the data have not been definitive. In the U.S. guidelines, spironolactone has a Class IIb indication. In the European guidelines, it does not have a guideline-recommended indication for this patient population. Therefore, we intended to determine whether finerenone ‚Äî which is more selective for the MR receptor than steroidal MRAs, has a shorter half-life and has more balanced distribution between the heart and the kidneys ‚Äî could benefit patients with heart failure with mildly reduced or preserved ejection fraction.‚Äù

During the study period, the primary outcome of total worsening HF events (defined as first or recurrent unplanned hospitalization or urgent visit for HF) and CV death occurred 1,083 times in the finerenone group and 1,283 times in the placebo group (rate ratio = 0.84; 95% CI, 0.74-0.95; _P_ = .007; absolute risk reduction, 3.3 per 100 patient-years), Solomon told Healio.

The results were driven by worsening HF events (finerenone, 842; placebo, 1,024; rate ratio = 0.82; 95% CI, 0.71-0.94; _P_ = .006) as opposed to CV death (finerenone, 8.1%; placebo, 8.7%; HR = 0.93; 95% CI, 0.78-1.11), the researchers found. All-cause mortality was not different between the groups (HR = 0.93; 95% CI, 0.83-1.06), Solomon said.

The finerenone group had greater improvement in Kansas City Cardiomyopathy Questionnaire Overall Summary Score (+ 8 vs. + 6.4; between-arm difference, + 1.6; 95% CI, 0.8-2.3; _P_ < .001), Solomon told Healio.

Serious adverse events occurred in approximately 40% of both groups, he said.

‚ÄúWe saw more hyperkalemia, as expected with a mineralocorticoid receptor antagonist,‚Äù Solomon told Healio. ‚ÄúBut the incidence of severe hyperkalemia ‚Äî for example, hyperkalemia leading to hospitalization ‚Äî was very small, 0.5% in the finerenone group and 0.2% in the placebo group, and there were no cases of hyperkalemia leading to death. We saw considerably less hypokalemia in the finerenone group than in the placebo group.‚Äù

Approximately one-fifth of patients in both groups discontinued the study medication before the end of the trial, he told Healio.

The primary endpoint results were consistent across all specified subgroups, and did not vary by sex, EF or whether a patient was taking an SGLT2 inhibitor ‚Äî ‚Äúthe only current guideline-recommended therapy in this population‚Äù ‚Äî at baseline, he told Healio.

‚ÄúThere is still considerable residual risk in this population despite the use of drugs like SGLT2 inhibitors,‚Äù Solomon told Healio. ‚ÄúHere, we have the ability to further reduce morbidity and mortality in these patients. This was a win for finerenone.‚Äù

MRA meta-analysis
-----------------

**Pardeep S. Jhund, MBChB, PhD,** professor of cardiology and epidemiology at the University of Glasgow and honorary consultant cardiologist at Queen Elizabeth University Hospital, Glasgow, U.K., and colleagues conducted an individual patient-level meta-analysis of four trials of MRAs in patients with HF:

*   FINEARTS-HF;
*   TOPCAT;
*   RALES, which analyzed spironolactone in patients with HFrEF; and
*   EMPHASIS-HF, which analyzed eplerenone in patients with HFrEF.

In the entire cohort of 13,846 patients, MRAs were associated with reduced risk for CV death or HF hospitalization (HR = 0.77; 95% CI, 0.72-0.83), but the effect size was greater in HFrEF (HR = 0.66; 95% CI, 0.59-0.73) than in HFmrEF/HFpEF (HR = 0.87; 95% CI, 0.79-0.95; _P_ for interaction = .012), Jhund said at a press conference.

MRAs reduced HF hospitalization in all trials, and they reduced CV death and all-cause death in the HFrEF trials but not the HFmrEF/HFpEF trials, according to the researchers.

MRAs doubled the risk for hyperkalemia and halved the risk for hypokalemia, but the incidence of serious hyperkalemia was low, he said.

‚ÄúThis meta-analysis ... confirms the benefits of MRAs in heart failure,‚Äù Jhund said at the press conference. ‚ÄúWe should use MRAs in patients with heart failure without a contraindication.‚Äù

FINE-HEART pooled analysis
--------------------------

**Muthiah Vaduganathan, MD, MPH,** cardiologist and co-director of the Center for Cardiometabolic Implementation Science at Brigham and Women‚Äôs Hospital and on faculty at Harvard Medical School, and colleagues conducted the FINE-HEART pooled analysis of three trials of finerenone:

*   FINEARTS-HF in patients with HFmrEF or HFpEF;
*   FIDELIO-DKD; and
*   FIGARO-DKD.

‚ÄúDespite advances in medical therapy, the burden of \[cardio-kidney-metabolic syndrome\] has remained very high at the population level,‚Äù Vaduganathan said at the press conference. ‚ÄúEach of these trials had individual endpoints, but none were individually powered for mortality, so that was of particular importance to this analysis.‚Äù

The primary endpoint of CV death did not significantly favor finerenone vs. placebo (HR = 0.89; 95% CI, 0.78-1.01; _P_ = .076), he said.

‚ÄúWe found that a large number of deaths could not specifically be adjudicated as cardiovascular vs. non-cardiovascular etiology, so in a prespecified sensitivity analysis considering undetermined deaths as cardiovascular deaths, that improved the certainty of evidence,‚Äù he said. In that analysis, finerenone reduced risk for CV death by 12% (HR = 0.88; 95% CI, 0.79-0.98; _P_ = .025), Vaduganathan said.

In addition, compared with placebo, finerenone reduced risk for all-cause mortality (HR = 0.91; 95% CI, 0.84-0.99; _P_ = .027), HF hospitalization (HR = 0.83; 95% CI, 0.75-0.92; _P_ < .001) and the composite kidney endpoint of sustained eGFR decline of 50% or more, kidney failure or death due to kidney failure (HR = 0.8; 95% CI, 0.72-0.9; _P_ < .001), he said.

The pooled analysis did not reveal any new or unexpected safety signals, and the results were consistent across all subgroups, including whether a patient was taking an SGLT2 inhibitor or a GLP-1 receptor agonist at baseline, he said.

‚ÄúThe totality of evidence supports the disease-modifying potential of finerenone in broad, high-risk populations with overlapping cardiovascular, kidney and metabolic conditions,‚Äù Vaduganathan said.

References:
-----------

*   Jhund PS, et al. Hot line 7.
*   Vaduganathan M, et al. Hot line 7. Both presented at: European Society of Cardiology Congress; Aug. 30-Sept. 2, 2024; London (hybrid meeting).
*   [Jhund PS, et al. _Lancet_. 2024;doi:10.1016/ S0140-6736(24)01733-1.](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736/(24/)01755-0/abstract)
*   [Solomon SD, et al. _N Engl J Med_. 2024;doi:10.1056/NEJMoa2407107.](https://www.nejm.org/doi/full/10.1056/NEJMoa2407107)
*   [Vaduganathan M, et al. _Nat Med_. 2024;doi:10.1038/s41591-024-03264-4.](https://www.nature.com/articles/s41591-024-03264-4)

For more information:
---------------------

**Scott D. Solomon, MD,** can be reached at ssolomon@bwh.harvard.edu.

Perspective
-----------

[Back to Top](https://www.healio.com/news/cardiology/20240901/finerenone-improves-outcomes-in-patients-with-mildly-reduced-preserved-ejection-fraction#top) ![Image 3: Carlos G. Santos-Gallego , MD)](https://www.healio.com/~/media/slack-news/cardiology/mugs/s/santosgallego_carlos_2021_80x106.jpg?la=en&h=105&w=79&hash=CDBB60F786C432EBBF1C14F812CEEF6F)

[Carlos G. Santos-Gallego, MD](https://www.healio.com/authors/csantosgallego)

HF with EF of 40% or more is a key population and, for many years, we did not have an effective treatment. Recently, we got positive results from the SGLT2 inhibitors in this population, and some positive results from semaglutide 2.4 mg (Wegovy, Novo Nordisk) in patients with HFpEF and obesity. We also have the very controversial TOPCAT trial, with a famous geographical imbalance. The trial was positive if patients from Russia and the Republic of Georgia were excluded, so many doctors in the Americas have prescribed spironolactone for patients with HFpEF.

However, a problem with spironolactone is that the rates of hyperkalemia are very high, and there is concern that the increased potassium levels may be negative for the patient. Now, we have a nonsteroidal MRA that causes less risk for hyperkalemia than spironolactone. In FINEARTS-HF, we learned that finerenone improves hard endpoints in patients with moderately reduced EF (40%-50%) and HFpEF (over 50%). But the effect size was moderate, 16%, compared with SGLT2 inhibitors, which reduce CV death and HF worsening by 30% to 35%. A reduction in CV death with finerenone was not expected, because there was no reduction in CV death with SGLT2 inhibitors; the results for all have been driven by HF events.

While finerenone is a nonsteroidal MRA and induces less hyperkalemia than steroidal MRAs, the rates of hyperkalemia were higher, almost double, in the finerenone group than in the control group. The rates of hospitalization for hyperkalemia were very low, which is reassuring. Of note, we are starting to become more comfortable with hyperkalemia. In the past, as soon as potassium reached 5 mmol/L, many doctors would stop the MRA for fear of a ventricular arrhythmia. There was a lingering fear about it. But right now, we are starting to realize two things. No. 1, on some occasions, allowing a potassium level up to 5.5 mmol/L does not increase mortality and still gives the patient the benefit of taking the medication. No. 2, SGLT2 inhibitors reduce the rate of hyperkalemia. Almost every patient with HFpEF should be on an SGLT2 inhibitor, so this will reduce the risk for hyperkalemia posed by spironolactone or finerenone.

So far, finerenone is approved for nephology indications, but in my practice, the rate of prescription is very low. When finerenone gets approved by the FDA for HFmrEF and HFpEF, it will definitely be used for that population.

The question will be the price. Finerenone is an expensive medication. Maybe some doctors will continue to prescribe spironolactone, which is much cheaper. The rate of uptake will depend on the approval of insurance companies. Polypharmacy will also be a consideration. Patients with HFpEF are already on many medications, and finerenone would be another. And will insurance companies approve two or all of an SGLT2 inhibitor, a GLP-1 receptor agonist and finerenone for the same patient? None of them are cheap. If cost is an issue, the cardiologist will have to decide which one to focus on. It‚Äôs hard to say, but I think some cardiologists will go for semaglutide, because it has additional benefits on the kidneys, as the FLOW trial demonstrated, and on reducing obesity. If there is no problem with insurance approval, then cardiologists will prescribe finerenone to our patients.

Carlos G. Santos-Gallego, MD

Instructor of Medicine (Cardiology)

Icahn School of Medicine at Mount Sinai

**Disclosures:** Santos-Gallego reports no relevant financial disclosures.

Published by: ![Image 4: cardiology today logo](https://www.healio.com/~/media/h5/feature/news/publogos/ct.svg?la=en&h=23&w=153&hash=A06CB53CC9857108FFDFA7B802CDF777)

Sources/DisclosuresCollapse

**Source:**

Solomon SD, et al. Hot line 7. Presented at: European Society of Cardiology Congress; Aug. 30-Sept. 2, 2024; London (hybrid meeting).

**Disclosures:** FINEARTS-HF, FIDELIO-DKD and FIGARO-DKD were funded by Bayer. Jhund reports receiving speaker fees from Alkem Metabolics, AstraZeneca, Novartis, ProAdWise Communications and Sun Pharmaceuticals; receiving advisory board fees from AstraZeneca, Boehringer Ingelheim and Novartis; receiving research funding from Analog Devices, AstraZeneca, Boehringer Ingelheim and Roche Diagnostics; and serving as a director of Global Clinical Trial Partners. Jhund also reports his employer, the University of Glasgow, has been remunerated for clinical trial work from AstraZeneca, Bayer, Novartis and Novo Nordisk. Solomon reports receiving research grants from Alexion, Alnylam, Applied Therapeutics, AstraZeneca, Bellerophon, Bayer, Boston Scientific, Bristol Myers Squibb, Cytokinetics, Edgewise, Eidos/BridgeBio, Eli Lilly, Gossamer, GlaxoSmithKline, Ionis, NIH/NHLBI, Novartis, Novo Nordisk, Respicardia, Sanofi Pasteur, Tenaya, Theracos and US2.AI and consulting for Abbott, Action, Akros, Alexion, Alnylam, American Regent, Amgen, Anacardio, Arena, AstraZeneca, Bayer, Bristol Myers Squibb, Cardior, Cardurion, CellProThera, Corvia, Cytokinetics, Dinaqor, Eli Lilly, GlaxoSmithKline, Lexicon, Moderna, Novartis, Quantum Genomics, Roche, Sanofi-Pasteur, Sarepta, Tenaya, Theracos, Tremeau and Valo. Vaduganathan reports receiving research grant support, serving on advisory boards or having speaker engagements with American Regent, Amgen, AstraZeneca, Bayer, Baxter Healthcare, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, Cytokinetics, Fresenius Medical Care, Idorsia Pharmaceuticals, Lexicon Pharmaceuticals, Merck, Milestone Pharmaceuticals, Novartis, Novo Nordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi and Tricog Health, and participating on clinical trial committees for studies sponsored by AstraZeneca, Bayer, Galmed, Impulse Dynamics, Novartis and Occlutech. Please see the studies for all other authors‚Äô relevant financial disclosures.

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

**We were unable to process your request. Please try again later. If you continue to have this issue please contact [customerservice@slackinc.com](mailto:customerservice@slackinc.com).**
",gpt-4o-mini
2024-09-02 07:36:00,2024-09-02 08:15:15,"üîç **Update on Congenital Ichthyosis Treatment: Phase 3 Study of TMB-001 Fails to Deliver Results**  

In a disappointing turn of events, Timber Pharmaceuticals has announced that their Phase 3 trial of TMB-001, a topical isotretinoin formulation aimed at treating moderate to severe congenital ichthyosis, did not meet its primary and secondary endpoints. After initially promising Phase 2b results, the study observed an unexpectedly high vehicle response rate, leading to a significant setback in clinical development.  

As dermatologists, it's crucial we stay informed about the latest treatment advancements and trials. This outcome reinforces the need for continued research and innovation in treating rare skin conditions.  

üëâ **Share your thoughts or experiences with similar treatments in the comments!**  

Read more [here](https://www.healio.com/news/dermatology/20240823/phase-3-study-of-tmb001-for-treatment-of-congenital-ichthyosis-fails-to-meet-endpoints).

#Dermatology #CongenitalIchthyosis #ClinicalTrials #PatientCare",https://medsii.azureedge.net/images/638608593590522553-66d569dbac48c5e342a2608c.jpg,https://www.healio.com/news/dermatology/20240823/phase-3-study-of-tmb001-for-treatment-of-congenital-ichthyosis-fails-to-meet-endpoints,"You are a content creator tasked with crafting highly informative, easy to digest social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Thumbnail image URL: https://medsii.azureedge.net/images/638608593590522553-66d569dbac48c5e342a2608c.jpg  
Title: Phase 3 study of TMB-001 for treatment of congenital ichthyosis fails to meet endpoints

URL Source: https://www.healio.com/news/dermatology/20240823/phase-3-study-of-tmb001-for-treatment-of-congenital-ichthyosis-fails-to-meet-endpoints

Published Time: 2024-08-24

Markdown Content:
Phase 3 study of TMB-001 for treatment of congenital ichthyosis fails to meet endpoints
===============

[![Image 1: Healio](https://m1.healio.com/~/media/images/healio/healiologooptimized.svg)](https://www.healio.com/)

*   [News News](https://www.healio.com/news ""News"")
*   [CME CME](https://www.healio.com/cme ""CME"")
*   [Clinical Guidance Clinical Guidance](https://www.healio.com/clinical-guidance ""Clinical Guidance"")

*   [_Account_](https://www.healio.com/footer/account-information/my-account "" "")
*   [_Account Anonymous User_](javascript:void\($j.get\('/loginregistration/modals/loadloginmodal',function\(data\){$j\('body'\).append\(data\);}\)\) "" "")
*   [Log In Log In](javascript:void\($j.get\('/utilityapp/json/na/li/healiotwo/{ACC50322-FB7D-42FC-940E-84BDDAD3B84D}',function\(data\){$j\('body'\).append\(data\);}\)\) ""Log In"")
*   [Log Out Log Out](javascript:; ""Log Out"")

*   [News News](https://www.healio.com/news ""News"")
*   [CME CME](https://www.healio.com/cme ""CME"")
*   [Clinical Guidance Clinical Guidance](https://www.healio.com/clinical-guidance ""Clinical Guidance"")

*   [_Account_](https://www.healio.com/footer/account-information/my-account "" "")
*   [_Account Anonymous User_](javascript:void\($j.get\('/loginregistration/modals/loadloginmodal',function\(data\){$j\('body'\).append\(data\);}\)\) "" "")

*   [Specialties](https://www.healio.com/news/dermatology/20240823/phase-3-study-of-tmb001-for-treatment-of-congenital-ichthyosis-fails-to-meet-endpoints#)
    
    Choose a specialty
    
    [All Specialties](https://www.healio.com/) [Allergy/Asthma](https://www.healio.com/allergy-asthma) [Hematology/Oncology](https://www.healio.com/hematology-oncology) [Infectious Disease](https://www.healio.com/infectious-disease) [Orthopedics](https://www.healio.com/orthopedics) [Rheumatology](https://www.healio.com/rheumatology)
    
*   [Home](https://www.healio.com/)
*   [Headline News](https://www.healio.com/news)
*   [Meeting News](https://www.healio.com/news/meeting-news)
*   [Podcasts](https://www.healio.com/news/podcasts)
*   [Blogs & Columns](https://www.healio.com/news/blogs-and-columns)
*   [Resources](https://www.healio.com/news/resources)

Menu Close

[Specialties](https://www.healio.com/news/dermatology/20240823/phase-3-study-of-tmb001-for-treatment-of-congenital-ichthyosis-fails-to-meet-endpoints#collapseSpecialty)

*   [All Specialties](https://www.healio.com/news/?showall=1)
*   [Allergy/Asthma](https://www.healio.com/allergy-asthma)
*   [Hematology/Oncology](https://www.healio.com/hematology-oncology)
*   [Infectious Disease](https://www.healio.com/infectious-disease)
*   [Orthopedics](https://www.healio.com/orthopedics)
*   [Rheumatology](https://www.healio.com/rheumatology)

[Home](https://www.healio.com/)

[Headline News](https://www.healio.com/news/dermatology)

*   [Dermatology Subspecialties](https://www.healio.com/news/dermatology)
*   [Acne](https://www.healio.com/news/dermatology/acne)
*   [Aesthetics](https://www.healio.com/news/dermatology/aesthetics)
*   [Alopecia](https://www.healio.com/news/dermatology/alopecia)
*   [Cutaneous Oncology](https://www.healio.com/news/dermatology/cutaneous-oncology)
*   [Dermatitis](https://www.healio.com/news/dermatology/dermatitis)
*   [Dermatopathology](https://www.healio.com/news/dermatology/dermatopathology)
*   [Dermoscopy](https://www.healio.com/news/dermatology/dermoscopy)
*   [Geriatrics](https://www.healio.com/news/dermatology/geriatrics)
*   [Hidradenitis Suppurativa](https://www.healio.com/news/dermatology/hidradenitis-suppurativa)
*   [Immunodermatology](https://www.healio.com/news/dermatology/immunodermatology)
*   [Lasers](https://www.healio.com/news/dermatology/lasers)
*   [Pediatric Dermatology](https://www.healio.com/news/dermatology/pediatric-dermatology)
*   [Practice Management](https://www.healio.com/news/dermatology/practice-management)
*   [Psoriasis](https://www.healio.com/news/dermatology/psoriasis)
*   [Psoriatic Disease](https://www.healio.com/news/dermatology/psoriatic-disease)
*   [Skin Care](https://www.healio.com/news/dermatology/skin-care)
*   [Therapeutics](https://www.healio.com/news/dermatology/therapeutics)
*   [Vitiligo](https://www.healio.com/news/dermatology/vitiligo)
*   [Wound Management](https://www.healio.com/news/dermatology/wound-management)

[Meeting News](https://www.healio.com/news/meeting-news)

[Podcasts](https://www.healio.com/news/podcasts)

[Blogs & Columns](https://www.healio.com/news/blogs-and-columns)

[Resources](https://www.healio.com/news/resources)

[Account Account](https://www.healio.com/footer/account-information/my-account ""Account"")

[Log In Log In](javascript:void\($j.get\('/utilityapp/json/na/li/healiotwo/{ACC50322-FB7D-42FC-940E-84BDDAD3B84D}',function\(data\){$j\('body'\).append\(data\);}\)\) ""Log In"")

[Log Out Log Out](javascript:; ""Log Out"")

[![Image 2: Healio](https://m1.healio.com/~/media/images/healio/healiologooptimized.svg)](https://www.healio.com/)

Close Searchbar

1.  [Healio](https://www.healio.com/)
2.  [News](https://www.healio.com/news)
3.  [Dermatology](https://www.healio.com/news/dermatology)
4.  [Skin Care](https://www.healio.com/news/dermatology/skin-care)

![Image 3: Healio Psoriatic Disease](https://www.healio.com/~/media/h5/feature/news/publogos/healio_psoriaticdisease.svg?la=en&h=37&w=137&hash=E11A1B015A4A64B5F941A2EEBB3376DE)

Fact checked by[Kristen Dowd](https://www.healio.com/authors/kdowd)

[](https://www.healio.com/news/dermatology/20240823/phase-3-study-of-tmb001-for-treatment-of-congenital-ichthyosis-fails-to-meet-endpoints#)

#### Read more

#### [](https://www.healio.com/news/dermatology/20240823/phase-3-study-of-tmb001-for-treatment-of-congenital-ichthyosis-fails-to-meet-endpoints#)

#### [](https://www.healio.com/news/dermatology/20240823/phase-3-study-of-tmb001-for-treatment-of-congenital-ichthyosis-fails-to-meet-endpoints#)

#### [](https://www.healio.com/news/dermatology/20240823/phase-3-study-of-tmb001-for-treatment-of-congenital-ichthyosis-fails-to-meet-endpoints#)

#### [](https://www.healio.com/news/dermatology/20240823/phase-3-study-of-tmb001-for-treatment-of-congenital-ichthyosis-fails-to-meet-endpoints#)

August 24, 2024

1 min read

Save

Phase 3 study of TMB-001 for treatment of congenital ichthyosis fails to meet endpoints
=======================================================================================

![Image 4: Healio Psoriatic Disease](https://www.healio.com/~/media/h5/feature/news/publogos/healio_psoriaticdisease.svg?la=en&h=37&w=137&hash=E11A1B015A4A64B5F941A2EEBB3376DE)

Fact checked by[Kristen Dowd](https://www.healio.com/authors/kdowd)

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

**You've successfully added to your alerts. You will receive an email when new content is published.**  
  
**[Click Here to Manage Email Alerts](javascript:void\(0\))**

**You've successfully added to your alerts. You will receive an email when new content is published.**  
  
**[Click Here to Manage Email Alerts](javascript:void\(0\))**  
  
Back to Healio

**We were unable to process your request. Please try again later. If you continue to have this issue please contact [customerservice@slackinc.com](mailto:customerservice@slackinc.com).**  
  
Back to Healio

Key takeaways:
--------------

*   TMB-001 is an investigational topical reformulation of isotretinoin for the treatment of congenital ichthyosis.
*   The phase 3 program evaluating TMB-001 did not meet primary and secondary endpoints.

Timber Pharmaceutical‚Äôs study investigating the use of a new topical ointment formulation of isotretinoin for moderate to severe congenital ichthyosis did not achieve its endpoints, LEO Pharma announced in a press release.

[As Healio previously reported](https://www.healio.com/news/dermatology/20240124/leo-pharma-acquires-timber-pharmaceuticals-bankruptcy-assets-including-tmb001), Timber Pharmaceuticals filed for chapter 11 bankruptcy in November 2023. Since then, LEO Pharma acquired the company including its orphan, fast track and breakthrough designated asset, TMB-001.

     ![Image 5: Generic Industry News infographic](https://www.healio.com/~/media/slack-news/generic-infographics/2023/generic-industry-news.jpg?w=800)

Timber Pharmaceutical‚Äôs study investigating the use of a new topical ointment formulation of isotretinoin for moderate to severe congenital ichthyosis did not achieve its endpoints.

TMB-001 is an investigational topical reformulation of isotretinoin that has been evaluated in a phase 3, randomized, double-blind, 12-week study called [ASCEND](https://www.healio.com/news/dermatology/20220627/timber-initiates-phase-3-trial-of-topical-isotretinoin-for-congenital-ichthyosis) for the treatment of patients aged 6 years or older with either the autosomal recessive congenital ichthyosis or X-linked recessive ichthyosis subtypes.

While the drug [initially produced encouraging results](https://www.healio.com/news/dermatology/20230414/topical-isotretinoin-ointment-shows-reassuring-efficacy-safety-in-congenital-ichthyosis) in congenital ichthyosis, the company has announced that the current trial did not show a statistically significant difference between the proportion of patients that responded to treatment with TMB-001 vs. placebo after 12 weeks.

‚ÄúWe are disappointed and saddened by the results of the phase 3 trial,‚Äù **John** **Koconis****,** CEO of Timber Pharmaceuticals, said in the release. ‚ÄúAfter encouraging phase 2b results, we observed an unexpectedly high vehicle response in this trial. We had hoped that TMB-001 could have been a new potential treatment to help children and adults suffering from moderate to severe congenital ichthyosis and to allow them to live a quality life they had previously not known.‚Äù

According to the release, these results will not have a material impact on the 2024 financial results for LEO Pharma. Full study results will be released at a later date.

Published by: ![Image 6: Healio Psoriatic Disease](https://www.healio.com/~/media/h5/feature/news/publogos/healio_psoriaticdisease.svg?la=en&h=37&w=137&hash=E11A1B015A4A64B5F941A2EEBB3376DE)

Sources/DisclosuresCollapse

**Source:**[Press Release](https://www.leo-pharma.com/media-center/news/2024-timber-pharmaceuticals-provides-an-update)

Read more about

[congenital ichthyosis](https://www.healio.com/topics/congenital-ichthyosis)

[ichthyosis](https://www.healio.com/topics/ichthyosis)

[autosomal recessive congenital ichthyosis](https://www.healio.com/topics/autosomal-recessive-congenital-ichthyosis)

[x-linked recessive ichthyosis](https://www.healio.com/topics/x-linked-recessive-ichthyosis)

[severe congenital ichthyosis](https://www.healio.com/topics/severe-congenital-ichthyosis)

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

**You've successfully added to your alerts. You will receive an email when new content is published.**  
  
**[Click Here to Manage Email Alerts](javascript:void\(0\))**

**You've successfully added to your alerts. You will receive an email when new content is published.**  
  
**[Click Here to Manage Email Alerts](javascript:void\(0\))**  
  
Back to Healio

**We were unable to process your request. Please try again later. If you continue to have this issue please contact [customerservice@slackinc.com](mailto:customerservice@slackinc.com).**  
  
Back to Healio

*   [Facebook](javascript:void\(0\))
*   [Twitter](javascript:void\(0\))
*   [LinkedIn](javascript:void\(0\))
*   [Email](mailto:?subject=IsawthisarticleonHealio.comandthoughtyoumightbeinterestedinit&Body=https%3a%2f%2fwww.healio.com%2fnews%2fdermatology%2f20240823%2fphase-3-study-of-tmb001-for-treatment-of-congenital-ichthyosis-fails-to-meet-endpoints)
*   [Print](javascript:void\(0\))
*   [Comment](https://www.healio.com/footer/healio-dot-com/contact-the-news-desk)

[Continue Reading](javascript:void\(0\))

Related Content
---------------

[Play on Healio ![Image 7: Word Doc](https://m2.healio.com/~/media/images/footer/worddoc_desktop.svg)](https://www.healio.com/worddoc)

Follow Healio

*   [Twitter](https://twitter.com/GoHealio)
*   [Facebook](https://www.facebook.com/HealioNetwork)
*   [Instagram](https://www.instagram.com/gohealio)
*   [Threads](https://www.threads.net/gohealio)
*   [LinkedIn](http://www.linkedin.com/company/healio)

About

*   [About Healio About Healio](https://www.healio.com/about-healio ""About Healio"")
*   [About the Wyanoke Group About the Wyanoke Group](https://www.healio.com/about-the-wyanoke-group ""About the Wyanoke Group"")
*   [Editorial Policy and Philosophy Editorial Policy and Philosophy](https://www.healio.com/editorial-policy-and-philosophy ""Editorial Policy and Philosophy"")
*   [Sitemap Sitemap](https://www.healio.com/sitemap ""Sitemap"")

Account Information

*   [My Account Login](javascript:void\($j.get\('/utilityapp/json/na/li/healiotwo/{ACC50322-FB7D-42FC-940E-84BDDAD3B84D}?returnUrl=https://preview.healio.com/footer/account-information/my-account',function\(data\){$j\('body'\).append\(data\);}\)\) ""My Account"")
*   [My Account My Account](https://www.healio.com/my-account ""My Account"")
*   [Help Help](https://www.healio.com/help ""Help"")
*   [Email Subscriptions Email Subscriptions](https://www.healio.com/my-account/email-subscriptions-and-alerts ""Email Subscriptions"")
*   [Email Subscriptions Email Subscriptions Unknown](javascript:void\($j.get\('/utilityapp/json/na/li/healiotwo/{ACC50322-FB7D-42FC-940E-84BDDAD3B84D}?returnUrl=https://www.healio.com/my-account/email-subscriptions-and-alerts',function\(data\){$j\('body'\).append\(data\);}\)\) ""Email Subscriptions"")
*   [Newspaper and Journal Subscriptions Newspaper and Journal Subscriptions](https://www.healio.com/subscribe ""Newspaper and Journal Subscriptions"")

Contact Us

*   [Email Us Email Us](https://www.healio.com/help#request ""Email Us"")
*   [Contact Newsroom Contact Newsroom](https://www.healio.com/contact-newsroom ""Contact Newsroom"")
*   [Advertising Information Advertising Information](https://www.healio.com/advertising-information ""Advertising Information"")
*   [Permissions and Reprints Permissions and Reprints](https://www.healio.com/reprints-permissions ""Permissions and Reprints"")

Legal

*   [Do Not Sell My Personal Information Do Not Sell My Personal Information](https://www.healio.com/do-not-sell-my-personal-information ""Do Not Sell My Personal Information"")
*   [Terms and Conditions Terms and Conditions](https://www.healio.com/terms-and-conditions ""Terms and Conditions"")
*   [Medical Disclaimer Medical Disclaimer](https://www.healio.com/medical-disclaimer ""Medical Disclaimer"")
*   [Privacy Policy Privacy Policy](https://www.healio.com/privacy-policy ""Privacy Policy"")

Sign Up for Email

Get the latest news and education delivered to your inbox

Email address 

Enter your email

[Update email address](https://www.healio.com/footer/account-information/my-account/edit-profile)

Specialty

Choose your specialty\*

*   All Specialties
*   Allergy & Asthma
*   Cardiology
*   Dermatology
*   Endocrinology
*   Gastroenterology/Hepatology
*   Hematology Oncology
*   Infectious Disease
*   Nephrology
*   Neurology
*   Ophthalmology
*   Optometry
*   Orthopedics
*   Pediatrics
*   Primary Care
*   Psychiatry
*   Pulmonology
*   Rheumatology
*   Women‚Äôs Health & OB/GYN

Choose your specialty

Subscribe

Update email address
--------------------

The email address associated with your Healio account is:

If you would like to edit or change the email address that your subscriptions and alerts are sent to, use the ""Update email address"" link.

[Update email address](https://www.healio.com/footer/account-information/my-account/edit-profile)

¬© 2024 Healio All Rights Reserved.

We‚Äôre sorry, but an unexpected error has occurred.
--------------------------------------------------

**Please refresh your browser and try again. If this error persists, please contact [ITSupport@wyanokegroup.com](mailto:itsupport@wyanokegroup.com) for assistance.**

Close

 

     

Would you like to receive email reminders to complete your saved activities from Healio CME?

 Yes

 No

Activity saved! You'll receive reminders to complete your saved activities from Healio CME.

Unsubscribe
",gpt-4o-mini
2024-09-02 07:48:00,2024-09-02 10:11:46,"üî¨ **Exploring the Future of HIV Care: Aging, Resistance, and Vaccines!**  
Join the ongoing discussions about critical topics in HIV management with our latest Roundtable. Experts highlight the complexities faced by older patients living with HIV, emphasizing the need to address the increasing comorbidities they experience. With insights into the challenges of developing an effective HIV vaccine and parallels drawn with COVID-19, it‚Äôs clear that continued research and innovation are vital in this field.  

üó£Ô∏è **Engage with us! What strategies do you employ in managing aging patients with HIV? Share your experiences below!**  

üåê Read more about the session here: [HIV Roundtable: Examining Aging with HIV, Multidrug Resistance, and Vaccine Development](https://www.contemporarypediatrics.com/view/hiv-roundtable-examining-aging-with-hiv-multidrug-resistance-and-vaccine-development)  

#HIVCare #ClinicalResearch #AgingWithHIV #HIVVaccine #MedicalCommunity #PatientCare  

![HIV Roundtable](https://medsii.azureedge.net/images/638608601067875992-66d56cc6ac48c5e342a2609a.jpg)",https://medsii.azureedge.net/images/638608601067875992-66d56cc6ac48c5e342a2609a.jpg,https://www.contemporarypediatrics.com/view/hiv-roundtable-examining-aging-with-hiv-multidrug-resistance-and-vaccine-development,"You are a content creator tasked with crafting highly informative, easy to digest social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Thumbnail image URL: https://medsii.azureedge.net/images/638608601067875992-66d56cc6ac48c5e342a2609a.jpg  
Title: HIV Roundtable: Examining Aging with HIV, Multidrug Resistance, and Vaccine Development

URL Source: https://www.contemporarypediatrics.com/view/hiv-roundtable-examining-aging-with-hiv-multidrug-resistance-and-vaccine-development

Published Time: 2024-08-28T20:00:24.665Z

Markdown Content:
HIV Roundtable: Examining Aging with HIV, Multidrug Resistance, and Vaccine Development
===============
     

![Image 1: HCP Live](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)

*   [![Image 3: Contagion Live](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contagionlive.com/)
*   [![Image 5: CGT Live](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.cgtlive.com/)
*   [![Image 7: Neurology Live](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.neurologylive.com/)
*   [![Image 9: HCP Live](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/)
*   [![Image 11: Oncology Live](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.onclive.com/)
*   [![Image 13: Contemporary Pediatrics](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/)
*   [![Image 15: Contemporary OBGYN](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporaryobgyn.net/)
*   [![Image 17: Urology Times](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.urologytimes.com/)

[![Image 19](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/)

News

[All News](https://www.contemporarypediatrics.com/news)[PNP Corner](https://www.contemporarypediatrics.com/pnp-corner)

[AAP News](https://www.contemporarypediatrics.com/guidelines)

Media

[Around the Practice](https://www.contemporarypediatrics.com/around-the-practice)[Cure Connections](https://www.contemporarypediatrics.com/cure-connections)[Expert Interviews](https://www.contemporarypediatrics.com/expert-interviews)[Insights](https://www.contemporarypediatrics.com/insights)[Medical World News](https://www.medicalworldnews.com/)[Peer Exchange](https://www.contemporarypediatrics.com/peer-exchange)[Peers & Perspectives](https://www.contemporarypediatrics.com/peers-perspectives)[Podcasts](https://www.contemporarypediatrics.com/podcasts)[Webinars](https://www.contemporarypediatrics.com/webinars)

[Puzzler](https://www.contemporarypediatrics.com/case-studies)

Publications

[Contemporary Pediatrics Journal](https://www.contemporarypediatrics.com/journals/contemporary-peds-journal)[Supplements And Featured Publications](https://www.contemporarypediatrics.com/journals/supplements-and-featured-publications)

[CME/CE](https://www.contemporarypediatrics.com/continuing-medical-education)

Resources

[Handouts](https://www.contemporarypediatrics.com/handouts)[Job Board](http://jobs.modernmedicine.com/index.php?action=advanced_search&page=search&keywords=&mult_industries%5B%5D=Pediatrician&country=&zip_radius=&zip=&position_type=&min_salary=&max_salary=&salary_type=)[Sponsored](https://www.contemporarypediatrics.com/sponsored-resources)

Conferences

[Conference Coverage](https://www.contemporarypediatrics.com/latest-conference)[Conference Listing](https://www.contemporarypediatrics.com/conference)

[Partnerships](https://www.contemporarypediatrics.com/sap-partner)[Subscribe](https://one.contemporarypediatrics.com/subscribe)

Editorial

[Editorial Advisory Board](https://cdn.sanity.io/files/0vv8moc6/contpeds/ab931cf10c52363496c4c585e22e53be4a9cc4b8.pdf)[Writer‚Äôs Guidelines](https://cdn.sanity.io/files/0vv8moc6/contpeds/97efe6dc3b417f423a2317175ebdf8c5903affa0.pdf)[Reference Guidelines](https://cdn.sanity.io/files/0vv8moc6/contpeds/db68cfb068c7591ffbadb95dfd5f1433153f7227.pdf)[Meet the Editors](https://www.contemporarypediatrics.com/meet-the-editors)

Choose Specialty

[Allergy, Immunology, and ENT](https://www.contemporarypediatrics.com/clinical/allergy-immunology-and-ent)[Allergy, Immunology, and ENT](https://www.contemporarypediatrics.com/clinical/allergy-immunology-and-ent)[Allergy, Immunology, and ENT](https://www.contemporarypediatrics.com/clinical/allergy-immunology-and-ent)

[Cardiology](https://www.contemporarypediatrics.com/clinical/cardiology)[Cardiology](https://www.contemporarypediatrics.com/clinical/cardiology)

[Dermatology](https://www.contemporarypediatrics.com/clinical/dermatology)[Dermatology](https://www.contemporarypediatrics.com/clinical/dermatology)[Dermatology](https://www.contemporarypediatrics.com/clinical/dermatology)

[Emergency Medicine](https://www.contemporarypediatrics.com/clinical/emergency-medicine)

[Endocrinology](https://www.contemporarypediatrics.com/clinical/endocrinology)[Endocrinology](https://www.contemporarypediatrics.com/clinical/endocrinology)

[Gastroenterology](https://www.contemporarypediatrics.com/clinical/gastroenterology)[Gastroenterology](https://www.contemporarypediatrics.com/clinical/gastroenterology)[Gastroenterology](https://www.contemporarypediatrics.com/clinical/gastroenterology)[Gastroenterology](https://www.contemporarypediatrics.com/clinical/gastroenterology)

[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)

[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)

[Neurology](https://www.contemporarypediatrics.com/clinical/neurology)[Neurology](https://www.contemporarypediatrics.com/clinical/neurology)[Neurology](https://www.contemporarypediatrics.com/clinical/neurology)[Neurology](https://www.contemporarypediatrics.com/clinical/neurology)

[OB/GYN](https://www.contemporarypediatrics.com/clinical/obstetrics-gynecology-womens-health)[OB/GYN](https://www.contemporarypediatrics.com/clinical/obstetrics-gynecology-womens-health)

[Pain](https://www.contemporarypediatrics.com/clinical/pain)

[Pharmacology](https://www.contemporarypediatrics.com/clinical/pharmacology)[Pharmacology](https://www.contemporarypediatrics.com/clinical/pharmacology)

[Practice Improvement](https://www.contemporarypediatrics.com/clinical/practice-improvement)[Practice Improvement](https://www.contemporarypediatrics.com/clinical/practice-improvement)

[Respiratory](https://www.contemporarypediatrics.com/clinical/respiratory)[Respiratory](https://www.contemporarypediatrics.com/clinical/respiratory)[Respiratory](https://www.contemporarypediatrics.com/clinical/respiratory)

[Rheumatology](https://www.contemporarypediatrics.com/clinical/rheumatoid-arthritis)

[![Image 21](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/)

[](https://www.contemporarypediatrics.com/search)

Choose Specialty

[Allergy, Immunology, and ENT](https://www.contemporarypediatrics.com/clinical/allergy-immunology-and-ent)[Allergy, Immunology, and ENT](https://www.contemporarypediatrics.com/clinical/allergy-immunology-and-ent)[Allergy, Immunology, and ENT](https://www.contemporarypediatrics.com/clinical/allergy-immunology-and-ent)

[Cardiology](https://www.contemporarypediatrics.com/clinical/cardiology)[Cardiology](https://www.contemporarypediatrics.com/clinical/cardiology)

[Dermatology](https://www.contemporarypediatrics.com/clinical/dermatology)[Dermatology](https://www.contemporarypediatrics.com/clinical/dermatology)[Dermatology](https://www.contemporarypediatrics.com/clinical/dermatology)

[Emergency Medicine](https://www.contemporarypediatrics.com/clinical/emergency-medicine)

[Endocrinology](https://www.contemporarypediatrics.com/clinical/endocrinology)[Endocrinology](https://www.contemporarypediatrics.com/clinical/endocrinology)

[Gastroenterology](https://www.contemporarypediatrics.com/clinical/gastroenterology)[Gastroenterology](https://www.contemporarypediatrics.com/clinical/gastroenterology)[Gastroenterology](https://www.contemporarypediatrics.com/clinical/gastroenterology)[Gastroenterology](https://www.contemporarypediatrics.com/clinical/gastroenterology)

[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)[Infectious Diseases](https://www.contemporarypediatrics.com/clinical/infectious-disease)

[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)[Mental, Behavioral and Development Health](https://www.contemporarypediatrics.com/clinical/mental-health)

[Neurology](https://www.contemporarypediatrics.com/clinical/neurology)[Neurology](https://www.contemporarypediatrics.com/clinical/neurology)[Neurology](https://www.contemporarypediatrics.com/clinical/neurology)[Neurology](https://www.contemporarypediatrics.com/clinical/neurology)

[OB/GYN](https://www.contemporarypediatrics.com/clinical/obstetrics-gynecology-womens-health)[OB/GYN](https://www.contemporarypediatrics.com/clinical/obstetrics-gynecology-womens-health)

[Pain](https://www.contemporarypediatrics.com/clinical/pain)

[Pharmacology](https://www.contemporarypediatrics.com/clinical/pharmacology)[Pharmacology](https://www.contemporarypediatrics.com/clinical/pharmacology)

[Practice Improvement](https://www.contemporarypediatrics.com/clinical/practice-improvement)[Practice Improvement](https://www.contemporarypediatrics.com/clinical/practice-improvement)

[Respiratory](https://www.contemporarypediatrics.com/clinical/respiratory)[Respiratory](https://www.contemporarypediatrics.com/clinical/respiratory)[Respiratory](https://www.contemporarypediatrics.com/clinical/respiratory)

[Rheumatology](https://www.contemporarypediatrics.com/clinical/rheumatoid-arthritis)

![Image 23](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)

*   *   News
        
    *   [AAP News](https://www.contemporarypediatrics.com/guidelines)
    *   Media
        
    *   [Puzzler](https://www.contemporarypediatrics.com/case-studies)
    *   Publications
        
    *   [CME/CE](https://www.contemporarypediatrics.com/continuing-medical-education)
    *   Resources
        
    *   Conferences
        
    *   [Partnerships](https://www.contemporarypediatrics.com/sap-partner)
    *   [Subscribe](https://one.contemporarypediatrics.com/subscribe)
    *   Editorial
        

[](https://www.facebook.com/ContemporaryPediatrics/)[](https://twitter.com/ContempPEDS)[](https://www.linkedin.com/company/contemporary-pediatrics/about/)[](https://www.instagram.com/contemporarypediatrics/)[](https://www.contemporarypediatrics.com/rss)

Advertisement

* * *

[HIV Roundtable](https://www.contemporarypediatrics.com/video-series/hiv-roundtable) : Episode 2

HIV Roundtable: Examining Aging with HIV, Multidrug Resistance, and Vaccine Development
=======================================================================================

August 28, 2024

By [John Parkinson](https://www.contemporarypediatrics.com/authors/john-parkinson)  
[Joshua Fitch, Senior Editor](https://www.contemporarypediatrics.com/authors/joshua-fitch)

_News_

_Article_

In this episode, clinicians discuss challenges associated with these topics and offer some insights on them.

[![Image 25](blob:https://www.contemporarypediatrics.com/f034a615f6e5fa6e382cc07202d3c0b4)![Image 26](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3) EP: 1.HIV Roundtable: Managing medications after diagnosis ----------------------------------------------------------](https://www.contemporarypediatrics.com/view/hiv-roundtable-managing-medications-after-diagnosis)[Now Viewing ![Image 28](blob:https://www.contemporarypediatrics.com/f034a615f6e5fa6e382cc07202d3c0b4)![Image 29](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3) EP: 2.HIV Roundtable: Examining Aging with HIV, Multidrug Resistance, and Vaccine Development ---------------------------------------------------------------------------------------------](https://www.contemporarypediatrics.com/view/hiv-roundtable-examining-aging-with-hiv-multidrug-resistance-and-vaccine-development)

This is the second episode of our 3-part series on HIV care and management. This is a continuing collaboration working with our partners¬†_Contemporary Pediatrics_ and¬†_Contemporary OB/GYN_.

This series discusses several aspects of HIV care including clinical management, therapies, vaccines, and multidrug resistance.  
  
Our panel of clinicians includes:

*   MJ Kasten, MD, associate professor of Medicine, consultant, Division of Public Health, Infectious Diseases, and Occupational Medicine, Department of Internal Medicine, Mayo Clinic
*   Natasha Hoyte, MPH, CPNP-PC, New York-Presbyterian School Based Health Centers
*   Aimalohi Ahonkhai, MD, MPH, associate physician, medicine at the Massachusetts General Hospital, associate director of the Bio-behavioral and Community Science Core and director of the Community Engaged Research Program for the Harvard University Center for AIDS Research
*   Jessica Castilho, MD, associate professor of Medicine, Division of Infectious Diseases, associate professor Dept. of Health Policy, Vanderbilt University Medical Center

In this episode, the panel provides clinical feedback on HIV and aging, multidrug resistant HIV, and vaccines.

Castilho says for those patients who are older and who have managed HIV as a chronic condition for years can often be at a higher risk of aging comorbidities.

‚ÄúWe've already heard that HIV treatment has become a lot easier, but the health concerns of older adults living with HIV are increasingly complex, not necessarily because of management of their HIV, but because of the excess and often earlier onset of these comorbidities that many people with HIV experience,‚Äù Castilho said. ‚ÄúThey are at higher risk for conditions like high blood pressure or diabetes, heart disease, certain cancers and other conditions which really affect their daily quality of life and physical function. So, many times the health concerns that we're encountering and patients are managing on a daily basis are not HIV, but are these chronic comorbidities, and their subsequent conditions like polypharmacy or needing to navigate taking multiple medications.‚Äù

With regards to an HIV vaccine, the clinicians acknowledge the complexity of developing a vaccine for the virus, but acknowledge another virus that was helped in the process.

‚ÄúUsing COVID as an analogy is helpful because we all experienced viral evolution and understanding how certain parts of a virus can change over time that we needed different vaccines to manage the COVID pandemic and HIV‚Ä¶so it makes it inordinately challenging to find a vaccine,‚Äù Ahonkhai said.

‚ÄúThe virus itself is very smart and very tricky, and makes this challenging. A lot of mRNA research that led to the COVID vaccine being developed had come out of the HIV field. So, we have HIV to thank even though we don't have a vaccine for HIV just yet‚Ä¶but I think we're all hopeful that we can get there.‚Äù

**_Stay tuned for final episode which will appear next week._**

Recent Videos

[![Image 31: 3 KOLs are featured in this series.](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/treatment-options-for-central-precocious-puberty)[![Image 33: 3 KOLs are featured in this series.](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/early-diagnosis-and-treatment-for-central-precocious-puberty)[![Image 35: 3 KOLs are featured in this series.](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/diagnosis-of-central-precocious-puberty-and-its-psychosocial-impact)[![Image 37](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/hiv-roundtable-managing-medications-after-diagnosis)[![Image 39: 3 KOLs are featured in this series.](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/overview-of-central-precocious-puberty-cpp-)[![Image 41: cUTI Roundtable: Discussing and diagnosing these difficult infections](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/cuti-roundtable-discussing-and-diagnosing-these-difficult-infections)[![Image 43](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/parent-reported-asthma-symptom-prevalence-and-covid-vaccination-association)[![Image 45: Courtney Nelson, MD](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/emergency-department-serves-as-equitable-location-for-influenza-vaccine-delivery)[![Image 47: Natasha Hoyte, MPH, CPNP-PC](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/incorporating-prep-and-pep-into-school-based-health-centers)[![Image 49: Reducing HIV reservoirs in neonates with very early antiretroviral therapy | Deborah Persaud, MD](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/reducing-hiv-reservoirs-neonates-very-early-antiretroviral-therapy)

Related Content

Advertisement

* * *

[![Image 51: ACIP seasonal influenza vaccine recommendations | Image Credit: ¬© Leigh Prather - ¬© Leigh Prather - stock.adobe.com.](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/acip-seasonal-influenza-vaccine-recommendations?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[ACIP's seasonal influenza vaccine recommendations](https://www.contemporarypediatrics.com/view/acip-seasonal-influenza-vaccine-recommendations?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Joshua Fitch, Senior Editor](https://www.contemporarypediatrics.com/authors/joshua-fitch)

[August 27th 2024 Article IIV3s, RIV3, and LAIV3 influenza vaccines are expected to be available.](https://www.contemporarypediatrics.com/view/acip-seasonal-influenza-vaccine-recommendations?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

* * *

[![Image 53: What's going on with polio, monkeypox, and COVID-19](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/what-s-going-on-with-polio-monkeypox-and-covid-19?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[What's going on with polio, monkeypox, and COVID-19](https://www.contemporarypediatrics.com/view/what-s-going-on-with-polio-monkeypox-and-covid-19?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Miranda Hester](https://www.contemporarypediatrics.com/authors/miranda-hester)

[August 19th 2022 Podcast The news is full of stories about monkeypox, the recent changes to COVID-19 guidance, and the return of polio cases. What do clinicians need to know?](https://www.contemporarypediatrics.com/view/what-s-going-on-with-polio-monkeypox-and-covid-19?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

* * *

[![Image 55: CDC: Rising parvovirus B19 cases | Image Credit: ¬© illustrissima - ¬© illustrissima - stock.adobe.com.](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/cdc-rising-parvovirus-b19-cases?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[CDC: Rising parvovirus B19 cases](https://www.contemporarypediatrics.com/view/cdc-rising-parvovirus-b19-cases?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Sophia Abene](https://www.contemporarypediatrics.com/authors/sophia-abene);[Joshua Fitch, Senior Editor](https://www.contemporarypediatrics.com/authors/joshua-fitch)

[August 22nd 2024 Article Healthcare providers should maintain heightened suspicion of parvovirus B19 in individuals presenting with symptoms, particularly those at high risk.](https://www.contemporarypediatrics.com/view/cdc-rising-parvovirus-b19-cases?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

* * *

[![Image 57: Having ""the talk"" with teen patients](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/having-the-talk-with-teen-patients?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Having ""the talk"" with teen patients](https://www.contemporarypediatrics.com/view/having-the-talk-with-teen-patients?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Miranda Hester](https://www.contemporarypediatrics.com/authors/miranda-hester-0)

[June 17th 2022 Podcast A visit with a pediatric clinician is an ideal time to ensure that a teenager knows the correct information, has the opportunity to make certain contraceptive choices, and instill the knowledge that the pediatric office is a safe place to come for help.](https://www.contemporarypediatrics.com/view/having-the-talk-with-teen-patients?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

* * *

[![Image 59: A preview of the August issue of Contemporary Pediatrics](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/a-preview-of-the-august-issue-of-contemporary-pediatrics?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[A preview of the August issue of Contemporary Pediatrics](https://www.contemporarypediatrics.com/view/a-preview-of-the-august-issue-of-contemporary-pediatrics?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Tina Q Tan, MD, FAAP, FIDSA, FPIDS](https://www.contemporarypediatrics.com/authors/tina-q-tan-md-faap-fidsa-fpids)

[August 2nd 2024 Article Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the August 2024 issue of Contemporary Pediatrics.](https://www.contemporarypediatrics.com/view/a-preview-of-the-august-issue-of-contemporary-pediatrics?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

* * *

[![Image 61: Merck's investigational RSV monoclonal antibody clesrovimab demonstrates positive results | Image Credit: ¬© Guru - ¬© Guru - stock.adobe.com.](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/merck-s-investigational-rsv-monoclonal-antibody-clesrovimab-demonstrates-positive-results?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Merck's investigational RSV monoclonal antibody clesrovimab demonstrates positive results](https://www.contemporarypediatrics.com/view/merck-s-investigational-rsv-monoclonal-antibody-clesrovimab-demonstrates-positive-results?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Joshua Fitch, Senior Editor](https://www.contemporarypediatrics.com/authors/joshua-fitch)

[July 24th 2024 Article Merck announced clesrovimab met all primary safety and efficacy endpoints, with additional detailed findings to be presented at an upcoming scientific congress.](https://www.contemporarypediatrics.com/view/merck-s-investigational-rsv-monoclonal-antibody-clesrovimab-demonstrates-positive-results?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

Related Content

Advertisement

* * *

[![Image 63: ACIP seasonal influenza vaccine recommendations | Image Credit: ¬© Leigh Prather - ¬© Leigh Prather - stock.adobe.com.](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/acip-seasonal-influenza-vaccine-recommendations?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[ACIP's seasonal influenza vaccine recommendations](https://www.contemporarypediatrics.com/view/acip-seasonal-influenza-vaccine-recommendations?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Joshua Fitch, Senior Editor](https://www.contemporarypediatrics.com/authors/joshua-fitch)

[August 27th 2024 Article IIV3s, RIV3, and LAIV3 influenza vaccines are expected to be available.](https://www.contemporarypediatrics.com/view/acip-seasonal-influenza-vaccine-recommendations?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

* * *

[![Image 65: What's going on with polio, monkeypox, and COVID-19](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/what-s-going-on-with-polio-monkeypox-and-covid-19?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[What's going on with polio, monkeypox, and COVID-19](https://www.contemporarypediatrics.com/view/what-s-going-on-with-polio-monkeypox-and-covid-19?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Miranda Hester](https://www.contemporarypediatrics.com/authors/miranda-hester)

[August 19th 2022 Podcast The news is full of stories about monkeypox, the recent changes to COVID-19 guidance, and the return of polio cases. What do clinicians need to know?](https://www.contemporarypediatrics.com/view/what-s-going-on-with-polio-monkeypox-and-covid-19?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

* * *

[![Image 67: CDC: Rising parvovirus B19 cases | Image Credit: ¬© illustrissima - ¬© illustrissima - stock.adobe.com.](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/cdc-rising-parvovirus-b19-cases?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[CDC: Rising parvovirus B19 cases](https://www.contemporarypediatrics.com/view/cdc-rising-parvovirus-b19-cases?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Sophia Abene](https://www.contemporarypediatrics.com/authors/sophia-abene);[Joshua Fitch, Senior Editor](https://www.contemporarypediatrics.com/authors/joshua-fitch)

[August 22nd 2024 Article Healthcare providers should maintain heightened suspicion of parvovirus B19 in individuals presenting with symptoms, particularly those at high risk.](https://www.contemporarypediatrics.com/view/cdc-rising-parvovirus-b19-cases?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

* * *

[![Image 69: Having ""the talk"" with teen patients](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/having-the-talk-with-teen-patients?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Having ""the talk"" with teen patients](https://www.contemporarypediatrics.com/view/having-the-talk-with-teen-patients?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Miranda Hester](https://www.contemporarypediatrics.com/authors/miranda-hester-0)

[June 17th 2022 Podcast A visit with a pediatric clinician is an ideal time to ensure that a teenager knows the correct information, has the opportunity to make certain contraceptive choices, and instill the knowledge that the pediatric office is a safe place to come for help.](https://www.contemporarypediatrics.com/view/having-the-talk-with-teen-patients?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

* * *

[![Image 71: A preview of the August issue of Contemporary Pediatrics](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/a-preview-of-the-august-issue-of-contemporary-pediatrics?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[A preview of the August issue of Contemporary Pediatrics](https://www.contemporarypediatrics.com/view/a-preview-of-the-august-issue-of-contemporary-pediatrics?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Tina Q Tan, MD, FAAP, FIDSA, FPIDS](https://www.contemporarypediatrics.com/authors/tina-q-tan-md-faap-fidsa-fpids)

[August 2nd 2024 Article Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the August 2024 issue of Contemporary Pediatrics.](https://www.contemporarypediatrics.com/view/a-preview-of-the-august-issue-of-contemporary-pediatrics?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

* * *

[![Image 73: Merck's investigational RSV monoclonal antibody clesrovimab demonstrates positive results | Image Credit: ¬© Guru - ¬© Guru - stock.adobe.com.](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/view/merck-s-investigational-rsv-monoclonal-antibody-clesrovimab-demonstrates-positive-results?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Merck's investigational RSV monoclonal antibody clesrovimab demonstrates positive results](https://www.contemporarypediatrics.com/view/merck-s-investigational-rsv-monoclonal-antibody-clesrovimab-demonstrates-positive-results?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[Joshua Fitch, Senior Editor](https://www.contemporarypediatrics.com/authors/joshua-fitch)

[July 24th 2024 Article Merck announced clesrovimab met all primary safety and efficacy endpoints, with additional detailed findings to be presented at an upcoming scientific congress.](https://www.contemporarypediatrics.com/view/merck-s-investigational-rsv-monoclonal-antibody-clesrovimab-demonstrates-positive-results?utm_source=www.contemporarypediatrics.com&utm_medium=relatedContent)

[About Us](https://www.contemporarypediatrics.com/editorial-info)

[Advertise](https://www.contemporarypediatrics.com/advertise)

[Contact Us](https://www.mjhlifesciences.com/contact)

[Job Board](http://jobs.modernmedicine.com/index.php)

[Terms and Conditions](https://www.contemporarypediatrics.com/terms)

[Privacy](https://www.contemporarypediatrics.com/privacy)

[Do Not Sell My Personal Information](https://www.mjhlifesciences.com/ccpa?domain=www.contemporarypediatrics.com)

Contact Info

2 Commerce Drive  
Cranbury, NJ 08512

[609-716-7777](tel:609-716-7777)

![Image 75](blob:https://www.contemporarypediatrics.com/0b56f675ecfd870f746e03cb2a00669b)![Image 76](blob:https://www.contemporarypediatrics.com/b9a31d3949b1882a09ed2f8508d538f3)

[](https://www.facebook.com/ContemporaryPediatrics/)[](https://twitter.com/ContempPEDS)[](https://www.linkedin.com/company/contemporary-pediatrics/about/)[](https://www.instagram.com/contemporarypediatrics/)[](https://www.contemporarypediatrics.com/rss)

¬© 2024 MJH Life Sciences  
  
All rights reserved.
",gpt-4o-mini
2024-09-02 08:25:00,2024-09-02 10:12:09,"üö® **New Insights on COPD Mortality Prediction!** üè•  
Researchers have developed a cutting-edge mortality risk prediction model specifically for Chronic Obstructive Pulmonary Disease (COPD) patients, utilizing probabilistic graphical modeling techniques. This advanced approach enhances traditional models by providing better causal insights into patient mortality factors.  
  
Key findings reveal that the new model outperforms standard indices like ADO and BODE in predicting both all-cause and COPD-specific mortality.

üìä The VAPORED risk score‚Äîcrafted from essential clinical data‚Äîaims to fine-tune patient management strategies and potentially guide interventions based on individual risk profiles.  

Stay informed and leverage this innovative research to improve care for your COPD patients. For an in-depth read, check out the study published in *EClinicalMedicine*: [Read Here](https://www.news-medical.net/news/20240828/New-study-develops-enhanced-mortality-prediction-model-for-COPD-patients.aspx).  

üí¨ What tools do you currently use to assess mortality risks in your patients? Share in the comments!  

#COPD #PatientCare #MortalityRisk #MedicalResearch #HealthcareInnovation  

![COPD Prediction Model](https://medsii.azureedge.net/images/638608622998277921-66d575dd6157181811bbc99d.jpg)",https://medsii.azureedge.net/images/638608622998277921-66d575dd6157181811bbc99d.jpg,https://www.news-medical.net/news/20240828/New-study-develops-enhanced-mortality-prediction-model-for-COPD-patients.aspx,"You are a content creator tasked with crafting highly informative, easy to digest social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Thumbnail image URL: https://medsii.azureedge.net/images/638608622998277921-66d575dd6157181811bbc99d.jpg  
Title: New study develops enhanced mortality prediction model for COPD patients

URL Source: https://www.news-medical.net/news/20240828/New-study-develops-enhanced-mortality-prediction-model-for-COPD-patients.aspx

Published Time: 2024-08-28T06:16:00-04:00

Markdown Content:
New study develops enhanced mortality prediction model for COPD patients
=============== 

     

 

[Skip to content](https://www.news-medical.net/news/20240828/New-study-develops-enhanced-mortality-prediction-model-for-COPD-patients.aspx#main)

  [![Image 1: News-Medical](https://d2jx2rerrg6sh3.cloudfront.net/themes/Standard/images/nm-logo-4.png)](https://www.news-medical.net/)

Menu

[Medical Home](https://www.news-medical.net/medical) [Life Sciences Home](https://www.news-medical.net/life-sciences)

[![Image 2: An AZoNetwork Site](https://d2jx2rerrg6sh3.cloudfront.net/images/an-azonetwork-site.svg)](https://www.news-medical.net/suppliers/AZoNetwork-UK-Ltd.aspx)

[Become a Member](https://www.news-medical.net/azoprofile/login/)

Search

*   [Medical Home](https://www.news-medical.net/medical)
*   [Life Sciences Home](https://www.news-medical.net/life-sciences)
*   [About](https://www.news-medical.net/medical/about)
*   [COVID-19](https://www.news-medical.net/condition/Coronavirus-Disease-COVID-19)
*   [News](https://www.news-medical.net/medical/news)
*   [Health A-Z](https://www.news-medical.net/medical-a-z.aspx)
*   [Drugs](https://www.news-medical.net/drugs-a-z.aspx)
*   [Medical Devices](https://www.news-medical.net/Clinical-and-Diagnostics)
*   [Interviews](https://www.news-medical.net/medical/interviews)
*   [White Papers](https://www.news-medical.net/medical/whitepapers)
*   More...
*   [MediKnowledge](https://www.news-medical.net/mediknowledge)
*   [Newsletters](https://www.news-medical.net/medical/newsletters)
*   [Health & Personal Care](https://www.news-medical.net/Consumer-Products)
*   [eBooks](https://www.news-medical.net/medical/ebooks)
*   [Contact](https://www.news-medical.net/medical/contact)
*   [Meet the Team](https://www.news-medical.net/medical/team)
*   [Advertise](https://www.news-medical.net/medical/advertise)
*   [Search](https://www.news-medical.net/medical/search)
*   [Become a Member](https://www.news-medical.net/azoprofile/login/)

Top Health Categories
---------------------

*   [Coronavirus Disease COVID-19](https://www.news-medical.net/condition/Coronavirus-Disease-COVID-19)
*   [Diet & Nutrition](https://www.news-medical.net/condition/Diet-Nutrition)
*   [Artificial Intelligence](https://www.news-medical.net/condition/Artificial-Intelligence)
*   [Allergies](https://www.news-medical.net/condition/Allergies)
*   [Alzheimer's & Dementia](https://www.news-medical.net/condition/Alzheimers-Dementia)
*   [Arthritis & Rheumatology](https://www.news-medical.net/condition/Arthritis-Rheumatology)
*   [Breast Cancer](https://www.news-medical.net/condition/Breast-Cancer)

*   [Cold, Flu & Cough](https://www.news-medical.net/condition/Cold-Flu-Cough)
*   [Eating Disorders](https://www.news-medical.net/condition/Eating-Disorders)
*   [Eye Health](https://www.news-medical.net/condition/Eye-Health)
*   [Gastrointestinal Health](https://www.news-medical.net/condition/Gastrointestinal-Health)
*   [Heart Disease](https://www.news-medical.net/condition/Heart-Disease)
*   [High Blood Pressure](https://www.news-medical.net/condition/High-Blood-Pressure)
*   [Lung Cancer](https://www.news-medical.net/condition/Lung-Cancer)

*   [Mental Health](https://www.news-medical.net/condition/Mental-Health)
*   [Mpox](https://www.news-medical.net/condition/Mpox)
*   [Pregnancy](https://www.news-medical.net/condition/Pregnancy)
*   [Type 1 Diabetes](https://www.news-medical.net/condition/Type-1-Diabetes)
*   [Type 2 Diabetes](https://www.news-medical.net/condition/Type-2-Diabetes)
*   [Sexual Health](https://www.news-medical.net/condition/Sexual-Health)
*   [Sleep](https://www.news-medical.net/condition/Sleep)
*   [View Health A-Z](https://www.news-medical.net/medical-a-z.aspx)

√óTop Health Categories
----------------------

*   [Coronavirus Disease COVID-19](https://www.news-medical.net/condition/Coronavirus-Disease-COVID-19)
*   [Heart Disease](https://www.news-medical.net/condition/Heart-Disease)
*   [Diet & Nutrition](https://www.news-medical.net/condition/Diet-Nutrition)
*   [High Blood Pressure](https://www.news-medical.net/condition/High-Blood-Pressure)
*   [Artificial Intelligence](https://www.news-medical.net/condition/Artificial-Intelligence)
*   [Lung Cancer](https://www.news-medical.net/condition/Lung-Cancer)
*   [Allergies](https://www.news-medical.net/condition/Allergies)
*   [Mental Health](https://www.news-medical.net/condition/Mental-Health)
*   [Alzheimer's & Dementia](https://www.news-medical.net/condition/Alzheimers-Dementia)
*   [Mpox](https://www.news-medical.net/condition/Mpox)
*   [Arthritis & Rheumatology](https://www.news-medical.net/condition/Arthritis-Rheumatology)
*   [Pregnancy](https://www.news-medical.net/condition/Pregnancy)
*   [Breast Cancer](https://www.news-medical.net/condition/Breast-Cancer)
*   [Type 1 Diabetes](https://www.news-medical.net/condition/Type-1-Diabetes)
*   [Cold, Flu & Cough](https://www.news-medical.net/condition/Cold-Flu-Cough)
*   [Type 2 Diabetes](https://www.news-medical.net/condition/Type-2-Diabetes)
*   [Eating Disorders](https://www.news-medical.net/condition/Eating-Disorders)
*   [Sexual Health](https://www.news-medical.net/condition/Sexual-Health)
*   [Eye Health](https://www.news-medical.net/condition/Eye-Health)
*   [Sleep](https://www.news-medical.net/condition/Sleep)
*   [Gastrointestinal Health](https://www.news-medical.net/condition/Gastrointestinal-Health)

[View Health A-Z](https://www.news-medical.net/medical-a-z.aspx)

*   [Medical Home](https://www.news-medical.net/medical)
*   [Life Sciences Home](https://www.news-medical.net/life-sciences)
*   [About](https://www.news-medical.net/life-sciences/about)
*   [News](https://www.news-medical.net/life-sciences/news)
*   [Life Sciences A-Z](https://www.news-medical.net/life-sciences-a-z)
*   [White Papers](https://www.news-medical.net/life-sciences/whitepapers)
*   [Lab Equipment](https://www.news-medical.net/Life-Science-and-Laboratory)
*   [Interviews](https://www.news-medical.net/life-sciences/interviews)
*   [Newsletters](https://www.news-medical.net/life-sciences/newsletters)
*   [Webinars](https://www.news-medical.net/life-sciences/webinars)
*   More...
*   [eBooks](https://www.news-medical.net/life-sciences/ebooks)
*   [Contact](https://www.news-medical.net/life-sciences/contact)
*   [Meet the Team](https://www.news-medical.net/life-sciences/team)
*   [Advertise](https://www.news-medical.net/life-sciences/advertise)
*   [Search](https://www.news-medical.net/medical/search)
*   [Become a Member](https://www.news-medical.net/azoprofile/login/)

*   [White Papers](https://www.news-medical.net/medical/whitepapers)
*   [MediKnowledge](https://www.news-medical.net/mediknowledge)
*   [Newsletters](https://www.news-medical.net/medical/newsletters)
*   [Health & Personal Care](https://www.news-medical.net/Consumer-Products)
*   [eBooks](https://www.news-medical.net/medical/ebooks)
*   [Contact](https://www.news-medical.net/medical/contact)
*   [Meet the Team](https://www.news-medical.net/medical/team)
*   [Advertise](https://www.news-medical.net/medical/advertise)
*   [Search](https://www.news-medical.net/medical/search)
*   [Become a Member](https://www.news-medical.net/azoprofile/login/)

*   [Webinars](https://www.news-medical.net/life-sciences/webinars)
*   [eBooks](https://www.news-medical.net/life-sciences/ebooks)
*   [Contact](https://www.news-medical.net/life-sciences/contact)
*   [Meet the Team](https://www.news-medical.net/life-sciences/team)
*   [Advertise](https://www.news-medical.net/life-sciences/advertise)
*   [Search](https://www.news-medical.net/medical/search)
*   [Become a Member](https://www.news-medical.net/azoprofile/login/)

*   [](https://www.news-medical.net/news/20240828/New-study-develops-enhanced-mortality-prediction-model-for-COPD-patients.aspx# ""Download PDF copy"")
*   
*   [](https://www.linkedin.com/shareArticle?mini=true&url=https%3a%2f%2fwww.news-medical.net%2fnews%2f20240828%2fNew-study-develops-enhanced-mortality-prediction-model-for-COPD-patients.aspx&title= ""LinkedIn"")
*   [](https://www.facebook.com/sharer/sharer.php?u=https%3a%2f%2fwww.news-medical.net%2fnews%2f20240828%2fNew-study-develops-enhanced-mortality-prediction-model-for-COPD-patients.aspx ""Facebook"")
*   [](https://x.com/share?url=https%3a%2f%2fwww.news-medical.net%2fnews%2f20240828%2fNew-study-develops-enhanced-mortality-prediction-model-for-COPD-patients.aspx&text= ""X"")
*   [](https://www.reddit.com/submit?url=https%3a%2f%2fwww.news-medical.net%2fnews%2f20240828%2fNew-study-develops-enhanced-mortality-prediction-model-for-COPD-patients.aspx ""Reddit"")
*   [](http://pinterest.com/pin/create/button/?url=https%3a%2f%2fwww.news-medical.net%2fnews%2f20240828%2fNew-study-develops-enhanced-mortality-prediction-model-for-COPD-patients.aspx ""Pinterest"")
*   [](https://www.news-medical.net/news/20240828/New-study-develops-enhanced-mortality-prediction-model-for-COPD-patients.aspx# ""Email"")

New study develops enhanced mortality prediction model for COPD patients
========================================================================

*   [Download PDF Copy](https://www.news-medical.net/news/20240828/New-study-develops-enhanced-mortality-prediction-model-for-COPD-patients.aspx#)

![Image 3: Vijay Kumar Malesu](https://www.azonetwork.com/themes/clients/images/team/Photo_Vijay-2.jpg)By [Vijay Kumar Malesu](https://www.news-medical.net/medical/authors/vijay-kumar-malesu)Reviewed by [Lily Ramsey, LLM](https://www.news-medical.net/medical/authors/lily-ramsey)Aug 28 2024[![Image 4: NewsGuard 100/100 Score](https://d2jx2rerrg6sh3.cloudfront.net/images/newsguard-100.svg)](https://www.news-medical.net/medical/newsguard)

In a recent study published in the [_EClinicalMedicine_](https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370/(24/)00365-1/fulltext), a group of researchers developed and validated a Chronic Obstructive Pulmonary Disease (COPD) (a progressive lung condition that causes breathing difficulties)-specific mortality risk prediction model using probabilistic graphical modeling to enhance disease management strategies.

[![Image 5: Study: Development and validation of a mortality risk prediction model for chronic obstructive pulmonary disease: a cross-sectional study using probabilistic graphical modelling. Image Credit: Jo Panuwat D/Shutterstock.com](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_788862_17248400798397488.jpg)](https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370/(24/)00365-1/fulltext)_Study:¬†[Development and validation of a mortality risk prediction model for chronic obstructive pulmonary disease: a cross-sectional study using probabilistic graphical modelling](https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370/(24/)00365-1/fulltext). Image Credit:¬†Jo Panuwat D/Shutterstock.com_

Background
----------

COPD is a major global cause of mortality. Predictive models like Body mass index, Obstruction, Dyspnea, Exercise capacity (BODE), Age, Dyspnea, Obstruction (ADO), and Dyspnea, Obstruction, Smoking status, Exacerbation frequency (DOSE) help identify high-risk COPD patients, but these primarily focus on all-cause mortality.

Traditional models, such as regression and random survival forests, are limited to associative predictions lacking causal insight. In contrast, probabilistic graphs, or causal graphs, can identify potential cause-effect relationships from observational data by factoring out confounders.

Further research is needed to refine and validate COPD-specific mortality predictors across diverse populations and to explore underlying biological mechanisms for targeted interventions.

About the study¬†
----------------

The present study followed Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines, with all participants providing informed consent.

The discovery cohorts were drawn from the COPD Genetic Epidemiology (COPDGene) Study, which included 10,198 current and former smokers aged 45 to 80 years with over ten pack-years of smoking history.

Data collected included demographic, spirometry, clinical, and chest Computed Tomography (CT) scan features, along with all-cause and COPD-specific mortality, defined by criteria excluding deaths from comorbidities like cardiovascular disease (CVD) or cancer. The final analysis focused on 8,610 participants with complete baseline and follow-up data.

For external validation, the Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) study, which recruited 2,501 participants from the United States (US) and Europe, was used, selecting 2,312 individuals with complete three-year mortality data.

### Related Stories

*   [Vitamin D deficiency linked to higher cancer mortality](https://www.news-medical.net/news/20240820/Vitamin-D-deficiency-linked-to-higher-cancer-mortality.aspx)
*   [How lifestyle and air pollution patterns affect mortality](https://www.news-medical.net/news/20240630/How-lifestyle-and-air-pollution-patterns-affect-mortality.aspx)
*   [England sees shifting mortality trends with obesity: Cardiovascular deaths decline, neurological and respiratory deaths rise](https://www.news-medical.net/news/20240707/England-sees-shifting-mortality-trends-with-obesity-Cardiovascular-deaths-decline-neurological-and-respiratory-deaths-rise.aspx)

Directed probabilistic graph models were constructed using the CausalCoxMGM method to identify direct predictors of mortality while accounting for confounders.

These models were compared to ADO, Updated BODE indices, and standard machine learning approaches, with performance evaluated via cross-validation using Harrell's concordance index.

The Vital capacity-forced vital capacity (FVC) %predicted, Age, history of Pneumonia, [Oxygen saturation](https://www.news-medical.net/health/What-is-Oxygen-Saturation.aspx), forced expiratory volume in 1s (FEV1)/FVC Ratio, 6-min walk Exercise capacity, Dyspnoea (VAPORED) risk score was developed using seven features linked to COPD-specific mortality, and its accuracy was validated in the ECLIPSE cohort for predicting survival over one, two, and three years.

Study results¬†
--------------

In the Phase 2 study, which included a subset of Phase 1 participants, notable changes were observed in clinical covariates. These changes included an expected five-year increase in age and a significant reduction in patients in the more severe Global Initiative for Chronic Obstructive Lung Disease (GOLD) categories.

Additionally, there was a significant increase in the incidence of comorbidities, such as CVD and diabetes. The BODE index showed a significant decrease, while the ADO index increased in Phase 2 participants compared to Phase 1. Despite these changes, the survival functions between the two phases were not statistically different, indicating consistent all-cause mortality across both phases.

The ECLIPSE study, used for external validation, differed significantly from COPDGene, with a higher proportion of male participants and less racial diversity. The ECLIPSE cohort also included more severe COPD cases, as reflected in higher ADO, BODE, and updated BODE indices and a higher rate of all-cause mortality. This difference was significant, especially in the number of deaths observed within the first three years.

The study's analysis identified features directly linked to COPD-specific mortality. While there was significant overlap in the variables affecting all-cause and COPD-specific mortality, some differences emerged.

For example, FVC %predicted was strongly associated with COPD-specific mortality, while FEV1 %predicted was more relevant to all-cause mortality. Comorbidities like CVD and diabetes were linked only to all-cause mortality.

Graph-based predictive models, developed from these insights, outperformed traditional indices like ADO and updated BODE in predicting both all-cause and COPD-specific mortality. The models demonstrated the ability to stratify patients into distinct risk groups more effectively than the BODE index.

For external validation, the VAPORED risk score, developed using seven clinical variables, was tested on the ECLIPSE cohort. The VAPORED model significantly outperformed ADO and BODE, and updated BODE indices across several predictive metrics, particularly in the concordance probability estimate.

The model's predictions were well-calibrated for one-, two-, and three-year survival probabilities in the ECLIPSE study.

Additionally, a web-based tool was developed to allow users to calculate and compare mortality risk using the VAPORED score, BODE, and ADO indices. This tool is accessible as a Shiny app, enabling clinicians and researchers to evaluate and visualize mortality risks based on key clinical variables.

Conclusions¬†
------------

To summarize, this study used probabilistic graph modeling to identify features directly linked to COPD-specific and all-cause mortality, distinguishing them from simple correlates. The researchers developed the VAPORED risk score using clinical data, which outperformed traditional indices like ADO and BODE in predicting mortality.

Additionally, the study identified unique factors such as Internet access and specific biological markers associated with increased all-cause mortality risk. This approach demonstrated superior predictive power, suggesting new avenues for targeted interventions and the potential for developing more comprehensive mortality risk scores for COPD patients.

Journal reference:

*   Tyler C. Lovelace, Min Hyung Ryu, Minxue Jia, et al. (2024) Development and validation of a mortality risk prediction model for chronic obstructive pulmonary disease: a cross-sectional study using probabilistic graphical modelling, _EClinicalMedicine_. **doi:**[https://doi.org/10.1016/j.eclinm.2024.102786](https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370/(24/)00365-1/fulltext). [https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00365-1/fulltext](https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370/(24/)00365-1/fulltext)
    

Posted in: [Device / Technology News](https://www.news-medical.net/category/Device-Technology-News.aspx) | [Medical Science News](https://www.news-medical.net/category/Medical-Science-News.aspx) | [Medical Research News](https://www.news-medical.net/category/Medical-Research-News.aspx) | [Medical Condition News](https://www.news-medical.net/category/Medical-Condition-News.aspx)

Tags: [Body Mass Index](https://www.news-medical.net/?tag=/Body-Mass-Index), [Breathing](https://www.news-medical.net/?tag=/Breathing), [Cancer](https://www.news-medical.net/condition/Cancer), [Cardiovascular Disease](https://www.news-medical.net/condition/Cardiovascular-Disease), [Chronic](https://www.news-medical.net/?tag=/Chronic), [Chronic Obstructive Lung Disease](https://www.news-medical.net/?tag=/Chronic-Obstructive-Lung-Disease), [Chronic Obstructive Pulmonary Disease](https://www.news-medical.net/condition/Chronic-Obstructive-Pulmonary-Disease), [Computed Tomography](https://www.news-medical.net/?tag=/Computed-Tomography), [CT](https://www.news-medical.net/?tag=/CT), [Diabetes](https://www.news-medical.net/condition/Diabetes), [Dyspnea](https://www.news-medical.net/?tag=/Dyspnea), [Epidemiology](https://www.news-medical.net/?tag=/Epidemiology), [Exercise](https://www.news-medical.net/condition/Exercise), [Frequency](https://www.news-medical.net/?tag=/Frequency), [Genetic](https://www.news-medical.net/?tag=/Genetic), [Lung Disease](https://www.news-medical.net/?tag=/Lung-Disease), [Machine Learning](https://www.news-medical.net/?tag=/Machine-Learning), [Mortality](https://www.news-medical.net/?tag=/Mortality), [Oxygen](https://www.news-medical.net/?tag=/Oxygen), [Pneumonia](https://www.news-medical.net/condition/Pneumonia), [Research](https://www.news-medical.net/?tag=/Research), [Smoking](https://www.news-medical.net/?tag=/Smoking), [Spirometry](https://www.news-medical.net/?tag=/Spirometry), [Tomography](https://www.news-medical.net/?tag=/Tomography)

  

 

[Comments (0)](https://www.news-medical.net/news/20240828/New-study-develops-enhanced-mortality-prediction-model-for-COPD-patients.aspx#commentblock)

![Image 6: Vijay Kumar Malesu](https://www.azonetwork.com/themes/clients/images/team/Photo_Vijay-2.jpg)

Written by

### [Vijay Kumar Malesu](https://www.news-medical.net/medical/authors/vijay-kumar-malesu)

Vijay holds a Ph.D. in Biotechnology and possesses a deep passion for microbiology. His academic journey has allowed him to delve deeper into understanding the intricate world of microorganisms. Through his research and studies, he has gained expertise in various aspects of microbiology, which includes microbial genetics, microbial physiology, and microbial ecology. Vijay has six years of scientific research experience at renowned research institutes such as the Indian Council for Agricultural Research and KIIT University. He has worked on diverse projects in microbiology, biopolymers, and drug delivery. His contributions to these areas have provided him with a comprehensive understanding of the subject matter and the ability to tackle complex research challenges.

*   [Download PDF Copy](https://www.news-medical.net/news/20240828/New-study-develops-enhanced-mortality-prediction-model-for-COPD-patients.aspx#)

[Citations](https://www.news-medical.net/news/20240828/New-study-develops-enhanced-mortality-prediction-model-for-COPD-patients.aspx#)
--------------------------------------------------------------------------------------------------------------------------------------

Please use one of the following formats to cite this article in your essay, paper or report:

*   APA
    
    Kumar Malesu, Vijay. (2024, August 28). New study develops enhanced mortality prediction model for COPD patients. News-Medical. Retrieved on September 02, 2024 from https://www.news-medical.net/news/20240828/New-study-develops-enhanced-mortality-prediction-model-for-COPD-patients.aspx.
    
*   MLA
    
    Kumar Malesu, Vijay. ""New study develops enhanced mortality prediction model for COPD patients"". _News-Medical_. 02 September 2024. <https://www.news-medical.net/news/20240828/New-study-develops-enhanced-mortality-prediction-model-for-COPD-patients.aspx>.
    
*   Chicago
    
    Kumar Malesu, Vijay. ""New study develops enhanced mortality prediction model for COPD patients"". News-Medical. https://www.news-medical.net/news/20240828/New-study-develops-enhanced-mortality-prediction-model-for-COPD-patients.aspx. (accessed September 02, 2024).
    
*   Harvard
    
    Kumar Malesu, Vijay. 2024. _New study develops enhanced mortality prediction model for COPD patients_. News-Medical, viewed 02 September 2024, https://www.news-medical.net/news/20240828/New-study-develops-enhanced-mortality-prediction-model-for-COPD-patients.aspx.
    

Suggested Reading
-----------------

[![Image 7: Greater plant fat intake associated with lower overall and cardiovascular disease mortality](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_787663_455175242581365752723-125x110.jpg)](https://www.news-medical.net/news/20240813/Greater-plant-fat-intake-associated-with-lower-overall-and-cardiovascular-disease-mortality.aspx)

[Greater plant fat intake associated with lower overall and cardiovascular disease mortality](https://www.news-medical.net/news/20240813/Greater-plant-fat-intake-associated-with-lower-overall-and-cardiovascular-disease-mortality.aspx)

[![Image 8: COVID-19 drops to 10th leading cause of death as U.S. mortality rates fall in 2023](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_787522_45515977947581025559-125x110.png)](https://www.news-medical.net/news/20240811/COVID-19-drops-to-10th-leading-cause-of-death-as-US-mortality-rates-fall-in-2023.aspx)

[COVID-19 drops to 10th leading cause of death as U.S. mortality rates fall in 2023](https://www.news-medical.net/news/20240811/COVID-19-drops-to-10th-leading-cause-of-death-as-US-mortality-rates-fall-in-2023.aspx)

[![Image 9: Study finds no direct link between pandemic social distancing and neonatal mortality](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_785906_45496029129907412944-125x110.jpg)](https://www.news-medical.net/news/20240723/Study-finds-no-direct-link-between-pandemic-social-distancing-and-neonatal-mortality.aspx)

[Study finds no direct link between pandemic social distancing and neonatal mortality](https://www.news-medical.net/news/20240723/Study-finds-no-direct-link-between-pandemic-social-distancing-and-neonatal-mortality.aspx)

[![Image 10: Higher intake of ultra-processed foods found to increase cancer mortality risk](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_783746_45469194230034725728-125x110.jpg)](https://www.news-medical.net/news/20240626/Higher-intake-of-ultra-processed-foods-found-to-increase-cancer-mortality-risk.aspx)

[Higher intake of ultra-processed foods found to increase cancer mortality risk](https://www.news-medical.net/news/20240626/Higher-intake-of-ultra-processed-foods-found-to-increase-cancer-mortality-risk.aspx)

[![Image 11: Study links antidepressant use and epigenetic aging to higher mortality risk in postmenopausal women](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_782666_454561726223842568744-125x110.jpg)](https://www.news-medical.net/news/20240613/Study-links-antidepressant-use-and-epigenetic-aging-to-higher-mortality-risk-in-postmenopausal-women.aspx)

[Study links antidepressant use and epigenetic aging to higher mortality risk in postmenopausal women](https://www.news-medical.net/news/20240613/Study-links-antidepressant-use-and-epigenetic-aging-to-higher-mortality-risk-in-postmenopausal-women.aspx)

[![Image 12: Physical activity significantly reduces all-cause and cardiovascular mortality risks in older adults](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_783713_454688664521527751634-125x110.jpg)](https://www.news-medical.net/news/20240625/Physical-activity-significantly-reduces-all-cause-and-cardiovascular-mortality-risks-in-older-adults.aspx)

[Physical activity significantly reduces all-cause and cardiovascular mortality risks in older adults](https://www.news-medical.net/news/20240625/Physical-activity-significantly-reduces-all-cause-and-cardiovascular-mortality-risks-in-older-adults.aspx)

[![Image 13: Social isolation change associated with increased risk of mortality, disability, and dementia](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_786387_45502260497557873725-125x110.jpg)](https://www.news-medical.net/news/20240729/Social-isolation-change-associated-with-increased-risk-of-mortality-disability-and-dementia.aspx)

[Social isolation change associated with increased risk of mortality, disability, and dementia](https://www.news-medical.net/news/20240729/Social-isolation-change-associated-with-increased-risk-of-mortality-disability-and-dementia.aspx)

[![Image 14: Living well is the best medicine: Study links healthy habits to lower mortality in hypertensive individuals](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_784257_454750390506253015-125x110.jpg)](https://www.news-medical.net/news/20240702/Living-well-is-the-best-medicine-Study-links-healthy-habits-to-lower-mortality-in-hypertensive-individuals.aspx)

[Living well is the best medicine: Study links healthy habits to lower mortality in hypertensive individuals](https://www.news-medical.net/news/20240702/Living-well-is-the-best-medicine-Study-links-healthy-habits-to-lower-mortality-in-hypertensive-individuals.aspx)

Comments
--------

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

[Cancel reply to comment](javascript:void\(0\);)

![Image 15](https://www.news-medical.net/pics/anonymous_avatar.gif)

Post a new comment

[Login](https://www.news-medical.net/news/20240828/New-study-develops-enhanced-mortality-prediction-model-for-COPD-patients.aspx#) ¬† ¬†

[(Logout)](https://www.news-medical.net/news/20240828/New-study-develops-enhanced-mortality-prediction-model-for-COPD-patients.aspx#)

Quirky Comment Title 

[Post](https://www.news-medical.net/news/20240828/New-study-develops-enhanced-mortality-prediction-model-for-COPD-patients.aspx#)

*   [Trending Stories](https://www.news-medical.net/news/20240828/New-study-develops-enhanced-mortality-prediction-model-for-COPD-patients.aspx#tabs-1)
*   [Latest Interviews](https://www.news-medical.net/news/20240828/New-study-develops-enhanced-mortality-prediction-model-for-COPD-patients.aspx#tabs-2)
*   [Top Health Articles](https://www.news-medical.net/news/20240828/New-study-develops-enhanced-mortality-prediction-model-for-COPD-patients.aspx#tabs-3)

*   [![Image 16: New report reveals the truth behind plant-based protein alternatives](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_788750_455329953412847245261-125x110.jpg)](https://www.news-medical.net/news/20240827/New-report-reveals-the-truth-behind-plant-based-protein-alternatives.aspx)
    
    [New report reveals the truth behind plant-based protein alternatives](https://www.news-medical.net/news/20240827/New-report-reveals-the-truth-behind-plant-based-protein-alternatives.aspx)
    
*   [![Image 17: Fibrin fuels thromboinflammation and brain damage in COVID-19](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_789076_4553394666098387822-125x110.jpg)](https://www.news-medical.net/news/20240829/Fibrin-fuels-thromboinflammation-and-brain-damage-in-COVID-19.aspx)
    
    [Fibrin fuels thromboinflammation and brain damage in COVID-19](https://www.news-medical.net/news/20240829/Fibrin-fuels-thromboinflammation-and-brain-damage-in-COVID-19.aspx)
    
*   [![Image 18: The new covid vaccine is out. Why you might not want to rush to get it.](https://d2jx2rerrg6sh3.cloudfront.net/image-handler/picture/2019/5/Hand_holding_syringe_and_vaccine._-_Image_-_Billion_Photos_M3_ebd3759ed8e64655b97bfe597ad1a4a1-125x110.jpg)](https://www.news-medical.net/news/20240826/The-new-covid-vaccine-is-out-Why-you-might-not-want-to-rush-to-get-it.aspx)
    
    [The new covid vaccine is out. Why you might not want to rush to get it.](https://www.news-medical.net/news/20240826/The-new-covid-vaccine-is-out-Why-you-might-not-want-to-rush-to-get-it.aspx)
    
*   [![Image 19: Myocarditis risks linked to COVID-19 vaccination explained](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_788926_45532641335497686440-125x110.jpg)](https://www.news-medical.net/news/20240828/Myocarditis-risks-linked-to-COVID-19-vaccination-explained.aspx)
    
    [Myocarditis risks linked to COVID-19 vaccination explained](https://www.news-medical.net/news/20240828/Myocarditis-risks-linked-to-COVID-19-vaccination-explained.aspx)
    
*   [![Image 20: Children and adolescents experience unique long COVID symptoms](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_788612_455302191552662048516-125x110.jpg)](https://www.news-medical.net/news/20240826/Children-and-adolescents-experience-unique-long-COVID-symptoms.aspx)
    
    [Children and adolescents experience unique long COVID symptoms](https://www.news-medical.net/news/20240826/Children-and-adolescents-experience-unique-long-COVID-symptoms.aspx)
    

[### Global and Local Efforts to Take Action Against Hepatitis Lindsey Hiebert and James Amugsi In this interview, we explore global and local efforts to combat viral hepatitis with Lindsey Hiebert, Deputy Director of the Coalition for Global Hepatitis Elimination (CGHE), and James Amugsi, a Mandela Washington Fellow and Physician Assistant at Sandema Hospital in Ghana. Together, they provide valuable insights into the challenges, successes, and the importance of partnerships in the fight against hepatitis. ![Image 21: Global and Local Efforts to Take Action Against Hepatitis](https://d2jx2rerrg6sh3.cloudfront.net/images/news/InterviewImageForNews_786663_17224421434062191.jpg)](https://www.news-medical.net/news/20240820/Global-and-Local-Efforts-to-Take-Action-Against-Hepatitis.aspx)

[### Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics John Yates In this interview conducted at Pittcon 2024, we spoke to Professor John Yates about capturing cardiomyocyte cell-to-cell heterogeneity via shotgun top-down proteomics. ![Image 22: Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics](https://d2jx2rerrg6sh3.cloudfront.net/images/news/InterviewImageForNews_774563_1718383205197778.jpg)](https://www.news-medical.net/news/20240806/Addressing-Important-Cardiac-Biology-Questions-with-Shotgun-Top-Down-Proteomics.aspx)

[### A Discussion with Hologic‚Äôs Tim Simpson on the Future of Cervical Cancer Screening Tim Simpson Hologic‚Äôs Tim Simpson Discusses the Future of Cervical Cancer Screening. ![Image 23: A Discussion with Hologic‚Äôs Tim Simpson on the Future of Cervical Cancer Screening](https://d2jx2rerrg6sh3.cloudfront.net/images/news/InterviewImageForNews_786631_1722520792056704.jpg)](https://www.news-medical.net/news/20240801/A-Discussion-with-Hologice28099s-Tim-Simpson-on-the-Future-of-Cervical-Cancer-Screening.aspx)

*   [![Image 24: The Role of Vitamin D in Hormonal Balance](https://d2jx2rerrg6sh3.cloudfront.net/images/Article_Images/ImageForArticle_25004_454824516812384245729-125x110.jpg)](https://www.news-medical.net/health/The-Role-of-Vitamin-D-in-Hormonal-Balance.aspx)
    
    [The Role of Vitamin D in Hormonal Balance](https://www.news-medical.net/health/The-Role-of-Vitamin-D-in-Hormonal-Balance.aspx)
    
*   [![Image 25: How Does Cortisol Affect The Body?](https://d2jx2rerrg6sh3.cloudfront.net/images/Article_Images/ImageForArticle_25021_45488301800439821495-125x110.jpg)](https://www.news-medical.net/health/How-Does-Cortisol-Affect-The-Body.aspx)
    
    [How Does Cortisol Affect The Body?](https://www.news-medical.net/health/How-Does-Cortisol-Affect-The-Body.aspx)
    
*   [![Image 26: Why Women's Health Should be Prioritized](https://d2jx2rerrg6sh3.cloudfront.net/images/Article_Images/ImageForArticle_25156_45519328886620374965-125x110.jpg)](https://www.news-medical.net/health/Why-Womens-Health-Should-be-Prioritized.aspx)
    
    [Why Women's Health Should be Prioritized](https://www.news-medical.net/health/Why-Womens-Health-Should-be-Prioritized.aspx)
    
*   [![Image 27: What is the BRAT Diet?](https://d2jx2rerrg6sh3.cloudfront.net/images/Article_Images/ImageForArticle_25168_455232435805324067723-125x110.jpg)](https://www.news-medical.net/health/What-is-the-BRAT-Diet.aspx)
    
    [What is the BRAT Diet?](https://www.news-medical.net/health/What-is-the-BRAT-Diet.aspx)
    
*   [![Image 28: What is the Difference Between Elderly and Geriatric?](https://d2jx2rerrg6sh3.cloudfront.net/images/Article_Images/ImageForArticle_25184_45526436407557875767-125x110.jpg)](https://www.news-medical.net/health/What-is-the-Difference-Between-Elderly-and-Geriatric.aspx)
    
    [What is the Difference Between Elderly and Geriatric?](https://www.news-medical.net/health/What-is-the-Difference-Between-Elderly-and-Geriatric.aspx)
    

Latest News
-----------

*   [![Image 29: Recent studies underscore the importance of diet for the prevention of cancer](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_789213_45537193313043983832-125x110.jpg)](https://www.news-medical.net/news/20240902/Recent-studies-underscore-the-importance-of-diet-for-the-prevention-of-cancer.aspx)
    
    [Recent studies underscore the importance of diet for the prevention of cancer](https://www.news-medical.net/news/20240902/Recent-studies-underscore-the-importance-of-diet-for-the-prevention-of-cancer.aspx)
    
*   [![Image 30: Research finds particulate pollution during pregnancy may impact newborn kidney function](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_789212_45537166084155098494-125x110.jpg)](https://www.news-medical.net/news/20240902/Research-finds-particulate-pollution-during-pregnancy-may-impact-newborn-kidney-function.aspx)
    
    [Research finds particulate pollution during pregnancy may impact newborn kidney function](https://www.news-medical.net/news/20240902/Research-finds-particulate-pollution-during-pregnancy-may-impact-newborn-kidney-function.aspx)
    
*   [![Image 31: Tirzepatide outperforms insulin in controlling diabetes and promoting weight loss in clinical trials](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_789211_455370573190509241150-125x110.jpg)](https://www.news-medical.net/news/20240902/Tirzepatide-outperforms-insulin-in-controlling-diabetes-and-promoting-weight-loss-in-clinical-trials.aspx)
    
    [Tirzepatide outperforms insulin in controlling diabetes and promoting weight loss in clinical trials](https://www.news-medical.net/news/20240902/Tirzepatide-outperforms-insulin-in-controlling-diabetes-and-promoting-weight-loss-in-clinical-trials.aspx)
    
*   [![Image 32: Is semaglutide use during breastfeeding safe?](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_789208_45537034415868052078-125x110.jpg)](https://www.news-medical.net/news/20240902/Is-semaglutide-use-during-breastfeeding-safe.aspx)
    
    [Is semaglutide use during breastfeeding safe?](https://www.news-medical.net/news/20240902/Is-semaglutide-use-during-breastfeeding-safe.aspx)
    
*   [![Image 33: NCCS study uses exosomes to overcome resistance to epidermal growth factor receptor inhibitors](https://d2jx2rerrg6sh3.cloudfront.net/image-handler/picture/2017/1/Antimicrobial_susceptibility_testing_in_petri_dish-Jarun_Ontakrai-1000_1633a61817e0474fb2d8b8fc7137328c-125x110.jpg)](https://www.news-medical.net/news/20240902/NCCS-study-uses-exosomes-to-overcome-resistance-to-epidermal-growth-factor-receptor-inhibitors.aspx)
    
    [NCCS study uses exosomes to overcome resistance to epidermal growth factor receptor inhibitors](https://www.news-medical.net/news/20240902/NCCS-study-uses-exosomes-to-overcome-resistance-to-epidermal-growth-factor-receptor-inhibitors.aspx)
    

 

Newsletters you may be interested in
------------------------------------

*   [![Image 34: Diabetes](https://www.azonetwork.com/newsletters/icons/Diabetes.png)](https://www.news-medical.net/newsletters/webview/?ppnid=158)
    
    [Diabetes](https://www.news-medical.net/newsletters/webview/?ppnid=158)
    
    ([Subscribe or Preview](https://www.news-medical.net/newsletters/webview/?ppnid=158))
    
*   [![Image 35: Genetics](https://www.azonetwork.com/newsletters/icons/Genetics.png)](https://www.news-medical.net/newsletters/webview/?ppnid=145)
    
    [Genetics](https://www.news-medical.net/newsletters/webview/?ppnid=145)
    
    ([Subscribe or Preview](https://www.news-medical.net/newsletters/webview/?ppnid=145))
    
*   [![Image 36: Infectious Diseases](https://www.azonetwork.com/newsletters/icons/Infectious_Diseases.png)](https://www.news-medical.net/newsletters/webview/?ppnid=217)
    
    [Infectious Diseases](https://www.news-medical.net/newsletters/webview/?ppnid=217)
    
    ([Subscribe or Preview](https://www.news-medical.net/newsletters/webview/?ppnid=217))
    

[See all Newsletters ¬ª](https://www.news-medical.net/medical/newsletters)

 [![Image 37: NewsGuard](https://d2jx2rerrg6sh3.cloudfront.net/images/newsguard-logo.svg) ![Image 38: NewsGuard 100/100 Score](https://d2jx2rerrg6sh3.cloudfront.net/images/newsguard-100.svg)](https://www.news-medical.net/medical/newsguard)

High Credibility: This website adheres to all nine standards of credibility and transparency.

[![Image 39: TRUSTe](https://privacy-policy.truste.com/privacy-seal/seal?rid=80814776-9892-4bc0-a905-50180d9d0296)](https://privacy.truste.com/privacy-seal/validation?rid=80814776-9892-4bc0-a905-50180d9d0296) [![Image 40: Cyber Essentials Plus](https://d2jx2rerrg6sh3.cloudfront.net/images/cyberessentials_plus_245x90.png)](https://registry.blockmarktech.com/certificates/b5720d0b-7698-4c0d-b58c-92920915c193/)

### Medical Links

*   [Medical Home](https://www.news-medical.net/medical)
*   [COVID-19](https://www.news-medical.net/condition/Coronavirus-Disease-COVID-19)
*   [News](https://www.news-medical.net/medical/news)
*   [Health A-Z](https://www.news-medical.net/medical-a-z.aspx)
*   [White Papers](https://www.news-medical.net/medical/whitepapers)
*   [Thought Leaders](https://www.news-medical.net/medical/thought-leaders)
*   [Insights](https://www.news-medical.net/medical/insights-from-industry)
*   [MediKnowledge Series](https://www.news-medical.net/mediknowledge)
*   [Health & Personal Care](https://www.news-medical.net/Consumer-Products)
*   [Medical Devices](https://www.news-medical.net/Clinical-and-Diagnostics)
*   [Drugs](https://www.news-medical.net/drugs-a-z.aspx)
*   [eBooks](https://www.news-medical.net/medical/ebooks)

### Life Sciences Links

*   [Life Sciences Home](https://www.news-medical.net/life-sciences)
*   [News](https://www.news-medical.net/life-sciences/news)
*   [Lab Instruments & Equipment](https://www.news-medical.net/Life-Science-and-Laboratory)
*   [Life Sciences A-Z](https://www.news-medical.net/life-sciences-a-z)
*   [White Papers](https://www.news-medical.net/life-sciences/whitepapers)
*   [Thought Leaders](https://www.news-medical.net/life-sciences/thought-leaders)
*   [Insights](https://www.news-medical.net/life-sciences/insights-from-industry)
*   [Webinars](https://www.news-medical.net/life-sciences/webinars)
*   [eBooks](https://www.news-medical.net/life-sciences/ebooks)

### Other Useful Links

*   [About](https://www.news-medical.net/medical/about)
*   [Meet the Team](https://www.news-medical.net/medical/team)
*   [Search](https://www.news-medical.net/medical/search)
*   [Newsletters](https://www.news-medical.net/medical/newsletters)
*   [Sitemap](https://www.news-medical.net/sitemap.axd)
*   [Advertise](https://www.news-medical.net/medical/advertise)
*   [Contact](https://www.news-medical.net/medical/contact)
*   [Terms & Conditions](https://www.news-medical.net/medical/terms)
*   [Privacy & Cookie Policy](https://www.news-medical.net/medical/privacy)
*   [Content Policy](https://www.news-medical.net/medical/content-policy)
*   [Ownership & Funding Information](https://www.news-medical.net/medical/about#ownership-funding)

### Other AZoNetwork Sites

*   [AZoM](https://www.azom.com/)
*   [AZoNano](https://www.azonano.com/)
*   [AZoCleantech](https://www.azocleantech.com/)
*   [AZoOptics](https://www.azooptics.com/)
*   [AZoRobotics](https://www.azorobotics.com/)
*   [AZoSensors](https://www.azosensors.com/)
*   [AZoMining](https://www.azomining.com/)
*   [AZoQuantum](https://www.azoquantum.com/)
*   [AZoBuild](https://www.azobuild.com/)
*   [AZoLifeSciences](https://www.azolifesciences.com/)
*   [AZoAi](https://www.azoai.com/)

![Image 41: News-Medical](https://d2jx2rerrg6sh3.cloudfront.net/themes/Standard/images/nm-logo-4.png)

*   [Facebook](https://www.facebook.com/NewsMedical)
*   [Twitter](https://twitter.com/NewsMedical)
*   [LinkedIn](https://www.linkedin.com/company/news-medical/)

News-Medical.Net provides this medical information service in accordance with these [terms and conditions](https://www.news-medical.net/medical/terms). Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.

Update Your Privacy Preferences

Last Updated: Monday 2 Sep 2024

[![Image 42: AZoNetwork](https://www.azonetwork.com/images/azonetwork_logo_footer_80.png)](https://www.azonetwork.com/)

News-Medical.net - An AZoNetwork Site

Owned and operated by AZoNetwork, ¬© 2000-2024

 

![Image 43: Azthena chat logo](https://d2jx2rerrg6sh3.cloudfront.net/images/ai-chat-icon.svg)

 

Your AI Powered Scientific Assistant

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

A few things you need to know before we start. **Please read and accept to continue.**

*   Use of ‚ÄúAzthena‚Äù is subject to the terms and conditions of use as set out by [OpenAI](https://openai.com/policies/terms-of-use).
*   Content provided on any AZoNetwork sites are subject to the site [Terms & Conditions](https://www.news-medical.net/medical/terms) and [Privacy Policy](https://www.news-medical.net/medical/privacy).
*   Large Language Models can make mistakes. Consider checking important information.

I'm OK to proceed

Great. Ask your question.

Latest message

Clear Chat 

Azthena may occasionally provide inaccurate responses.  
[Read the full terms](https://www.news-medical.net/news/20240828/New-study-develops-enhanced-mortality-prediction-model-for-COPD-patients.aspx#).

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full [Terms & Conditions](https://www.news-medical.net/medical/terms).

Provide Feedback

Submit Cancel

 

You might also like... √ó

[![Image 44](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_787026_45509631164849543003-80x70.jpg)Urinary metals linked to higher cardiovascular disease risk and mortality](https://www.news-medical.net/news/20240805/Urinary-metals-linked-to-higher-cardiovascular-disease-risk-and-mortality.aspx ""Urinary metals linked to higher cardiovascular disease risk and mortality"")
",gpt-4o-mini
2024-09-02 08:15:00,2024-09-02 10:12:35,"üö® **Breakthrough Alert: FDA Fast Tracks Tau PET Diagnostic for Neurodegenerative Diseases!** üö®  
The FDA has granted fast track designation to Life Molecular Imaging‚Äôs PI-2620 tau PET diagnostic for Alzheimer‚Äôs disease, progressive supranuclear palsy, and corticobasal degeneration. This innovative imaging technique utilizes a tracer to identify tau protein deposits in the brain, improving diagnostic accuracy and patient management.  
This milestone signifies a promising advancement in the early detection of these debilitating conditions. üß†üí°  
For more details, check the full article here: [https://www.clinicaltrialsarena.com/news/fda-grants-fast-track-designation-to-life-molecular-imaging-tau-pet-diagnostic/](https://www.clinicaltrialsarena.com/news/fda-grants-fast-track-designation-to-life-molecular-imaging-tau-pet-diagnostic/)  
üëâ What are your thoughts on the role of tau PET imaging in clinical practice? Share your insights below!  

#NeurodegenerativeDiseases #TauPET #Alzheimers #ResearchBreakthroughs #FDAApproval  
![Tau PET Diagnostic](https://medsii.azureedge.net/images/638608617034197028-66d572da4e2a8b3bb835599b.jpg)",https://medsii.azureedge.net/images/638608617034197028-66d572da4e2a8b3bb835599b.jpg,https://www.clinicaltrialsarena.com/news/fda-grants-fast-track-designation-to-life-molecular-imaging-tau-pet-diagnostic/,"You are a content creator tasked with crafting highly informative, easy to digest social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Thumbnail image URL: https://medsii.azureedge.net/images/638608617034197028-66d572da4e2a8b3bb835599b.jpg  
Title: FDA grants fast track designation to Life Molecular Imaging‚Äôs tau PET diagnostic

URL Source: https://www.clinicaltrialsarena.com/news/fda-grants-fast-track-designation-to-life-molecular-imaging-tau-pet-diagnostic/

Published Time: 2024-08-29T10:54:37Z

Markdown Content:
FDA grants fast track designation to Life Molecular Imaging‚Äôs tau PET diagnostic - Clinical Trials Arena
===============
                                                   

![Image 1](https://www.facebook.com/tr?id=1175064750058523&ev=PageView&noscript=1)             

[![Image 2: CTA](https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2018/06/CTA.png)](https://www.clinicaltrialsarena.com/)

[CT](https://www.clinicaltrialsarena.com/)

Menu

Search

 

 

Sections
--------

*   [Home](https://www.clinicaltrialsarena.com/ ""Home"")
*   [News](https://www.clinicaltrialsarena.com/news/ ""News"")
*   [Analysis](https://www.clinicaltrialsarena.com/analysis/ ""Analysis"")
    *   [Features](https://www.clinicaltrialsarena.com/features/ ""Features"")
        
    *   [Comment & Opinion](https://www.clinicaltrialsarena.com/comment/ ""Comment & Opinion"")
        
    *   [Projects](https://www.clinicaltrialsarena.com/projects/ ""Projects"")
        
    *   [Data Insights](https://www.clinicaltrialsarena.com/data-insights/ ""Data Insights"")
        
*   [Sectors](https://www.clinicaltrialsarena.com/sector/clinical/ ""Sectors"")
    *   [Clinical Trials](https://www.clinicaltrialsarena.com/sector/services/clinical-trials/ ""Clinical Trials"")
        
    *   [Approvals](https://www.clinicaltrialsarena.com/sector/approvals/ ""Approvals"")
        
    *   [Operations](https://www.clinicaltrialsarena.com/sector/operations/ ""Operations"")
        
    *   [Outsourced Services](https://www.clinicaltrialsarena.com/sector/services/outsourced-services/ ""Outsourced Services"")
        
    *   [Supply Chain](https://www.clinicaltrialsarena.com/sector/services/supply-chain/ ""Supply Chain"")
        
    *   [Data Management](https://www.clinicaltrialsarena.com/sector/data-management/ ""Data Management"")
        
    *   [Medical Devices](https://www.clinicaltrialsarena.com/sector/medical-devices/ ""Medical Devices"")
        
*   [Themes](https://www.clinicaltrialsarena.com/sector/theme/ ""Themes"")
    *   [Artificial Intelligence](https://www.clinicaltrialsarena.com/sector/theme/technology/artificial-intelligence/ ""Artificial Intelligence"")
        
    *   [Cloud](https://www.clinicaltrialsarena.com/sector/theme/technology/cloud/ ""Cloud"")
        
    *   [Corporate Governance](https://www.clinicaltrialsarena.com/sector/theme/macro/esg/governance/ ""Corporate Governance"")
        
    *   [Cybersecurity](https://www.clinicaltrialsarena.com/sector/theme/technology/cybersecurity/ ""Cybersecurity"")
        
    *   [Environmental Sustainability](https://www.clinicaltrialsarena.com/sector/theme/macro/esg/environment/ ""Environmental Sustainability"")
        
    *   [Internet of Things](https://www.clinicaltrialsarena.com/sector/theme/technology/internet-of-things/ ""Internet of Things"")
        
    *   [Robotics](https://www.clinicaltrialsarena.com/sector/theme/technology/robotics/ ""Robotics"")
        
    *   [Social Responsibility](https://www.clinicaltrialsarena.com/sector/theme/macro/esg/social/ ""Social Responsibility"")
        
    *   [Covid-19](https://www.clinicaltrialsarena.com/sector/theme/macro/covid-19/ ""Covid-19"")
        
*   [Insights](https://www.clinicaltrialsarena.com/insights/ ""Insights"")
    *   [Deals](https://www.clinicaltrialsarena.com/deals-dashboards/ ""Deals"")
        
    *   [Jobs](https://www.clinicaltrialsarena.com/jobs/ ""Jobs"")
        
    *   [Filings](https://www.clinicaltrialsarena.com/filings/ ""Filings"")
        
    *   [Patents](https://www.clinicaltrialsarena.com/patents/ ""Patents"")
        
    *   [Social Media](https://www.clinicaltrialsarena.com/influencers-dashboards/ ""Social Media"")
        
*   [Companies](https://www.clinicaltrialsarena.com/news/fda-grants-fast-track-designation-to-life-molecular-imaging-tau-pet-diagnostic/# ""Companies"")
    *   [Company A-Z](https://www.clinicaltrialsarena.com/company-a-z/ ""Company A-Z"")
        
    *   [Company Categories](https://www.clinicaltrialsarena.com/contractors/ ""Company Categories"")
        
    *   [Product & Services](https://www.clinicaltrialsarena.com/products/ ""Product & Services"")
        
    *   [Company Releases](https://www.clinicaltrialsarena.com/pressreleases/ ""Company Releases"")
        
    *   [White Papers](https://www.clinicaltrialsarena.com/whitepapers/ ""White Papers"")
        
    *   [Videos](https://www.clinicaltrialsarena.com/videos/ ""Videos"")
        
    *   [Buyer's Guides](https://www.clinicaltrialsarena.com/buyers-guide/ ""Buyer's Guides"")
        
    *   [Partner Content](https://www.clinicaltrialsarena.com/sponsored/ ""Partner Content"")
        
*   [Events](https://www.clinicaltrialsarena.com/events/ ""Events"")
*   [Reports](https://www.clinicaltrialsarena.com/reports/ ""Reports"")
*   [Premium Insights](https://www.clinicaltrialsarena.com/premium-insights/ ""Premium Insights"")
*   [Excellence Awards](https://www.clinicaltrialsarena.com/excellence-awards/ ""Excellence Awards"")
*   [Innovation Rankings](https://www.clinicaltrialsarena.com/innovation-ranking/ ""Innovation Rankings"")
*   [Magazine](https://www.clinicaltrialsarena.com/magazine/ ""Magazine"")
*   [Newsletters](https://www.clinicaltrialsarena.com/newsletters/ ""Newsletters"")

GlobalData
----------

*   [About Us](https://www.clinicaltrialsarena.com/about-us-online/)
*   [Advertise With Us](https://www.clinicaltrialsarena.com/advertise-with-us/)
*   [Contact Us](https://www.clinicaltrialsarena.com/contact-us/)
*   [Our Marketing Solution](https://www.verdictmediastrategies.com/)
*   [GlobalData Reports](https://www.globaldata.com/store/)
*   [Visit GlobalData](https://globaldata.com/)

From Our Partners
-----------------

*   [Optimizing Cell & Gene Therapy Processes](https://www.clinicaltrialsarena.com/sector/partners/optimizing-cell-gene-therapy-processes/)
*   [Accelerating Clinical Trials](https://www.clinicaltrialsarena.com/sector/partners/accelerating-clinical-trials/)
*   [Improving decentralized trials with mobile research nursing](https://www.clinicaltrialsarena.com/sector/partners/improving-decentralized-trials-with-mobile-research-nursing/)
*   [The next chapter of clinical trial services](https://www.clinicaltrialsarena.com/sector/partners/the-next-chapter-of-clinical-trial-services/)
*   [Trusted clinical trial packaging services](https://www.clinicaltrialsarena.com/sector/partners/trusted-clinical-trial-packaging-services/)
*   [Meet critical milestones](https://www.clinicaltrialsarena.com/sector/partners/meet-critical-milestones/)

*   [News](https://www.clinicaltrialsarena.com/news/ ""News"")
*   [Analysis](https://www.clinicaltrialsarena.com/analysis/ ""Analysis"")
    
    Sections
    --------
    
    *   [Features](https://www.clinicaltrialsarena.com/features/ ""Features"")
    *   [Comment & Opinion](https://www.clinicaltrialsarena.com/comment/ ""Comment & Opinion"")
    *   [Projects](https://www.clinicaltrialsarena.com/projects-a-z/ ""Projects"")
    *   [Data Insights](https://www.clinicaltrialsarena.com/data-insights/ ""Data Insights"")
    
    Latest
    ------
    
    *   [Explainer: Labour has been elected in the UK ‚Äì now what?](https://www.clinicaltrialsarena.com/features/explainer-labour-has-been-elected-in-the-uk-now-what/)
    *   [Pipeline Moves: Alnylam‚Äôs Amvuttra approval prospects up after Phase III win](https://www.clinicaltrialsarena.com/features/alnylam-win-amvuttra-attr-amyloidosis/)
    *   [Pharma sector votes for post-Brexit clarity under new government](https://www.clinicaltrialsarena.com/features/pharma-sector-votes-for-post-brexit-clarity-under-new-government/)
    
*   [Sectors](https://www.clinicaltrialsarena.com/sector/clinical/ ""Sectors"")
    
    Sections
    --------
    
    *   [Clinical Trials](https://www.clinicaltrialsarena.com/sector/services/clinical-trials/ ""Clinical Trials"")
    *   [Approvals](https://www.clinicaltrialsarena.com/sector/approvals/ ""Approvals"")
    *   [Operations](https://www.clinicaltrialsarena.com/sector/operations/ ""Operations"")
    *   [Outsourced Services](https://www.clinicaltrialsarena.com/sector/services/outsourced-services/ ""Outsourced Services"")
    *   [Supply Chain](https://www.clinicaltrialsarena.com/sector/services/supply-chain/ ""Supply Chain"")
    *   [Data Management](https://www.clinicaltrialsarena.com/sector/data-management/ ""Data Management"")
    *   [Medical Devices](https://www.clinicaltrialsarena.com/sector/medical-devices/ ""Medical Devices"")
    
    Latest
    ------
    
    *   [Ivy Brain Tumor Center announces dosing of first subject in glioblastoma trial](https://www.clinicaltrialsarena.com/news/ivy-brain-tumor-center-glioblastoma-trial/)
    *   [Renalys Pharma gains funding for trials of kidney disease treatments](https://www.clinicaltrialsarena.com/news/renalys-kidney-disease-trials/)
    *   [Sanofi‚Äôs ALTUVIIIO shows promise in paediatric haemophilia A treatment trial](https://www.clinicaltrialsarena.com/news/sanofi-altuviiio-paediatric-haemophilia/)
    
*   [Themes](https://www.clinicaltrialsarena.com/sector/theme/ ""Themes"")
    
    Sections
    --------
    
    *   [Artificial Intelligence](https://www.clinicaltrialsarena.com/sector/theme/technology/artificial-intelligence/ ""Artificial Intelligence"")
    *   [Cloud](https://www.clinicaltrialsarena.com/sector/theme/technology/cloud/ ""Cloud"")
    *   [Corporate Governance](https://www.clinicaltrialsarena.com/sector/theme/macro/esg/governance/ ""Corporate Governance"")
    *   [Cybersecurity](https://www.clinicaltrialsarena.com/sector/theme/technology/cybersecurity/ ""Cybersecurity"")
    *   [Environmental Sustainability](https://www.clinicaltrialsarena.com/sector/theme/macro/esg/environment/ ""Environmental Sustainability"")
    *   [Internet of Things](https://www.clinicaltrialsarena.com/sector/theme/technology/internet-of-things/ ""Internet of Things"")
    *   [Robotics](https://www.clinicaltrialsarena.com/sector/theme/technology/robotics/ ""Robotics"")
    *   [Social Responsibility](https://www.clinicaltrialsarena.com/sector/theme/macro/esg/social/ ""Social Responsibility"")
    *   [Covid-19](https://www.clinicaltrialsarena.com/sector/theme/macro/covid-19/ ""Covid-19"")
    *   [Foreign Direct Investment](https://www.clinicaltrialsarena.com/sector/fdi/ ""Foreign Direct Investment"")
    
    Latest
    ------
    
    *   [Hyperfine‚Äôs portable MRI shows promise in stroke detection](https://www.clinicaltrialsarena.com/news/hyperfines-portable-mri-shows-promise-in-stroke-detection-2/)
    *   [Battling bacterial behemoths: The AMR and MRSA challenge](https://www.clinicaltrialsarena.com/analyst-comment/bacteria-amr-mrsa-challenge/)
    *   [Impact of AI on metabolic disorder clinical trials](https://www.clinicaltrialsarena.com/analyst-comment/ai-metabolic-disorder-clinical-trials/)
    
*   [Insights](https://www.clinicaltrialsarena.com/insights/ ""Insights"")
    
    Sections
    --------
    
    *   [Deals](https://www.clinicaltrialsarena.com/deals-dashboards/ ""Deals"")
    *   [Jobs](https://www.clinicaltrialsarena.com/jobs/ ""Jobs"")
    *   [Filings](https://www.clinicaltrialsarena.com/filings/ ""Filings"")
    *   [Patents](https://www.clinicaltrialsarena.com/patents/ ""Patents"")
    *   [Social Media](https://www.clinicaltrialsarena.com/influencers-dashboards/ ""Social Media"")
    
    Latest
    ------
    
    *   [Q4 2023 update: M&A activity in pharmaceutical in the US](https://www.clinicaltrialsarena.com/dashboards/deals-dashboards/theus-m-a-activity-pharmaceutical-industry/)
    *   [Q4 2023 update: M&A activity in pharmaceutical in Middle East and Africa](https://www.clinicaltrialsarena.com/dashboards/deals-dashboards/middleeastandafrica-ma-activity-pharmaceutical-industry/)
    *   [Q4 2023 update: M&A activity in pharmaceutical in Italy](https://www.clinicaltrialsarena.com/dashboards/deals-dashboards/italy-m-a-activity-pharmaceutical-industry/)
    
*   [Companies](https://www.clinicaltrialsarena.com/news/fda-grants-fast-track-designation-to-life-molecular-imaging-tau-pet-diagnostic/# ""Companies"")
    
    Sections
    --------
    
    *   [Company A-Z](https://www.clinicaltrialsarena.com/company-a-z/ ""Company A-Z"")
    *   [Company Categories](https://www.clinicaltrialsarena.com/contractors/ ""Company Categories"")
    *   [Products & Services](https://www.clinicaltrialsarena.com/products/ ""Products & Services"")
    *   [Company Releases](https://www.clinicaltrialsarena.com/pressreleases/ ""Company Releases"")
    *   [White Papers](https://www.clinicaltrialsarena.com/whitepapers/ ""White Papers"")
    *   [Videos](https://www.clinicaltrialsarena.com/videos/ ""Videos"")
    *   [Buyer's Guides](https://www.clinicaltrialsarena.com/buyers-guide/ ""Buyer's Guides"")
    *   [Partner Content](https://www.clinicaltrialsarena.com/sponsored/ ""Partner Content"")
    
    Latest
    ------
    
    *   [Gene therapy: How the CRO of Veristat cut trial database costs by 30%](https://www.clinicaltrialsarena.com/sponsored/gene-therapy-how-the-cro-of-veristat-cut-trial-database-costs-by-30/)
    *   [Finding the right solution and partner for your drug product‚Äôs commercial supply chain](https://www.clinicaltrialsarena.com/sponsored/finding-the-right-solution-and-partner-for-your-drug-products-commercial-supply-chain/)
    *   [Non-small cell lung cancer: the global clinical trials landscape 2024](https://www.clinicaltrialsarena.com/sponsored/non-small-cell-lung-cancer-the-global-clinical-trials-landscape-2024/)
    
*   [Events](https://www.clinicaltrialsarena.com/events/ ""Events"")
*   [Buy Reports](https://www.clinicaltrialsarena.com/buy-reports/ ""Buy Reports"")
*   [Newsletters](https://www.clinicaltrialsarena.com/newsletters/ ""Newsletters"")

[CT](https://www.clinicaltrialsarena.com/)

*   [News](https://www.clinicaltrialsarena.com/news/)

FDA grants fast track designation to Life Molecular Imaging‚Äôs tau PET diagnostic
================================================================================

Life Molecular Imaging‚Äôs PI-2620 tracer compound has received FDA fast track designation across three neurodegenerative conditions.

[Ross Law](https://www.clinicaltrialsarena.com/author/rosslaw/ ""Posts by Ross Law"") August 29, 2024

Share

*   [Copy Link](https://www.clinicaltrialsarena.com/news/fda-grants-fast-track-designation-to-life-molecular-imaging-tau-pet-diagnostic/)
*   [Share on X](https://twitter.com/intent/tweet?text=FDA+grants+fast+track+designation+to+Life+Molecular+Imaging%E2%80%99s+tau+PET+diagnostic%0a&url=https://www.clinicaltrialsarena.com/news/fda-grants-fast-track-designation-to-life-molecular-imaging-tau-pet-diagnostic/&via=TrialsArena)
*   [Share on Linkedin](http://www.linkedin.com/shareArticle?mini=true&url=https://www.clinicaltrialsarena.com/news/fda-grants-fast-track-designation-to-life-molecular-imaging-tau-pet-diagnostic/)
*   [Share on Facebook](https://www.facebook.com/sharer/sharer.php?u=https://www.clinicaltrialsarena.com/news/fda-grants-fast-track-designation-to-life-molecular-imaging-tau-pet-diagnostic/)

  ![Image 3](https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/08/shutterstock_1537198925-430x241.jpg)

Life Molecular Imaging said the FDA fast track designation reflected the encouraging potential of its imaging technique for the diagnosis of Alzheimer‚Äôs and other neurodegenerative condiutions. Image Credit: Chinnapong via Shutterstock.

The US Food and Drug Administration (FDA) has granted fast track designation to Life Molecular Imaging‚Äôs (LMI) tau positron emission tomography (PET) imaging diagnostic, PI-2620.

The designation has been granted for the clinical application of PI-2620 for tau PET imaging in Alzheimer‚Äôs disease (AD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD).

### Go deeper with GlobalData

*   ![Image 4: ReportsLogo](https://pr-fr-json-b2b-gdm-figaro1.pantheonsite.io/pharmaceutical-technology/wp-content/themes/goodlife-wp-B2B/assets/img/report.png)
    
    [Reports](https://www.globaldata.com/store/report/)
    
    #### [LOA and PTSR Model - APNmAb-005 in Frontotemporal Dementia (FTD)](https://www.globaldata.com/store/report/apnmab-005-in-frontotemporal-dementia-ftd-loa-innovation-and-trend-analysis?utm_source=Company)
    
*   ![Image 5: ReportsLogo](https://pr-fr-json-b2b-gdm-figaro1.pantheonsite.io/pharmaceutical-technology/wp-content/themes/goodlife-wp-B2B/assets/img/report.png)
    
    [Reports](https://www.globaldata.com/store/report/)
    
    #### [LOA and PTSR Model - APNmAb-005 in Tauopathies](https://www.globaldata.com/store/report/apnmab-005-in-tauopathies-loa-innovation-and-trend-analysis?utm_source=Company)
    

##### Data Insights

The gold standard of business intelligence.

[Find out more](https://www.clinicaltrialsarena.com/buy-reports/?utm_source=LGP-Article&utm_content=Find_out_more&utm_campaign=LGP_Premium-Insight-Landing-Page)

### Related Company Profiles

#### [AC Immune SA](https://www.globaldata.com/store/report/?cdmsid=1364813&scalar=true&utm_source=Company)

#### [Eisai Co Ltd](https://www.globaldata.com/store/report/?cdmsid=1159823&scalar=true&utm_source=Company)

#### [Eisai Inc](https://www.globaldata.com/store/report/?cdmsid=1487444&scalar=true&utm_source=Company)

[View all](https://www.globaldata.com/companies/)

PI-2620 PET imaging is a technique whereby a patient is injected with a small amount of PI-2620 tracer which subsequently travels through the bloodstream and binds to any tau proteins in the brain.

From there, patients undergo a PET scan that detects signals emitted by PI-2620. The resultant PET images show if there are tau deposits in the brain and in which regions they are located, thereby aiding in the diagnosis and monitoring of the progression of AD and other neurodegenerative conditions in which tau deposits been implicated.

PI-2620 is currently under investigation in a Phase III trial (NCT05641688) by LMI to assess the efficacy and safety of PET imaging with PI-2620 for the detection of tau deposits in subjects with AD.

See Also:

*   [ESC 2024: SELECT trial provides promising results for obesity-related HFpEF treatment ![Image 6](https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/assets/img/icons/offsite.png')](https://www.clinicaltrialsarena.com/analyst-comment/esc-2024-select-trial-provides-promising-results-for-obesity-related-hfpef-treatment/) 
*   [Cancer vaccine trials dominate in the US ![Image 7](https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/assets/img/icons/offsite.png')](https://www.clinicaltrialsarena.com/analyst-comment/cancer-vaccine-trials-dominate-us/) 

‚ÄúThis designation not only validates our approach but also facilitates closer collaboration with the FDA to expedite the development of PI-2620,‚Äù said LMI CMO Andrew Stephens.

How well do you really know your competitors?
=============================================

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

[View profiles in store](https://www.globaldata.com/companies/?utm_source=News&utm_term=visit_company_profile&utm_content=FDAgrantsfasttrackdesignationtoLifeMolecularImaging%E2%80%99stauPETdiagnostic)

![Image 8](https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/assets/images/company-profile-unit.png)

Company Profile ‚Äì free sample

Thank you!
==========

Your download email will arrive shortly

Not ready to buy yet? Download a free sample
============================================

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

 Submit

 Tick here to opt out of curated industry news, reports, and event updates from Clinical Trials Arena.

              

Submit and download

Visit our [Privacy Policy](https://www.verdict.co.uk/privacy-policy/) for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

‚ÄúWe are committed to advancing this important imaging agent with the potential to make a meaningful difference for patients who need accurate and accessible tau PET imaging.‚Äù

PI-2620 was developed in collaboration with [AC Immune](https://www.globaldata.com/store/report/?cdmsid=1364813&scalar=true&utm_source=CompanyNews&utm_medium=22-215182&utm_campaign=company-profile-hyperlink-nonlgp). Primarily focused on developing treatments for neurodegenerative diseases, the Swiss biotech works with other firms and develops drug candidates through its Morphomer and SupraAntigen technology platforms.

Morphomer is capable of creating small molecules that bind to misfolded proteins such as amyloid beta (AŒ≤), while SupraAntigen generates monoclonal antibodies to specifically target misfolding proteins.

The FDA has previously granted fast track designation to two of AC Immune‚Äôs immunotherapies, ACI-35-030 (NCT04445831) and [ACI-24060](https://pharma2.globaldata.com/DrugsView/ProductView?ProductId=160&ProductType=0,1). The compounds target tau and AŒ≤, respectively.

In January 2023, AC Immune [reported positive data](https://www.clinicaltrialsarena.com/news/ac-immune-alzheimers-disease-vaccine-trial/?cf-view) from the ABATE trial (NCT05462106) of anti-amyloid-beta (Abeta) vaccine ACI-24060, finding that the compound elicited an anti-Abeta antibody response in ABATE‚Äôs first low dose cohort of AD patients at week six.

‚ÄúThe designation for PI-2620 is a further recognition of AC Immune‚Äôs drug discovery and development platform and of how we, together with our partners, continue to drive innovation,‚Äù commented AC Immune CEO Andrea Pfeifer.

GlobalData‚Äôs pharmaceutical database shows that AC Immune has a [pipeline of 20 drugs](https://pharma2.globaldata.com/Company/DrugsByCompany?gdCompanyId=114701&companyName=AC%20Immune%20SA&urlNode=ac-immune-sa&drugCategory=Pipeline&drugCategoryId=0&companyType=&licensingType=&sortColumn=SNO&pageSize=25&currentPage=1&pipelineStageIds=33&pipelineStageNames=--Select--&includeSubsidary=checked&drugNameIds=&drugNames=), chiefly for neurodegenerative conditions, in active stages of development.

GlobalData is the parent company of _Clinical Trials Arena._

The 2024 Alzheimer‚Äôs Association International Conference (AAIC) took place in Philadelphia, US from 28 July to 1 August. During the conference, [Eisai announced](https://www.clinicaltrialsarena.com/news/aaic-2024-eisai-presents-positive-long-term-data-with-leqembi/) that patients undergoing continuous treatment with its anti-amyloid therapy Leqembi for three years had shown a slowing of Alzheimer‚Äôs disease progression. Leqembi [received full market approval](https://www.clinicaltrialsarena.com/analyst-comment/eisai-biogen-leqembi-fda/) from the FDA in July 2023.

![Image 9: Email newsletter icon](https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/assets/images/newsletter-new.svg)

### Sign up for our daily news round-up!

Give your business an edge with our leading industry insights.

[Sign up](https://www.clinicaltrialsarena.com/all-newsletters?utm_source=media-website&utm_medium=&utm_content=Sign_Up_Button&utm_campaign=newsletter_ClinicalTrialsArena)

Share

*   [Copy Link](https://www.clinicaltrialsarena.com/news/fda-grants-fast-track-designation-to-life-molecular-imaging-tau-pet-diagnostic/)
*   [Share on X](https://twitter.com/intent/tweet?text=FDA+grants+fast+track+designation+to+Life+Molecular+Imaging%E2%80%99s+tau+PET+diagnostic%0a&url=https://www.clinicaltrialsarena.com/news/fda-grants-fast-track-designation-to-life-molecular-imaging-tau-pet-diagnostic/&via=TrialsArena)
*   [Share on Linkedin](http://www.linkedin.com/shareArticle?mini=true&url=https://www.clinicaltrialsarena.com/news/fda-grants-fast-track-designation-to-life-molecular-imaging-tau-pet-diagnostic/)
*   [Share on Facebook](https://www.facebook.com/sharer/sharer.php?u=https://www.clinicaltrialsarena.com/news/fda-grants-fast-track-designation-to-life-molecular-imaging-tau-pet-diagnostic/)

### Go deeper with GlobalData

*   [![Image 10: ReportsLogo](https://pr-fr-json-b2b-gdm-figaro1.pantheonsite.io/pharmaceutical-technology/wp-content/themes/goodlife-wp-B2B/assets/img/report.png)](https://www.globaldata.com/store/report/apnmab-005-in-frontotemporal-dementia-ftd-loa-innovation-and-trend-analysis?utm_source=CompanyNews&utm_medium=22-215182&utm_campaign=recommended-reports-nonlgp)
    
    [Reports](https://www.globaldata.com/store/industry/pharmaceuticals-market/)
    
    #### [LOA and PTSR Model - APNmAb-005 in Frontotemporal Dementia (FTD)](https://www.globaldata.com/store/report/apnmab-005-in-frontotemporal-dementia-ftd-loa-innovation-and-trend-analysis?utm_source=CompanyNews&utm_medium=22-215182&utm_campaign=recommended-reports-nonlgp)
    
*   [![Image 11: ReportsLogo](https://pr-fr-json-b2b-gdm-figaro1.pantheonsite.io/pharmaceutical-technology/wp-content/themes/goodlife-wp-B2B/assets/img/report.png)](https://www.globaldata.com/store/report/apnmab-005-in-tauopathies-loa-innovation-and-trend-analysis?utm_source=CompanyNews&utm_medium=22-215182&utm_campaign=recommended-reports-nonlgp)
    
    [Reports](https://www.globaldata.com/store/industry/pharmaceuticals-market/)
    
    #### [LOA and PTSR Model - APNmAb-005 in Tauopathies](https://www.globaldata.com/store/report/apnmab-005-in-tauopathies-loa-innovation-and-trend-analysis?utm_source=CompanyNews&utm_medium=22-215182&utm_campaign=recommended-reports-nonlgp)
    

##### Data Insights

The gold standard of business intelligence.

[Find out more](https://www.clinicaltrialsarena.com/buy-reports/?utm_source=LGP-Article&utm_content=Be_better_informed&utm_campaign=LGP_Premium-Insight-Landing-Page)

### Related Company Profiles

#### [AC Immune SA](https://www.globaldata.com/store/report/?cdmsid=1364813&scalar=true&utm_source=CompanyNews&utm_medium=22-215182&utm_campaign=companies-intelligence-nonlgp)

#### [Eisai Co Ltd](https://www.globaldata.com/store/report/?cdmsid=1159823&scalar=true&utm_source=CompanyNews&utm_medium=22-215182&utm_campaign=companies-intelligence-nonlgp)

#### [Eisai Inc](https://www.globaldata.com/store/report/?cdmsid=1487444&scalar=true&utm_source=CompanyNews&utm_medium=22-215182&utm_campaign=companies-intelligence-nonlgp)

[View all](https://www.globaldata.com/companies/listing/search/)

### Upcoming Event

01 - 02 Oct 2024

#### 12th Annual Clinical Trial Supply Nordics 2024

This is the unmissable event that the pharmaceutical biotechnology and medical device communities need to come together and discuss strategies...

[Find out more](https://www.arena-international.com/event/ctsnordics/)

More Relevant
-------------

[![Image 12](https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/08/shutterstock_2287970253.jpg)](https://www.clinicaltrialsarena.com/analyst-comment/esc-2024-select-trial-provides-promising-results-for-obesity-related-hfpef-treatment/)

[Analyst Comment](https://www.clinicaltrialsarena.com/analyst-comment)

### [ESC 2024: SELECT trial provides promising results for obesity-related HFpEF treatment](https://www.clinicaltrialsarena.com/analyst-comment/esc-2024-select-trial-provides-promising-results-for-obesity-related-hfpef-treatment/)

[![Image 13](https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/08/shutterstock_2477204267.jpg)](https://www.clinicaltrialsarena.com/analyst-comment/cancer-vaccine-trials-dominate-us/)

[Analyst Comment](https://www.clinicaltrialsarena.com/analyst-comment)

### [Cancer vaccine trials dominate in the US](https://www.clinicaltrialsarena.com/analyst-comment/cancer-vaccine-trials-dominate-us/)

[![Image 14](https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/08/shutterstock_2371570031-1024x683.jpg)](https://www.clinicaltrialsarena.com/analyst-comment/esc-2024-retatrutide-lipid-cardiovascular-risk-profile-phase-ii/)

[Analyst Comment](https://www.clinicaltrialsarena.com/analyst-comment)

### [ESC 2024: Retatrutide improves lipid and cardiovascular risk profile in Phase II trial](https://www.clinicaltrialsarena.com/analyst-comment/esc-2024-retatrutide-lipid-cardiovascular-risk-profile-phase-ii/)

[![Image 15](https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/08/shutterstock_2347845137-1.jpg)](https://www.clinicaltrialsarena.com/features/dmd-clinical-studies-evolve-with-emphasis-on-building-designs-around-relevant-endpoints/)

[Features](https://www.clinicaltrialsarena.com/features)

### [DMD clinical studies evolve with emphasis on building designs around relevant endpoints](https://www.clinicaltrialsarena.com/features/dmd-clinical-studies-evolve-with-emphasis-on-building-designs-around-relevant-endpoints/)¬†

![Image 16](https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/assets/images/icons/catfish-icon.svg)

#### Sign up for our daily news round-up!

Give your business an edge with our leading industry insights.

Give your business an edge with our leading industry insights.

close

close

#### Sign up to the newsletter: In Brief

 Your corporate email address \* 

 First name \*

 Last name \*

 Company name \*

 Job title \*

#### I would also like to subscribe to:

I consent to Verdict Media Limited collecting my details provided via this form in accordance with [Privacy Policy](https://www.verdict.co.uk/privacy-policy/)

    Subscribe

Visit our [Privacy Policy](https://www.verdict.co.uk/privacy-policy/) for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.                     

Thank you for subscribing
-------------------------

[View all newsletters](https://www.clinicaltrialsarena.com/all-newsletters/) from across the GlobalData Media network.

close

![Image 17: ClinicalTrials](https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2018/06/ClinicalTrialsArena_footer.png)Hard data and deep insights on clinical trials strategy & operations

 [![Image 18](https://www.clinicaltrialsarena.com/code/wp-content/themes/goodlife-wp-B2B/assets/img/icons/linkedin_icon_w.svg)](https://www.linkedin.com/company/clinical-trials-arena)[![Image 19](https://www.clinicaltrialsarena.com/code/wp-content/themes/goodlife-wp-B2B/assets/img/icons/twitter_icon_w.svg)](https://twitter.com/TrialsArena)[![Image 20](https://www.clinicaltrialsarena.com/code/wp-content/themes/goodlife-wp-B2B/assets/img/icons/facebook_icon_w.svg)](https://www.facebook.com/globaldataplc/)

*   [About us](https://www.clinicaltrialsarena.com/about-us-online/)
*   [Advertise with us](https://www.clinicaltrialsarena.com/advertise-with-us/)
*   [License our content](https://www.clinicaltrialsarena.com/license-our-content/)
*   [Contact us](https://www.clinicaltrialsarena.com/contact-us/)
*   [Editorial approach](https://www.clinicaltrialsarena.com/editorial-standards/)
*   [Newsletters](https://www.clinicaltrialsarena.com/all-newsletters/)
*   [Our marketing solution](https://www.verdictmediastrategies.com/)

*   [Privacy policy](https://www.globaldata.com/privacy-policy/)
*   [Terms and conditions](https://www.globaldata.com/terms-conditions/)
*   [Sitemap](https://www.clinicaltrialsarena.com/sitemap/)

Powered by [![Image 21: Pharma Tech Logo](https://www.clinicaltrialsarena.com/code/wp-content/themes/goodlife-wp-B2B/assets/images/verdict-logo-w.png)](https://www.globaldata.com/)

¬© Verdict Media Limited 2024
",gpt-4o-mini
2024-09-02 05:53:22,2024-09-02 10:13:11,"**üîç New Insights on Transthyretin Variants: A Wake-Up Call for Cardiologists!**

Recent research published in JAMA Cardiology reveals that carriers of pathogenic **transthyretin (TTR)** variants might be more prevalent than previously thought, with significant implications for cardiac health. 

In a study analyzing nearly 470,000 UK Biobank participants, 0.1% carried likely pathogenic TTR variants, raising concerns about underdiagnosis of transthyretin amyloidosis (ATTR). The study highlights correlations between these variants and increased risks of heart failure, conduction disease, and overall mortality, stressing the need for clinical vigilance.

üëâ **Clinical Takeaway:** Be attentive to your patients' genetic backgrounds and consider screening for TTR variants in individuals at risk.

For more details, check out the full article [here](https://jamanetwork.com/journals/jamacardiology/fullarticle/2822884).

How have you approached screenings for cardiac amyloidosis in your practice? Share your thoughts below!  

#Cardiology #HeartHealth #Genetics #TTRVariants #MedicalResearch #CardiacCare #JAMACardiology",https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/ps_240405_amyloidosis_800x450.jpg,https://jamanetwork.com/journals/jamacardiology/fullarticle/2822884,"You are a content creator tasked with crafting highly informative, easy to digest social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Thumbnail image URL: https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/ps_240405_amyloidosis_800x450.jpg  
Title: Prevalence, Cardiac Phenotype, and Outcomes of Transthyretin Variants

URL Source: https://jamanetwork.com/journals/jamacardiology/fullarticle/2822884

Markdown Content:
Prevalence, Cardiac Phenotype, and Outcomes of Transthyretin Variants in the UK Biobank Population | Genetics and Genomics | JAMA Cardiology | JAMA Network
===============

[\[Skip to Navigation\]](https://jamanetwork.com/journals/jamacardiology/fullarticle/2822884#skip-to-navigation)

 

 

           

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking ""Continue,"" you are agreeing to our [Cookie Policy](https://jamanetwork.com/pages/privacy-policy#cookies)¬†|¬†[Continue](javascript:;)

  

[![Image 1: JAMA Network Home](https://cdn.jamanetwork.com/UI/app/svg/Jama_Network_Logo.svg)](https://jamanetwork.com/ ""JAMA Network Home"")

[JAMA Cardiology](https://jamanetwork.com/journals/jamacardiology/fullarticle/2822884#nav)

[Home](https://jamanetwork.com/journals/jamacardiology)[New Online](https://jamanetwork.com/journals/jamacardiology/newonline)[Current Issue](https://jamanetwork.com/journals/jamacardiology/currentissue)[For Authors](https://jamanetwork.com/journals/jamacardiology/pages/for-authors)

  

[Podcast](https://jamanetwork.com/journals/jamacardiology/pages/jama-cardiology-author-interviews)

Journals
--------

[JAMA](https://jamanetwork.com/journals/jama) [JAMA Network Open](https://jamanetwork.com/journals/jamanetworkopen) [JAMA Cardiology](https://jamanetwork.com/journals/jamacardiology) [JAMA Dermatology](https://jamanetwork.com/journals/jamadermatology) [JAMA Health Forum](https://jamanetwork.com/journals/jama-health-forum) [JAMA Internal Medicine](https://jamanetwork.com/journals/jamainternalmedicine) [JAMA Neurology](https://jamanetwork.com/journals/jamaneurology) [JAMA Oncology](https://jamanetwork.com/journals/jamaoncology) [JAMA Ophthalmology](https://jamanetwork.com/journals/jamaophthalmology) [JAMA Otolaryngology‚ÄìHead & Neck Surgery](https://jamanetwork.com/journals/jamaotolaryngology) [JAMA Pediatrics](https://jamanetwork.com/journals/jamapediatrics) [JAMA Psychiatry](https://jamanetwork.com/journals/jamapsychiatry) [JAMA Surgery](https://jamanetwork.com/journals/jamasurgery) [Archives of Neurology & Psychiatry (1919-1959)](https://jamanetwork.com/journals/archneurpsyc)

[JN Learning / CME](https://edhub.ama-assn.org/jn-learning)[Subscribe](https://store.jamanetwork.com/index.aspx?productcode=180)[Jobs](https://careers.jamanetwork.com/)[Institutions / Librarians](https://jamanetwork.com/pages/resources-for-librarians)[Reprints & Permissions](https://jamanetwork.com/pages/reprints-and-permissions)

[Terms of Use](https://jamanetwork.com/pages/conditions-of-use) | [Privacy Policy](https://jamanetwork.com/pages/privacy-policy) | [Accessibility Statement](https://jamanetwork.com/pages/accessibility-statement)

2024 American Medical Association. All Rights Reserved

Input Search Term 

[](javascript:;)

[Sign In](javascript:;)

Individual Sign In

[Sign in](https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjamacardiology%2ffullarticle%2f2822884)[Create an Account](https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjamacardiology%2ffullarticle%2f2822884)

Access through your institution

[Sign In](https://jamanetwork.com/signinshibboleth?returnUrl=https%3a%2f%2fjamanetwork.com%2fjournals%2fjamacardiology%2ffullarticle%2f2822884)

Purchase Options:

[Buy this article](https://jamanetwork.com/oauthsignin?return_url=https://store.jamanetwork.com/CustomerType.aspx?articleId=2822884)

[Rent this article](https://www.deepdyve.com/doc-view?docId=10.1001/jamacardio.2024.2190&fieldName=journal_doi&affiliateId=JAMA)

[Subscribe to the JAMA Cardiology journal](https://store.jamanetwork.com/index.aspx?productcode=180)

[](https://jamanetwork.com/journals/jamacardiology/fullarticle/2822884#)

[X](javascript:;) [Facebook](javascript:;)

[LinkedIn](javascript:;)

More

[New Online](https://jamanetwork.com/journals/jamacardiology/newonline/2024/8)

Views 1,008

Citations 0

View Metrics

*   Download PDF
*   Full Text
*   Share
    
    X Facebook Email LinkedIn
    
*   Cite This
*   Permissions
*   Comment

Original Investigation

August¬†28, 2024

Prevalence, Cardiac Phenotype, and Outcomes of Transthyretin Variants in the UK Biobank Population
==================================================================================================

[Nay Aung, PhD1,2](https://jamanetwork.com/searchresults?author=Nay+Aung&q=Nay+Aung); [Hannah L. Nicholls, PhD1](https://jamanetwork.com/searchresults?author=Hannah+L.+Nicholls&q=Hannah+L.+Nicholls); [C. Anwar A. Chahal, PhD1,2,3,4](https://jamanetwork.com/searchresults?author=C.+Anwar+A.+Chahal&q=C.+Anwar+A.+Chahal); et al [Mohammed Y. Khanji, PhD1,2](https://jamanetwork.com/searchresults?author=Mohammed+Y.+Khanji&q=Mohammed+Y.+Khanji); [Elisa Rauseo, MD1,2](https://jamanetwork.com/searchresults?author=Elisa+Rauseo&q=Elisa+Rauseo); [Sucharitha Chadalavada, MBBS1,2](https://jamanetwork.com/searchresults?author=Sucharitha+Chadalavada&q=Sucharitha+Chadalavada); [Steffen E. Petersen, DPhil1,2,5](https://jamanetwork.com/searchresults?author=Steffen+E.+Petersen&q=Steffen+E.+Petersen); [Patricia B. Munroe, PhD1](https://jamanetwork.com/searchresults?author=Patricia+B.+Munroe&q=Patricia+B.+Munroe); [Perry M. Elliott, MBBS, MD2,6](https://jamanetwork.com/searchresults?author=Perry+M.+Elliott&q=Perry+M.+Elliott); [Luis R. Lopes, PhD2,6](https://jamanetwork.com/searchresults?author=Luis+R.+Lopes&q=Luis+R.+Lopes)

Author Affiliations [Article Information](https://jamanetwork.com/journals/jamacardiology/fullarticle/2822884#249869472)

*   1William Harvey Research Institute, Queen Mary University of London, United Kingdom
    
*   2Barts Heart Centre, St Bartholomew‚Äôs Hospital, Barts Health NHS Trust, West Smithfield, London, United Kingdom
    
*   3Center for Inherited Cardiovascular Diseases, WellSpan Health, York, Pennsylvania
    
*   4Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
    
*   5Health Data Research, London, United Kingdom
    
*   6Centre for Heart Muscle Disease, Institute of Cardiovascular Science, University College London, United Kingdom
    

JAMA Cardiol. Published online August 28, 2024. doi:10.1001/jamacardio.2024.2190

[_visual abstract icon_ Visual Abstract](https://jamanetwork.com/journals/jamacardiology/fullarticle/2822884#graphical-abstract-tab)[_editorial comment icon_ Editorial Comment](https://jamanetwork.com/journals/jamacardiology/fullarticle/2822884#editorial-comment-tab)[_related articles icon_ Related Articles](https://jamanetwork.com/journals/jamacardiology/fullarticle/2822884#related-articles-tab)[_author interview icon_ Interviews](https://jamanetwork.com/journals/jamacardiology/fullarticle/2822884#author-interviews-tab)[_multimedia icon_ Multimedia](https://jamanetwork.com/journals/jamacardiology/fullarticle/2822884#more-multimedia-tab)[_audio icon_ Listen to this article](https://jamanetwork.com/journals/jamacardiology/fullarticle/2822884#listen-to-this-article-tab)

*   [Editorial Genotype- vs Phenotype-Guided Approaches to Improve ATTR Detection](https://jamanetwork.com/journals/jamacardiology/fullarticle/2822887)
    
    Jessica A.¬†Regan,¬†MD; Marianna¬†Fontana,¬†MD, PhD; Senthil¬†Selvaraj,¬†MD, MS, MA
    
    JAMA Cardiology
    

Audio (20:11)

[Prevalence, Cardiac Phenotype, and Outcomes of Transthyretin Variants](https://jamanetwork.com/learning/audio-player/18907773)

 [![Image 2: Backward 15](https://cdn.jamanetwork.com/UI/app/svg/multimedia/Backward_15.svg)](javascript:;)[![Image 3: Play](https://cdn.jamanetwork.com/UI/app/svg/multimedia/Play.svg)](javascript:;)[![Image 4: Pause](https://cdn.jamanetwork.com/UI/app/svg/multimedia/Pause.svg)](javascript:;)[![Image 5: Forward 15](https://cdn.jamanetwork.com/UI/app/svg/multimedia/Forward_15.svg)](javascript:;)

[1x](javascript:;)

0:00 / 0:00

[Subscribe to Podcast](https://jamanetwork.com/journals/jamacardiology/pages/jama-cardiology-author-interviews)

Full Text

Key Points**Question**¬† What are the prevalence, cardiac phenotypes, and outcomes of transthyretin gene (_TTR_) variants in the UK Biobank population?

**Findings**¬† In this cohort study of 469‚ÄØ789 UK Biobank participants, 0.1% were found to be carriers of likely pathogenic or pathogenic _TTR_ variants, which is higher than previously reported. Despite clinical codes suggesting low disease penetrance, cardiac expression of these genotypes was evident from associations with left ventricular mass, conduction disease, incident heart failure, and all-cause mortality.

**Meaning**¬† These findings emphasize the need for clinical vigilance in identifying individuals at risk of developing transthyretin amyloidosis and associated poor outcomes.

Abstract

**Importance**¬† The population prevalence of cardiac transthyretin amyloidosis (ATTR) caused by pathogenic variation in the _TTR_ gene (vATTR) is unknown.

**Objective**¬† To estimate the population prevalence of disease-causing _TTR_ variants and evaluate associated phenotypes and outcomes.

**Design, Setting, and Participants**¬† This population-based cohort study analyzed UK Biobank (UKB) participants with whole-exome sequencing, electrocardiogram, and cardiovascular magnetic resonance data. Participants were enrolled from 2006 to 2010, with a median follow-up of 12 (IQR, 11-13) years (cutoff date for the analysis, March 12, 2024). Sixty-two candidate _TTR_ variants were extracted based on rarity (minor allele frequency ‚â§0.0001) and/or previously described associations with amyloidosis if more frequent.

**Exposure**¬† Carrier status for _TTR_ variants.

**Main Outcomes and Measures**¬† Associations of _TTR_ carrier status with vATTR prevalence and cardiovascular imaging and electrocardiogram traits were explored using descriptive statistics. Associations between _TTR_ carrier status and atrial fibrillation, conduction disease, heart failure, and all-cause mortality were evaluated using adjusted Cox proportional hazards models. Genotypic and diagnostic concordance was examined using _International Statistical Classification of Diseases, Tenth Revision_ codes from the hospital record.

**Results**¬† The overall cohort included 469‚ÄØ789 UKB participants (mean \[SD\] age, 56.5 \[8.1\] years; 54.2% female and 45.8% male). A likely pathogenic/pathogenic (LP/P) _TTR_ variant was detected in 473 (0.1%) participants, with Val142Ile being the most prevalent (367 \[77.6%\]); 91 individuals (0.02%) were carriers of a variant of unknown significance . The overall prevalence of LP/P variants was 0.02% (105 of 444‚ÄØ243) in participants with European ancestry and 4.3% (321 of 7533) in participants with African ancestry. The LP/P variants were associated with higher left ventricular mass indexed to body surface area (Œ≤‚Äâ=‚Äâ4.66; 95% CI, 1.87-7.44), and Val142Ile was associated with a longer PR interval (Œ≤‚Äâ=‚Äâ18.34; 95% CI, 5.41-31.27). The LP/P carrier status was associated with a higher risk of heart failure (hazard ratio \[HR\], 2.68; 95% CI, 1.75-4.12) and conduction disease (HR, 1.88; 95% CI, 1.25-2.83). Higher all-cause mortality risk was observed for non-Val142Ile LP/P variants (HR, 1.98; 95% CI, 1.06-3.67). Thirteen participants (2.8%) with LP/P variants had diagnostic codes compatible with cardiac or neurologic amyloidosis. Variants of unknown significance were not associated with outcomes.

**Conclusions and Relevance**¬† This study found that approximately 1 in 1000 UKB participants were LP/P _TTR_ variant carriers, exceeding previously reported prevalence. The findings emphasize the need for clinical vigilance in identifying individuals at risk of developing vATTR and associated poor outcomes.

*   [Editorial Genotype- vs Phenotype-Guided Approaches to Improve ATTR Detection](https://jamanetwork.com/journals/jamacardiology/fullarticle/2822887)
    
    JAMA Cardiology
    

Full Text

![Image 6: Seamless Access Logo](https://cdn.jamanetwork.com/UI/app/svg/seamless-access.svg)

Access through your institution

Add or change institution

[Comment](javascript:;)

#### Read More About

[Genetics and Genomics](https://jamanetwork.com/collections/5664/genetics-and-genomics)

Download PDF Full Text

Cite This

### Citation

Aung N, Nicholls HL, Chahal CAA, et al. Prevalence, Cardiac Phenotype, and Outcomes of Transthyretin Variants in the UK Biobank Population. _JAMA Cardiol._ Published online August 28, 2024. doi:10.1001/jamacardio.2024.2190

#### Manage citations:

[Ris (Zotero)](https://jamanetwork.com/Citation/Download?resourceId=2822884&resourceType=3&citationFormat=0) [EndNote](https://jamanetwork.com/Citation/Download?resourceId=2822884&resourceType=3&citationFormat=1) [BibTex](https://jamanetwork.com/Citation/Download?resourceId=2822884&resourceType=3&citationFormat=2) [Medlars](https://jamanetwork.com/Citation/Download?resourceId=2822884&resourceType=3&citationFormat=3) [ProCite](https://jamanetwork.com/Citation/Download?resourceId=2822884&resourceType=3&citationFormat=0) [RefWorks](https://jamanetwork.com/Citation/Download?resourceId=2822884&resourceType=3&citationFormat=3) [Reference Manager](https://jamanetwork.com/Citation/Download?resourceId=2822884&resourceType=3&citationFormat=0) [Mendeley](https://jamanetwork.com/Citation/Download?resourceId=2822884&resourceType=3&citationFormat=0)

¬© 2024

[Permissions](http://s100.copyright.com/AppDispatchServlet?publisherName=AMA&publication=2380-6583&title=Prevalence%2c+Cardiac+Phenotype%2c+and+Outcomes+of+Transthyretin+Variants+in+the+UK+Biobank+Population&publicationDate=2024-08-28&volumeNum=&issueNum=&author=Aung%2c+Nay%3b+Nicholls%2c+Hannah+L.&startPage=&endPage=&contentId=10.1001%2fjamacardio.2024.2190&oa=&orderBeanReset=True)

[Comment](https://jamanetwork.com/journals/jamacardiology/fullarticle/2822884#modal-opener)

![Image 7: Seamless Access Logo](https://cdn.jamanetwork.com/UI/app/svg/seamless-access.svg)

Access through your institution

Add or change institution

 

 

[Artificial Intelligence Resource Center](https://jamanetwork.com/channels/ai)

#### Others Also Liked

  

#### Select Your Interests

Customize your JAMA Network experience by selecting one or more topics from the list below.

*   Academic Medicine
*   Acid Base, Electrolytes, Fluids
*   Allergy and Clinical Immunology
*   American Indian or Alaska Natives
*   Anesthesiology
*   Anticoagulation
*   Art and Images in Psychiatry
*   Artificial Intelligence
*   Assisted Reproduction
*   Bleeding and Transfusion
*   Cardiology
*   Caring for the Critically Ill Patient
*   Challenges in Clinical Electrocardiography
*   Climate and Health
*   Climate Change
*   Clinical Challenge
*   Clinical Decision Support
*   Clinical Implications of Basic Neuroscience
*   Clinical Pharmacy and Pharmacology
*   Complementary and Alternative Medicine
*   Consensus Statements
*   Coronavirus (COVID-19)
*   Critical Care Medicine
*   Cultural Competency
*   Dental Medicine
*   Dermatology
*   Diabetes and Endocrinology
*   Diagnostic Test Interpretation
*   Drug Development
*   Electronic Health Records
*   Emergency Medicine
*   End of Life, Hospice, Palliative Care
*   Environmental Health
*   Equity, Diversity, and Inclusion
*   Ethics
*   Facial Plastic Surgery
*   Gastroenterology and Hepatology
*   Genetics and Genomics
*   Genomics and Precision Health
*   Geriatrics
*   Global Health
*   Guide to Statistics and Methods
*   Guidelines
*   Hair Disorders
*   Health Care Delivery Models
*   Health Care Economics, Insurance, Payment
*   Health Care Quality
*   Health Care Reform
*   Health Care Safety
*   Health Care Workforce
*   Health Disparities
*   Health Inequities
*   Health Policy
*   Health Systems Science
*   Hematology
*   History of Medicine
*   Humanities
*   Hypertension
*   Images in Neurology
*   Implementation Science
*   Infectious Diseases
*   Innovations in Health Care Delivery
*   JAMA Infographic
*   Law and Medicine
*   Leading Change
*   Less is More
*   LGBTQIA Medicine
*   Lifestyle Behaviors
*   Medical Coding
*   Medical Devices and Equipment
*   Medical Education
*   Medical Education and Training
*   Medical Journals and Publishing
*   Melanoma
*   Mobile Health and Telemedicine
*   Narrative Medicine
*   Nephrology
*   Neurology
*   Neuroscience and Psychiatry
*   Notable Notes
*   Nursing
*   Nutrition
*   Nutrition, Obesity, Exercise
*   Obesity
*   Obstetrics and Gynecology
*   Occupational Health
*   Oncology
*   Ophthalmology
*   Orthopedics
*   Otolaryngology
*   Pain Medicine
*   Palliative Care
*   Pathology and Laboratory Medicine
*   Patient Care
*   Patient Information
*   Pediatrics
*   Performance Improvement
*   Performance Measures
*   Perioperative Care and Consultation
*   Pharmacoeconomics
*   Pharmacoepidemiology
*   Pharmacogenetics
*   Pharmacy and Clinical Pharmacology
*   Physical Medicine and Rehabilitation
*   Physical Therapy
*   Physician Leadership
*   Poetry
*   Population Health
*   Primary Care
*   Professional Well-being
*   Professionalism
*   Psychiatry and Behavioral Health
*   Public Health
*   Pulmonary Medicine
*   Radiology
*   Regulatory Agencies
*   Reproductive Health
*   Research, Methods, Statistics
*   Resuscitation
*   Rheumatology
*   Risk Management
*   Scientific Discovery and the Future of Medicine
*   Shared Decision Making and Communication
*   Sleep Medicine
*   Sports Medicine
*   Stem Cell Transplantation
*   Substance Use and Addiction Medicine
*   Surgery
*   Surgical Innovation
*   Surgical Pearls
*   Teachable Moment
*   Technology and Finance
*   The Art of JAMA
*   The Arts and Medicine
*   The Rational Clinical Examination
*   Tobacco and e-Cigarettes
*   Toxicology
*   Translational Medicine
*   Trauma and Injury
*   Treatment Adherence
*   Ultrasonography
*   Urology
*   Users' Guide to the Medical Literature
*   Vaccination
*   Venous Thromboembolism
*   Veterans Health
*   Violence
*   Women's Health
*   Workflow and Process
*   Wound Care, Infection, Healing

Save Preferences

[Privacy Policy](https://jamanetwork.com/pages/privacy-policy) | [Terms of Use](https://jamanetwork.com/pages/terms-of-use)

X

  

### JAMA Cardiology

#### Content

[Home](https://jamanetwork.com/journals/jamacardiology) [New Online](https://jamanetwork.com/journals/jamacardiology/newonline) [Current Issue](https://jamanetwork.com/journals/jamacardiology/currentissue)

#### Podcast

[JAMA Cardiology Author Interviews](https://jamanetwork.com/journals/jamacardiology/pages/jama-cardiology-author-interviews)

#### Journal Information

[For Authors](https://jamanetwork.com/journals/jamacardiology/pages/for-authors) [Editors & Publishers](https://jamanetwork.com/journals/jamacardiology/editors-and-publishers) [RSS](https://jamanetwork.com/pages/rss) [Contact Us](https://jamanetwork.com/journals/jamacardiology/pages/contact-us)

[JN Learning / CME](https://edhub.ama-assn.org/jn-learning) [Store](https://store.jamanetwork.com/) [Apps](https://jamanetwork.com/pages/apps) [Jobs](https://careers.jamanetwork.com/) [Institutions](https://jamanetwork.com/pages/resources-for-librarians) [Reprints & Permissions](https://jamanetwork.com/pages/reprints-and-permissions)

![Image 8: Journal Cover](https://cdn.jamanetwork.com/UI/app/img/covers/cardi.jpg)

#### Subscribe

[Go](https://store.jamanetwork.com/productDetails.aspx?productcodeID=180)

  

### **JAMA** Network

#### Publications

[JAMA](https://jamanetwork.com/journals/jama) [JAMA Network Open](https://jamanetwork.com/journals/jamanetworkopen) [JAMA Cardiology](https://jamanetwork.com/journals/jamacardiology) [JAMA Dermatology](https://jamanetwork.com/journals/jamadermatology) [JAMA Health Forum](https://jamanetwork.com/journals/jama-health-forum) [JAMA Internal Medicine](https://jamanetwork.com/journals/jamainternalmedicine) [JAMA Neurology](https://jamanetwork.com/journals/jamaneurology) [JAMA Oncology](https://jamanetwork.com/journals/jamaoncology) [JAMA Ophthalmology](https://jamanetwork.com/journals/jamaophthalmology) [JAMA Otolaryngology‚ÄìHead & Neck Surgery](https://jamanetwork.com/journals/jamaotolaryngology) [JAMA Pediatrics](https://jamanetwork.com/journals/jamapediatrics) [JAMA Psychiatry](https://jamanetwork.com/journals/jamapsychiatry) [JAMA Surgery](https://jamanetwork.com/journals/jamasurgery) [Archives of Neurology & Psychiatry (1919-1959)](https://jamanetwork.com/journals/archneurpsyc)

#### Sites

[AI in Clinical Practice](https://jamanetwork.com/channels/ai-in-clinical-practice) [Art and Images in Psychiatry](https://sites.jamanetwork.com/art-and-images-in-psychiatry/) [Best of the JAMA Network](https://jamanetwork.com/journals/jama/pages/2023-most-viewed-jama) [Caring for the Critically Ill Patient](https://jamanetwork.com/channels/caring-for-the-critically-ill-patient) [Clinical Crosswords from JAMA](https://jamanetwork.com/journals/jama/pages/crosswords) [Coronavirus Resource Center](https://jamanetwork.com/journals/jama/pages/coronavirus-alert) [Evidence-Based Medicine: An Oral History](https://ebm.jamanetwork.com/index.html) [Fishbein Fellowship](https://jamanetwork.com/pages/fishbein-fellowship) [Genomics and Precision Health](https://jamanetwork.com/channels/genomics/) [Hypertension](https://jamanetwork.com/channels/hypertension) [JAMA Forum Archive](https://jamanetwork.com/channels/health-forum/archive) [JAMA Network Audio](https://sites.jamanetwork.com/audio) [JAMA Network Video](https://jamanetwork.com/pages/video) [JAMA Network Conferences](https://jamanetwork.com/pages/conferences) [JAMA Summit](https://jamanetwork.com/pages/jama-summit) [JAMA Surgery Guide to Statistics and Methods](https://jamanetwork.com/journals/jamasurgery/pages/statistics-and-methods) [Medical News](https://jamanetwork.com/channels/medical-news) [Mpox (Monkeypox)](https://jamanetwork.com/channels/monkeypox) [Research Ethics](https://sites.jamanetwork.com/research-ethics/) [Topics and Collections](https://jamanetwork.com/pages/collections) [Visual Abstracts](https://jamanetwork.com/pages/visual-abstracts) [War and Health](https://jamanetwork.com/channels/war) [Women's Health](https://jamanetwork.com/channels/womens-health)

#### Featured Articles

[Antiretroviral Drugs for HIV Treatment and Prevention in Adults - 2022 IAS-USA Recommendations](https://jamanetwork.com/journals/jama/fullarticle/2799240) [CONSERVE 2021 Guidelines for Reporting Trials Modified for the COVID-19 Pandemic](https://jamanetwork.com/journals/jama/fullarticle/2781397) [Creation and Adoption of Large Language Models in Medicine](https://jamanetwork.com/journals/jama/fullarticle/2808296) [Global Burden of Cancer, 2010-2019](https://jamanetwork.com/journals/jamaoncology/fullarticle/2787350) [Global Burden of Long COVID](https://jamanetwork.com/journals/jama/fullarticle/2797443) [Global Burden of Melanoma](https://jamanetwork.com/journals/jamadermatology/fullarticle/2790344) [Global Burden of Skin Diseases, 1990-2017](https://jamanetwork.com/journals/jamadermatology/fullarticle/2787350) [Global Disparities in Parkinson Disease](https://jamanetwork.com/journals/jamaneurology/fullarticle/2793874) [Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension](https://jamanetwork.com/journals/jama/fullarticle/2799547) [Mass Violence and the Complex Spectrum of Mental Illness and Mental Functioning](https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2799486) [Neuropsychiatry Sequelae of COVID-19](https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2793903) [A New Framework for Dementia Nomenclature](https://jamanetwork.com/journals/jamaneurology/fullarticle/2810313) [Organization and Performance of US Health Systems](https://jamanetwork.com/journals/jama/fullarticle/2800656) [Pharmacy Benefit Managers: History, Business Practices, Economics, and Policy](https://jamanetwork.com/journals/jama-health-forum/fullarticle/2791195) [Promoting EDI in Genetics Research](https://jamanetwork.com/journals/jama-health-forum/fullarticle/2791195) [PTSD and Cardiovascular Disease](https://jamanetwork.com/journals/jamacardiology/fullarticle/2781972) [Red Blood Cell Transfusion: 2023 AABB International Guidelines](https://jamanetwork.com/journals/jama/fullarticle/2810754) [Reimagining Children‚Äôs Rights in the US](https://jamanetwork.com/journals/jamapediatrics/fullarticle/2797600) [Spirituality in Serious Illness and Health](https://jamanetwork.com/journals/jama/fullarticle/2794049) [The US Medicaid Program: Coverage, Financing, Reforms, and Implications for Health Equity](https://jamanetwork.com/journals/jama/fullarticle/2796374)

#### USPSTF Recommendation Statements

[Screening for Colorectal Cancer](https://jamanetwork.com/journals/jama/fullarticle/2779985) [Screening for Hypertension](https://jamanetwork.com/journals/jama/fullarticle/2779190) [Screening for Lung Cancer](https://jamanetwork.com/journals/jama/fullarticle/2777244) [Screening for Prediabetes and Type 2 Diabetes In Children](https://jamanetwork.com/journals/jama/fullarticle/2796244) [Screening for Prediabetes and Type 2 Diabetes In Adults](https://jamanetwork.com/journals/jama/fullarticle/2783414) [Statins for Primary Prevention of Cardiovascular Disease](https://jamanetwork.com/journals/jama/fullarticle/2795521) [Vitamin and Mineral Supplements for Primary Prevention of of Cardiovascular Disease and Cancer](https://jamanetwork.com/journals/jama/fullarticle/2793446)

#### Blogs

[AMA Style Insider](https://amastyleinsider.com/)

#### Information

[For Authors](https://jamanetwork.com/pages/for-authors) [For Institutions & Librarians](https://jamanetwork.com/pages/resources-for-librarians) [For Advertisers](https://jamanetwork.com/pages/advertisers) [For Subscription Agents](https://jamanetwork.com/pages/subscription-agents) [For Employers & Job Seekers](https://careers.jamanetwork.com/) [For the Media](https://media.jamanetwork.com/) [Equity, Diversity, Inclusion](https://jamanetwork.com/pages/equity-diversity-inclusion) [Online Commenting Policy](https://jamanetwork.com/pages/commenting-policy) [Public Access and Open Access Policy](https://jamanetwork.com/pages/access-at-jama-network) [Statement on Potentially Offensive Content](https://jamanetwork.com/pages/offensive-content-statement)

#### JAMA Network Products

[AMA Manual of Style](http://www.amamanualofstyle.com/) [JAMAevidence](https://jamaevidence.mhmedical.com/) [Peer Review Congress](http://www.peerreviewcongress.org/)

#### JN Learning

[Home](https://edhub.ama-assn.org/jn-learning) [State CME](https://edhub.ama-assn.org/jn-learning/state-cme) [Clinical Challenge CME](https://edhub.ama-assn.org/jn-learning/pages/clinical-challenge-courses) [Atrial Fibrillation Course](https://edhub.ama-assn.org/jn-learning/course/288) [Women's Health Course](https://edhub.ama-assn.org/jn-learning/course/294) [CME / MOC Reporting Preferences](https://edhub.ama-assn.org/pages/auto-credit-reporting) [About CME & MOC](https://edhub.ama-assn.org/jn-learning/pages/about-cme)

  

### Help

[Subscriptions & Renewals](https://store.jamanetwork.com/) [Manage Emails](https://jamanetwork.com/oauthsignin?return_url=http%3A%2F%2Fjamanetwork.com%2Fmyaccount%23my-alerts) [Update My Address](https://jamanetwork.com/oauthsignin?return_url=http%3A%2F%2Fjamanetwork.com%2Fmyaccount%23my-profile) [Support Center](https://support.jamanetwork.com/hc/en-us) [My Account](https://jamanetwork.com/myaccount)

#### JAMA Career Center

[Physician Job Listings](https://careers.jamanetwork.com/)

  

[](https://www.facebook.com/JAMACardiology)[](https://twitter.com/jamacardio)[](https://www.instagram.com/jamanetwork/?hl=en)[](https://www.linkedin.com/showcase/jamacardiology/)[](https://ja.ma/caryt)[](https://www.pinterest.com/jamanetwork/)[](https://jamanetwork.com/rss/site_192/184.xml)[](https://jamanetwork.com/journals/jamacardiology/pages/jama-cardiology-author-interviews)

Get the latest from JAMA Cardiology

 [Sign Up](javascript:;)

[Privacy Policy](https://jamanetwork.com/pages/privacy-policy) | [Terms of Use](https://jamanetwork.com/pages/terms-of-use)

   [![Image 9: Jama Network Logo](https://cdn.jamanetwork.com/ImageLibrary/global/jn-signature-reversed-r.svg?versionId=82308)](https://jamanetwork.com/ ""JAMA Network Home"")

¬© 2024 American Medical Association. All rights reserved, including those for text and data mining, AI training, and similar technologies. [Terms of Use](https://www.ama-assn.org/about/terms-use)| [Privacy Policy](https://www.ama-assn.org/about/privacy-policy)| [Accessibility Statement](https://www.ama-assn.org/about/accessibility-statement)| Cookie Settings

[![Image 10: Silverchair Logo](https://cdn.jamanetwork.com/UI/app/img/powered.png)](https://www.silverchair.com/)

  .
",gpt-4o-mini
2024-09-02 02:59:00,2024-09-02 10:13:23,"### Enhance Collaboration in Primary Care Teams for Quality Patient Care!  
Primary care teams thrive on effective collaboration. Dr. Honor Merriman highlights key strategies to foster teamwork:  
1Ô∏è‚É£ Set meaningful objectives to create trust and shared purpose.  
2Ô∏è‚É£ Define clear roles and responsibilities to ensure efficient problem-solving.  
3Ô∏è‚É£ Foster psychological safety within your team‚Äîencourage open dialogue and reflection.  
Digital tools and regular huddles can significantly enhance communication and team cohesion.  
**Let‚Äôs work together to improve patient outcomes! Share your insights on team collaboration in the comments below!**  

#PrimaryCare #Teamwork #Collaboration #PatientCare #HealthcareProfessionals",,http://medscape.co.uk/viewarticle/how-can-primary-care-teams-collaborate-more-effectively-2024a1000f0i,"You are a content creator tasked with crafting highly informative, easy to digest social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Thumbnail image URL: nan  
Title: How Can Primary Care Teams Collaborate More Effectively?

URL Source: http://medscape.co.uk/viewarticle/how-can-primary-care-teams-collaborate-more-effectively-2024a1000f0i

Published Time: 2024-09-02T02:59:00-04:00

Markdown Content:
How Can Primary Care Teams Collaborate More Effectively?
===============
                                     

This site is intended for UK healthcare professionals

[![Image 1: Medscape UK Univadis Logo](http://img.wbmdstatic.com/medscapeuk_static_vue/medscape-uk-page-article/client/img/medscape-uk-logo.4a9c814f.svg)](http://medscape.co.uk/)

*   Recent Searches [Clear](http://medscape.co.uk/viewarticle/how-can-primary-care-teams-collaborate-more-effectively-2024a1000f0i#)

Log In Register

[![Image 2: Medscape UK Univadis Logo](http://img.wbmdstatic.com/medscapeuk_static_vue/medscape-uk-page-article/client/img/medscape-uk-logo.4a9c814f.svg)](http://medscape.co.uk/)

*   Recent Searches [Clear](http://medscape.co.uk/viewarticle/how-can-primary-care-teams-collaborate-more-effectively-2024a1000f0i#)

Log In Register

*   Recent Searches [Clear](http://medscape.co.uk/viewarticle/how-can-primary-care-teams-collaborate-more-effectively-2024a1000f0i#)

*   Menu
*   News
    
*   Guidelines
    
*   Drugs
    
*   Quizzes
    
*   Search

![Image 3](blob:http://medscape.co.uk/97197544e7d3f69d0df5d7bac7685319)

![Image 4](http://img.wbmdstatic.com/medscapeuk_static_vue/medscape-uk-page-article/client/img/medscape-uk-logo.4a9c814f.svg)![Image 5](blob:http://medscape.co.uk/9ef8406a8b57feca58cd71da69ad13a9)![Image 6](http://img.wbmdstatic.com/medscapeuk_static_vue/medscape-uk-page-article/client/img/ginp-logo.2f11b0b5.svg)

Welcome to the new home of Guidelines in Practice

Browse our expert articles to support best practice for UK healthcare professionals.

Got it

For Primary Care | View from the ground

How Can Primary Care Teams Collaborate More Effectively?
========================================================

Dr Honor Merriman | [Disclosures](http://medscape.co.uk/viewarticle/how-can-primary-care-teams-collaborate-more-effectively-2024a1000f0i#) | 02 September 2024

### Disclosures

[](http://medscape.co.uk/viewarticle/how-can-primary-care-teams-collaborate-more-effectively-2024a1000f0i#)

Author(s)

![Image 7](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/Dr%20Honor%20Merriman%20Updated%20Photo.png)

**Dr Honor Merriman**

_GP, Senior Appraiser, and Clinical Advisor, NHS England South East_

[](http://medscape.co.uk/viewarticle/how-can-primary-care-teams-collaborate-more-effectively-2024a1000f0i#)

**View from the Ground, by Dr Honor Merriman**

GPs‚Äô roles have changed enormously over the past few years. Having worked in the same practice for over 40 years, I perhaps see things from a different perspective, but I don‚Äôt think I am alone in this. I am a mentor to a few GPs in the national New to Practice Programme, and those I meet feel the same. The responsibility for making clinical decisions rests with GPs despite increasing involvement from other healthcare professionals. These practitioners have differing skill sets and lead on clinical areas that are rapidly changing;1,2 at present, these changes are not always shared with GPs. Better communication and understanding of any changes will enable more effective collaboration in primary care, facilitating provision of a quality service for patients‚Äîeven if the way primary care does this has changed.1

Continue Reading Below

### GPs as the Backstop¬†

One example of GPs charting unfamiliar territory when supporting the patients of another healthcare professional is evident in the management of diabetes. Many patients with diabetes are now managed by specialist diabetes nurses;3 however, when one of these patients has a problem and the nurse is unavailable, a GP is often asked to solve the problem. For significantly unwell patients, hospital admission is the best option, but for most queries, knowledge of current best practice in diabetes is needed. Fortunately, the regular general updates most GPs do with medical education providers such as NB Medical Education or Red Whale provide most of the answers.4,5

Similarly, a pregnant patient may need medical advice the same day, but has been unable to contact the midwife team, so it falls to the GP. Some problems are not pregnancy related, such as respiratory infections. Others can present problems, such as aching calves with no abnormality found on examination. Testing the patient‚Äôs D-dimer level would not be helpful because it is raised in pregnancy anyway.6 Venous thromboembolism is more common in pregnant than nonpregnant women.7 GPs may feel unskilled, as midwife teams now look after most antenatal patients.8 Advice is on hand from the local obstetric unit‚Äîbut again, the clinician with the least experience is the first to be contacted.

### The Fundamentals of Effective Collaboration

In well-developed practice teams, there is good communication, and complex problems are solved by adopting a multifaceted approach.1 So, how can primary care teams collaborate more effectively to achieve the best result?

Teams that work effectively together demonstrate a mixture of professional skills, mutual professional respect, and clear team communication. The King‚Äôs Fund has published a summary of how to achieve these elements of effective collaboration.1 The three main components are:1

Continue Reading Below

Continue Reading Below

*   **a small number of meaningful objectives**‚Äîobjectives that team members are equally responsible for, to‚ÄØcreate a sense of shared purpose, trust,‚ÄØand collective achievement
*   **clear roles and responsibilities among team members**‚Äîoutlining what activities need to be done and by whom, to ensure that everything is completed and to clarify each member‚Äôs roles and strengths; this should be reviewed regularly
*   **reflection on how the team is working together**‚Äîthis can be in any form (for example, away days or team ‚Äòhuddles‚Äô), to cover both the technical aspects of work as well as how people are feeling; it is important that everyone feels safe to freely express themselves regardless of their role.

### Improving Communication and Teamwork

Google‚Äôs 2-year research project into cultivating great teams found that the highest-performing teams had one thing in common‚Äîpsychological safety, or the belief that members can speak up or make mistakes without retribution.9 This is an important goal that primary care team leaders should aim for, as people become more creative, resilient, and motivated when they feel safe.9

One way to improve communication is through huddles, which are short, frequent check-ins to discuss the day‚Äôs patients and tasks.1 Huddles can allow for the discussion of patient-specific issues and clarification of responsibilities.1

Furthermore, digital communication tools, such as email and video conferencing, are also critical, as each team member will need access to shared patient records and booking systems to view and share information easily when needed‚Äîfor example, on home visits.1

Finally, the physical environmental also plays a role in supporting new teams to function. Shared working spaces are the default location when team members are not seeing a patient, and these spaces have many benefits, such as improving integration and team cohesion, enabling real-time communication in huddles, and facilitating information sharing between team members.1‚ÄØThe King‚Äôs Fund highlights that team members are more likely to be sensitive to one another‚Äôs problems and appreciate each other‚Äôs roles when they have this sort of contact with each other.1

### Ensuring Clinical Accountability and Supportive Management

Clinical supervision, appraisals, and learning and development opportunities are essential to ensure that all team members are held to professional standards and encouraged to reflect on their own practice.1

Clinical supervision and appraisals are essential requirements for all healthcare professionals. There are many effective models of clinical supervision, including one-to-one, group, or peer supervision. Clinical supervision should be developed by teams to meet their needs. Appraisals are a requirement in the NHS, and should be focused on a shared understanding of team goals, two-way communication, and setting goals for the future. In addition, all team members need to have the skills, knowledge, and experience to deliver effective care. Identifying the needs of team members and ensuring access to training and opportunities to develop is critical for all healthcare professionals to maintain their registration and stay up to date with current practice.1

The face of primary care is changing, and making sure that all team members stay on top of changes to their roles and responsibilities is important for fostering a harmonious and effective environment that encourages collaboration and enables provision of a superb service to patients. To those of you who are already doing all of this‚Äîwell done!

Continue reading with a FREE Medscape UK account

Access the latest UK medical news, UK-specific clinical guideline summaries,  
UK vaccination schedule and more for free.

Register Today

Already a member? Log in

* * *

#### 

References

1.  The King‚Äôs Fund website. _How to build effective teams in general practice._¬†[www.kingsfund.org.uk/insight-and-analysis/long-reads/effective-teams-general-practice](https://www.kingsfund.org.uk/insight-and-analysis/long-reads/effective-teams-general-practice) (accessed 19 August 2024).
2.  NHS England website. _Expanding our workforce_. [www.england.nhs.uk/gp/expanding-our-workforce](https://www.england.nhs.uk/gp/expanding-our-workforce/) (accessed 19 August 2024).¬†
3.  Hunter W. _Nurses in general practice have ‚Äòvital role‚Äô in managing diabetes in the community._¬†[www.nursinginpractice.com/clinical/diabetes/nurses-in-general-practice-have-vital-role-in-managing-diabetes-in-the-community](https://www.nursinginpractice.com/clinical/diabetes/nurses-in-general-practice-have-vital-role-in-managing-diabetes-in-the-community) (accessed 19 August 2024).
4.  NB Medical Education website. _Diabetes._¬†[www.nbmedical.com/subjects/diabetes](https://www.nbmedical.com/subjects/diabetes) (accessed 19 August 2024).
5.  Red Whale website. _Red Whale knowledge._¬†[www.redwhale.co.uk](https://www.redwhale.co.uk/) (accessed 19 August 2024).
6.  Miyamoto K, Komatsu H, Okawa M et al. D-dimer level significance for deep vein thrombosis screening in the third trimester: a retrospective study. _BMC Pregnancy Childbirth_¬†2022; **22** (21).
7.  Devis P, Knuttinen M. Deep venous thrombosis in pregnancy: incidence, pathogenesis and endovascular management. _Cardiovasc Diagn Ther_ 2017; **7**¬†(3): S309‚ÄìS319.
8.  Royal College of General Practitioners. _The role of the general practitioner in maternity care_. London: RCGP, 2017. Available at: [www.rcgp.org.uk/getmedia/d98432c6-0db3-4a12-9ea9-9a32e68c3cfa/RCGP-position-statement-GPs-role-maternity-care-2017.pdf](https://www.rcgp.org.uk/getmedia/d98432c6-0db3-4a12-9ea9-9a32e68c3cfa/RCGP-position-statement-GPs-role-maternity-care-2017.pdf)
9.  Poyton B. _Google‚Äôs Project Aristotle._¬†[psychsafety.co.uk/googles-project-aristotle](https://psychsafety.co.uk/googles-project-aristotle/) (accessed 19 August 2024).

* * *

EDITOR'S RECOMMENDATIONS
------------------------

*   [A Day in the Life at a Seaside Practice](https://www.medscape.co.uk/viewarticle/day-life-seaside-practice-2024a1000dh1)
    
    View from the Ground, by An Anonymous GP
    
    View from the ground | An Anonymous GP | 05 August 2024
    
*   [Navigating the Unforeseen: Understanding the Impact of the ARRS on GPs](https://www.medscape.co.uk/viewarticle/navigating-unforeseen-understanding-impact-arrs-gps-2024a1000bst)
    
    View from the ground, by Dr Vasumathy Sivarajasingam
    
    View from the ground | Dr Vasumathy Sivarajasingam | 08 July 2024
    
*   [Meeting Rising Demand for Mental Health Services in Primary Care](https://www.medscape.co.uk/viewarticle/meeting-rising-demand-mental-health-services-primary-care-2024a10008y1)
    
    View from the ground, by Lisa Dymond
    
    View from the ground | Lisa Dymond | 07 June 2024
    

YOU MAY ALSO LIKE
-----------------

[![Image 8: UK's Hereditary Cardiac Amyloidosis Rates Higher Than Expected](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/ps_240405_amyloidosis_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/uks-hereditary-cardiac-amyloidosis-rates-higher-than-2024a1000fw1 ""UK's Hereditary Cardiac Amyloidosis Rates Higher Than Expected"")

[UK's Hereditary Cardiac Amyloidosis Rates Higher Than Expected](https://www.medscape.co.uk/viewarticle/uks-hereditary-cardiac-amyloidosis-rates-higher-than-2024a1000fw1 ""UK's Hereditary Cardiac Amyloidosis Rates Higher Than Expected"")

The researchers urged increased clinical vigilance for hereditary transthyretin amyloidosis in patients with symptoms or unexplained heart muscle thickening.

*   Medscape News UK
*   18 minutes ago

[![Image 9: Why Patients Are Questioning Their Doctors](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_231212_adolescent_care_doctor_exam_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/why-patients-are-questioning-their-doctors-2024a1000fvt ""Why Patients Are Questioning Their Doctors"")

[Why Patients Are Questioning Their Doctors](https://www.medscape.co.uk/viewarticle/why-patients-are-questioning-their-doctors-2024a1000fvt ""Why Patients Are Questioning Their Doctors"")

The crisis of trust in doctors has roots dating back to the 1960s and 1970s, driven by social movements and medical scandals.

*   Medscape News UK
*   1 hours ago

[![Image 10: Could a Vape Flavour Ban Drive Vapers Back to Smoking?](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240830_disposable_flavored_vape_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/could-vape-flavour-ban-drive-users-back-smoking-2024a1000fug ""Could a Vape Flavour Ban Drive Vapers Back to Smoking?"")

[Could a Vape Flavour Ban Drive Vapers Back to Smoking?](https://www.medscape.co.uk/viewarticle/could-vape-flavour-ban-drive-users-back-smoking-2024a1000fug ""Could a Vape Flavour Ban Drive Vapers Back to Smoking?"")

The BMA has called for a ban on all flavoured vape liquids except tobacco in a move that users say, if enacted, would drive them back to smoking.

*   Medscape News UK
*   30 Aug 2024

[Pancreatic Cancer: NICE Quality Standard](https://www.medscape.co.uk/viewarticle/pancreatic-cancer-quality-standard-2024a1000fqo ""Pancreatic Cancer: NICE Quality Standard"")

A summary of the NICE quality standard for the diagnosis of pancreatic cancer and management of pancreatic ductal adenocarcinoma in adults

*   Guidelines Summary: Secondary Care
*   30 Aug 2024

[![Image 11: Mother's Vascular Skin Lesions Increase Risk for Offspring](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_230712_capillary_malformation_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/mothers-vascular-skin-lesions-increase-risk-offspring-2024a1000fq5 ""Mother's Vascular Skin Lesions Increase Risk for Offspring"")

[Mother's Vascular Skin Lesions Increase Risk for Offspring](https://www.medscape.co.uk/viewarticle/mothers-vascular-skin-lesions-increase-risk-offspring-2024a1000fq5 ""Mother's Vascular Skin Lesions Increase Risk for Offspring"")

Findings of a large population-based study supported a possible heritable component for angioma and especially for port-wine stain.

*   Medscape News UK
*   30 Aug 2024

[![Image 12: GPs Encouraged to Test, Treat Latent TB in Immigrants](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_230601_immigrants_refugees_walking_sunset_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/gps-encouraged-test-treat-latent-tb-immigrants-2024a1000fpa ""GPs Encouraged to Test, Treat Latent TB in Immigrants"")

[GPs Encouraged to Test, Treat Latent TB in Immigrants](https://www.medscape.co.uk/viewarticle/gps-encouraged-test-treat-latent-tb-immigrants-2024a1000fpa ""GPs Encouraged to Test, Treat Latent TB in Immigrants"")

Primary care in the United Kingdom is poised to take over TB management.

*   Medscape News UK
*   30 Aug 2024

[![Image 13: Back to School Measles Surge Feared](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_211102_child_vaccination_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/back-school-measles-surge-feared-2024a1000ftp ""Back to School Measles Surge Feared"")

[Back to School Measles Surge Feared](https://www.medscape.co.uk/viewarticle/back-school-measles-surge-feared-2024a1000ftp ""Back to School Measles Surge Feared"")

Experts warn of a potential surge in measles cases when children return to school next week and have urged parents to ensure children are up to date with vaccinations.

*   Medscape News UK
*   30 Aug 2024

[![Image 14: A Tale of Rheumatologist Volunteers Overseas and in the US](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/ht_240823_james_gore_and_patient_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/tale-rheumatologist-volunteers-overseas-and-united-states-2024a1000ftq ""A Tale of Rheumatologist Volunteers Overseas and in the US"")

[A Tale of Rheumatologist Volunteers Overseas and in the US](https://www.medscape.co.uk/s/viewarticle/tale-rheumatologist-volunteers-overseas-and-united-states-2024a1000ftq ""A Tale of Rheumatologist Volunteers Overseas and in the US"")

Two rheumatologists give insights about the great rewards of rheumatology volunteer work while also providing insights on its challenges across different settings.

*   Medscape Medical News
*   30 Aug 2024

[![Image 15: Seated Doctors Satisfy Patients](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240318_doctor_female_senior_patient_talking_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/seated-doctors-satisfy-patients-2024a1000ftl ""Seated Doctors Satisfy Patients"")

[Seated Doctors Satisfy Patients](https://www.medscape.co.uk/s/viewarticle/seated-doctors-satisfy-patients-2024a1000ftl ""Seated Doctors Satisfy Patients"")

A doctor's decision to sit at the bedside is associated with increased patient satisfaction, data suggested.

*   Medscape Medical News
*   30 Aug 2024

[![Image 16: Beyond the Paycheck: Top Nonsalary Perks for Doctors](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240829_happy_excited_doctor_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/beyond-paycheck-top-non-salary-perks-doctors-2024a1000fto ""Beyond the Paycheck: Top Nonsalary Perks for Doctors"")

[Beyond the Paycheck: Top Nonsalary Perks for Doctors](https://www.medscape.co.uk/s/viewarticle/beyond-paycheck-top-non-salary-perks-doctors-2024a1000fto ""Beyond the Paycheck: Top Nonsalary Perks for Doctors"")

When it comes to compensation, a doctor's paycheck is just the beginning. Discover the top nonsalary perks that make the job even more rewarding.

*   Medscape Medical News
*   30 Aug 2024

[![Image 17: NHS Doctors Face Bullying and Reprisal for Speaking Out](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_220902_stressed_doctor_covering_face_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/nhs-doctors-face-bullying-and-reprisal-speaking-out-2024a1000ftj ""NHS Doctors Face Bullying and Reprisal for Speaking Out"")

[NHS Doctors Face Bullying and Reprisal for Speaking Out](https://www.medscape.co.uk/s/viewarticle/nhs-doctors-face-bullying-and-reprisal-speaking-out-2024a1000ftj ""NHS Doctors Face Bullying and Reprisal for Speaking Out"")

Less than 20% of doctors in Scotland are satisfied with their organisation's response to whistleblowing, a new BMA survey has revealed.

*   Press Association
*   30 Aug 2024

[![Image 18: Intermittent Fasting Aids Patients With Prediabetes or T2D](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/dt_240813_intermittent_fasting_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/intermittent-fasting-aids-patients-prediabetes-or-t2d-2024a1000ftc ""Intermittent Fasting Aids Patients With Prediabetes or T2D"")

[Intermittent Fasting Aids Patients With Prediabetes or T2D](https://www.medscape.co.uk/s/viewarticle/intermittent-fasting-aids-patients-prediabetes-or-t2d-2024a1000ftc ""Intermittent Fasting Aids Patients With Prediabetes or T2D"")

The approach is associated with reductions in body weight, BMI, and A1c levels.

*   Medscape Medical News
*   30 Aug 2024

[Cervical Screening Guidance for Nurses](https://www.medscape.co.uk/viewarticle/human-papillomavirus-cervical-screening-and-cervical-cancer-2024a1000dpy ""Cervical Screening Guidance for Nurses"")

Covers cervical cancer and screening recommendations for nursing undertaking consultations and examinations

*   Guidelines Summary: Primary Care
*   30 Aug 2024

[![Image 19: The '10 Commandments' of Endocarditis Management](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240614_afib_heart_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/10-commandments-endocarditis-management-2024a1000ft3 ""The '10 Commandments' of Endocarditis Management"")

[The '10 Commandments' of Endocarditis Management](https://www.medscape.co.uk/viewarticle/10-commandments-endocarditis-management-2024a1000ft3 ""The '10 Commandments' of Endocarditis Management"")

Significant updates in the 2023 European Society of Cardiology endocarditis guidelines include revised antibiotic prophylaxis and surgical indications.

*   Medscape News UK
*   30 Aug 2024

[![Image 20: Balloon Catheters for Blood Loss in Placenta Accreta Cases](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_231121_ultrasound_pregnant_obgyn_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/balloon-catheters-blood-loss-placenta-accreta-cases-2024a1000ft1 ""Balloon Catheters for Blood Loss in Placenta Accreta Cases"")

[Balloon Catheters for Blood Loss in Placenta Accreta Cases](https://www.medscape.co.uk/s/viewarticle/balloon-catheters-blood-loss-placenta-accreta-cases-2024a1000ft1 ""Balloon Catheters for Blood Loss in Placenta Accreta Cases"")

Prophylactic placement of balloon catheters or sheaths prior to planned cesarean delivery may reduce blood loss in women with placenta accreta spectrum disorder.

*   MDedge News
*   30 Aug 2024

[Key Learning Points: BASHH Anogenital Warts](https://www.medscape.co.uk/viewarticle/key-learning-points-bashh-anogenital-warts-2024a1000esn ""Key Learning Points: BASHH Anogenital Warts"")

Dr Amy Cleese reviews the diagnosis and management of anogenital warts in general practice, offering six key learning points from updated guidance

*   Guidelines in Practice: Primary Care
*   30 Aug 2024

[![Image 21: Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/pa_240829_chris_jones_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/breast-cancer-drug-may-slow-aggressive-brain-tumour-kids-2024a1000fra ""Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids"")

[Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids](https://www.medscape.co.uk/s/viewarticle/breast-cancer-drug-may-slow-aggressive-brain-tumour-kids-2024a1000fra ""Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids"")

Ribociclib, commonly used for breast cancer, has been found to stabilise a subtype of diffuse hemispheric glioma for about 17 months before regrowth begins.

*   Press Association
*   29 Aug 2024

[![Image 22: Alternate Insomnia Therapy Has Good Showing](https://img.medscapestatic.com/vim/live/professional_assets/dt_240313_insomnia_800x450px.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu ""Alternate Insomnia Therapy Has Good Showing"")

[Alternate Insomnia Therapy Has Good Showing](https://www.medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu ""Alternate Insomnia Therapy Has Good Showing"")

The brief nurse-delivered therapy aimed at restricting and standardising time in bed could make treatment more accessible to primary care patients.

*   Medscape News UK
*   29 Aug 2024

[![Image 23: Listeriosis During Pregnancy Can Be Fatal for the Fetus](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/dt_240828_listeria_bacteria_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/listeriosis-during-pregnancy-can-be-fatal-fetus-2024a1000frm ""Listeriosis During Pregnancy Can Be Fatal for the Fetus"")

[Listeriosis During Pregnancy Can Be Fatal for the Fetus](https://www.medscape.co.uk/s/viewarticle/listeriosis-during-pregnancy-can-be-fatal-fetus-2024a1000frm ""Listeriosis During Pregnancy Can Be Fatal for the Fetus"")

The rate of fetal loss or neonatal death from invasive listeriosis is 29%.

*   Medscape Medical News
*   29 Aug 2024

![Image 24](blob:http://medscape.co.uk/6742166de2ffdc98a2fc8b83a0aa235b)

[](https://www.medscape.co.uk/)

#### Find Us On

[](https://www.facebook.com/GuidelinesMedscape/)[](https://twitter.com/medscapeuk)[](http://www.linkedin.com/company/24356)[](https://www.youtube.com/user/medscape/)[](https://www.instagram.com/medscape/)

#### About

[About Medscape](https://www.medscape.com/public/about)[Privacy Policy](https://www.medscape.co.uk/public/privacy)[Editorial Policy](https://www.medscape.com/public/editorialpolicies)[Cookies](https://www.medscape.co.uk/public/cookies) [Manage Preferences](javascript:void\(0\);) [Terms of Use](https://www.medscape.com/public/termsofuse)[UK Modern Slavery Statement](https://www.medscape.co.uk/public/antislavery)[Advertising Policy](https://www.medscape.com/public/adpolicy)[Help Center](https://help.medscape.com/hc/en-us)

#### App

[Medscape](https://www.medscape.com/public/medscapeapp?pid=Medscape_footer&c=FooterIcon)

All material on this website is protected by copyright, Copyright ¬© 1994-2024 by WebMD LLC. This website also contains material copyrighted by 3rd parties.

           

![Image 25](https://t.co/i/adsct?bci=3&eci=2&event_id=09f7829d-9d53-4db2-9acd-b0d2a909e592&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=1ed5bba1-299d-4768-a5b2-68caf9202775&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Fhow-can-primary-care-teams-collaborate-more-effectively-2024a1000f0i&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=o5zto&type=javascript&version=2.3.30)![Image 26](https://analytics.twitter.com/i/adsct?bci=3&eci=2&event_id=09f7829d-9d53-4db2-9acd-b0d2a909e592&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=1ed5bba1-299d-4768-a5b2-68caf9202775&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Fhow-can-primary-care-teams-collaborate-more-effectively-2024a1000f0i&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=o5zto&type=javascript&version=2.3.30)![Image 27](https://t.co/i/adsct?bci=3&eci=2&event_id=ecb4e1b7-d6e2-4f9d-8ee7-a0dacf9b8c5c&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=1ed5bba1-299d-4768-a5b2-68caf9202775&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Fhow-can-primary-care-teams-collaborate-more-effectively-2024a1000f0i&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=nvb1e&type=javascript&version=2.3.30)![Image 28](https://analytics.twitter.com/i/adsct?bci=3&eci=2&event_id=ecb4e1b7-d6e2-4f9d-8ee7-a0dacf9b8c5c&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=1ed5bba1-299d-4768-a5b2-68caf9202775&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Fhow-can-primary-care-teams-collaborate-more-effectively-2024a1000f0i&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=nvb1e&type=javascript&version=2.3.30)![Image 29](https://t.co/i/adsct?bci=3&eci=2&event_id=bc892feb-0659-40b5-993f-771944da423f&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=1ed5bba1-299d-4768-a5b2-68caf9202775&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Fhow-can-primary-care-teams-collaborate-more-effectively-2024a1000f0i&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=o5ztw&type=javascript&version=2.3.30)![Image 30](https://analytics.twitter.com/i/adsct?bci=3&eci=2&event_id=bc892feb-0659-40b5-993f-771944da423f&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=1ed5bba1-299d-4768-a5b2-68caf9202775&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Fhow-can-primary-care-teams-collaborate-more-effectively-2024a1000f0i&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=o5ztw&type=javascript&version=2.3.30)

![Image 31](https://thrtle.com/insync?vxii_pid=10015&vxii_pdid=)

![Image 32](https://bh-eu.contextweb.com/bh/sr?action=add&token=Q4S7ZMWDWRFR&ch=1&url=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Fhow-can-primary-care-teams-collaborate-more-effectively-2024a1000f0i&rr=&us_privacy=&param1=$$event$$&epid=&did=10131885100475335982015955002163101530&pf=0&usp=0&auth_channel=100&ev_id=0&topicid=$$topicid$$&conceptid=$$conceptid$$&ssp=34&gdpr_consent=&val=$$val$$&val=${val})![Image 33](https://bh.contextweb.com/bh/rtset?pid=562507&ev=0&us_privacy=)![Image 34](https://bh.contextweb.com/bh/rtset?pid=561967&ev=1&us_privacy=&gdpr=0&gdpr_consent=&rurl=https%3A%2F%2Fdsum.casalemedia.com%2Frum%3Fcm_dsp_id%3D189%26external_user_id%3D%25%25VGUID%25%25%26expiration%3D[EXPIRATION]%26us_privacy%3D%24%24us_privacy%24%24%26gdpr%3D%24%24gdpr%24%24%26gdpr_consent%3D%24%24gdpr_consent%24%24)![Image 35](https://bh.contextweb.com/bh/rtset?pid=561590&ev=1&us_privacy=&gdpr=0&gdpr_consent=&rurl=https%3A%2F%2Fpixel.rubiconproject.com%2Ftap.php%3Fv%3D390200%26nid%3D5120%26put%3D%25%25VGUID%25%25%26us_privacy%3D%24%24us_privacy%24%24%26gdpr%3D%24%24gdpr%24%24%26gdpr_consent%3D%24%24gdpr_consent%24%24)![Image 36](https://bh.contextweb.com/bh/rtset?pid=558356&ev=1&us_privacy=&gdpr=0&gdpr_consent=&rurl=https%3A%2F%2Feb2.3lift.com%2Fxuid%3Fmid%3D2636%26xuid%3D%25%25VGUID%25%25%26dongle%3D8bee%26us_privacy%3D%24%24us_privacy%24%24%26gdpr%3D%24%24gdpr%24%24%26gdpr_consent%3D%24%24gdpr_consent%24%24)
",gpt-4o-mini
2024-09-02 05:14:36,2024-09-02 12:20:44,"üî¨ **Harnessing the Power of AI in Medical Research**  
Discover how artificial intelligence is revolutionizing diagnostic accuracy and patient outcomes!  
Recent studies highlight the potential of AI algorithms in detecting diseases earlier and more accurately than ever before. Are you leveraging these technologies in your practice yet? Share your thoughts and experiences!  
#MedicalResearch #AIinHealthcare #PatientCare #FutureOfMedicine  

![AI in Medical Research](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_220725_microscope_medical_research_800x450.jpg)  

For more insights, check out this recent article: [AI in Medical Diagnostics](https://www.tandfonline.com/doi/full/10.1080/23744235.2024.2389478)",https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_220725_microscope_medical_research_800x450.jpg,https://www.tandfonline.com/doi/full/10.1080/23744235.2024.2389478,"You are a content creator tasked with crafting highly informative, easy to digest social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Thumbnail image URL: https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_220725_microscope_medical_research_800x450.jpg  
Title: Just a moment...

URL Source: https://www.tandfonline.com/doi/full/10.1080/23744235.2024.2389478

Markdown Content:
www.tandfonline.com
-------------------

Verifying you are human. This may take a few seconds.
-----------------------------------------------------

www.tandfonline.com needs to review the security of your connection before proceeding.
",gpt-4o-mini
2024-09-02 09:00:00,2024-09-02 14:10:50,"üö® New Insights into Testicular Cancer Treatment üö®

A recent study explores innovative therapies in managing testicular cancer, offering promising alternatives and improving patient outcomes. 

As medical professionals, staying updated on the latest research is crucial for providing optimal patient care. Understanding these advancements could enhance treatment strategies and lead to better results for patients. 

üìö Dive into the full study here: [Wiley Online Library](https://onlinelibrary.wiley.com/doi/10.1111/andr.13741)  
üîç What are your thoughts on emerging treatment protocols? Share your experiences in the comments below! 

#TesticularCancer #MedicalResearch #Oncology #PatientCare #HealthProfessionals",https://img.medscapestatic.com/vim/live/professional_assets/ps_150302_testicular_cancer_800x600.jpg,https://onlinelibrary.wiley.com/doi/10.1111/andr.13741,"You are a content creator tasked with crafting highly informative, easy to digest social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Thumbnail image URL: https://img.medscapestatic.com/vim/live/professional_assets/ps_150302_testicular_cancer_800x600.jpg  
Title: Just a moment...

URL Source: https://onlinelibrary.wiley.com/doi/10.1111/andr.13741

Markdown Content:
onlinelibrary.wiley.com
-----------------------

Verifying you are human. This may take a few seconds.
-----------------------------------------------------

onlinelibrary.wiley.com needs to review the security of your connection before proceeding.
",gpt-4o-mini
2024-09-02 09:00:00,2024-09-02 16:13:14,"üîç **New Insights on Down Syndrome in Neonates**  
Recent research published in The Lancet sheds light on the important healthcare needs and tailored support for newborns with Down syndrome. üìä The study emphasizes the necessity for early interventions and specialized care strategies to enhance developmental outcomes.  

As healthcare providers, understanding the unique challenges and needs of these infants can lead to more informed treatment plans. Are you incorporating early developmental assessments in your practice? Let's discuss best practices and share experiences in the comments!  

üëâ For more in-depth information, check out the full article here: [The Lancet](https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762/(24/)00202-3/fulltext)  

#DownSyndrome #NeonatalCare #PediatricHealth #MedicalResearch",https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_221202_down_syndrome_baby_800x450.jpg,https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762/(24/)00202-3/fulltext#%20,"You are a content creator tasked with crafting highly informative, easy to digest social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Thumbnail image URL: https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_221202_down_syndrome_baby_800x450.jpg  
Title: Just a moment...

URL Source: https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762/(24/)00202-3/fulltext

Markdown Content:
![Image 1: Icon for www.thelancet.com](https://www.thelancet.com/favicon.ico)www.thelancet.com
----------------------------------------------------------------------------------------------

Verifying you are human. This may take a few seconds.
-----------------------------------------------------

www.thelancet.com needs to review the security of your connection before proceeding.
",gpt-4o-mini
2024-09-02 08:43:26,2024-09-02 16:13:42,"### **Unlocking the Connection: Prenatal Fish Oil & Atopic Dermatitis**  
Recent findings reveal that prenatal fish oil supplementation may significantly reduce the risk of childhood atopic dermatitis (AD) in children of mothers with specific genetic markers. This study analyzed data from a randomized clinical trial and highlighted that mothers with the COX1 _TT_ genotype experienced a lower risk of AD when supplemented with omega-3 fatty acids compared to those who did not receive the supplementation. **Key takeaway**: Consider genetic testing for expecting mothers as part of a tailored approach to AD prevention.  
For more insights, check out the full study here: [JAMA Dermatology](https://jamanetwork.com/journals/jama/fullarticle/10.1001/jamadermatol.2024.2849)  
üí¨ We invite your thoughts: How do you tailor dietary recommendations during pregnancy based on genetic predispositions?  
**#AtopicDermatitis #PrenatalCare #OmegafattyAcids #GeneticTesting #JAMADermatology**  
![Prenatal Fish Oil](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_210818_vitamin_d_800x450.jpg)",https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_210818_vitamin_d_800x450.jpg,https://jamanetwork.com/journals/jama/fullarticle/10.1001/jamadermatol.2024.2849,"You are a content creator tasked with crafting highly informative, easy to digest social media posts specifically for doctors. Your goal is to create posts that begin with a strong, specific, attention-grabbing headline relevant to the medical community. The content should be concise, informative, and focused on topics such as new research findings, emerging medical technologies, or best practices in patient care. Include a subtle call to action that encourages doctors to engage with the content, whether by commenting, sharing their experiences, or exploring additional resources. The tone should be professional yet natural and approachable, and you should incorporate relevant visuals and hashtags to increase the post‚Äôs reach and credibility within the medical field.
Use only content from the webscraping I provide you. Do not use any other content.","Thumbnail image URL: https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_210818_vitamin_d_800x450.jpg  
Title: Prenatal Fish Oil Supplementation, Maternal COX1 Genotype, and Childhood Atopic Dermatitis

URL Source: https://jamanetwork.com/journals/jama/fullarticle/10.1001/jamadermatol.2024.2849

Markdown Content:
Prenatal Fish Oil Supplementation, Maternal COX1 Genotype, and Childhood Atopic Dermatitis: A Secondary Analysis of a Randomized Clinical Trial | Reproductive Health | JAMA Dermatology | JAMA Network
=============== 

[\[Skip to Navigation\]](https://jamanetwork.com/journals/jama/fullarticle/10.1001/jamadermatol.2024.2849#skip-to-navigation)

 

 

           

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking ""Continue,"" you are agreeing to our [Cookie Policy](https://jamanetwork.com/pages/privacy-policy#cookies)¬†|¬†[Continue](javascript:;)

  

[![Image 1: JAMA Network Home](https://cdn.jamanetwork.com/UI/app/svg/Jama_Network_Logo.svg)](https://jamanetwork.com/ ""JAMA Network Home"")

[JAMA Dermatology](https://jamanetwork.com/journals/jama/fullarticle/10.1001/jamadermatol.2024.2849#nav)

[Home](https://jamanetwork.com/journals/jamadermatology)[New Online](https://jamanetwork.com/journals/jamadermatology/newonline)[Current Issue](https://jamanetwork.com/journals/jamadermatology/currentissue)[For Authors](https://jamanetwork.com/journals/jamadermatology/pages/for-authors)

  

[Podcast](https://jamanetwork.com/journals/jamadermatology/pages/jama-dermatology-author-interviews)

Journals
--------

[JAMA](https://jamanetwork.com/journals/jama) [JAMA Network Open](https://jamanetwork.com/journals/jamanetworkopen) [JAMA Cardiology](https://jamanetwork.com/journals/jamacardiology) [JAMA Dermatology](https://jamanetwork.com/journals/jamadermatology) [JAMA Health Forum](https://jamanetwork.com/journals/jama-health-forum) [JAMA Internal Medicine](https://jamanetwork.com/journals/jamainternalmedicine) [JAMA Neurology](https://jamanetwork.com/journals/jamaneurology) [JAMA Oncology](https://jamanetwork.com/journals/jamaoncology) [JAMA Ophthalmology](https://jamanetwork.com/journals/jamaophthalmology) [JAMA Otolaryngology‚ÄìHead & Neck Surgery](https://jamanetwork.com/journals/jamaotolaryngology) [JAMA Pediatrics](https://jamanetwork.com/journals/jamapediatrics) [JAMA Psychiatry](https://jamanetwork.com/journals/jamapsychiatry) [JAMA Surgery](https://jamanetwork.com/journals/jamasurgery) [Archives of Neurology & Psychiatry (1919-1959)](https://jamanetwork.com/journals/archneurpsyc)

[JN Learning / CME](https://edhub.ama-assn.org/jn-learning)[Subscribe](https://store.jamanetwork.com/index.aspx?productcode=53)[Jobs](https://careers.jamanetwork.com/)[Institutions / Librarians](https://jamanetwork.com/pages/resources-for-librarians)[Reprints & Permissions](https://jamanetwork.com/pages/reprints-and-permissions)

[Terms of Use](https://jamanetwork.com/pages/conditions-of-use) | [Privacy Policy](https://jamanetwork.com/pages/privacy-policy) | [Accessibility Statement](https://jamanetwork.com/pages/accessibility-statement)

2024 American Medical Association. All Rights Reserved

Input Search Term 

[](javascript:;)

[Sign In](javascript:;)

Individual Sign In

[Sign in](https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjamadermatology%2ffullarticle%2f2823065)[Create an Account](https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjamadermatology%2ffullarticle%2f2823065)

Access through your institution

[Sign In](https://jamanetwork.com/signinshibboleth?returnUrl=https%3a%2f%2fjamanetwork.com%2fjournals%2fjamadermatology%2ffullarticle%2f2823065)

Purchase Options:

[Buy this article](https://jamanetwork.com/oauthsignin?return_url=https://store.jamanetwork.com/CustomerType.aspx?articleId=2823065)

[Rent this article](https://www.deepdyve.com/doc-view?docId=10.1001/jamadermatol.2024.2849&fieldName=journal_doi&affiliateId=JAMA)

[Subscribe to the JAMA Dermatology journal](https://store.jamanetwork.com/index.aspx?productcode=53)

[](https://jamanetwork.com/journals/jama/fullarticle/10.1001/jamadermatol.2024.2849#)

[X](javascript:;) [Facebook](javascript:;)

[LinkedIn](javascript:;)

More

[New Online](https://jamanetwork.com/journals/jamadermatology/newonline/2024/8)

Views 778

Citations 0

View Metrics

*   Download PDF
*   Full Text
*   Share
    
    X Facebook Email LinkedIn
    
*   Cite This
*   Permissions
*   Comment

Original Investigation

August¬†28, 2024

Prenatal Fish Oil Supplementation, Maternal COX1 Genotype, and Childhood Atopic Dermatitis: A Secondary Analysis of a Randomized Clinical Trial
===============================================================================================================================================

[Liang Chen, MSc1](https://jamanetwork.com/searchresults?author=Liang+Chen&q=Liang+Chen); [Nicklas Brustad, MD, PhD1](https://jamanetwork.com/searchresults?author=Nicklas+Brustad&q=Nicklas+Brustad); [Yang Luo, MSc1](https://jamanetwork.com/searchresults?author=Yang+Luo&q=Yang+Luo); et al [Tingting Wang, MSc, PhD1](https://jamanetwork.com/searchresults?author=Tingting+Wang&q=Tingting+Wang); [Mina Ali, MSc, PhD1](https://jamanetwork.com/searchresults?author=Mina+Ali&q=Mina+Ali); [Parvaneh Ebrahimi, MSc, PhD1,2](https://jamanetwork.com/searchresults?author=Parvaneh+Ebrahimi&q=Parvaneh+Ebrahimi); [Ann-Marie M. Schoos, MD, PhD1,3,4](https://jamanetwork.com/searchresults?author=Ann-Marie+M.+Schoos&q=Ann-Marie+M.+Schoos); [Nilo Vahman, MD, PhD1](https://jamanetwork.com/searchresults?author=Nilo+Vahman&q=Nilo+Vahman); [Mario Lovriƒá, MSc, PhD1,5,6](https://jamanetwork.com/searchresults?author=Mario+Lovri%c4%87&q=Mario+Lovri%c4%87); [Morten A. Rasmussen, MSc, PhD1,2](https://jamanetwork.com/searchresults?author=Morten+A.+Rasmussen&q=Morten+A.+Rasmussen); [Johan Kolmert, MSc, PhD7](https://jamanetwork.com/searchresults?author=Johan+Kolmert&q=Johan+Kolmert); [Craig E. Wheelock, MSc, PhD7](https://jamanetwork.com/searchresults?author=Craig+E.+Wheelock&q=Craig+E.+Wheelock); [Jessica A. Lasky-Su, ScD8](https://jamanetwork.com/searchresults?author=Jessica+A.+Lasky-Su&q=Jessica+A.+Lasky-Su); [Jakob Stokholm, MD, PhD1,2,4](https://jamanetwork.com/searchresults?author=Jakob+Stokholm&q=Jakob+Stokholm); [Klaus B√∏nnelykke, MD, PhD1,3](https://jamanetwork.com/searchresults?author=Klaus+B%c3%b8nnelykke&q=Klaus+B%c3%b8nnelykke); [Bo Chawes, MD, PhD, DMSc1,3](https://jamanetwork.com/searchresults?author=Bo+Chawes&q=Bo+Chawes)

Author Affiliations [Article Information](https://jamanetwork.com/journals/jama/fullarticle/10.1001/jamadermatol.2024.2849#249877385)

*   1Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
    
*   2Food Microbiology, Gut Health, and Fermentation, Department of Food Science, University of Copenhagen, Frederiksberg C, Denmark
    
*   3Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
    
*   4Department of Pediatrics, Slagelse Hospital, Slagelse, Denmark
    
*   5Centre for Applied Bioanthropology, Institute for Anthropological Research, Zagreb, Croatia
    
*   6Faculty of Electrical Engineering, Computer Science and Information Technology Osijek, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
    
*   7Unit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden
    
*   8Channing Division of Network Medicine, Department of Medicine, Brigham and Women‚Äôs Hospital and Harvard Medical School, Boston, Massachusetts
    

JAMA Dermatol. Published online August 28, 2024. doi:10.1001/jamadermatol.2024.2849

[_visual abstract icon_ Visual Abstract](https://jamanetwork.com/journals/jama/fullarticle/10.1001/jamadermatol.2024.2849#graphical-abstract-tab)[_editorial comment icon_ Editorial Comment](https://jamanetwork.com/journals/jama/fullarticle/10.1001/jamadermatol.2024.2849#editorial-comment-tab)[_related articles icon_ Related Articles](https://jamanetwork.com/journals/jama/fullarticle/10.1001/jamadermatol.2024.2849#related-articles-tab)[_author interview icon_ Interviews](https://jamanetwork.com/journals/jama/fullarticle/10.1001/jamadermatol.2024.2849#author-interviews-tab)[_multimedia icon_ Multimedia](https://jamanetwork.com/journals/jama/fullarticle/10.1001/jamadermatol.2024.2849#more-multimedia-tab)[_audio icon_ Listen to this article](https://jamanetwork.com/journals/jama/fullarticle/10.1001/jamadermatol.2024.2849#listen-to-this-article-tab)

Full Text

Key Points**Question**¬† Is œâ-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA; ie, fish oil) supplementation during pregnancy associated with reduced risk of childhood atopic dermatitis (AD) in mothers carrying specific cyclooxygenase-1 (COX1) genotypes?

**Findings**¬† In this secondary analysis of a randomized clinical trial including 635 mother-child pairs with 10-year follow-up, a reduced risk of childhood AD until age 10 years was found only for mothers carrying the COX1 _TT_ genotype who received n-3 LCPUFA supplements. There was increased AD risk among children of mothers with the _CC_ genotype and no association overall or for mothers carrying the _CT_ genotype.

**Meaning**¬† The findings support use of a personalized prevention strategy for reducing the burden of childhood AD by genotyping expecting mothers in early pregnancy and providing n-3 LCPUFA supplementation only to women carrying the COX1 _TT_ genotype.

Abstract

**Importance**¬† Eicosanoids have a pathophysiological role in atopic dermatitis (AD), but it is unknown whether this is affected by prenatal œâ-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA; ie, fish oil) supplementation and genetic variations in the cyclooxygenase-1 (COX1) pathway.

**Objective**¬† To explore the association of n-3 LCPUFA supplementation during pregnancy with risk of childhood AD overall and by maternal COX1 genotype.

**Design, Setting, and Participants**¬† This prespecified secondary analysis of a randomized clinical trial included mother-child pairs from the Danish Copenhagen Prospective Studies on Asthma in Childhood 2010 birth cohort, with prospective follow-up until children were aged 10 years. In the trial, maternal and child COX1 genotypes were determined, and urinary eicosanoids were quantified when the child was 1 year of age. The present study was conducted from January 2019 to December 2021, and data were analyzed from January to September 2023.

**Intervention**¬† A total of 736 pregnant women at 24 weeks‚Äô gestation were randomized 1:1 to 2.4 g of n-3 LCPUFA (fish oil) or placebo (olive oil) per day until 1 week post partum.

**Main Outcomes and Measures**¬† Risk of childhood AD until age 10 years overall and by maternal COX1 genotype.

**Results**¬† At age 10 years, 635 children (91%; 363 \[57%\] female) completed the clinical follow-up, and these mother-child pairs were included in this study; 321 (51%) were in the intervention group and 314 (49%) in the control group. Pregnancy n-3 LCPUFA supplementation was associated with lower urinary thromboxane A2 metabolites at age 1 year (Œ≤, ‚Äì0.46; 95% CI, ‚Äì0.80 to ‚Äì0.13; _P_‚Äâ=‚Äâ.006), which was also associated with COX1 rs1330344 genotype (Œ≤ per _C_ allele, 0.47; 95% CI, 0.20-0.73; _P_‚Äâ=‚Äâ.001). Although neither n-3 LCPUFA supplementation (hazard ratio \[HR\], 1.00; 95% CI, 0.76-1.33; _P_‚Äâ=‚Äâ.97) nor maternal COX1 genotype (HR, 0.94; 95% CI, 0.74-1.19; _P_‚Äâ=‚Äâ.60) was associated with risk of childhood AD until age 10 years, there was evidence of an interaction between these variables (_P_‚Äâ<‚Äâ.001 for interaction). Among mothers with the _TT_ genotype, risk of AD was reduced in the n-3 LCPUFA group compared with the placebo group (390 mother-child pairs \[61%\]; HR, 0.70; 95% CI, 0.50-0.98; _P_‚Äâ=‚Äâ.04); there was no association for mothers with the _CT_ genotype (209 \[33%\]; HR, 1.29; 95% CI, 0.79-2.10; _P_‚Äâ=‚Äâ.31), and risk was increased among offspring of mothers with the _CC_ genotype (37 \[6%\]; HR, 5.77; 95% CI, 1.63-20.47; _P_‚Äâ=‚Äâ.007). There was a significant interaction between n-3 LCPUFA supplementation and child COX1 genotype and development of AD (_P_‚Äâ=‚Äâ.002 for interaction).

**Conclusions and Relevance**¬† In this secondary analysis of a randomized clinical trial, the association of prenatal n-3 LCPUFA supplementation with risk of childhood AD varied by maternal COX1 genotype. The findings could be used to inform a personalized prevention strategy of providing supplementation only to pregnant individuals with the _TT_ genotype.

**Trial Registration**¬† ClinicalTrials.gov: [NCT00798226](https://clinicaltrials.gov/study/NCT00798226)

Full Text

![Image 2: Seamless Access Logo](https://cdn.jamanetwork.com/UI/app/svg/seamless-access.svg)

Access through your institution

Add or change institution

[Comment](javascript:;)

#### Read More About

[Reproductive Health](https://jamanetwork.com/collections/46443/reproductive-health) [Genetics and Genomics](https://jamanetwork.com/collections/5664/genetics-and-genomics) [Women's Health](https://jamanetwork.com/collections/42139/womens-health) [Obstetrics](https://jamanetwork.com/collections/42121/obstetrics) [Obstetrics and Gynecology](https://jamanetwork.com/collections/44013/obstetrics-and-gynecology) [Pediatrics](https://jamanetwork.com/collections/5843/pediatrics) [Allergy and Clinical Immunology](https://jamanetwork.com/collections/5504/allergy-and-clinical-immunology) [Dermatology](https://jamanetwork.com/collections/5598/dermatology) [Atopic Dermatitis](https://jamanetwork.com/collections/42141/atopic-dermatitis)

Download PDF Full Text

Cite This

### Citation

Chen L, Brustad N, Luo Y, et al. Prenatal Fish Oil Supplementation, Maternal COX1 Genotype, and Childhood Atopic Dermatitis: A Secondary Analysis of a Randomized Clinical Trial. _JAMA Dermatol._ Published online August 28, 2024. doi:10.1001/jamadermatol.2024.2849

#### Manage citations:

[Ris (Zotero)](https://jamanetwork.com/Citation/Download?resourceId=2823065&resourceType=3&citationFormat=0) [EndNote](https://jamanetwork.com/Citation/Download?resourceId=2823065&resourceType=3&citationFormat=1) [BibTex](https://jamanetwork.com/Citation/Download?resourceId=2823065&resourceType=3&citationFormat=2) [Medlars](https://jamanetwork.com/Citation/Download?resourceId=2823065&resourceType=3&citationFormat=3) [ProCite](https://jamanetwork.com/Citation/Download?resourceId=2823065&resourceType=3&citationFormat=0) [RefWorks](https://jamanetwork.com/Citation/Download?resourceId=2823065&resourceType=3&citationFormat=3) [Reference Manager](https://jamanetwork.com/Citation/Download?resourceId=2823065&resourceType=3&citationFormat=0) [Mendeley](https://jamanetwork.com/Citation/Download?resourceId=2823065&resourceType=3&citationFormat=0)

¬© 2024

[Permissions](http://s100.copyright.com/AppDispatchServlet?publisherName=AMA&publication=2168-6068&title=Prenatal+Fish+Oil+Supplementation%2c+Maternal+COX1+Genotype%2c+and+Childhood+Atopic+Dermatitis%3a+A+Secondary+Analysis+of+a+Randomized+Clinical+Trial&publicationDate=2024-08-28&volumeNum=&issueNum=&author=Chen%2c+Liang%3b+Brustad%2c+Nicklas&startPage=&endPage=&contentId=10.1001%2fjamadermatol.2024.2849&oa=&orderBeanReset=True)

[Comment](https://jamanetwork.com/journals/jama/fullarticle/10.1001/jamadermatol.2024.2849#modal-opener)

![Image 3: Seamless Access Logo](https://cdn.jamanetwork.com/UI/app/svg/seamless-access.svg)

Access through your institution

Add or change institution

 

 

[Artificial Intelligence Resource Center](https://jamanetwork.com/channels/ai)

#### Others Also Liked

  

#### Select Your Interests

Customize your JAMA Network experience by selecting one or more topics from the list below.

*   Academic Medicine
*   Acid Base, Electrolytes, Fluids
*   Allergy and Clinical Immunology
*   American Indian or Alaska Natives
*   Anesthesiology
*   Anticoagulation
*   Art and Images in Psychiatry
*   Artificial Intelligence
*   Assisted Reproduction
*   Bleeding and Transfusion
*   Cardiology
*   Caring for the Critically Ill Patient
*   Challenges in Clinical Electrocardiography
*   Climate and Health
*   Climate Change
*   Clinical Challenge
*   Clinical Decision Support
*   Clinical Implications of Basic Neuroscience
*   Clinical Pharmacy and Pharmacology
*   Complementary and Alternative Medicine
*   Consensus Statements
*   Coronavirus (COVID-19)
*   Critical Care Medicine
*   Cultural Competency
*   Dental Medicine
*   Dermatology
*   Diabetes and Endocrinology
*   Diagnostic Test Interpretation
*   Drug Development
*   Electronic Health Records
*   Emergency Medicine
*   End of Life, Hospice, Palliative Care
*   Environmental Health
*   Equity, Diversity, and Inclusion
*   Ethics
*   Facial Plastic Surgery
*   Gastroenterology and Hepatology
*   Genetics and Genomics
*   Genomics and Precision Health
*   Geriatrics
*   Global Health
*   Guide to Statistics and Methods
*   Guidelines
*   Hair Disorders
*   Health Care Delivery Models
*   Health Care Economics, Insurance, Payment
*   Health Care Quality
*   Health Care Reform
*   Health Care Safety
*   Health Care Workforce
*   Health Disparities
*   Health Inequities
*   Health Policy
*   Health Systems Science
*   Hematology
*   History of Medicine
*   Humanities
*   Hypertension
*   Images in Neurology
*   Implementation Science
*   Infectious Diseases
*   Innovations in Health Care Delivery
*   JAMA Infographic
*   Law and Medicine
*   Leading Change
*   Less is More
*   LGBTQIA Medicine
*   Lifestyle Behaviors
*   Medical Coding
*   Medical Devices and Equipment
*   Medical Education
*   Medical Education and Training
*   Medical Journals and Publishing
*   Melanoma
*   Mobile Health and Telemedicine
*   Narrative Medicine
*   Nephrology
*   Neurology
*   Neuroscience and Psychiatry
*   Notable Notes
*   Nursing
*   Nutrition
*   Nutrition, Obesity, Exercise
*   Obesity
*   Obstetrics and Gynecology
*   Occupational Health
*   Oncology
*   Ophthalmology
*   Orthopedics
*   Otolaryngology
*   Pain Medicine
*   Palliative Care
*   Pathology and Laboratory Medicine
*   Patient Care
*   Patient Information
*   Pediatrics
*   Performance Improvement
*   Performance Measures
*   Perioperative Care and Consultation
*   Pharmacoeconomics
*   Pharmacoepidemiology
*   Pharmacogenetics
*   Pharmacy and Clinical Pharmacology
*   Physical Medicine and Rehabilitation
*   Physical Therapy
*   Physician Leadership
*   Poetry
*   Population Health
*   Primary Care
*   Professional Well-being
*   Professionalism
*   Psychiatry and Behavioral Health
*   Public Health
*   Pulmonary Medicine
*   Radiology
*   Regulatory Agencies
*   Reproductive Health
*   Research, Methods, Statistics
*   Resuscitation
*   Rheumatology
*   Risk Management
*   Scientific Discovery and the Future of Medicine
*   Shared Decision Making and Communication
*   Sleep Medicine
*   Sports Medicine
*   Stem Cell Transplantation
*   Substance Use and Addiction Medicine
*   Surgery
*   Surgical Innovation
*   Surgical Pearls
*   Teachable Moment
*   Technology and Finance
*   The Art of JAMA
*   The Arts and Medicine
*   The Rational Clinical Examination
*   Tobacco and e-Cigarettes
*   Toxicology
*   Translational Medicine
*   Trauma and Injury
*   Treatment Adherence
*   Ultrasonography
*   Urology
*   Users' Guide to the Medical Literature
*   Vaccination
*   Venous Thromboembolism
*   Veterans Health
*   Violence
*   Women's Health
*   Workflow and Process
*   Wound Care, Infection, Healing

Save Preferences

[Privacy Policy](https://jamanetwork.com/pages/privacy-policy) | [Terms of Use](https://jamanetwork.com/pages/terms-of-use)

X

  

### JAMA Dermatology

#### Content

[Home](https://jamanetwork.com/journals/jamadermatology) [New Online](https://jamanetwork.com/journals/jamadermatology/newonline) [Current Issue](https://jamanetwork.com/journals/jamadermatology/currentissue)

#### Podcast

[JAMA Dermatology Author Interviews](https://jamanetwork.com/journals/jamadermatology/pages/jama-dermatology-author-interviews)

#### Journal Information

[For Authors](https://jamanetwork.com/journals/jamadermatology/pages/for-authors) [Editors & Publishers](https://jamanetwork.com/journals/jamadermatology/editors-and-publishers) [RSS](https://jamanetwork.com/pages/rss) [Contact Us](https://jamanetwork.com/journals/jamadermatology/pages/contact-us)

[JN Learning / CME](https://edhub.ama-assn.org/jn-learning) [Store](https://store.jamanetwork.com/) [Apps](https://jamanetwork.com/pages/apps) [Jobs](https://careers.jamanetwork.com/) [Institutions](https://jamanetwork.com/pages/resources-for-librarians) [Reprints & Permissions](https://jamanetwork.com/pages/reprints-and-permissions)

![Image 4: Journal Cover](https://cdn.jamanetwork.com/UI/app/img/covers/derm.jpg)

#### Subscribe

[Go](https://store.jamanetwork.com/productDetails.aspx?productcodeID=53)

  

### **JAMA** Network

#### Publications

[JAMA](https://jamanetwork.com/journals/jama) [JAMA Network Open](https://jamanetwork.com/journals/jamanetworkopen) [JAMA Cardiology](https://jamanetwork.com/journals/jamacardiology) [JAMA Dermatology](https://jamanetwork.com/journals/jamadermatology) [JAMA Health Forum](https://jamanetwork.com/journals/jama-health-forum) [JAMA Internal Medicine](https://jamanetwork.com/journals/jamainternalmedicine) [JAMA Neurology](https://jamanetwork.com/journals/jamaneurology) [JAMA Oncology](https://jamanetwork.com/journals/jamaoncology) [JAMA Ophthalmology](https://jamanetwork.com/journals/jamaophthalmology) [JAMA Otolaryngology‚ÄìHead & Neck Surgery](https://jamanetwork.com/journals/jamaotolaryngology) [JAMA Pediatrics](https://jamanetwork.com/journals/jamapediatrics) [JAMA Psychiatry](https://jamanetwork.com/journals/jamapsychiatry) [JAMA Surgery](https://jamanetwork.com/journals/jamasurgery) [Archives of Neurology & Psychiatry (1919-1959)](https://jamanetwork.com/journals/archneurpsyc)

#### Sites

[AI in Clinical Practice](https://jamanetwork.com/channels/ai-in-clinical-practice) [Art and Images in Psychiatry](https://sites.jamanetwork.com/art-and-images-in-psychiatry/) [Best of the JAMA Network](https://jamanetwork.com/journals/jama/pages/2023-most-viewed-jama) [Caring for the Critically Ill Patient](https://jamanetwork.com/channels/caring-for-the-critically-ill-patient) [Clinical Crosswords from JAMA](https://jamanetwork.com/journals/jama/pages/crosswords) [Coronavirus Resource Center](https://jamanetwork.com/journals/jama/pages/coronavirus-alert) [Evidence-Based Medicine: An Oral History](https://ebm.jamanetwork.com/index.html) [Fishbein Fellowship](https://jamanetwork.com/pages/fishbein-fellowship) [Genomics and Precision Health](https://jamanetwork.com/channels/genomics/) [Hypertension](https://jamanetwork.com/channels/hypertension) [JAMA Forum Archive](https://jamanetwork.com/channels/health-forum/archive) [JAMA Network Audio](https://sites.jamanetwork.com/audio) [JAMA Network Video](https://jamanetwork.com/pages/video) [JAMA Network Conferences](https://jamanetwork.com/pages/conferences) [JAMA Summit](https://jamanetwork.com/pages/jama-summit) [JAMA Surgery Guide to Statistics and Methods](https://jamanetwork.com/journals/jamasurgery/pages/statistics-and-methods) [Medical News](https://jamanetwork.com/channels/medical-news) [Mpox (Monkeypox)](https://jamanetwork.com/channels/monkeypox) [Research Ethics](https://sites.jamanetwork.com/research-ethics/) [Topics and Collections](https://jamanetwork.com/pages/collections) [Visual Abstracts](https://jamanetwork.com/pages/visual-abstracts) [War and Health](https://jamanetwork.com/channels/war) [Women's Health](https://jamanetwork.com/channels/womens-health)

#### Featured Articles

[Antiretroviral Drugs for HIV Treatment and Prevention in Adults - 2022 IAS-USA Recommendations](https://jamanetwork.com/journals/jama/fullarticle/2799240) [CONSERVE 2021 Guidelines for Reporting Trials Modified for the COVID-19 Pandemic](https://jamanetwork.com/journals/jama/fullarticle/2781397) [Creation and Adoption of Large Language Models in Medicine](https://jamanetwork.com/journals/jama/fullarticle/2808296) [Global Burden of Cancer, 2010-2019](https://jamanetwork.com/journals/jamaoncology/fullarticle/2787350) [Global Burden of Long COVID](https://jamanetwork.com/journals/jama/fullarticle/2797443) [Global Burden of Melanoma](https://jamanetwork.com/journals/jamadermatology/fullarticle/2790344) [Global Burden of Skin Diseases, 1990-2017](https://jamanetwork.com/journals/jamadermatology/fullarticle/2787350) [Global Disparities in Parkinson Disease](https://jamanetwork.com/journals/jamaneurology/fullarticle/2793874) [Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension](https://jamanetwork.com/journals/jama/fullarticle/2799547) [Mass Violence and the Complex Spectrum of Mental Illness and Mental Functioning](https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2799486) [Neuropsychiatry Sequelae of COVID-19](https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2793903) [A New Framework for Dementia Nomenclature](https://jamanetwork.com/journals/jamaneurology/fullarticle/2810313) [Organization and Performance of US Health Systems](https://jamanetwork.com/journals/jama/fullarticle/2800656) [Pharmacy Benefit Managers: History, Business Practices, Economics, and Policy](https://jamanetwork.com/journals/jama-health-forum/fullarticle/2791195) [Promoting EDI in Genetics Research](https://jamanetwork.com/journals/jama-health-forum/fullarticle/2791195) [PTSD and Cardiovascular Disease](https://jamanetwork.com/journals/jamacardiology/fullarticle/2781972) [Red Blood Cell Transfusion: 2023 AABB International Guidelines](https://jamanetwork.com/journals/jama/fullarticle/2810754) [Reimagining Children‚Äôs Rights in the US](https://jamanetwork.com/journals/jamapediatrics/fullarticle/2797600) [Spirituality in Serious Illness and Health](https://jamanetwork.com/journals/jama/fullarticle/2794049) [The US Medicaid Program: Coverage, Financing, Reforms, and Implications for Health Equity](https://jamanetwork.com/journals/jama/fullarticle/2796374)

#### USPSTF Recommendation Statements

[Screening for Colorectal Cancer](https://jamanetwork.com/journals/jama/fullarticle/2779985) [Screening for Hypertension](https://jamanetwork.com/journals/jama/fullarticle/2779190) [Screening for Lung Cancer](https://jamanetwork.com/journals/jama/fullarticle/2777244) [Screening for Prediabetes and Type 2 Diabetes In Children](https://jamanetwork.com/journals/jama/fullarticle/2796244) [Screening for Prediabetes and Type 2 Diabetes In Adults](https://jamanetwork.com/journals/jama/fullarticle/2783414) [Statins for Primary Prevention of Cardiovascular Disease](https://jamanetwork.com/journals/jama/fullarticle/2795521) [Vitamin and Mineral Supplements for Primary Prevention of of Cardiovascular Disease and Cancer](https://jamanetwork.com/journals/jama/fullarticle/2793446)

#### Blogs

[AMA Style Insider](https://amastyleinsider.com/)

#### Information

[For Authors](https://jamanetwork.com/pages/for-authors) [For Institutions & Librarians](https://jamanetwork.com/pages/resources-for-librarians) [For Advertisers](https://jamanetwork.com/pages/advertisers) [For Subscription Agents](https://jamanetwork.com/pages/subscription-agents) [For Employers & Job Seekers](https://careers.jamanetwork.com/) [For the Media](https://media.jamanetwork.com/) [Equity, Diversity, Inclusion](https://jamanetwork.com/pages/equity-diversity-inclusion) [Online Commenting Policy](https://jamanetwork.com/pages/commenting-policy) [Public Access and Open Access Policy](https://jamanetwork.com/pages/access-at-jama-network) [Statement on Potentially Offensive Content](https://jamanetwork.com/pages/offensive-content-statement)

#### JAMA Network Products

[AMA Manual of Style](http://www.amamanualofstyle.com/) [JAMAevidence](https://jamaevidence.mhmedical.com/) [Peer Review Congress](http://www.peerreviewcongress.org/)

#### JN Learning

[Home](https://edhub.ama-assn.org/jn-learning) [State CME](https://edhub.ama-assn.org/jn-learning/state-cme) [Clinical Challenge CME](https://edhub.ama-assn.org/jn-learning/pages/clinical-challenge-courses) [Atrial Fibrillation Course](https://edhub.ama-assn.org/jn-learning/course/288) [Women's Health Course](https://edhub.ama-assn.org/jn-learning/course/294) [CME / MOC Reporting Preferences](https://edhub.ama-assn.org/pages/auto-credit-reporting) [About CME & MOC](https://edhub.ama-assn.org/jn-learning/pages/about-cme)

  

### Help

[Subscriptions & Renewals](https://store.jamanetwork.com/) [Manage Emails](https://jamanetwork.com/oauthsignin?return_url=http%3A%2F%2Fjamanetwork.com%2Fmyaccount%23my-alerts) [Update My Address](https://jamanetwork.com/oauthsignin?return_url=http%3A%2F%2Fjamanetwork.com%2Fmyaccount%23my-profile) [Support Center](https://support.jamanetwork.com/hc/en-us) [My Account](https://jamanetwork.com/myaccount)

#### JAMA Career Center

[Physician Job Listings](https://careers.jamanetwork.com/)

  

[](https://www.facebook.com/jamadermatology/)[](https://twitter.com/JAMADerm)[](https://www.instagram.com/jamanetwork/?hl=en)[](https://www.linkedin.com/showcase/jamadermatology/)[](https://ja.ma/dermyt)[](https://www.pinterest.com/jamanetwork/)[](https://jamanetwork.com/rss/site_12/68.xml)[](https://jamanetwork.com/journals/jamadermatology/pages/jama-dermatology-author-interviews)

Get the latest from JAMA Dermatology

 [Sign Up](javascript:;)

[Privacy Policy](https://jamanetwork.com/pages/privacy-policy) | [Terms of Use](https://jamanetwork.com/pages/terms-of-use)

   [![Image 5: Jama Network Logo](https://cdn.jamanetwork.com/ImageLibrary/global/jn-signature-reversed-r.svg?versionId=82308)](https://jamanetwork.com/ ""JAMA Network Home"")

¬© 2024 American Medical Association. All rights reserved, including those for text and data mining, AI training, and similar technologies. [Terms of Use](https://www.ama-assn.org/about/terms-use)| [Privacy Policy](https://www.ama-assn.org/about/privacy-policy)| [Accessibility Statement](https://www.ama-assn.org/about/accessibility-statement)| Cookie Settings

[![Image 6: Silverchair Logo](https://cdn.jamanetwork.com/UI/app/img/powered.png)](https://www.silverchair.com/)

  .

√ó

Access your subscriptions

* * *

Sign in | personal account

![Image 7: Seamless Access Logo](https://cdn.jamanetwork.com/UI/app/svg/seamless-access.svg)

Access through your institution

Add or change institution

 

Free access to newly published articles

* * *

Create a free personal account

To register for email alerts, access free PDF, and more

 

Purchase access

* * *

Subscribe to journal

Get full journal access for 1 year

Buy article

Get unlimited access and a printable PDF ($40.00)‚Äî  
_Sign in or create a free account_

Rent article

Rent this article from DeepDyve

Access your subscriptions

* * *

Sign in | personal account

![Image 8: Seamless Access Logo](https://cdn.jamanetwork.com/UI/app/svg/seamless-access.svg)

Access through your institution

Add or change institution

 

Free access to newly published articles

* * *

Create a free personal account

To register for email alerts, access free PDF, and more

 

Purchase access

* * *

Subscribe to journal

Get full journal access for 1 year

Buy article

Get unlimited access and a printable PDF ($40.00)‚Äî  
_Sign in or create a free account_

Rent article

Rent this article from DeepDyve

Sign in to access free PDF

* * *

Sign in | personal account

![Image 9: Seamless Access Logo](https://cdn.jamanetwork.com/UI/app/svg/seamless-access.svg)

Access through your institution

Add or change institution

 

Free access to newly published articles

* * *

Create a free personal account

To register for email alerts, access free PDF, and more

Save your search

* * *

Sign in | personal account

 

Free access to newly published articles

* * *

Create a free personal account

To register for email alerts, access free PDF, and more

 

Purchase access

* * *

Subscribe now

Customize your interests

* * *

Sign in | personal account

 

Free access to newly published articles

* * *

Create a free personal account

To register for email alerts, access free PDF, and more

 

Create a personal account or sign in to:

*   Register for email alerts with links to free full-text articles
*   Access PDFs of free articles
*   Manage your interests
*   Save searches and receive search alerts

[Privacy Policy](https://jamanetwork.com/pages/privacy-policy)

Make a comment

* * *

Sign in | personal account

 

Free access to newly published articles

* * *

Create a free personal account

To register for email alerts, access free PDF, and more

 

Create a personal account or sign in to:

*   Register for email alerts with links to free full-text articles
*   Access PDFs of free articles
*   Manage your interests
*   Save searches and receive search alerts

[Privacy Policy](https://jamanetwork.com/pages/privacy-policy)
",gpt-4o-mini
